<!DOCTYPE html><html lang="en-us" >

<head>

  <meta charset="utf-8">
  <meta name="viewport" content="width=device-width, initial-scale=1">
  <meta http-equiv="X-UA-Compatible" content="IE=edge">
  <meta name="generator" content="Source Themes Academic 4.8.0">

  

  
  
  
  
  
  

  

  
  
  
    
  
  <meta name="description" content="Table 1. List of all 3043 articles with abstract clustered as treatment in PlatOMICs for mesothelioma. *Curation represents the number of person that analyzed the information   Title  Journal      Weekly systemic combination of cisplatin and interferon alpha 2a in diffuse malignant pleural mesothelioma.">

  
  <link rel="alternate" hreflang="en-us" href="/mesothelioma/tables/abstract/treatment/">

  


  
  
  
  <meta name="theme-color" content="#2962ff">
  

  
  

  
  
  
  
    
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/academicons/1.8.6/css/academicons.min.css" integrity="sha256-uFVgMKfistnJAfoCUQigIl+JfUaP47GrRKjf6CTPVmw=" crossorigin="anonymous">
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/5.12.0-1/css/all.min.css" integrity="sha256-4w9DunooKSr3MFXHXWyFER38WmPdm361bQS/2KUWZbU=" crossorigin="anonymous">
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/fancybox/3.5.7/jquery.fancybox.min.css" integrity="sha256-Vzbj7sDDS/woiFS3uNKo8eIuni59rjyNGtXfstRzStA=" crossorigin="anonymous">

    
    
    
      
    
    
      
      
        
          <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/highlight.js/9.18.1/styles/github.min.css" crossorigin="anonymous" title="hl-light">
          <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/highlight.js/9.18.1/styles/dracula.min.css" crossorigin="anonymous" title="hl-dark" disabled>
        
      
    

    

    

    
    
      

      
      

      
    
      

      
      

      
    
      

      
      

      
    
      

      
      

      
    
      

      
      

      
    
      

      
      

      
    
      

      
      

      
    
      

      
      

      
    
      

      
      

      
    
      

      
      

      
    
      

      
      

      
        <script src="https://cdnjs.cloudflare.com/ajax/libs/lazysizes/5.1.2/lazysizes.min.js" integrity="sha256-Md1qLToewPeKjfAHU1zyPwOutccPAm5tahnaw7Osw0A=" crossorigin="anonymous" async></script>
      
    
      

      
      

      
    
      

      
      

      
    
      

      
      
        
      

      
    
      

      
      

      
    

  

  
  
  
  <link rel="stylesheet" href="https://fonts.googleapis.com/css?family=Montserrat:400,700%7CRoboto:400,400italic,700%7CRoboto+Mono&display=swap">
  

  
  
  
  
  <link rel="stylesheet" href="/mesothelioma/css/academic.css">

  





<script async src="https://www.googletagmanager.com/gtag/js?id=google_analytics_ID"></script>
<script>
  window.dataLayer = window.dataLayer || [];

  function gtag() {
      dataLayer.push(arguments);
  }

  function trackOutboundLink(url, target) {
    gtag('event', 'click', {
         'event_category': 'outbound',
         'event_label': url,
         'transport_type': 'beacon',
         'event_callback': function () {
           if (target !== '_blank') {
             document.location = url;
           }
         }
    });
    console.debug("Outbound link clicked: " + url);
  }

  function onClickCallback(event) {
    if ((event.target.tagName !== 'A') || (event.target.host === window.location.host)) {
      return;
    }
    trackOutboundLink(event.target, event.target.getAttribute('target'));  
  }

  gtag('js', new Date());
  gtag('config', 'google_analytics_ID', {});

  
  document.addEventListener('click', onClickCallback, false);
</script>


  


  
  

  

  <link rel="manifest" href="/mesothelioma/index.webmanifest">
  <link rel="icon" type="image/png" href="/mesothelioma/images/icon_hu3365e08ad5ef6cb6d886bc511b9ad2b3_313689_32x32_fill_lanczos_center_2.png">
  <link rel="apple-touch-icon" type="image/png" href="/mesothelioma/images/icon_hu3365e08ad5ef6cb6d886bc511b9ad2b3_313689_192x192_fill_lanczos_center_2.png">

  <link rel="canonical" href="/mesothelioma/tables/abstract/treatment/">

  
  
  
  
  
  
  
    
    
  
  
  <meta property="twitter:card" content="summary">
  
  <meta property="og:site_name" content="mesothelioma">
  <meta property="og:url" content="/mesothelioma/tables/abstract/treatment/">
  <meta property="og:title" content="Treatment Articles | mesothelioma">
  <meta property="og:description" content="Table 1. List of all 3043 articles with abstract clustered as treatment in PlatOMICs for mesothelioma. *Curation represents the number of person that analyzed the information   Title  Journal      Weekly systemic combination of cisplatin and interferon alpha 2a in diffuse malignant pleural mesothelioma."><meta property="og:image" content="/mesothelioma/images/icon_hu3365e08ad5ef6cb6d886bc511b9ad2b3_313689_512x512_fill_lanczos_center_2.png">
  <meta property="twitter:image" content="/mesothelioma/images/icon_hu3365e08ad5ef6cb6d886bc511b9ad2b3_313689_512x512_fill_lanczos_center_2.png"><meta property="og:locale" content="en-us">
  
    
      <meta property="article:published_time" content="2018-09-09T00:00:00&#43;00:00">
    
    <meta property="article:modified_time" content="2018-09-09T00:00:00&#43;00:00">
  

  



  


  


  





  <title>Treatment Articles | mesothelioma</title>

</head>

<body id="top" data-spy="scroll" data-offset="70" data-target="#TableOfContents" >

  <aside class="search-results" id="search">
  <div class="container">
    <section class="search-header">

      <div class="row no-gutters justify-content-between mb-3">
        <div class="col-6">
          <h1>Search</h1>
        </div>
        <div class="col-6 col-search-close">
          <a class="js-search" href="#"><i class="fas fa-times-circle text-muted" aria-hidden="true"></i></a>
        </div>
      </div>

      <div id="search-box">
        
        <input name="q" id="search-query" placeholder="Search..." autocapitalize="off"
        autocomplete="off" autocorrect="off" spellcheck="false" type="search">
        
      </div>

    </section>
    <section class="section-search-results">

      <div id="search-hits">
        
      </div>

    </section>
  </div>
</aside>


  







<nav class="navbar navbar-expand-lg navbar-light compensate-for-scrollbar" id="navbar-main">
  <div class="container">

    
    <div class="d-none d-lg-inline-flex">
      <a class="navbar-brand" href="/mesothelioma/">mesothelioma</a>
    </div>
    

    
    <button type="button" class="navbar-toggler" data-toggle="collapse"
            data-target="#navbar-content" aria-controls="navbar" aria-expanded="false" aria-label="Toggle navigation">
    <span><i class="fas fa-bars"></i></span>
    </button>
    

    
    <div class="navbar-brand-mobile-wrapper d-inline-flex d-lg-none">
      <a class="navbar-brand" href="/mesothelioma/">mesothelioma</a>
    </div>
    

    
    
    <div class="navbar-collapse main-menu-item collapse justify-content-start" id="navbar-content">

      
      <ul class="navbar-nav d-md-inline-flex">
        

        

        
        
        
          
        

        
        
        
        
        
        

        <li class="nav-item">
          <a class="nav-link " href="/mesothelioma/syntax/"><span>Syntax</span></a>
        </li>

        
        

        

        
        
        
          
        

        
        
        
        
        
        

        <li class="nav-item">
          <a class="nav-link " href="/mesothelioma/genepanel/"><span>Gene Panel</span></a>
        </li>

        
        

        

        
        
        
          
        

        
        
        
        
        
        

        <li class="nav-item">
          <a class="nav-link " href="/mesothelioma/drugpanel/"><span>Drug Panel</span></a>
        </li>

        
        

        

        
        
        
          
        

        
        
        
        
        
        

        <li class="nav-item">
          <a class="nav-link " href="/mesothelioma/tissuepanel/"><span>Tissue Panel</span></a>
        </li>

        
        

        

        
        
        
          
        

        
        
        
        
        
        

        <li class="nav-item">
          <a class="nav-link " href="/mesothelioma/syntax_summary/"><span>Literature Consensus</span></a>
        </li>

        
        

        

        
        
        
          
        

        
        
        
        
        
        
          
          
          
            
          
          
        

        <li class="nav-item">
          <a class="nav-link " href="/mesothelioma/#about"><span>Contact</span></a>
        </li>

        
        

      

        
      </ul>
    </div>

    <ul class="nav-icons navbar-nav flex-row ml-auto d-flex pl-md-2">
      
      <li class="nav-item">
        <a class="nav-link js-search" href="#"><i class="fas fa-search" aria-hidden="true"></i></a>
      </li>
      

      

      

    </ul>

  </div>
</nav>


  

<div class="container-fluid docs">
  <div class="row flex-xl-nowrap">
    <div class="col-12 col-md-3 col-xl-2 docs-sidebar">
      





  
    
  




<form class="docs-search d-flex align-items-center">
  <button class="btn docs-toggle d-md-none p-0 mr-3" type="button" data-toggle="collapse" data-target="#docs-nav" aria-controls="docs-nav" aria-expanded="false" aria-label="Toggle section navigation">
    <span><i class="fas fa-bars"></i></span>
  </button>

  
  <input name="q" type="search" class="form-control" placeholder="Search..." autocomplete="off">
  
</form>

<nav class="collapse docs-links" id="docs-nav">
  

  
  
  
  
  <div class="docs-toc-item">
    <a class="docs-toc-link" href="/mesothelioma/tables/abstract/">Table List</a>
    <ul class="nav docs-sidenav">
      
      <li >
        <a href="/mesothelioma/tables/abstract/diagnose/">Diagnosis</a>
      </li>
      
      <li class="active">
        <a href="/mesothelioma/tables/abstract/treatment/">Treatment</a>
      </li>
      
      <li >
        <a href="/mesothelioma/tables/abstract/epidemiology/">Epidemiology</a>
      </li>
      
      <li >
        <a href="/mesothelioma/tables/abstract/transmission/">Transmission</a>
      </li>
      
      <li >
        <a href="/mesothelioma/tables/abstract/signs/">Clinical, signs &amp; Symptoms</a>
      </li>
      
      <li >
        <a href="/mesothelioma/tables/abstract/no_category/">No Category</a>
      </li>
      
      <li >
        <a href="/mesothelioma/tables/abstract/no_abstract/">No Abstract</a>
      </li>
      
    </ul>
    

  </div>
  
  
</nav>

    </div>

    

    <main class="col-12 col-md-9 col-xl-8 py-md-3 pl-md-5 docs-content" role="main">

      <article class="article">

        <div class="docs-article-container">
          <h1>Treatment Articles</h1>

          <div class="article-style">
            
<script src="/mesotheliomarmarkdown-libs/kePrint/kePrint.js"></script>


<br>
<p style="font-size:12px" align="center">
<strong>Table 1.</strong> List of all 3043 articles with abstract clustered as treatment in PlatOMICs for mesothelioma. <br>*Curation represents the number of person that analyzed the information
</p>
<hr />
<table class="table table-striped" style="width: auto !important; margin-left: auto; margin-right: auto;">
<thead>
<tr>
<th style="text-align:left;position: sticky; top:0; background-color: #FFFFFF;">
Title
</th>
<th style="text-align:left;position: sticky; top:0; background-color: #FFFFFF;">
Journal
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Weekly systemic combination of cisplatin and interferon alpha 2a in diffuse malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
The clinical importance of magnetic resonance imaging versus computed tomography in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Factors influencing the outcome of radiotherapy in malignant mesothelioma of the pleura–a single-institution experience with 189 patients.
</td>
<td style="text-align:left;">
Int. J. Radiat. Oncol. Biol. Phys.
</td>
</tr>
<tr>
<td style="text-align:left;">
Pleural space perfusion with cisplatin in the multimodality treatment of malignant mesothelioma: a feasibility and pharmacokinetic study.
</td>
<td style="text-align:left;">
J. Thorac. Cardiovasc. Surg.
</td>
</tr>
<tr>
<td style="text-align:left;">
[Primary pericardial mesothelioma: report of a case (author’s transl)].
</td>
<td style="text-align:left;">
G Ital Cardiol
</td>
</tr>
<tr>
<td style="text-align:left;">
Impressive remission in a patient with locally advanced malignant pleural mesothelioma treated with gemcitabine.
</td>
<td style="text-align:left;">
Anticancer Drugs
</td>
</tr>
<tr>
<td style="text-align:left;">
Results of a phase II trial of combined chemotherapy for patients with diffuse malignant mesothelioma of the pleura.
</td>
<td style="text-align:left;">
Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Establishment of four new mesothelioma cell lines: characterization by ultrastructural and immunophenotypic analysis.
</td>
<td style="text-align:left;">
Eur. Respir. J.
</td>
</tr>
<tr>
<td style="text-align:left;">
[Case series of mesotheliomas from hospital archives as contribution to preventive intervention].
</td>
<td style="text-align:left;">
Ann. Ist. Super. Sanita
</td>
</tr>
<tr>
<td style="text-align:left;">
[Pleural mesotheliomas. Current knowledge].
</td>
<td style="text-align:left;">
Ann Chir
</td>
</tr>
<tr>
<td style="text-align:left;">
[Malignant pleural mesotheliomas].
</td>
<td style="text-align:left;">
Medicina (B Aires)
</td>
</tr>
<tr>
<td style="text-align:left;">
Cisplatin in combination with irinotecan in the treatment of patients with malignant pleural mesothelioma: a pilot phase II clinical trial and pharmacokinetic profile.
</td>
<td style="text-align:left;">
Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Indications for pneumonectomy. Extrapleural pneumonectomy.
</td>
<td style="text-align:left;">
Chest Surg. Clin. N. Am.
</td>
</tr>
<tr>
<td style="text-align:left;">
A Phase II study of gemcitabine in patients with malignant pleural mesothelioma. European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group.
</td>
<td style="text-align:left;">
Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
[Pleural mesothelioma. A case report].
</td>
<td style="text-align:left;">
Recenti Prog Med
</td>
</tr>
<tr>
<td style="text-align:left;">
Ifosfamide in malignant mesothelioma: a phase II study.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Pleural mesothelioma.
</td>
<td style="text-align:left;">
Curr Opin Pulm Med
</td>
</tr>
<tr>
<td style="text-align:left;">
[Therapy of malignant pleural mesothelioma–a permanent dilemma].
</td>
<td style="text-align:left;">
Pneumologie
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma: a problematic review.
</td>
<td style="text-align:left;">
Surg Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma: the spectrum of manifestations on CT in 70 cases.
</td>
<td style="text-align:left;">
Clin Radiol
</td>
</tr>
<tr>
<td style="text-align:left;">
How should we treat malignant pleural mesothelioma (MPM)?
</td>
<td style="text-align:left;">
Acta Chir Hung
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma of the pleural space.
</td>
<td style="text-align:left;">
Oncology (Williston Park, N.Y.)
</td>
</tr>
<tr>
<td style="text-align:left;">
Cisplatin, mitomycin, and interferon-alpha2a combination chemoimmunotherapy in the treatment of diffuse malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Chest
</td>
</tr>
<tr>
<td style="text-align:left;">
Advances in the treatment of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Chest
</td>
</tr>
<tr>
<td style="text-align:left;">
Late results.
</td>
<td style="text-align:left;">
Chest Surg. Clin. N. Am.
</td>
</tr>
<tr>
<td style="text-align:left;">
High-dose methotrexate in combination with interferons in the treatment of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Br. J. Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Cerebral metastases in malignant mesothelioma: a case report.
</td>
<td style="text-align:left;">
Eur J Cancer Care (Engl)
</td>
</tr>
<tr>
<td style="text-align:left;">
Subcutaneous seeding after ultrasound-guided placement of intrapleural catheter. An unusual complication of the intracavitary palliative treatment of pleural mesothelioma.
</td>
<td style="text-align:left;">
Support Care Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Inhibition of interleukin-8 reduces human malignant pleural mesothelioma propagation in nude mouse model.
</td>
<td style="text-align:left;">
Oncol. Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
Edatrexate (10-ethyl-deaza-aminopterin) (NSC #626715) with or without leucovorin rescue for malignant mesothelioma. Sequential phase II trials by the cancer and leukemia group B.
</td>
<td style="text-align:left;">
Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Important prognostic factors in patients with malignant pleural mesothelioma, managed surgically.
</td>
<td style="text-align:left;">
Ann. Thorac. Surg.
</td>
</tr>
<tr>
<td style="text-align:left;">
[Malignant pleural mesothelioma].
</td>
<td style="text-align:left;">
Bull Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Staging of malignant pleural mesothelioma: comparison of CT and MR imaging.
</td>
<td style="text-align:left;">
AJR Am J Roentgenol
</td>
</tr>
<tr>
<td style="text-align:left;">
Palliative treatment of malignant pleural effusions by video-assisted thoracoscopic surgery.
</td>
<td style="text-align:left;">
Acta Chir Hung
</td>
</tr>
<tr>
<td style="text-align:left;">
Video-assisted thoracoscopic pleurodesis for malignant pleural effusions.
</td>
<td style="text-align:left;">
Acta Chir Hung
</td>
</tr>
<tr>
<td style="text-align:left;">
Pharmacokinetics of intrapleural cisplatin for the treatment of malignant pleural effusions.
</td>
<td style="text-align:left;">
Oncol. Rep.
</td>
</tr>
<tr>
<td style="text-align:left;">
Pleuro-pulmonary tumours detected by clinical and chest X-ray analyses in rats transplanted with mesothelioma cells.
</td>
<td style="text-align:left;">
Br. J. Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Surgical treatment of mesothelioma: pleurectomy.
</td>
<td style="text-align:left;">
Chest
</td>
</tr>
<tr>
<td style="text-align:left;">
Pleuropneumonectomy in the treatment of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Chest
</td>
</tr>
<tr>
<td style="text-align:left;">
Emerging translational therapies for mesothelioma.
</td>
<td style="text-align:left;">
Chest
</td>
</tr>
<tr>
<td style="text-align:left;">
Antisense to SV40 early gene region induces growth arrest and apoptosis in T-antigen-positive human pleural mesothelioma cells.
</td>
<td style="text-align:left;">
Cancer Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
Contemporary management of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Oncologist
</td>
</tr>
<tr>
<td style="text-align:left;">
Talc induces apoptosis in human malignant mesothelioma cells in vitro.
</td>
<td style="text-align:left;">
Am. J. Respir. Crit. Care Med.
</td>
</tr>
<tr>
<td style="text-align:left;">
[VATS in malignant pleural effusions].
</td>
<td style="text-align:left;">
Zhonghua Wai Ke Za Zhi
</td>
</tr>
<tr>
<td style="text-align:left;">
Long term survival of a patient with malignant pleural mesothelioma as a late complication of radiotherapy for Hodgkin’s disease treated with 90yttrium-silicate.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
[The incidence of malignant mesothelioma (1977-1996) and asbestos exposure in the population of an area neighboring Lake Iseo, northern Italy].
</td>
<td style="text-align:left;">
Med Lav
</td>
</tr>
<tr>
<td style="text-align:left;">
Sister chromatid exchange rate from pleural fluid cells in patients with malignant mesothelioma.
</td>
<td style="text-align:left;">
Mutat. Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
Monitoring of impending myocardial damage after pleuropneumonectomy and intraoperative photodynamic therapy for malignant pleural mesothelioma using biochemical markers.
</td>
<td style="text-align:left;">
Photochem. Photobiol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Manganese superoxide dismutase as a diagnostic marker for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Br. J. Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Mesothelioma: new concepts in diagnosis and management.
</td>
<td style="text-align:left;">
Curr Opin Pulm Med
</td>
</tr>
<tr>
<td style="text-align:left;">
Intrapleural administration of tumour necrosis factor-alpha (TNFalpha) in patients with mesothelioma: cytokine patterns and acute-phase protein response.
</td>
<td style="text-align:left;">
Eur. J. Clin. Invest.
</td>
</tr>
<tr>
<td style="text-align:left;">
[Chemotherapy in combination with whole-body hyperthermia in advanced malignant pleural mesothelioma].
</td>
<td style="text-align:left;">
Dtsch. Med. Wochenschr.
</td>
</tr>
<tr>
<td style="text-align:left;">
Current Therapy for Mesothelioma.
</td>
<td style="text-align:left;">
Cancer Control
</td>
</tr>
<tr>
<td style="text-align:left;">
18-FDG positron emission tomography in the evaluation of malignant pleural diseases - a pilot study.
</td>
<td style="text-align:left;">
Eur J Cardiothorac Surg
</td>
</tr>
<tr>
<td style="text-align:left;">
The diagnostic yield of pleural fluid cytology in malignant pleural effusions.
</td>
<td style="text-align:left;">
Singapore Med J
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural diseases.
</td>
<td style="text-align:left;">
Monaldi Arch Chest Dis
</td>
</tr>
<tr>
<td style="text-align:left;">
Adenovirus-mediated wild-type p53 overexpression reverts tumourigenicity of human mesothelioma cells.
</td>
<td style="text-align:left;">
Int. J. Mol. Med.
</td>
</tr>
<tr>
<td style="text-align:left;">
[Primary biphasic synovial sarcoma of the pleura].
</td>
<td style="text-align:left;">
Rev Mal Respir
</td>
</tr>
<tr>
<td style="text-align:left;">
Positron emission tomography with f18-fluorodeoxyglucose in the staging and preoperative evaluation of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J. Thorac. Cardiovasc. Surg.
</td>
</tr>
<tr>
<td style="text-align:left;">
Docetaxel and irinotecan (CPT-11) in the treatment of malignant pleural mesothelioma–a feasibility study.
</td>
<td style="text-align:left;">
Anticancer Drugs
</td>
</tr>
<tr>
<td style="text-align:left;">
Management of malignant pleural mesothelioma: a critical review.
</td>
<td style="text-align:left;">
Curr Opin Pulm Med
</td>
</tr>
<tr>
<td style="text-align:left;">
The long-term morbidity of pleuroperitoneal shunts in the management of recurrent malignant effusions.
</td>
<td style="text-align:left;">
Eur J Cardiothorac Surg
</td>
</tr>
<tr>
<td style="text-align:left;">
Caelyx in malignant mesothelioma: a phase II EORTC study.
</td>
<td style="text-align:left;">
Ann. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Gene-modified PA1-STK cells home to tumor sites in patients with malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Ann. Thorac. Surg.
</td>
</tr>
<tr>
<td style="text-align:left;">
[Malignant mesothelioma of the pleura, pericardium and peritoneum. 1: Etiology, pathogenesis, pathology].
</td>
<td style="text-align:left;">
Chirurg
</td>
</tr>
<tr>
<td style="text-align:left;">
[Mesothelioma of the pleura and peritoneum. Diagnostic and therapeutic sequelae].
</td>
<td style="text-align:left;">
Chirurg
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant peritoneal mesothelioma associated with deep vein thrombosis following radiotherapy for seminoma of the testis.
</td>
<td style="text-align:left;">
Intern. Med.
</td>
</tr>
<tr>
<td style="text-align:left;">
Phase II study of vinorelbine in patients with malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J. Clin. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Comparison of the effectiveness of some pleural sclerosing agents used for control of effusions in malignant pleural mesothelioma: a review of 117 cases.
</td>
<td style="text-align:left;">
Respiration
</td>
</tr>
<tr>
<td style="text-align:left;">
[Surgical treatment for malignant pleural mesothelioma in eight cases].
</td>
<td style="text-align:left;">
Kyobu Geka
</td>
</tr>
<tr>
<td style="text-align:left;">
Well-differentiated papillary mesothelioma involving the peritoneal and pleural cavities: successful treatment by local and systemic administration of carboplatin.
</td>
<td style="text-align:left;">
Tumori
</td>
</tr>
<tr>
<td style="text-align:left;">
Extrapleural pneumonectomy for sarcomas report of two cases.
</td>
<td style="text-align:left;">
Tumori
</td>
</tr>
<tr>
<td style="text-align:left;">
p53 autoantibodies in patients with malignant mesothelioma: stability through disease progression.
</td>
<td style="text-align:left;">
Br. J. Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Huge malignant localized fibrous tumor of the pleura.
</td>
<td style="text-align:left;">
J Cardiovasc Surg (Torino)
</td>
</tr>
<tr>
<td style="text-align:left;">
Efficacy of repeated adenoviral suicide gene therapy in a localized murine tumor model.
</td>
<td style="text-align:left;">
Ann. Thorac. Surg.
</td>
</tr>
<tr>
<td style="text-align:left;">
A phase II study of combined intravenous and subcutaneous interleukin-2 in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Palliative and therapeutic activity of IL-2 immunotherapy in unresectable malignant pleural mesothelioma with pleural effusion: Results of a phase II study on 31 consecutive patients.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Solitary fibrous tumour of the pleura: surgical treatment.
</td>
<td style="text-align:left;">
Eur J Cardiothorac Surg
</td>
</tr>
<tr>
<td style="text-align:left;">
The alpha folate receptor is highly activated in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J. Thorac. Cardiovasc. Surg.
</td>
</tr>
<tr>
<td style="text-align:left;">
[Treatment of malignant pleural effusion by pleurodesis with talc].
</td>
<td style="text-align:left;">
Chir Ital
</td>
</tr>
<tr>
<td style="text-align:left;">
Radicular involvement and medullary invasion from a malignant mesothelioma.
</td>
<td style="text-align:left;">
Respiration
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Cancer Treat. Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
A pilot study of systemic corticosteroid administration in conjunction with intrapleural adenoviral vector administration in patients with malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Cancer Gene Ther.
</td>
</tr>
<tr>
<td style="text-align:left;">
SV40 and the pathogenesis of mesothelioma.
</td>
<td style="text-align:left;">
Semin. Cancer Biol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Immunotherapy-based treatment strategies for malignant mesothelioma.
</td>
<td style="text-align:left;">
Curr. Opin. Mol. Ther.
</td>
</tr>
<tr>
<td style="text-align:left;">
Trimodality management of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Eur J Cardiothorac Surg
</td>
</tr>
<tr>
<td style="text-align:left;">
Extrapleural pneumonectomy for diffuse malignant pleural mesothelioma. A treatment option in selected cases?
</td>
<td style="text-align:left;">
Jpn. J. Thorac. Cardiovasc. Surg.
</td>
</tr>
<tr>
<td style="text-align:left;">
Expression and prognostic significance of catalase in malignant mesothelioma.
</td>
<td style="text-align:left;">
Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Superior vena cava obstruction: is stenting necessary?
</td>
<td style="text-align:left;">
Support Care Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Combination chemotherapy with mitoxantrone, methotrexate, and mitomycin (MMM regimen) in malignant pleural mesothelioma: a phase II study.
</td>
<td style="text-align:left;">
Am. J. Clin. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Localised spontaneous regression in mesothelioma – possible immunological mechanism.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Treatment of malignant mesothelioma.
</td>
<td style="text-align:left;">
World J Surg
</td>
</tr>
<tr>
<td style="text-align:left;">
Synovial sarcoma and malignant mesothelioma of the pleura: review, differential diagnosis and possible role of apoptosis.
</td>
<td style="text-align:left;">
Pathology
</td>
</tr>
<tr>
<td style="text-align:left;">
Percutaneous balloon pericardiotomy for patients with malignant pericardial effusion including three malignant pleural mesotheliomas.
</td>
<td style="text-align:left;">
Angiology
</td>
</tr>
<tr>
<td style="text-align:left;">
Phase II trial of liposomal daunorubicin in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Ann. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
[Treatment of malignant pleural mesothelioma].
</td>
<td style="text-align:left;">
Minerva Chir
</td>
</tr>
<tr>
<td style="text-align:left;">
Wedge-shaped applicator for additional light delivery and dosimetry in the diaphragmal sinus during photodynamic therapy for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Phys Med Biol
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma from neighborhood exposure to anthophyllite asbestos.
</td>
<td style="text-align:left;">
Am. J. Ind. Med.
</td>
</tr>
<tr>
<td style="text-align:left;">
A case of repetitive intrapleural cancer chemotherapy using INFUSE-A-PORT for malignant mesothelioma.
</td>
<td style="text-align:left;">
Thorac Cardiovasc Surg
</td>
</tr>
<tr>
<td style="text-align:left;">
Combined regimen of cisplatin, doxorubicin, and alpha-2b interferon in the treatment of advanced malignant pleural mesothelioma: a Phase II multicenter trial of the Italian Group on Rare Tumors (GITR) and the Italian Lung Cancer Task Force (FONICAP).
</td>
<td style="text-align:left;">
Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
p14(ARF) modulates the cytolytic effect of ONYX-015 in mesothelioma cells with wild-type p53.
</td>
<td style="text-align:left;">
Cancer Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
[A case of desmoplastic malignant pleural mesothelioma].
</td>
<td style="text-align:left;">
Nihon Kokyuki Gakkai Zasshi
</td>
</tr>
<tr>
<td style="text-align:left;">
[Unusual case of mesothelioma of the tunica vaginalis associated with prostatic adenocarcinoma].
</td>
<td style="text-align:left;">
Minerva Urol Nefrol
</td>
</tr>
<tr>
<td style="text-align:left;">
Comparison of antibodies to HBME-1 and calretinin for the detection of mesothelial cells in effusion cytology.
</td>
<td style="text-align:left;">
Diagn. Cytopathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Prognostic significance of flow cytometric DNA analysis in patients with malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Hyaluronan content in pleural fluid as a prognostic factor in patients with malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
A phase II trial of surgical resection and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J. Thorac. Cardiovasc. Surg.
</td>
</tr>
<tr>
<td style="text-align:left;">
Intraoperative photodynamic therapy after pleuropneumonectomy in patients with malignant pleural mesothelioma: dose finding and toxicity results.
</td>
<td style="text-align:left;">
Chest
</td>
</tr>
<tr>
<td style="text-align:left;">
Prognostic factors in diffuse malignant pleural mesothelioma: effects of pretreatment clinical and laboratory characteristics.
</td>
<td style="text-align:left;">
Respir Med
</td>
</tr>
<tr>
<td style="text-align:left;">
[Incidence of malignant mesothelioma (1980-1999) and asbestos exposure in 190 cases diagnosed among residents of the province of Brescia].
</td>
<td style="text-align:left;">
Med Lav
</td>
</tr>
<tr>
<td style="text-align:left;">
Therapeutic outcome according to histologic subtype in 121 patients with malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Well-differentiated papillary mesothelioma.
</td>
<td style="text-align:left;">
Am. J. Surg. Pathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma following chemotherapy for breast cancer.
</td>
<td style="text-align:left;">
Anticancer Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
Technology evaluation: gene therapy (mesothelioma), NCI.
</td>
<td style="text-align:left;">
Curr. Opin. Mol. Ther.
</td>
</tr>
<tr>
<td style="text-align:left;">
Palliative surgical debulking in malignant mesothelioma. Predictors of survival and symptom control.
</td>
<td style="text-align:left;">
Eur J Cardiothorac Surg
</td>
</tr>
<tr>
<td style="text-align:left;">
[Malignant pleural mesothelioma].
</td>
<td style="text-align:left;">
Minerva Chir
</td>
</tr>
<tr>
<td style="text-align:left;">
Survival after conservative (palliative) management of pleural malignant mesothelioma.
</td>
<td style="text-align:left;">
J Surg Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
[Two cases of malignant mesothelioma of the pleura within one family].
</td>
<td style="text-align:left;">
Pol. Merkur. Lekarski
</td>
</tr>
<tr>
<td style="text-align:left;">
[Numerical alteration of chromosome 8 in pleural effusions].
</td>
<td style="text-align:left;">
Zhonghua Zhong Liu Za Zhi
</td>
</tr>
<tr>
<td style="text-align:left;">
[Results of phase II clinical trial of cycloplatam in refractory solid tumors].
</td>
<td style="text-align:left;">
Vopr Onkol
</td>
</tr>
<tr>
<td style="text-align:left;">
Induction of apoptosis in malignant pleural mesothelioma cells by activation of the Fas (Apo-1/CD95) death-signal pathway.
</td>
<td style="text-align:left;">
J. Thorac. Cardiovasc. Surg.
</td>
</tr>
<tr>
<td style="text-align:left;">
Cytoreductive surgery and intraoperative hyperthermic intrathoracic chemotherapy in patients with malignant pleural mesothelioma or pleural metastases of thymoma.
</td>
<td style="text-align:left;">
Chest
</td>
</tr>
<tr>
<td style="text-align:left;">
The pathogenesis of mesothelioma.
</td>
<td style="text-align:left;">
Semin. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
The role of imaging in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Semin. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Prognostic factors in mesothelioma.
</td>
<td style="text-align:left;">
Semin. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Multimodality treatment of diffuse malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Semin. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
The emerging role of antifolates in the treatment of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Semin. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Multicenter randomized controlled trial of the management of unresectable malignant mesothelioma proposed by the British Thoracic Society and the British Medical Research Council.
</td>
<td style="text-align:left;">
Semin. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
[Current insights in malignant pleural mesothelioma].
</td>
<td style="text-align:left;">
Bull Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
SV40 Tag-specific cytotoxic T lymphocytes generated from the peripheral blood of malignant pleural mesothelioma patients.
</td>
<td style="text-align:left;">
Cancer Immunol. Immunother.
</td>
</tr>
<tr>
<td style="text-align:left;">
Hyperthermia and mafosfamide in a human-derived malignant pleural mesothelioma cell line.
</td>
<td style="text-align:left;">
J. Cancer Res. Clin. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Clinical and immunological assessment of Mycobacterium vaccae (SRL172) with chemotherapy in patients with malignant mesothelioma.
</td>
<td style="text-align:left;">
Br. J. Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Localized pleural malignant mesothelioma.
</td>
<td style="text-align:left;">
Pathol. Int.
</td>
</tr>
<tr>
<td style="text-align:left;">
Phase II study of repeated intrapleural chemotherapy using implantable access system for management of malignant pleural effusion.
</td>
<td style="text-align:left;">
Chest
</td>
</tr>
<tr>
<td style="text-align:left;">
Diffuse malignant epithelial mesotheliomas of the peritoneum in women: a clinicopathologic study of 25 patients.
</td>
<td style="text-align:left;">
Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Phosphatase and tensin analog gene overexpression engenders cellular death in human malignant mesothelioma cells via inhibition of AKT phosphorylation.
</td>
<td style="text-align:left;">
Ann. Surg. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
[Malignant pleural mesothelioma. Present data and perspectives for treatment].
</td>
<td style="text-align:left;">
Presse Med
</td>
</tr>
<tr>
<td style="text-align:left;">
A phase II EORTC study of temozolomide in patients with malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Eur. J. Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
A case of malignant pleural mesothelioma with unexpectedly long survival without active treatment.
</td>
<td style="text-align:left;">
Respiration
</td>
</tr>
<tr>
<td style="text-align:left;">
Oxaliplatin and raltitrexed in the treatment of inoperable malignant pleural mesothelioma: results of a pilot study.
</td>
<td style="text-align:left;">
Tumori
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma: a phase II trial with docetaxel.
</td>
<td style="text-align:left;">
Ann. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
[Surgery and hyperthermic pleural perfusion–a new approach for malignancies with pleural involvement].
</td>
<td style="text-align:left;">
Harefuah
</td>
</tr>
<tr>
<td style="text-align:left;">
Pemetrexed for diffuse malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Semin. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Current therapy for malignant mesothelioma.
</td>
<td style="text-align:left;">
Curr Oncol Rep
</td>
</tr>
<tr>
<td style="text-align:left;">
Current surgical management of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Curr Oncol Rep
</td>
</tr>
<tr>
<td style="text-align:left;">
Photodynamic therapy for mesothelioma.
</td>
<td style="text-align:left;">
Curr Treat Options Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant peritoneal mesothelioma.
</td>
<td style="text-align:left;">
Curr Treat Options Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Pericardial mesothelioma.
</td>
<td style="text-align:left;">
Curr Treat Options Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Curr Treat Options Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Cyclooxygenase-2 expression is a novel prognostic factor in malignant mesothelioma.
</td>
<td style="text-align:left;">
Clin. Cancer Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
Intrapleural infusion of activated macrophages and gamma-interferon in malignant pleural mesothelioma: a phase II study.
</td>
<td style="text-align:left;">
Chest
</td>
</tr>
<tr>
<td style="text-align:left;">
[A case of desmoplastic malignant mesothelioma with elevated serum CYFRA 21-1].
</td>
<td style="text-align:left;">
Nihon Kokyuki Gakkai Zasshi
</td>
</tr>
<tr>
<td style="text-align:left;">
CT-guided percutaneous selective cordotomy for treatment of intractable pain in patients with malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Acta Neurochir (Wien)
</td>
</tr>
<tr>
<td style="text-align:left;">
Tumorigenicity of cellulose fibers injected into the rat peritoneal cavity.
</td>
<td style="text-align:left;">
Inhal Toxicol
</td>
</tr>
<tr>
<td style="text-align:left;">
The management of malignant pleural mesothelioma; single centre experience in 10 years.
</td>
<td style="text-align:left;">
Eur J Cardiothorac Surg
</td>
</tr>
<tr>
<td style="text-align:left;">
Diffuse malignant mesothelioma of the pleural space and its management.
</td>
<td style="text-align:left;">
Oncology (Williston Park, N.Y.)
</td>
</tr>
<tr>
<td style="text-align:left;">
Phase I clinical and pharmacokinetic study of pemetrexed and carboplatin in patients with malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J. Clin. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
A multicentre phase II study of cisplatin and gemcitabine for malignant mesothelioma.
</td>
<td style="text-align:left;">
Br. J. Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant gonadal mesothelioma.
</td>
<td style="text-align:left;">
Curr Treat Options Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Overexpression of gamma-glutamylcysteine synthetase in human malignant mesothelioma.
</td>
<td style="text-align:left;">
Hum. Pathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Synergistic effect of the anti-HER-2/neu antibody and cisplatin in immortalized and primary mesothelioma cell lines.
</td>
<td style="text-align:left;">
J. Cell. Physiol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Assessment of malignant pleural mesothelioma with (18)F-FDG dual-head gamma-camera coincidence imaging: comparison with histopathology.
</td>
<td style="text-align:left;">
J. Nucl. Med.
</td>
</tr>
<tr>
<td style="text-align:left;">
[Prognosis, staging and therapy of malignant pleural mesothelioma].
</td>
<td style="text-align:left;">
Med. Klin. (Munich)
</td>
</tr>
<tr>
<td style="text-align:left;">
Inhibition of epidermal growth factor receptor signaling in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Cancer Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
[Etiology and clinical diagnosis of diffuse pleural mesothelioma (author’s transl)].
</td>
<td style="text-align:left;">
Z Erkr Atmungsorgane
</td>
</tr>
<tr>
<td style="text-align:left;">
Synovial sarcoma of the pleura: a clinical and pathologic study of three cases.
</td>
<td style="text-align:left;">
J. Thorac. Cardiovasc. Surg.
</td>
</tr>
<tr>
<td style="text-align:left;">
Survival after pleural malignant mesothelioma: a population-based study in Italy.
</td>
<td style="text-align:left;">
Tumori
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma in a child: long-term survival with ICE-WAC chemotherapy regimen.
</td>
<td style="text-align:left;">
Turk. J. Pediatr.
</td>
</tr>
<tr>
<td style="text-align:left;">
Potential of interferon-alpha in solid tumours: part 2.
</td>
<td style="text-align:left;">
BioDrugs
</td>
</tr>
<tr>
<td style="text-align:left;">
Radical pleurectomy/decortication and intraoperative radiotherapy followed by conformal radiation with or without chemotherapy for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J. Thorac. Cardiovasc. Surg.
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma: options for management.
</td>
<td style="text-align:left;">
Surg. Clin. North Am.
</td>
</tr>
<tr>
<td style="text-align:left;">
Induction of apoptosis in mesothelioma cells by antisurvivin oligonucleotides.
</td>
<td style="text-align:left;">
Mol. Cancer Ther.
</td>
</tr>
<tr>
<td style="text-align:left;">
Experimental photodynamic therapy for malignant pleural mesothelioma with pegylated mTHPC.
</td>
<td style="text-align:left;">
Lasers Surg Med
</td>
</tr>
<tr>
<td style="text-align:left;">
Combination of raltitrexed and oxaliplatin is an active regimen in malignant mesothelioma: results of a phase II study.
</td>
<td style="text-align:left;">
J. Clin. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Interferons and their application in the diseases of the lung.
</td>
<td style="text-align:left;">
Chest
</td>
</tr>
<tr>
<td style="text-align:left;">
Pharmacokinetics of doxorubicin and cisplatin used in intraoperative hyperthermic intrathoracic chemotherapy after cytoreductive surgery for malignant pleural mesothelioma and pleural thymoma.
</td>
<td style="text-align:left;">
Anticancer Drugs
</td>
</tr>
<tr>
<td style="text-align:left;">
Molecular analyses, morphology and immunohistochemistry together differentiate pleural synovial sarcomas from mesotheliomas: clinical implications.
</td>
<td style="text-align:left;">
Anticancer Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
[Diagnosis and treatment of pleural mesothelioma].
</td>
<td style="text-align:left;">
Medicina (Kaunas)
</td>
</tr>
<tr>
<td style="text-align:left;">
The activity of raltitrexed (Tomudex) in malignant pleural mesothelioma: an EORTC phase II study (08992).
</td>
<td style="text-align:left;">
Eur. J. Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Emerging insights into the biology and therapy of malignant mesothelioma.
</td>
<td style="text-align:left;">
Semin. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Intensity-modulated radiotherapy following extrapleural pneumonectomy for the treatment of malignant mesothelioma: clinical implementation.
</td>
<td style="text-align:left;">
Int. J. Radiat. Oncol. Biol. Phys.
</td>
</tr>
<tr>
<td style="text-align:left;">
Intensity-modulated radiation therapy: a novel approach to the management of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Int. J. Radiat. Oncol. Biol. Phys.
</td>
</tr>
<tr>
<td style="text-align:left;">
Surgical treatment of malignant pleural mesothelioma: a review.
</td>
<td style="text-align:left;">
Chest
</td>
</tr>
<tr>
<td style="text-align:left;">
The usefulness of 99mTc-tetrofosmin SPECT in the detection of intrathoracic malignant lesions.
</td>
<td style="text-align:left;">
Int. J. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Pleuropneumonectomy in the management of diffuse malignant mesothelioma of the pleura. Experience with 29 patients.
</td>
<td style="text-align:left;">
Thorax
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma growth inhibition by agents that target the VEGF and VEGF-C autocrine loops.
</td>
<td style="text-align:left;">
Int. J. Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
The role of new imaging techniques in diagnosis and staging of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Curr Opin Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
The role of surgery in diagnosis and treatment of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Curr Opin Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Indications and limitations of radiotherapy in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Curr Opin Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Chemotherapy for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Curr Opin Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Chemotherapy of malignant diffuse mesothelioma.
</td>
<td style="text-align:left;">
Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Ifosfamide, carboplatin and etoposide combined with 41.8 degrees C whole body hyperthermia for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Chemotherapy for malignant pleural mesothelioma: past results and recent developments.
</td>
<td style="text-align:left;">
Br. J. Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Cytoreductive surgery combined with intraoperative hyperthermic intrathoracic chemotherapy for stage I malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Ann. Surg. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
[Pleuro-pneumonectomy, RT and CT for pleural mesothelioma. Prospective study].
</td>
<td style="text-align:left;">
Chir Ital
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma. Report of 19 cases.
</td>
<td style="text-align:left;">
J. Thorac. Cardiovasc. Surg.
</td>
</tr>
<tr>
<td style="text-align:left;">
A phase I study of Foscan-mediated photodynamic therapy and surgery in patients with mesothelioma.
</td>
<td style="text-align:left;">
Ann. Thorac. Surg.
</td>
</tr>
<tr>
<td style="text-align:left;">
[Cardiac tamponade due to pericardial mesothelioma in an 11-year-old dog: diagnosis, medical and interventional treatments].
</td>
<td style="text-align:left;">
Schweiz. Arch. Tierheilkd.
</td>
</tr>
<tr>
<td style="text-align:left;">
Phase II study of pemetrexed with and without folic acid and vitamin B12 as front-line therapy in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J. Clin. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Pemetrexed and its emerging role in the treatment of thoracic malignancies.
</td>
<td style="text-align:left;">
Expert Opin Investig Drugs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Gemcitabine improved QOL and survival in a case of diffuse malignant pleural mesothelioma].
</td>
<td style="text-align:left;">
Gan To Kagaku Ryoho
</td>
</tr>
<tr>
<td style="text-align:left;">
Gemcitabine combined with carboplatin in patients with malignant pleural mesothelioma: a multicentric phase II study.
</td>
<td style="text-align:left;">
Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Advances in the management of malignant mesothelioma.
</td>
<td style="text-align:left;">
Curr Oncol Rep
</td>
</tr>
<tr>
<td style="text-align:left;">
Menstruation in an unusual place: a case of thoracic endometriosis in Kampala, Uganda.
</td>
<td style="text-align:left;">
Afr Health Sci
</td>
</tr>
<tr>
<td style="text-align:left;">
[Malignant pleural mesothelioma].
</td>
<td style="text-align:left;">
Gan To Kagaku Ryoho
</td>
</tr>
<tr>
<td style="text-align:left;">
Induction of apoptosis and chemosensitization of mesothelioma cells by Bcl-2 and Bcl-xL antisense treatment.
</td>
<td style="text-align:left;">
Int. J. Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Diagnostic criteria for human diffuse malignant mesothelioma.
</td>
<td style="text-align:left;">
Acta Pathol. Jpn.
</td>
</tr>
<tr>
<td style="text-align:left;">
The value of chest computer tomography and cervical mediastinoscopy in the preoperative assessment of patients with malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Ann. Thorac. Surg.
</td>
</tr>
<tr>
<td style="text-align:left;">
[A case of benign asbestos pleural effusion suspected on thoracoscopic examination under local anesthesia].
</td>
<td style="text-align:left;">
Nihon Kokyuki Gakkai Zasshi
</td>
</tr>
<tr>
<td style="text-align:left;">
[Conservative, palliative therapy of malignant pleural mesothelioma].
</td>
<td style="text-align:left;">
Langenbecks Arch Chir Suppl Kongressbd
</td>
</tr>
<tr>
<td style="text-align:left;">
Microarray analysis and RNA silencing link fra-1 to cd44 and c-met expression in mesothelioma.
</td>
<td style="text-align:left;">
Cancer Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
[Cutaneous metastasis of pleural mesothelioma: two cases].
</td>
<td style="text-align:left;">
Ann Dermatol Venereol
</td>
</tr>
<tr>
<td style="text-align:left;">
Second-line treatment of advanced gastric cancer with oxaliplatin plus raltitrexed.
</td>
<td style="text-align:left;">
Onkologie
</td>
</tr>
<tr>
<td style="text-align:left;">
Non-melanoma and non-renal cell carcinoma malignancies treated with interleukin-2.
</td>
<td style="text-align:left;">
Hepatogastroenterology
</td>
</tr>
<tr>
<td style="text-align:left;">
Mesothelioma: Drug treatment and other interventions.
</td>
<td style="text-align:left;">
Drugs Today
</td>
</tr>
<tr>
<td style="text-align:left;">
[The in vitro release of hydroxyl radicals from dust containing fluoro-edenite fibers identified in the volcanic rocks of Biancavilla (eastern Sicily)].
</td>
<td style="text-align:left;">
Med Lav
</td>
</tr>
<tr>
<td style="text-align:left;">
Surgical experience of 15 solitary benign fibrous tumor of the pleura.
</td>
<td style="text-align:left;">
Crit. Rev. Oncol. Hematol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J. Clin. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
High-dose ifosfamide with mesna and granulocyte-colony-stimulating factor (recombinant human G-CSF) in patients with unresectable malignant mesothelioma.
</td>
<td style="text-align:left;">
Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Hemithoracic radiation after extrapleural pneumonectomy for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Int. J. Radiat. Oncol. Biol. Phys.
</td>
</tr>
<tr>
<td style="text-align:left;">
Interferon-alpha and -gamma in combination with chemotherapeutic drugs: in vitro sensitivity studies in four human mesothelioma cell lines.
</td>
<td style="text-align:left;">
Anticancer Drugs
</td>
</tr>
<tr>
<td style="text-align:left;">
Enhanced effectiveness of last generation antiblastic compounds vs. cisplatin on malignant pleural mesothelioma cell lines.
</td>
<td style="text-align:left;">
Eur. J. Pharmacol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Gene expression profiling of malignant mesothelioma.
</td>
<td style="text-align:left;">
Clin. Cancer Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
Pemetrexed (Alimta, MTA, multitargeted antifolate, LY231514) for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Semin. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Diffuse malignant pleural mesothelioma: Part I. An overview of diagnosis, staging, and treatment options.
</td>
<td style="text-align:left;">
Clin J Oncol Nurs
</td>
</tr>
<tr>
<td style="text-align:left;">
Elevated serum cytokine levels in mesothelioma patients who have undergone pleurectomy or extrapleural pneumonectomy and adjuvant intraoperative photodynamic therapy.
</td>
<td style="text-align:left;">
Photochem. Photobiol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Treatment of mesothelioma in Bloemfontein, South Africa.
</td>
<td style="text-align:left;">
Eur J Cardiothorac Surg
</td>
</tr>
<tr>
<td style="text-align:left;">
Mitomycin C and vindesine: an ineffective combination chemotherapy in the treatment of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Tumori
</td>
</tr>
<tr>
<td style="text-align:left;">
Treatment of intervention sites of malignant pleural mesothelioma with radiotherapy: a Dutch-Belgian survey.
</td>
<td style="text-align:left;">
Radiother Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Issues in the management of chest malignancies.
</td>
<td style="text-align:left;">
Clin. Chest Med.
</td>
</tr>
<tr>
<td style="text-align:left;">
[Spontaneous pneumothorax. Graduated concept of surgical therapy].
</td>
<td style="text-align:left;">
Zentralbl Chir
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma due to environmental mineral fiber exposure in Turkey. Analysis of 135 cases.
</td>
<td style="text-align:left;">
Chest
</td>
</tr>
<tr>
<td style="text-align:left;">
[Malignant peritoneal mesothelioma: its evolution and outlook].
</td>
<td style="text-align:left;">
Chir Ital
</td>
</tr>
<tr>
<td style="text-align:left;">
Mesothelial and related neoplasms in children and adolescents: a clinicopathologic and immunohistochemical analysis of eight cases.
</td>
<td style="text-align:left;">
Pediatr Pathol
</td>
</tr>
<tr>
<td style="text-align:left;">
Photodynamic therapy for thoracic malignancies.
</td>
<td style="text-align:left;">
Semin Surg Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
DNA analysis of malignant effusions. Comparison with cytologic diagnosis and carcinoembryonic antigen content.
</td>
<td style="text-align:left;">
Anal. Quant. Cytol. Histol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Survival of asbestos insulation workers with mesothelioma.
</td>
<td style="text-align:left;">
Br J Ind Med
</td>
</tr>
<tr>
<td style="text-align:left;">
A phase II evaluation of ifosfamide and mesna in unresectable diffuse malignant mesothelioma. A Southwest Oncology Group study.
</td>
<td style="text-align:left;">
Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Multimodality treatment programs for malignant pleural mesothelioma using high-dose hemithorax irradiation.
</td>
<td style="text-align:left;">
Int. J. Radiat. Oncol. Biol. Phys.
</td>
</tr>
<tr>
<td style="text-align:left;">
[A case of malignant localized visceral pleural mesothelioma].
</td>
<td style="text-align:left;">
Kyobu Geka
</td>
</tr>
<tr>
<td style="text-align:left;">
[Malignant mesothelioma of the vulva. About one case].
</td>
<td style="text-align:left;">
Gynecol Obstet Fertil
</td>
</tr>
<tr>
<td style="text-align:left;">
Stereotactic intensity-modulated radiation therapy (IMRT) and inverse treatment planning for advanced pleural mesothelioma. Feasibility and initial results.
</td>
<td style="text-align:left;">
Strahlenther Onkol
</td>
</tr>
<tr>
<td style="text-align:left;">
New strategies are needed in diffuse malignant mesothelioma.
</td>
<td style="text-align:left;">
Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Evaluation of Rare Tumors with [F-18]Fluorodeoxyglucose Positron Emission Tomography.
</td>
<td style="text-align:left;">
Clin. Positron Imaging
</td>
</tr>
<tr>
<td style="text-align:left;">
Autocrine inhibitory influences of alpha-melanocyte-stimulating hormone in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J. Leukoc. Biol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Chemotherapy for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Clin Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Diffuse malignant pleural mesothelioma: Part II. Symptom management.
</td>
<td style="text-align:left;">
Clin J Oncol Nurs
</td>
</tr>
<tr>
<td style="text-align:left;">
Tumor necrosis correlates with angiogenesis and is a predictor of poor prognosis in malignant mesothelioma.
</td>
<td style="text-align:left;">
Chest
</td>
</tr>
<tr>
<td style="text-align:left;">
A multicenter phase II study of gemcitabine and oxaliplatin for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Clin Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
[Diagnostic difficulties in pleural mesothelioma].
</td>
<td style="text-align:left;">
Wiad. Lek.
</td>
</tr>
<tr>
<td style="text-align:left;">
Mesothelin-family proteins and diagnosis of mesothelioma.
</td>
<td style="text-align:left;">
Lancet
</td>
</tr>
<tr>
<td style="text-align:left;">
Localized benign pleural mesothelioma: a case report.
</td>
<td style="text-align:left;">
Monaldi Arch Chest Dis
</td>
</tr>
<tr>
<td style="text-align:left;">
Implementation of a molecular epidemiology approach to human pleural malignant mesothelioma.
</td>
<td style="text-align:left;">
Mutat. Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
[“Disappearance” of retroperitoneal vessels - a case report].
</td>
<td style="text-align:left;">
Ultraschall Med
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma: surgical roles and novel therapies.
</td>
<td style="text-align:left;">
Clin Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Inadequacy of the new Response Evaluation Criteria in Solid Tumors (RECIST) in patients with malignant pleural mesothelioma: report of four cases.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Carboplatin and gemcitabine chemotherapy for malignant pleural mesothelioma: a phase II study of the GSTPV.
</td>
<td style="text-align:left;">
Clin Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma: evaluation with CT, MR imaging, and PET.
</td>
<td style="text-align:left;">
Radiographics
</td>
</tr>
<tr>
<td style="text-align:left;">
Cell protection, resistance and invasiveness of two malignant mesotheliomas as assessed by 10K-microarray.
</td>
<td style="text-align:left;">
Biochim. Biophys. Acta
</td>
</tr>
<tr>
<td style="text-align:left;">
Promising early local control of malignant pleural mesothelioma following postoperative intensity modulated radiotherapy (IMRT) to the chest.
</td>
<td style="text-align:left;">
Cancer J
</td>
</tr>
<tr>
<td style="text-align:left;">
Solitary cerebellar metastasis of malignant pleural mesothelioma: case report.
</td>
<td style="text-align:left;">
Surg Neurol
</td>
</tr>
<tr>
<td style="text-align:left;">
Modified RECIST criteria for assessment of response in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Ann. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
BTS randomised feasibility study of active symptom control with or without chemotherapy in malignant pleural mesothelioma: ISRCTN 54469112.
</td>
<td style="text-align:left;">
Thorax
</td>
</tr>
<tr>
<td style="text-align:left;">
[Localized pleural mesotheliomas. Clinicopathological considerations on a case report].
</td>
<td style="text-align:left;">
Minerva Chir
</td>
</tr>
<tr>
<td style="text-align:left;">
Gene expression profiles predict survival and progression of pleural mesothelioma.
</td>
<td style="text-align:left;">
Clin. Cancer Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
An extended phase II trial of ifosfamide plus mesna in malignant mesothelioma.
</td>
<td style="text-align:left;">
Invest New Drugs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Follow- up of a pleural malignant mesothelioma].
</td>
<td style="text-align:left;">
J Belge Radiol
</td>
</tr>
<tr>
<td style="text-align:left;">
Proteomic analysis of exosomes isolated from human malignant pleural effusions.
</td>
<td style="text-align:left;">
Am. J. Respir. Cell Mol. Biol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Microdissection, mRNA amplification and microarray: a study of pleural mesothelial and malignant mesothelioma cells.
</td>
<td style="text-align:left;">
Biochimie
</td>
</tr>
<tr>
<td style="text-align:left;">
Factors influencing long-term survival in mesothelioma patients–results of the German mesothelioma register.
</td>
<td style="text-align:left;">
Int Arch Occup Environ Health
</td>
</tr>
<tr>
<td style="text-align:left;">
Squamous cell carcinoma of the lung producing granulocyte colony-stimulating factor and resembling a malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Intern. Med.
</td>
</tr>
<tr>
<td style="text-align:left;">
Behaviour of the new asbestos amphibole fluor-edenite in different lung cell systems.
</td>
<td style="text-align:left;">
Int. J. Biochem. Cell Biol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Abrogation of p21 expression by flavopiridol enhances depsipeptide-mediated apoptosis in malignant pleural mesothelioma cells.
</td>
<td style="text-align:left;">
Clin. Cancer Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
[The locoregional treatment of neoplastic ascites with interferon-beta].
</td>
<td style="text-align:left;">
Recenti Prog Med
</td>
</tr>
<tr>
<td style="text-align:left;">
Patterns of lymphadenopathy in thoracic malignancies.
</td>
<td style="text-align:left;">
Radiographics
</td>
</tr>
<tr>
<td style="text-align:left;">
Ultrastructural and chromosomal studies on manganese superoxide dismutase in malignant mesothelioma.
</td>
<td style="text-align:left;">
Am. J. Respir. Cell Mol. Biol.
</td>
</tr>
<tr>
<td style="text-align:left;">
[A case of splenic hemorrhage in the course of malignant mesothelioma].
</td>
<td style="text-align:left;">
Nihon Kokyuki Gakkai Zasshi
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma–an update.
</td>
<td style="text-align:left;">
Int J Occup Environ Health
</td>
</tr>
<tr>
<td style="text-align:left;">
Cytotoxic T cell responses against mesothelioma by apoptotic cell-pulsed dendritic cells.
</td>
<td style="text-align:left;">
Am. J. Respir. Crit. Care Med.
</td>
</tr>
<tr>
<td style="text-align:left;">
[Possibilities of diagnosis and treatment of malignant pleural mesothelioma].
</td>
<td style="text-align:left;">
Medicina (Kaunas)
</td>
</tr>
<tr>
<td style="text-align:left;">
Capecitabine in malignant mesothelioma: a phase II trial by the Cancer and Leukemia Group B (39807).
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Integration of multimodality approaches in the management of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Clin Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma: diagnostic and management strategies for 1992.
</td>
<td style="text-align:left;">
Semin. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
[Evaluation of the therapeutic benefit of 41.8 degrees C whole body hyperthermia plus ifosfamide, carboplatin and etoposide (ICE) for patients with malignant pleural mesothelioma using the Modified Brunner-Score (MBS)].
</td>
<td style="text-align:left;">
Pneumologie
</td>
</tr>
<tr>
<td style="text-align:left;">
Pemetrexed alone and in combination with platinum compounds in the management of malignant mesothelioma.
</td>
<td style="text-align:left;">
Clin Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Novel combinations using pemetrexed in malignant mesothelioma.
</td>
<td style="text-align:left;">
Clin Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Multimodal treatment for resectable epithelial type malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
World J Surg Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma: risk factors and current management.
</td>
<td style="text-align:left;">
Nurs Times
</td>
</tr>
<tr>
<td style="text-align:left;">
[Surgery for malignant pleural mesothelioma].
</td>
<td style="text-align:left;">
Rev Pneumol Clin
</td>
</tr>
<tr>
<td style="text-align:left;">
Antisense oligonucleotides directed at the bcl-xl gene product augment chemotherapy response in mesothelioma.
</td>
<td style="text-align:left;">
Mol. Cancer Ther.
</td>
</tr>
<tr>
<td style="text-align:left;">
[Gene therapy in malignant mesothelioma].
</td>
<td style="text-align:left;">
Tuberk Toraks
</td>
</tr>
<tr>
<td style="text-align:left;">
Pemetrexed (Alimta): improving outcomes in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Expert Rev Anticancer Ther
</td>
</tr>
<tr>
<td style="text-align:left;">
Defective core-apoptosis signalling in diffuse malignant pleural mesothelioma: opportunities for effective drug development.
</td>
<td style="text-align:left;">
Lancet Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Role of 18F-FDG PET for evaluating malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Cancer Biother. Radiopharm.
</td>
</tr>
<tr>
<td style="text-align:left;">
[Malignant mesothelioma–a diagnostic challenge].
</td>
<td style="text-align:left;">
Rev Port Pneumol
</td>
</tr>
<tr>
<td style="text-align:left;">
A randomised trial of single-dose radiotherapy to prevent procedure tract metastasis by malignant mesothelioma.
</td>
<td style="text-align:left;">
Br. J. Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Nursing considerations for administering pemetrexed (Alimta) in combination with cisplatin for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Clin J Oncol Nurs
</td>
</tr>
<tr>
<td style="text-align:left;">
Intracavitary administration of interleukin-2 as palliative therapy for neoplastic effusions.
</td>
<td style="text-align:left;">
Tumori
</td>
</tr>
<tr>
<td style="text-align:left;">
Evaluation of malignant mesothelioma in central Anatolia: a study of 67 cases.
</td>
<td style="text-align:left;">
Can. Respir. J.
</td>
</tr>
<tr>
<td style="text-align:left;">
Phase II study of OK-432 intrapleural administration followed by systemic cisplatin and gemcitabine for non-small cell lung cancer with pleuritis carcinomatosa.
</td>
<td style="text-align:left;">
J. Exp. Ther. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
[Malignant pleural mesothelioma: radiotherapy for the prevention of seeding nodules].
</td>
<td style="text-align:left;">
Rev Mal Respir
</td>
</tr>
<tr>
<td style="text-align:left;">
Clinico-pathological and biological prognostic factors in pleural malignant mesothelioma.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Staging and response to therapy of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
The use of magnetic resonance imaging in malignant mesothelioma.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Positron emission tomography in the diagnosis of mesothelioma.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma–British surgical strategies.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Considerations for post-operative radiotherapy to the hemithorax following extrapleural pneumonectomy in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Chemotherapy for malignant pleural mesothelioma: past results and recent developments.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
The role of Alimta in the treatment of malignant pleural mesothelioma: an overview of preclinical and clinical trials.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma. Medical oncology: standards, new trends, trials–the French experience.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Pemetrexed: a novel antifolate agent enters clinical practice.
</td>
<td style="text-align:left;">
Expert Rev Anticancer Ther
</td>
</tr>
<tr>
<td style="text-align:left;">
Adapting the Lung Cancer Symptom Scale (LCSS) to mesothelioma: using the LCSS-Meso conceptual model for validation.
</td>
<td style="text-align:left;">
Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Interleukin-4 receptor cytotoxin as therapy for human malignant pleural mesothelioma xenografts.
</td>
<td style="text-align:left;">
Ann. Thorac. Surg.
</td>
</tr>
<tr>
<td style="text-align:left;">
Thoracic actinomycosis with mainly pleural involvement.
</td>
<td style="text-align:left;">
J. Infect. Chemother.
</td>
</tr>
<tr>
<td style="text-align:left;">
[Survival analysis of malignant mesothelioma treated in Brescia, northern Italy, 1982-2000].
</td>
<td style="text-align:left;">
Epidemiol Prev
</td>
</tr>
<tr>
<td style="text-align:left;">
The palliative benefits of MVP (mitomycin C, vinblastine and cisplatin) chemotherapy in patients with malignant mesothelioma.
</td>
<td style="text-align:left;">
Ann. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Neoadjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J. Clin. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
[Pleuromesothelioma – psychology and pathogenesis].
</td>
<td style="text-align:left;">
Pneumologie
</td>
</tr>
<tr>
<td style="text-align:left;">
Soluble type II transforming growth factor-beta receptor inhibits established murine malignant mesothelioma tumor growth by augmenting host antitumor immunity.
</td>
<td style="text-align:left;">
Clin. Cancer Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
Pleural mesothelioma: little evidence, still time to do trials.
</td>
<td style="text-align:left;">
Lancet
</td>
</tr>
<tr>
<td style="text-align:left;">
[Localized fibrous tumors of the pleura: clinical and surgical evaluation].
</td>
<td style="text-align:left;">
Arch. Bronconeumol.
</td>
</tr>
<tr>
<td style="text-align:left;">
The pathology associated with therapeutic procedures in malignant mesothelioma.
</td>
<td style="text-align:left;">
Histopathology
</td>
</tr>
<tr>
<td style="text-align:left;">
Methodology for lognormal modelling of malignant pleural mesothelioma survival time distributions: a study of 5580 case histories from Europe and USA.
</td>
<td style="text-align:left;">
Phys Med Biol
</td>
</tr>
<tr>
<td style="text-align:left;">
Susceptibility of mesothelioma cell lines to adeno-associated virus 2 vector-based suicide gene therapy.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
FDA drug approval summaries: pemetrexed (Alimta).
</td>
<td style="text-align:left;">
Oncologist
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma: update, current management, and newer therapeutic strategies.
</td>
<td style="text-align:left;">
Chest
</td>
</tr>
<tr>
<td style="text-align:left;">
A cytokeratin- and calretinin-negative staining sarcomatoid malignant mesothelioma.
</td>
<td style="text-align:left;">
Anticancer Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
[Extrapleural pneumonectomy for thoracic malignancies].
</td>
<td style="text-align:left;">
Kyobu Geka
</td>
</tr>
<tr>
<td style="text-align:left;">
[Extrapleural pneumonectomy for malignant pleural mesothelioma and primary lung cancer].
</td>
<td style="text-align:left;">
Kyobu Geka
</td>
</tr>
<tr>
<td style="text-align:left;">
[Extrapleural pneumonectomy of malignant pleural mesothelioma].
</td>
<td style="text-align:left;">
Kyobu Geka
</td>
</tr>
<tr>
<td style="text-align:left;">
[Extrapleural pneumonectomy for malignant pleural mesothelioma].
</td>
<td style="text-align:left;">
Kyobu Geka
</td>
</tr>
<tr>
<td style="text-align:left;">
[Multimodality therapy for diffuse malignant pleural mesothelioma].
</td>
<td style="text-align:left;">
Kyobu Geka
</td>
</tr>
<tr>
<td style="text-align:left;">
Pleural biopsy: a reliable method for determining the diagnosis but not subtype in mesothelioma.
</td>
<td style="text-align:left;">
Ann. Thorac. Surg.
</td>
</tr>
<tr>
<td style="text-align:left;">
Cerebral metastases in malignant mesothelioma: case report and literature review.
</td>
<td style="text-align:left;">
J Clin Neurosci
</td>
</tr>
<tr>
<td style="text-align:left;">
HMBA induces cell death and potentiates doxorubicin toxicity in malignant mesothelioma cells.
</td>
<td style="text-align:left;">
Cancer Chemother. Pharmacol.
</td>
</tr>
<tr>
<td style="text-align:left;">
[Spontaneous pneumothorax revealing malignant pleural mesothelioma. Three case reports].
</td>
<td style="text-align:left;">
Rev Pneumol Clin
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma: overview of the North American and European experience.
</td>
<td style="text-align:left;">
Thorac Surg Clin
</td>
</tr>
<tr>
<td style="text-align:left;">
Preoperative assessment and therapeutic options for patients with malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Thorac Surg Clin
</td>
</tr>
<tr>
<td style="text-align:left;">
Extrapleural pneumonectomy for diffuse malignant pleural mesothelioma: techniques and complications.
</td>
<td style="text-align:left;">
Thorac Surg Clin
</td>
</tr>
<tr>
<td style="text-align:left;">
Patterns of failure following surgical resection for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Thorac Surg Clin
</td>
</tr>
<tr>
<td style="text-align:left;">
Fibrinolysis of loculated pleural effusion in malignant mesothelioma.
</td>
<td style="text-align:left;">
Singapore Med J
</td>
</tr>
<tr>
<td style="text-align:left;">
Current chemotherapeutic treatment of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Expert Opin Pharmacother
</td>
</tr>
<tr>
<td style="text-align:left;">
Statistical validation of the EORTC prognostic model for malignant pleural mesothelioma based on three consecutive phase II trials.
</td>
<td style="text-align:left;">
J. Clin. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
[A case report of disseminated malignant mesothelioma of peritoneum responding remarkably to thalidomide, celecoxib, vinorelbine and CDDP].
</td>
<td style="text-align:left;">
Gan To Kagaku Ryoho
</td>
</tr>
<tr>
<td style="text-align:left;">
Phase II trial of vinorelbine and oxaliplatin as first-line therapy in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
[Long-term prognostic analysis of patients with malignant pleural mesothelioma].
</td>
<td style="text-align:left;">
Ai Zheng
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Am. J. Med. Sci.
</td>
</tr>
<tr>
<td style="text-align:left;">
Pemetrexed in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Oncology (Williston Park, N.Y.)
</td>
</tr>
<tr>
<td style="text-align:left;">
Chemotherapy options and new advances in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Ann. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Metastatic renal cell carcinoma presenting as multiple pleural tumours.
</td>
<td style="text-align:left;">
Respirology
</td>
</tr>
<tr>
<td style="text-align:left;">
Iodized talc pleurodesis for the treatment of pleural effusions.
</td>
<td style="text-align:left;">
J. Thorac. Cardiovasc. Surg.
</td>
</tr>
<tr>
<td style="text-align:left;">
Pemetrexed in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Clin. Cancer Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
[Second-line treatment of malignant pleural mesothelioma with Pemetrexed (Alimta) – a case report].
</td>
<td style="text-align:left;">
Pneumologie
</td>
</tr>
<tr>
<td style="text-align:left;">
[Management of malignant pleural effusions].
</td>
<td style="text-align:left;">
Pneumologie
</td>
</tr>
<tr>
<td style="text-align:left;">
A pilot trial of high-dose-rate intraoperative radiation therapy for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Brachytherapy
</td>
</tr>
<tr>
<td style="text-align:left;">
Extra-pleural pneumonectomy for malignant pleural mesothelioma: the risks of induction chemotherapy, right-sided procedures and prolonged operations.
</td>
<td style="text-align:left;">
Eur J Cardiothorac Surg
</td>
</tr>
<tr>
<td style="text-align:left;">
[Pleural mesothelioma–case with effusion in both pleural cavities].
</td>
<td style="text-align:left;">
Pol. Merkur. Lekarski
</td>
</tr>
<tr>
<td style="text-align:left;">
Assessment of immunological competence and SV40 specific recall immunity in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Vaccine
</td>
</tr>
<tr>
<td style="text-align:left;">
Pemetrexed therapy for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Ann Pharmacother
</td>
</tr>
<tr>
<td style="text-align:left;">
Farnesyltransferase inhibitors and human malignant pleural mesothelioma: a first-step comparative translational study.
</td>
<td style="text-align:left;">
Clin. Cancer Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
Pleurectomy/decortication plus chemotherapy: outcomes of 40 cases of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Chir Ital
</td>
</tr>
<tr>
<td style="text-align:left;">
Improved survival with VATS pleurectomy-decortication in advanced malignant mesothelioma.
</td>
<td style="text-align:left;">
Eur J Surg Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Gefitinib in patients with malignant mesothelioma: a phase II study by the Cancer and Leukemia Group B.
</td>
<td style="text-align:left;">
Clin. Cancer Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
Characterization of a tumor necrosis factor-alpha inhibitor activity in cancer patients.
</td>
<td style="text-align:left;">
Am. J. Respir. Cell Mol. Biol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Development of malignant mesothelioma during treatment for prolymphocytic leukemia: is asbestos or simian virus 40 a link?
</td>
<td style="text-align:left;">
Anticancer Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
Pemetrexed (Alimta) in small cell lung cancer.
</td>
<td style="text-align:left;">
Semin. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Second-line (post-study) chemotherapy received by patients treated in the phase III trial of pemetrexed plus cisplatin versus cisplatin alone in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Ann. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Surgical management of malignant pleural mesothelioma: a systematic review and evidence summary.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Quantitative evaluation of the apoptosis regulating genes Survivin, Bcl-2 and Bax in inflammatory and malignant pleural lesions.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Thalidomide in patients with malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
[Development in the treatment of malignant mesothelioma].
</td>
<td style="text-align:left;">
Ned Tijdschr Geneeskd
</td>
</tr>
<tr>
<td style="text-align:left;">
Regulatory T cells and cytokines in malignant pleural effusions secondary to mesothelioma and carcinoma.
</td>
<td style="text-align:left;">
Cancer Biol. Ther.
</td>
</tr>
<tr>
<td style="text-align:left;">
Epirubicin and gemcitabine as first-line treatment in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Tumori
</td>
</tr>
<tr>
<td style="text-align:left;">
The selective epidermal growth factor receptor tyrosine kinase inhibitor PD153035 suppresses expression of prometastasis phenotypes in malignant pleural mesothelioma cells in vitro.
</td>
<td style="text-align:left;">
J. Thorac. Cardiovasc. Surg.
</td>
</tr>
<tr>
<td style="text-align:left;">
Pemetrexed-cisplatin combination in mesothelioma.
</td>
<td style="text-align:left;">
Expert Rev Anticancer Ther
</td>
</tr>
<tr>
<td style="text-align:left;">
Intrapleural cisplatin and mitomycin for malignant mesothelioma following pleurectomy: pharmacokinetic studies.
</td>
<td style="text-align:left;">
J. Clin. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Irinotecan for malignant mesothelioma A phase II trial by the Cancer and Leukemia Group B.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Raltitrexed-Oxaliplatin combination chemotherapy is inactive as second-line treatment for malignant pleural mesothelioma patients.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Wnt2 as a new therapeutic target in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Int. J. Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
[Therapeutic options in malignant pleural mesothelioma].
</td>
<td style="text-align:left;">
Pneumologie
</td>
</tr>
<tr>
<td style="text-align:left;">
Phase II study of a liposome-entrapped cisplatin analog (L-NDDP) administered intrapleurally and pathologic response rates in patients with malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J. Clin. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Pleural mesothelioma.
</td>
<td style="text-align:left;">
Curr Opin Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Palliative intracavitary carboplatin therapy in a cat with suspected pleural mesothelioma.
</td>
<td style="text-align:left;">
J. Feline Med. Surg.
</td>
</tr>
<tr>
<td style="text-align:left;">
Photodynamic therapy as an adjunct to surgery for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Management of malignant pleural effusions.
</td>
<td style="text-align:left;">
Curr Opin Pulm Med
</td>
</tr>
<tr>
<td style="text-align:left;">
Integrated computed tomography-positron emission tomography in patients with potentially resectable malignant pleural mesothelioma: Staging implications.
</td>
<td style="text-align:left;">
J. Thorac. Cardiovasc. Surg.
</td>
</tr>
<tr>
<td style="text-align:left;">
New therapeutic options for mesothelioma.
</td>
<td style="text-align:left;">
Curr Oncol Rep
</td>
</tr>
<tr>
<td style="text-align:left;">
Clinical trials in malignant pleural mesothelioma in Australasia.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Overview on ongoing or planned clinical trials in Europe.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Epidemic of mesothelioma in Egypt.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
The role of PET in the surgical management of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
CT, RECIST, and malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma: staging systems.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Molecular prognostic markers in malignant mesothelioma.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Induction chemotherapy, extrapleural pneumonectomy, and radiotherapy in the treatment of malignant pleural mesothelioma: the Memorial Sloan-Kettering experience.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Treatment planning system evaluation for mesothelioma IMRT.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Inverse planned stereotactic intensity modulated radiotherapy (IMRT) in the palliative treatment of malignant mesothelioma of the pleura: the Heidelberg experience.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Limited efficacy of imatinib mesylate in malignant mesothelioma: a phase II trial.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Advances in the diagnosis, evaluation, and management of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Respirology
</td>
</tr>
<tr>
<td style="text-align:left;">
Validation of genomics-based prognostic tests in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Clin. Cancer Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
Pemetrexed disodium.
</td>
<td style="text-align:left;">
Nat Rev Drug Discov
</td>
</tr>
<tr>
<td style="text-align:left;">
New agents in the management of advanced mesothelioma.
</td>
<td style="text-align:left;">
Semin. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Monoclonal antibody K1 reacts with epithelial mesothelioma but not with lung adenocarcinoma.
</td>
<td style="text-align:left;">
Am. J. Surg. Pathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Pleural malignant mesothelioma, genetic susceptibility and asbestos exposure.
</td>
<td style="text-align:left;">
Mutat. Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
A phase II study evaluating the cisplatin and epirubicin combination in patients with unresectable malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Triplet chemotherapy with cisplatin, gemcitabine and vinorelbine for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Jpn. J. Clin. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
[Spinal cord compression from a malignant pleural mesothelioma].
</td>
<td style="text-align:left;">
Rev Pneumol Clin
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma with a pronounced myxoid stroma: a clinical and pathological evaluation of 19 cases.
</td>
<td style="text-align:left;">
Virchows Arch.
</td>
</tr>
<tr>
<td style="text-align:left;">
Intensity-modulated radiation therapy for mesothelioma: impact of multileaf collimator leaf width and pencil beam size on planning quality and delivery efficiency.
</td>
<td style="text-align:left;">
Int. J. Radiat. Oncol. Biol. Phys.
</td>
</tr>
<tr>
<td style="text-align:left;">
CT in differential diagnosis of benign and malignant pleural disease.
</td>
<td style="text-align:left;">
Monaldi Arch Chest Dis
</td>
</tr>
<tr>
<td style="text-align:left;">
Hemithoracic radiation therapy after pleurectomy/decortication for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Int. J. Radiat. Oncol. Biol. Phys.
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma.
</td>
<td style="text-align:left;">
Lancet
</td>
</tr>
<tr>
<td style="text-align:left;">
[The role of surgery in the treatment of malignant pleural mesothelioma].
</td>
<td style="text-align:left;">
Chir Ital
</td>
</tr>
<tr>
<td style="text-align:left;">
PET in lung cancer.
</td>
<td style="text-align:left;">
Chang Gung Med J
</td>
</tr>
<tr>
<td style="text-align:left;">
Open-label study of pemetrexed alone or in combination with cisplatin for the treatment of patients with peritoneal mesothelioma: outcomes of an expanded access program.
</td>
<td style="text-align:left;">
Clin Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Mesothelioma: treatment and survival of a patient population and review of the literature.
</td>
<td style="text-align:left;">
Anticancer Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
Radiation recall dermatitis with pemetrexed.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Immunocytochemical detection of XIAP in body cavity effusions and washes.
</td>
<td style="text-align:left;">
Mod. Pathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
The effects of thermochemotherapy using cyclophosphamide plus hyperthermia on the malignant pleural mesothelioma in vivo.
</td>
<td style="text-align:left;">
Ann. Anat.
</td>
</tr>
<tr>
<td style="text-align:left;">
Cox and mesothelioma: an overview.
</td>
<td style="text-align:left;">
Histol. Histopathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
The evolution of cancer research and drug discovery at Lilly Research Laboratories.
</td>
<td style="text-align:left;">
Adv. Enzyme Regul.
</td>
</tr>
<tr>
<td style="text-align:left;">
A case of diffuse pleural mesothelioma in which contralateral exploratory thoracoscopy assisted the selection of therapy.
</td>
<td style="text-align:left;">
Ann Thorac Cardiovasc Surg
</td>
</tr>
<tr>
<td style="text-align:left;">
High-dose methotrexate in the treatment of malignant mesothelioma of the pleura. A phase II study.
</td>
<td style="text-align:left;">
Br. J. Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Second cancers among 40,576 testicular cancer patients: focus on long-term survivors.
</td>
<td style="text-align:left;">
J. Natl. Cancer Inst.
</td>
</tr>
<tr>
<td style="text-align:left;">
Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada.
</td>
<td style="text-align:left;">
J. Clin. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
[Recent progress in treatment of malignant pleural mesothelioma].
</td>
<td style="text-align:left;">
Cancer Radiother
</td>
</tr>
<tr>
<td style="text-align:left;">
Physical and chemical stability of pemetrexed solutions in plastic syringes.
</td>
<td style="text-align:left;">
Ann Pharmacother
</td>
</tr>
<tr>
<td style="text-align:left;">
Long-term follow-up of patients with malignant pleural mesothelioma receiving high-dose adenovirus herpes simplex thymidine kinase/ganciclovir suicide gene therapy.
</td>
<td style="text-align:left;">
Clin. Cancer Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
Intraoperative photodynamic therapy of the chest cavity in malignant pleural mesothelioma bearing rats.
</td>
<td style="text-align:left;">
Lasers Surg Med
</td>
</tr>
<tr>
<td style="text-align:left;">
Review and update of uncommon primary pleural tumors: a practical approach to diagnosis.
</td>
<td style="text-align:left;">
Arch. Pathol. Lab. Med.
</td>
</tr>
<tr>
<td style="text-align:left;">
Needle-track metastases and prophylactic radiotherapy for mesothelioma.
</td>
<td style="text-align:left;">
Respir Med
</td>
</tr>
<tr>
<td style="text-align:left;">
Prolonged survival after talc poudrage for malignant pleural mesothelioma: case series.
</td>
<td style="text-align:left;">
Respirology
</td>
</tr>
<tr>
<td style="text-align:left;">
Clinicopathological analysis of lung cancer resembling malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Respirology
</td>
</tr>
<tr>
<td style="text-align:left;">
Update on malignant mesothelioma.
</td>
<td style="text-align:left;">
Oncology (Williston Park, N.Y.)
</td>
</tr>
<tr>
<td style="text-align:left;">
Pemetrexed: a multitargeted antifolate.
</td>
<td style="text-align:left;">
Clin Ther
</td>
</tr>
<tr>
<td style="text-align:left;">
Pemetrexed: a new cytotoxic agent in the development for first-line non-small-cell lung cancer.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Standard therapy for the treatment of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Seeking new options for the treatment of small-cell lung cancer.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Perspective on the development of new agents in thoracic cancers.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Cisplatin-induced GADD34 upregulation potentiates oncolytic viral therapy in the treatment of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Cancer Biol. Ther.
</td>
</tr>
<tr>
<td style="text-align:left;">
Inhibition of the met receptor in mesothelioma.
</td>
<td style="text-align:left;">
Clin. Cancer Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
[Asbestos and malignant pleural mesothelioma: molecular, cellular and physiopathological aspects].
</td>
<td style="text-align:left;">
Bull Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
A randomised trial in malignant mesothelioma (M) of early (E) versus delayed (D) chemotherapy in symptomatically stable patients: the MED trial.
</td>
<td style="text-align:left;">
Ann. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Molecular biology of malignant mesothelioma: a review.
</td>
<td style="text-align:left;">
Hematol. Oncol. Clin. North Am.
</td>
</tr>
<tr>
<td style="text-align:left;">
Multimodality treatments in the management of malignant pleural mesothelioma: an update.
</td>
<td style="text-align:left;">
Hematol. Oncol. Clin. North Am.
</td>
</tr>
<tr>
<td style="text-align:left;">
Radiotherapy for mesothelioma.
</td>
<td style="text-align:left;">
Hematol. Oncol. Clin. North Am.
</td>
</tr>
<tr>
<td style="text-align:left;">
Gene therapy for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Hematol. Oncol. Clin. North Am.
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma: a case report.
</td>
<td style="text-align:left;">
J Manipulative Physiol Ther
</td>
</tr>
<tr>
<td style="text-align:left;">
[Malignant pleural mesothelioma: early diagnosis and multimodality management].
</td>
<td style="text-align:left;">
G Chir
</td>
</tr>
<tr>
<td style="text-align:left;">
Multimodality approach in management of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Eur J Cardiothorac Surg
</td>
</tr>
<tr>
<td style="text-align:left;">
Patterns of recurrence and long-term survival after curative resection of localized fibrous tumors of the pleura.
</td>
<td style="text-align:left;">
Clin Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Pemetrexed-associated urticarial vasculitis.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Subcutaneous metastases of sarcomatoid mesothelioma with its differential diagnosis on fine needle aspiration–a case report.
</td>
<td style="text-align:left;">
Indian J Pathol Microbiol
</td>
</tr>
<tr>
<td style="text-align:left;">
EGFR overexpression in malignant pleural mesothelioma. An immunohistochemical and molecular study with clinico-pathological correlations.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Functional analysis of c-Met/hepatocyte growth factor pathway in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Cancer Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
Lung Cancer Highlights from ASCO 2005.
</td>
<td style="text-align:left;">
Oncologist
</td>
</tr>
<tr>
<td style="text-align:left;">
Chemotherapy for intrathoracic cancer in dogs and cats.
</td>
<td style="text-align:left;">
Probl Vet Med
</td>
</tr>
<tr>
<td style="text-align:left;">
Depletion of DNA methyltransferase 1 and/or DNA methyltransferase 3b mediates growth arrest and apoptosis in lung and esophageal cancer and malignant pleural mesothelioma cells.
</td>
<td style="text-align:left;">
J. Thorac. Cardiovasc. Surg.
</td>
</tr>
<tr>
<td style="text-align:left;">
Additional value of hybrid PET/CT fusion imaging vs. conventional CT scan alone in the staging and management of patients with malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Nucl Med Rev Cent East Eur
</td>
</tr>
<tr>
<td style="text-align:left;">
Intrapleural hypotonic cisplatin treatment for malignant pleural mesothelioma: in vitro experiments and clinical application.
</td>
<td style="text-align:left;">
Surg. Today
</td>
</tr>
<tr>
<td style="text-align:left;">
Short-term treatment-related symptoms and quality of life: results from an international randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an EORTC Lung-Cancer Group and National Cancer Institute, Canada, Intergroup Study.
</td>
<td style="text-align:left;">
J. Clin. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma in 2004: How advanced technology and new drugs are changing the perspectives of mesothelioma patients. Highlights from the VIIth Meeting of the International Mesothelioma Interest Group.
</td>
<td style="text-align:left;">
Med Lav
</td>
</tr>
<tr>
<td style="text-align:left;">
Computed tomographic characterization of malignant peritoneal mesothelioma.
</td>
<td style="text-align:left;">
Tumori
</td>
</tr>
<tr>
<td style="text-align:left;">
Clinical experience with pemetrexed in breast cancer.
</td>
<td style="text-align:left;">
Semin. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Imaging and therapy of malignant pleural mesothelioma using replication-competent herpes simplex viruses.
</td>
<td style="text-align:left;">
J Gene Med
</td>
</tr>
<tr>
<td style="text-align:left;">
Incidence and management of complications after neoadjuvant chemotherapy followed by extrapleural pneumonectomy for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Eur J Cardiothorac Surg
</td>
</tr>
<tr>
<td style="text-align:left;">
BCG therapy of pleural and peritoneal growth of transplanted rat tumours.
</td>
<td style="text-align:left;">
Int. J. Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Intrapleural topical application of cisplatin with the surgical carrier Vivostat increases the local drug concentration in an immune-competent rat model with malignant pleuromesothelioma.
</td>
<td style="text-align:left;">
J. Thorac. Cardiovasc. Surg.
</td>
</tr>
<tr>
<td style="text-align:left;">
Wnt inhibitory factor-1, a Wnt antagonist, is silenced by promoter hypermethylation in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Biochem. Biophys. Res. Commun.
</td>
</tr>
<tr>
<td style="text-align:left;">
Diffuse malignant mesothelioma.
</td>
<td style="text-align:left;">
Am. J. Clin. Pathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Mesothelioma environment comprises cytokines and T-regulatory cells that suppress immune responses.
</td>
<td style="text-align:left;">
Eur. Respir. J.
</td>
</tr>
<tr>
<td style="text-align:left;">
Novel orthotopic implantation model of human malignant pleural mesothelioma (EHMES-10 cells) highly expressing vascular endothelial growth factor and its receptor.
</td>
<td style="text-align:left;">
Cancer Sci.
</td>
</tr>
<tr>
<td style="text-align:left;">
Sequential chemotherapy with cisplatin/gemcitabine (CG) followed by mitoxantrone/methotrexate/mitomycin (MMM) in patients with malignant pleural mesothelioma. A multicenter Italian Phase II Study (SITMP1).
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J. Clin. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Clinical activity of pemetrexed: a multitargeted antifolate anticancer agent.
</td>
<td style="text-align:left;">
Future Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Recombinant GM-CSF plus autologous tumor cells as a vaccine for patients with mesothelioma.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Intracavitary cisplatin chemotherapy experience with six dogs.
</td>
<td style="text-align:left;">
J. Vet. Intern. Med.
</td>
</tr>
<tr>
<td style="text-align:left;">
[Thoracoscopic pleurodesis in malignant pleural effusions].
</td>
<td style="text-align:left;">
Rev Med Chir Soc Med Nat Iasi
</td>
</tr>
<tr>
<td style="text-align:left;">
Systemic chemotherapy in the management of malignant peritoneal mesothelioma.
</td>
<td style="text-align:left;">
Eur J Surg Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Suppression of pro-metastasis phenotypes expression in malignant pleural mesothelioma by the PI3K inhibitor LY294002 or the MEK inhibitor UO126.
</td>
<td style="text-align:left;">
Anticancer Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
Monitoring of lung motion in patients with malignant pleural mesothelioma using two-dimensional and three-dimensional dynamic magnetic resonance imaging: comparison with spirometry.
</td>
<td style="text-align:left;">
Invest Radiol
</td>
</tr>
<tr>
<td style="text-align:left;">
Pemetrexed, a novel antifolate therapeutic alternative for cancer chemotherapy.
</td>
<td style="text-align:left;">
Pharmacotherapy
</td>
</tr>
<tr>
<td style="text-align:left;">
[18-Fluoro-deoxy-glucose (15FDG) positon emission tomography (PET) for the evaluation of malignant pleural disease].
</td>
<td style="text-align:left;">
Rev Pneumol Clin
</td>
</tr>
<tr>
<td style="text-align:left;">
Imaging before and after multimodal treatment for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Radiol Med
</td>
</tr>
<tr>
<td style="text-align:left;">
Synchronous pulmonary carcinoma and pleural diffuse malignant mesothelioma.
</td>
<td style="text-align:left;">
Arch. Pathol. Lab. Med.
</td>
</tr>
<tr>
<td style="text-align:left;">
A novel radiation therapy technique for malignant pleural mesothelioma combining electrons with intensity-modulated photons.
</td>
<td style="text-align:left;">
Radiother Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Characterization of human malignant mesothelioma cell lines orthotopically implanted in the pleural cavity of immunodeficient mice for their ability to grow and form metastasis.
</td>
<td style="text-align:left;">
BMC Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Management of malignant mesothelioma by decortication and adjunct phototherapy.
</td>
<td style="text-align:left;">
Asian Cardiovasc Thorac Ann
</td>
</tr>
<tr>
<td style="text-align:left;">
Management of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Clin. Chest Med.
</td>
</tr>
<tr>
<td style="text-align:left;">
Physical and chemical stability of pemetrexed in infusion solutions.
</td>
<td style="text-align:left;">
Ann Pharmacother
</td>
</tr>
<tr>
<td style="text-align:left;">
Activity of intrapleural recombinant gamma-interferon in malignant mesothelioma.
</td>
<td style="text-align:left;">
Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Preoperative evaluation of patients with malignant pleural mesothelioma: role of integrated CT-PET imaging.
</td>
<td style="text-align:left;">
J Thorac Imaging
</td>
</tr>
<tr>
<td style="text-align:left;">
Dynamic contrast-enhanced MRI of malignant pleural mesothelioma: a feasibility study of noninvasive assessment, therapeutic follow-up, and possible predictor of improved outcome.
</td>
<td style="text-align:left;">
Chest
</td>
</tr>
<tr>
<td style="text-align:left;">
Preclinical comparison of mTHPC and verteporfin for intracavitary photodynamic therapy of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Eur Surg Res
</td>
</tr>
<tr>
<td style="text-align:left;">
Cellular and molecular parameters of mesothelioma.
</td>
<td style="text-align:left;">
J. Cell. Biochem.
</td>
</tr>
<tr>
<td style="text-align:left;">
Pemetrexed and malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Ann. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
The role of radiation therapy in malignant pleural mesothelioma: a systematic review.
</td>
<td style="text-align:left;">
Radiother Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Physical instability of frozen pemetrexed solutions in PVC bags.
</td>
<td style="text-align:left;">
Ann Pharmacother
</td>
</tr>
<tr>
<td style="text-align:left;">
Divided dose of cisplatin combined with gemcitabine in malignant mesothelioma.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Plasma and cerebrospinal fluid pharmacokinetics of pemetrexed after intravenous administration in non-human primates.
</td>
<td style="text-align:left;">
Cancer Chemother. Pharmacol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Radiotherapy for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Cochrane Database Syst Rev
</td>
</tr>
<tr>
<td style="text-align:left;">
p53-induced apoptosis occurs in the absence of p14(ARF) in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Neoplasia
</td>
</tr>
<tr>
<td style="text-align:left;">
The treatment of malignant mesothelioma of the pleura: review of a 5-year experience, with special reference to radiotherapy.
</td>
<td style="text-align:left;">
Am. J. Clin. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma: some aspects of epidemiology, differential diagnosis and prognosis. Histological and immunohistochemical evaluation and follow-up of mesotheliomas diagnosed from 1964 to January 1985.
</td>
<td style="text-align:left;">
Pathol. Res. Pract.
</td>
</tr>
<tr>
<td style="text-align:left;">
Tumor suppressor gene alterations in patients with malignant mesothelioma due to environmental asbestos exposure in Turkey.
</td>
<td style="text-align:left;">
J Carcinog
</td>
</tr>
<tr>
<td style="text-align:left;">
Effects of insulin-like growth factor-1 receptor inhibition in mesothelioma. Thoracic Surgery Directors Association Resident Research Award.
</td>
<td style="text-align:left;">
Ann. Thorac. Surg.
</td>
</tr>
<tr>
<td style="text-align:left;">
[Malignant mesothelioma–diagnosis and treatment strategies].
</td>
<td style="text-align:left;">
Gan To Kagaku Ryoho
</td>
</tr>
<tr>
<td style="text-align:left;">
Biology and management of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Eur. J. Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Pemetrexed-induced edema of the eyelid.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Positron emission tomography predicts survival in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J. Thorac. Cardiovasc. Surg.
</td>
</tr>
<tr>
<td style="text-align:left;">
[New challenges in thoracic surgery as exemplified in asbestos exposure and mesothelioma treatment].
</td>
<td style="text-align:left;">
Offentl Gesundheitswes
</td>
</tr>
<tr>
<td style="text-align:left;">
Early response evaluation in malignant pleural mesothelioma by positron emission tomography with [18F]fluorodeoxyglucose.
</td>
<td style="text-align:left;">
J. Clin. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Phase I study of decitabine-mediated gene expression in patients with cancers involving the lungs, esophagus, or pleura.
</td>
<td style="text-align:left;">
Clin. Cancer Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
Establishment and characterization of five human malignant mesothelioma cell lines derived from pleural effusions.
</td>
<td style="text-align:left;">
Int. J. Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
5-year prospective results of trimodality treatment for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J Cardiovasc Surg (Torino)
</td>
</tr>
<tr>
<td style="text-align:left;">
Unique uptake of acid-prepared mesoporous spheres by lung epithelial and mesothelioma cells.
</td>
<td style="text-align:left;">
Am. J. Respir. Cell Mol. Biol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Spindle cell tumors of the pleura: differential diagnosis.
</td>
<td style="text-align:left;">
Semin Diagn Pathol
</td>
</tr>
<tr>
<td style="text-align:left;">
The pathogenesis of mesothelioma.
</td>
<td style="text-align:left;">
Semin Diagn Pathol
</td>
</tr>
<tr>
<td style="text-align:left;">
Feasibility of boron neutron capture therapy (BNCT) for malignant pleural mesothelioma from a viewpoint of dose distribution analysis.
</td>
<td style="text-align:left;">
Int. J. Radiat. Oncol. Biol. Phys.
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma: a new standard of care.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Can pemetrexed help in malignant mesothelioma?
</td>
<td style="text-align:left;">
Drug Ther Bull
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma: a comprehensive review.
</td>
<td style="text-align:left;">
Cancer Control
</td>
</tr>
<tr>
<td style="text-align:left;">
Solitary fibrous tumor of the pleura.
</td>
<td style="text-align:left;">
Cancer Control
</td>
</tr>
<tr>
<td style="text-align:left;">
Mesothelioma with non-pleural malignancy: a red herring or just an uncommon pairing?
</td>
<td style="text-align:left;">
J Cardiothorac Surg
</td>
</tr>
<tr>
<td style="text-align:left;">
Hyperthermia combined with intra-thoracic chemotherapy and radiotherapy for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Int J Hyperthermia
</td>
</tr>
<tr>
<td style="text-align:left;">
Radiation-induced cellular DNA damage repair response enhances viral gene therapy efficacy in the treatment of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Ann. Surg. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma in a 14-year-old boy with right aortic arch.
</td>
<td style="text-align:left;">
Jpn. J. Thorac. Cardiovasc. Surg.
</td>
</tr>
<tr>
<td style="text-align:left;">
[Autopsy case of sarcomatoid malignant pleural mesothelioma].
</td>
<td style="text-align:left;">
Nihon Kokyuki Gakkai Zasshi
</td>
</tr>
<tr>
<td style="text-align:left;">
Single-arm, open label study of pemetrexed plus cisplatin in chemotherapy naïve patients with malignant pleural mesothelioma: outcomes of an expanded access program.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
PET: other thoracic malignancies.
</td>
<td style="text-align:left;">
Cancer Imaging
</td>
</tr>
<tr>
<td style="text-align:left;">
Guidelines of the French Speaking Society for Chest Medicine for management of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Respir Med
</td>
</tr>
<tr>
<td style="text-align:left;">
[A case of malignant mesothelioma presenting with recurrent pneumothorax].
</td>
<td style="text-align:left;">
Nihon Kokyuki Gakkai Zasshi
</td>
</tr>
<tr>
<td style="text-align:left;">
In vivo loss of expression of argininosuccinate synthetase in malignant pleural mesothelioma is a biomarker for susceptibility to arginine depletion.
</td>
<td style="text-align:left;">
Clin. Cancer Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
Efficacy and safety of first- or second-line irinotecan, cisplatin, and mitomycin in mesothelioma.
</td>
<td style="text-align:left;">
Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
A retrospective analysis of malignant pleural mesothelioma patients treated either with chemotherapy or best supportive care between 1990 and 2005 A single institution experience.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Pemetrexed disodium for the treatment of malignant pleural mesothelioma: a systematic review and economic evaluation.
</td>
<td style="text-align:left;">
Health Technol Assess
</td>
</tr>
<tr>
<td style="text-align:left;">
A phase II study of intrapleural immuno-chemotherapy, pleurectomy/decortication, radiotherapy, systemic chemotherapy and long-term sub-cutaneous IL-2 in stage II-III malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Eur J Cardiothorac Surg
</td>
</tr>
<tr>
<td style="text-align:left;">
Impact of lymph node metastasis on outcome after extrapleural pneumonectomy for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J. Thorac. Cardiovasc. Surg.
</td>
</tr>
<tr>
<td style="text-align:left;">
Thoracic stop-flow perfusion in the treatment of refractory malignant pleural mesothelioma: a phase I-II evaluation/trial.
</td>
<td style="text-align:left;">
In Vivo
</td>
</tr>
<tr>
<td style="text-align:left;">
The role of palliative radiotherapy in malignant mesothelioma.
</td>
<td style="text-align:left;">
Clin Oncol (R Coll Radiol)
</td>
</tr>
<tr>
<td style="text-align:left;">
[Immunotherapy and malignant mesothelioma: clinical perspectives].
</td>
<td style="text-align:left;">
Bull Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
[Survey of surgical treatment of malignant pleural mesothelioma in Japan].
</td>
<td style="text-align:left;">
Kyobu Geka
</td>
</tr>
<tr>
<td style="text-align:left;">
[Malignant pleural mesothelioma].
</td>
<td style="text-align:left;">
Kyobu Geka
</td>
</tr>
<tr>
<td style="text-align:left;">
[Diffuse malignant pleural mesothelioma].
</td>
<td style="text-align:left;">
Kyobu Geka
</td>
</tr>
<tr>
<td style="text-align:left;">
[Extrapleural pneumonectomy with wide resection of the chest wall, diaphragm, and pericardium for malignant pleural mesothelioma].
</td>
<td style="text-align:left;">
Kyobu Geka
</td>
</tr>
<tr>
<td style="text-align:left;">
Pemetrexed disodium in combination with cisplatin versus other cytotoxic agents or supportive care for the treatment of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Cochrane Database Syst Rev
</td>
</tr>
<tr>
<td style="text-align:left;">
[Clinical types of thoracic cancer. Pleural mesothelioma].
</td>
<td style="text-align:left;">
Rev Mal Respir
</td>
</tr>
<tr>
<td style="text-align:left;">
Morphological aspects as prognostic factors in malignant mesothelioma: a study of 58 cases.
</td>
<td style="text-align:left;">
J Bras Pneumol
</td>
</tr>
<tr>
<td style="text-align:left;">
Genomic profiling of malignant pleural mesothelioma with array-based comparative genomic hybridization shows frequent non-random chromosomal alteration regions including JUN amplification on 1p32.
</td>
<td style="text-align:left;">
Cancer Sci.
</td>
</tr>
<tr>
<td style="text-align:left;">
Novel marker D2-40, combined with calretinin, CEA, and TTF-1: an optimal set of immunodiagnostic markers for pleural mesothelioma.
</td>
<td style="text-align:left;">
Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
[Malignant peritoneal mesothelioma].
</td>
<td style="text-align:left;">
Chirurgia (Bucur)
</td>
</tr>
<tr>
<td style="text-align:left;">
Restored expression of the MYO18B gene suppresses orthotopic growth and the production of bloody pleural effusion by human malignant pleural mesothelioma cells in SCID mice.
</td>
<td style="text-align:left;">
Oncol. Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
Preliminary data suggestive of a novel translational approach to mesothelioma treatment: imatinib mesylate with gemcitabine or pemetrexed.
</td>
<td style="text-align:left;">
Thorax
</td>
</tr>
<tr>
<td style="text-align:left;">
A novel small-molecule inhibitor of transforming growth factor beta type I receptor kinase (SM16) inhibits murine mesothelioma tumor growth in vivo and prevents tumor recurrence after surgical resection.
</td>
<td style="text-align:left;">
Cancer Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
Molecular basis of antifolate resistance.
</td>
<td style="text-align:left;">
Cancer Metastasis Rev.
</td>
</tr>
<tr>
<td style="text-align:left;">
Case-control study between extrapleural pneumonectomy and radical pleurectomy/decortication for pathological N2 malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Eur J Cardiothorac Surg
</td>
</tr>
<tr>
<td style="text-align:left;">
Palliative intravenous cisplatin treatment for concurrent peritoneal and pleural mesothelioma in a dog.
</td>
<td style="text-align:left;">
J. Vet. Med. Sci.
</td>
</tr>
<tr>
<td style="text-align:left;">
[Immunohistochemistry and surgical approaches in solitary fibrous tumor of the pleura].
</td>
<td style="text-align:left;">
Cir Esp
</td>
</tr>
<tr>
<td style="text-align:left;">
Right extrapleural pneumonectomy for malignant mesothelioma via median sternotomy or thoracotomy? Short- and long-term results.
</td>
<td style="text-align:left;">
Eur J Cardiothorac Surg
</td>
</tr>
<tr>
<td style="text-align:left;">
Local recurrence model of malignant pleural mesothelioma for investigation of intrapleural treatment.
</td>
<td style="text-align:left;">
Eur J Cardiothorac Surg
</td>
</tr>
<tr>
<td style="text-align:left;">
[Clinico-pathological prognostic factors in malignant pleural mesothelioma].
</td>
<td style="text-align:left;">
Nihon Kokyuki Gakkai Zasshi
</td>
</tr>
<tr>
<td style="text-align:left;">
Emerging drugs for mesothelioma.
</td>
<td style="text-align:left;">
Expert Opin Emerg Drugs
</td>
</tr>
<tr>
<td style="text-align:left;">
The role of radiotherapy in the treatment of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Clin Oncol (R Coll Radiol)
</td>
</tr>
<tr>
<td style="text-align:left;">
Asbestos-related lung disease.
</td>
<td style="text-align:left;">
Am Fam Physician
</td>
</tr>
<tr>
<td style="text-align:left;">
Taurolidine and povidone-iodine induce different types of cell death in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Retroperitoneal malignant schwannoma and peritoneal malignant mesothelioma: a case report.
</td>
<td style="text-align:left;">
J BUON
</td>
</tr>
<tr>
<td style="text-align:left;">
Inhibition of survivin and aurora B kinase sensitizes mesothelioma cells by enhancing mitotic arrests.
</td>
<td style="text-align:left;">
Int. J. Radiat. Oncol. Biol. Phys.
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma: two cases in first degree relatives.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Induction chemotherapy, extrapleural pneumonectomy (EPP) and adjuvant hemi-thoracic radiation in malignant pleural mesothelioma (MPM): Feasibility and results.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Phase II trial of pralatrexate (10-propargyl-10-deazaaminopterin, PDX) in patients with unresectable malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Pemetrexed maintenance therapy in patients with malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Induction chemotherapy, extrapleural pneumonectomy, and postoperative high-dose radiotherapy for locally advanced malignant pleural mesothelioma: a phase II trial.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Pemetrexed alone or in combination with cisplatin in previously treated malignant pleural mesothelioma: outcomes from a phase IIIB expanded access program.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
The use of chemotherapy in patients with advanced malignant pleural mesothelioma: a systematic review and practice guideline.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Targeting mesothelioma using an infectivity enhanced survivin-conditionally replicative adenoviruses.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Pemetrexed as second-line treatment in malignant pleural mesothelioma after platinum-based first-line treatment.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Four-modality therapy in malignant pleural mesothelioma: a phase II study.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Diagnostic procedures of pleural malignant mesothelioma: our experience.
</td>
<td style="text-align:left;">
J BUON
</td>
</tr>
<tr>
<td style="text-align:left;">
[A case of malignant pleural mesothelioma with elevation of G-CSF and CYFRA in the serum and pleural fluid].
</td>
<td style="text-align:left;">
Nihon Kokyuki Gakkai Zasshi
</td>
</tr>
<tr>
<td style="text-align:left;">
Catheter-tract metastases associated with chronic indwelling pleural catheters.
</td>
<td style="text-align:left;">
Chest
</td>
</tr>
<tr>
<td style="text-align:left;">
Multicenter trial of neo-adjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Ann. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
[Treatment of malignant pleural mesothelioma].
</td>
<td style="text-align:left;">
Gan To Kagaku Ryoho
</td>
</tr>
<tr>
<td style="text-align:left;">
A large abdominal wall mass as an initial manifestation of malignant mesothelioma.
</td>
<td style="text-align:left;">
Am. J. Med. Sci.
</td>
</tr>
<tr>
<td style="text-align:left;">
Dose-dependent pulmonary toxicity after postoperative intensity-modulated radiotherapy for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Int. J. Radiat. Oncol. Biol. Phys.
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma following thoracic radiotherapy for lung cancer.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Computer-assisted diagnosis for early stage pleural mesothelioma: towards automated detection and quantitative assessment of pleural thickening from thoracic CT images.
</td>
<td style="text-align:left;">
Methods Inf Med
</td>
</tr>
<tr>
<td style="text-align:left;">
Utility of osteopontin and serum mesothelin in malignant pleural mesothelioma diagnosis and prognosis assessment.
</td>
<td style="text-align:left;">
Clin. Cancer Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
A preliminary experimental study of boron neutron capture therapy for malignant tumors spreading in thoracic cavity.
</td>
<td style="text-align:left;">
Jpn. J. Clin. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
[Severe cutaneous toxicity after Pemetrexed as second line treatment for a refractory non small cell lung cancer].
</td>
<td style="text-align:left;">
Rev Mal Respir
</td>
</tr>
<tr>
<td style="text-align:left;">
Management options for malignant pleural mesothelioma: clinical and cost considerations.
</td>
<td style="text-align:left;">
Drugs
</td>
</tr>
<tr>
<td style="text-align:left;">
Preclinical studies of the proteasome inhibitor bortezomib in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Cancer Chemother. Pharmacol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Local adoptive immunotherapy using lymphokine-activated killer cells and interleukin-2 against malignant pleural mesothelioma: report of two cases.
</td>
<td style="text-align:left;">
Jpn. J. Clin. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma: current concepts in treatment.
</td>
<td style="text-align:left;">
Nat Clin Pract Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Effect of the TAT-RasGAP(317-326) peptide on apoptosis of human malignant mesothelioma cells and fibroblasts exposed to meso-tetra-hydroxyphenyl-chlorin and light.
</td>
<td style="text-align:left;">
J. Photochem. Photobiol. B, Biol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Pseudomesotheliomatous carcinoma of the lung. A variant of peripheral lung cancer.
</td>
<td style="text-align:left;">
Am. J. Clin. Pathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
The essential role of the mitochondria and reactive oxygen species in Cisplatin-mediated enhancement of fas ligand-induced apoptosis in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J. Surg. Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
[Management of malignant pleural effusion].
</td>
<td style="text-align:left;">
Rev Prat
</td>
</tr>
<tr>
<td style="text-align:left;">
A randomised controlled trial of intervention site radiotherapy in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Radiother Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
[Peritoneal mesothelioma: an inusual clinical presentation in a patient without exposure to asbestos].
</td>
<td style="text-align:left;">
An Med Interna
</td>
</tr>
<tr>
<td style="text-align:left;">
Constrictive pericarditis after left extrapleural pneumonectomy and radiotherapy for malignant mesothelioma.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Inhibition of c-Src expression and activation in malignant pleural mesothelioma tissues leads to apoptosis, cell cycle arrest, and decreased migration and invasion.
</td>
<td style="text-align:left;">
Mol. Cancer Ther.
</td>
</tr>
<tr>
<td style="text-align:left;">
Trousseau syndrome due to pleural mesothelioma.
</td>
<td style="text-align:left;">
Neurologist
</td>
</tr>
<tr>
<td style="text-align:left;">
DNA methylation profile of 28 potential marker loci in malignant mesothelioma.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Polyhematoporphyrin-mediated photodynamic therapy and decortication in palliation of malignant pleural mesothelioma: a clinical pilot study.
</td>
<td style="text-align:left;">
Interact Cardiovasc Thorac Surg
</td>
</tr>
<tr>
<td style="text-align:left;">
Extended posterolateral-subcostal thoracotomy for extrapleural pneumonectomy: a surgical approach for radical operation of pleural mesothelioma.
</td>
<td style="text-align:left;">
Interact Cardiovasc Thorac Surg
</td>
</tr>
<tr>
<td style="text-align:left;">
Multidisciplinary treatment of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Oncologist
</td>
</tr>
<tr>
<td style="text-align:left;">
Influence of radiotherapy technique and dose on patterns of failure for mesothelioma patients after extrapleural pneumonectomy.
</td>
<td style="text-align:left;">
Int. J. Radiat. Oncol. Biol. Phys.
</td>
</tr>
<tr>
<td style="text-align:left;">
Optimising survival in malignant mesothelioma.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Early prediction of response to chemotherapy and survival in malignant pleural mesothelioma using a novel semiautomated 3-dimensional volume-based analysis of serial 18F-FDG PET scans.
</td>
<td style="text-align:left;">
J. Nucl. Med.
</td>
</tr>
<tr>
<td style="text-align:left;">
Phase II testing of sunitinib: the National Cancer Institute of Canada Clinical Trials Group IND Program Trials IND.182-185.
</td>
<td style="text-align:left;">
Curr Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Use of aprotinin in extrapleural pneumonectomy: effect on hemostasis and incidence of complications.
</td>
<td style="text-align:left;">
Ann. Thorac. Surg.
</td>
</tr>
<tr>
<td style="text-align:left;">
[Clinical utility of thoracoscopy under local anesthesia].
</td>
<td style="text-align:left;">
Kyobu Geka
</td>
</tr>
<tr>
<td style="text-align:left;">
Assessment of tumor response in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Cancer Treat. Rev.
</td>
</tr>
<tr>
<td style="text-align:left;">
Mitoxantrone in malignant pleural mesothelioma: a study by the EORTC Lung Cancer Cooperative Group.
</td>
<td style="text-align:left;">
Eur. J. Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Correlations between findings at computed tomography (CT) and at thoracoscopy/thoracotomy/autopsy in pleural mesothelioma.
</td>
<td style="text-align:left;">
Eur. Respir. J.
</td>
</tr>
<tr>
<td style="text-align:left;">
[Update of pemetrexed in thoracic oncology].
</td>
<td style="text-align:left;">
Bull Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
[Pemetrexed development in oncology].
</td>
<td style="text-align:left;">
Bull Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Accuracy of pleural biopsy using thoracoscopy for the diagnosis of histologic subtype in patients with malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
The therapeutic efficacy of anti vascular endothelial growth factor antibody, bevacizumab, and pemetrexed against orthotopically implanted human pleural mesothelioma cells in severe combined immunodeficient mice.
</td>
<td style="text-align:left;">
Clin. Cancer Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
Prognostic factors in the treatment of malignant pleural mesothelioma at a large tertiary referral center.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mediastinal tumor with bone formation–mesothelioma or sarcoma?
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma of the tunica vaginalis testis: a case report and review of the literature.
</td>
<td style="text-align:left;">
Med. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Retreatment with pemetrexed-based chemotherapy in malignant pleural mesothelioma (MPM): a second line treatment option.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Combined photon and electron three-dimensional conformal versus intensity-modulated radiotherapy with integrated boost for adjuvant treatment of malignant pleural mesothelioma after pleuropneumonectomy.
</td>
<td style="text-align:left;">
Int. J. Radiat. Oncol. Biol. Phys.
</td>
</tr>
<tr>
<td style="text-align:left;">
Mesothelin targeted cancer immunotherapy.
</td>
<td style="text-align:left;">
Eur. J. Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Phase II study of vinflunine in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J. Clin. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Increased pleural fluid adenosine deaminase levels in patients with malignant pleural effusions: a potential predictor of talc pleurodesis outcome.
</td>
<td style="text-align:left;">
Lung
</td>
</tr>
<tr>
<td style="text-align:left;">
Human agonistic TRAIL receptor antibodies Mapatumumab and Lexatumumab induce apoptosis in malignant mesothelioma and act synergistically with cisplatin.
</td>
<td style="text-align:left;">
Mol. Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Morphologic and functional imaging of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Eur J Radiol
</td>
</tr>
<tr>
<td style="text-align:left;">
Outcomes after extrapleural pneumonectomy and intensity-modulated radiation therapy for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Ann. Thorac. Surg.
</td>
</tr>
<tr>
<td style="text-align:left;">
Peritoneal mesothelioma presenting as an acute surgical abdomen due to jejunal perforation.
</td>
<td style="text-align:left;">
J Dig Dis
</td>
</tr>
<tr>
<td style="text-align:left;">
Flowcytometric immunophenotyping of peripheral-blood leukocytes in relation to immunopathology and cellular proliferation of pleural mesothelioma.
</td>
<td style="text-align:left;">
Egypt J Immunol
</td>
</tr>
<tr>
<td style="text-align:left;">
Gemcitabine and cisplatin in unresectable malignant mesothelioma of the pleura: a phase II study of the Southwest Oncology Group (SWOG 9810).
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Solitary fibrous tumor of the anterior mediastinum: a rare extrapleural neoplasm.
</td>
<td style="text-align:left;">
Tumori
</td>
</tr>
<tr>
<td style="text-align:left;">
Radical surgery for malignant pleural mesothelioma: results and prognosis.
</td>
<td style="text-align:left;">
Interact Cardiovasc Thorac Surg
</td>
</tr>
<tr>
<td style="text-align:left;">
[Renal cell carcinoma with malignant pleural mesothelioma after asbestos exposure: a case report].
</td>
<td style="text-align:left;">
Hinyokika Kiyo
</td>
</tr>
<tr>
<td style="text-align:left;">
The potential role of pemetrexed in gastrointestinal cancer.
</td>
<td style="text-align:left;">
Chemotherapy
</td>
</tr>
<tr>
<td style="text-align:left;">
Endoscopic ultrasound-guided fine needle aspiration is useful for nodal staging in patients with pleural mesothelioma.
</td>
<td style="text-align:left;">
Diagn. Cytopathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
EGFR and PDGFR differentially promote growth in malignant epithelioid mesothelioma of short and long term survivors.
</td>
<td style="text-align:left;">
Thorax
</td>
</tr>
<tr>
<td style="text-align:left;">
Symptoms and patient-reported well-being: do they predict survival in malignant pleural mesothelioma? A prognostic factor analysis of EORTC-NCIC 08983: randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J. Clin. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma: surgical management in 285 patients.
</td>
<td style="text-align:left;">
Ann. Thorac. Surg.
</td>
</tr>
<tr>
<td style="text-align:left;">
Localised malignant pleural mesothelioma: a separate clinical entity requiring aggressive local surgery.
</td>
<td style="text-align:left;">
Eur J Cardiothorac Surg
</td>
</tr>
<tr>
<td style="text-align:left;">
Phase II study of pemetrexed in combination with carboplatin in patients with malignant pleural mesothelioma (MPM).
</td>
<td style="text-align:left;">
Ann. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma: clinicopathologic and survival characteristics in a consecutive series of 394 patients.
</td>
<td style="text-align:left;">
Eur J Cardiothorac Surg
</td>
</tr>
<tr>
<td style="text-align:left;">
[Malignant pleural mesothelioma: interrogations and hopes concerning the expected epidemic].
</td>
<td style="text-align:left;">
Rev Pneumol Clin
</td>
</tr>
<tr>
<td style="text-align:left;">
Aberrant splicing and protease involvement in mesothelin release from epithelioid mesothelioma cells.
</td>
<td style="text-align:left;">
Cancer Sci.
</td>
</tr>
<tr>
<td style="text-align:left;">
Helical tomotherapy. Experiences of the first 150 patients in Heidelberg.
</td>
<td style="text-align:left;">
Strahlenther Onkol
</td>
</tr>
<tr>
<td style="text-align:left;">
Anesthetic management of patients undergoing extrapleural pneumonectomy for mesothelioma.
</td>
<td style="text-align:left;">
Curr Opin Anaesthesiol
</td>
</tr>
<tr>
<td style="text-align:left;">
Population based epidemiology and prognosis of mesothelioma in Leeds, UK.
</td>
<td style="text-align:left;">
Thorax
</td>
</tr>
<tr>
<td style="text-align:left;">
Evaluating target coverage and normal tissue sparing in the adjuvant radiotherapy of malignant pleural mesothelioma: helical tomotherapy compared with step-and-shoot IMRT.
</td>
<td style="text-align:left;">
Radiother Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Xanthomatous pleuritis mimicking mesothelioma.
</td>
<td style="text-align:left;">
Respiration
</td>
</tr>
<tr>
<td style="text-align:left;">
Advances in the systemic therapy of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Nat Clin Pract Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
[Environmental cancer: malignant pleural mesothelioma].
</td>
<td style="text-align:left;">
Bull Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
[Pleural mesothelioma: impact of the staging for the therapeutic strategy].
</td>
<td style="text-align:left;">
Rev Mal Respir
</td>
</tr>
<tr>
<td style="text-align:left;">
[Epidemiology, molecular biology, diagnostic and therapeutic strategy of malignant pleural mesothelioma in 2007 - an update].
</td>
<td style="text-align:left;">
Rev Mal Respir
</td>
</tr>
<tr>
<td style="text-align:left;">
Cost-effectiveness of pemetrexed plus cisplatin: malignant pleural mesothelioma treatment in UK clinical practice.
</td>
<td style="text-align:left;">
Value Health
</td>
</tr>
<tr>
<td style="text-align:left;">
PTEN expression is a strong predictor of survival in mesothelioma patients.
</td>
<td style="text-align:left;">
Eur J Cardiothorac Surg
</td>
</tr>
<tr>
<td style="text-align:left;">
Intensity-modulated radiotherapy for resected mesothelioma: the Duke experience.
</td>
<td style="text-align:left;">
Int. J. Radiat. Oncol. Biol. Phys.
</td>
</tr>
<tr>
<td style="text-align:left;">
Phase-contrast microscopy studies of early cisplatin-induced morphological changes of malignant mesothelioma cells and the correspondence to induced apoptosis.
</td>
<td style="text-align:left;">
Exp. Lung Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
[Malignant pleural mesothelioma: multidisciplinary experience in a public tertiary hospital].
</td>
<td style="text-align:left;">
J Bras Pneumol
</td>
</tr>
<tr>
<td style="text-align:left;">
Current concepts in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Expert Rev Anticancer Ther
</td>
</tr>
<tr>
<td style="text-align:left;">
Pericardial malignant mesothelioma: a latent complication of radiotherapy?
</td>
<td style="text-align:left;">
Eur J Cardiothorac Surg
</td>
</tr>
<tr>
<td style="text-align:left;">
Gemcitabine and vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Intracavitary radioimmunotherapy to treat solid tumors.
</td>
<td style="text-align:left;">
Cancer Biother. Radiopharm.
</td>
</tr>
<tr>
<td style="text-align:left;">
Biological characteristics of cancers involving the serosal cavities.
</td>
<td style="text-align:left;">
Crit Rev Oncog
</td>
</tr>
<tr>
<td style="text-align:left;">
Local recurrence of tumor at sites of intervention in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
[New diagnostic markers for malignant pleural mesothelioma].
</td>
<td style="text-align:left;">
Bull Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Characterization of human mesothelioma cell lines as tumor models for suicide gene therapy.
</td>
<td style="text-align:left;">
Onkologie
</td>
</tr>
<tr>
<td style="text-align:left;">
Localized malignant mesenteric mesothelioma causing small bowel obstruction.
</td>
<td style="text-align:left;">
Pathol. Int.
</td>
</tr>
<tr>
<td style="text-align:left;">
Extrapleural pneumonectomy versus pleurectomy/decortication in the surgical management of malignant pleural mesothelioma: results in 663 patients.
</td>
<td style="text-align:left;">
J. Thorac. Cardiovasc. Surg.
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma resistance to apoptosis: recent discoveries and their implication for effective therapeutic strategies.
</td>
<td style="text-align:left;">
Curr. Med. Chem.
</td>
</tr>
<tr>
<td style="text-align:left;">
[Malignant pleural effusion].
</td>
<td style="text-align:left;">
Ann Ital Chir
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma: utility of 18 F-FDG PET.
</td>
<td style="text-align:left;">
Ann Ital Chir
</td>
</tr>
<tr>
<td style="text-align:left;">
Regional pharmacokinetic selectivity of intrapleural cisplatin.
</td>
<td style="text-align:left;">
Eur. J. Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Erionite series minerals: mineralogical and carcinogenic properties.
</td>
<td style="text-align:left;">
Environ Geochem Health
</td>
</tr>
<tr>
<td style="text-align:left;">
Risk factors for major complications after extrapleural pneumonectomy for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Ann. Thorac. Surg.
</td>
</tr>
<tr>
<td style="text-align:left;">
Efficacy and safety of pemetrexed in elderly cancer patients: results of an integrated analysis.
</td>
<td style="text-align:left;">
Crit. Rev. Oncol. Hematol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Bcl-xL antisense oligonucleotide and cisplatin combination therapy extends survival in SCID mice with established mesothelioma xenografts.
</td>
<td style="text-align:left;">
Int. J. Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
alpha-Toxin of Staphylococcus aureus overcomes acquired cisplatin-resistance in malignant mesothelioma cells.
</td>
<td style="text-align:left;">
Cancer Lett.
</td>
</tr>
<tr>
<td style="text-align:left;">
Novel dual targeting strategy with vandetanib induces tumor cell apoptosis and inhibits angiogenesis in malignant pleural mesothelioma cells expressing RET oncogenic rearrangement.
</td>
<td style="text-align:left;">
Cancer Lett.
</td>
</tr>
<tr>
<td style="text-align:left;">
Therapy response in malignant pleural mesothelioma-role of MRI using RECIST, modified RECIST and volumetric approaches in comparison with CT.
</td>
<td style="text-align:left;">
Eur Radiol
</td>
</tr>
<tr>
<td style="text-align:left;">
Impact of tumor-infiltrating T cells on survival in patients with malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J. Thorac. Cardiovasc. Surg.
</td>
</tr>
<tr>
<td style="text-align:left;">
Phase III trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J. Clin. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
The role of muscle flap in preventing bronchus stump insufficiency after pneumonectomy for malignant pleural mesothelioma in high-risk patients.
</td>
<td style="text-align:left;">
Interact Cardiovasc Thorac Surg
</td>
</tr>
<tr>
<td style="text-align:left;">
Management of malignant pleural effusion associated with trapped lung syndrome.
</td>
<td style="text-align:left;">
Asian Cardiovasc Thorac Ann
</td>
</tr>
<tr>
<td style="text-align:left;">
Epidermal growth factor receptor gene mutation, amplification and protein expression in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J. Cancer Res. Clin. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Surgical treatment in the management of malignant pleural mesothelioma: a single institution’s experience.
</td>
<td style="text-align:left;">
Ann. Surg. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Outcome after extrapleural pneumonectomy for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Eur J Cardiothorac Surg
</td>
</tr>
<tr>
<td style="text-align:left;">
[Biomarkers for prevention and early diagnosis of malignant pleural mesothelioma].
</td>
<td style="text-align:left;">
G Ital Med Lav Ergon
</td>
</tr>
<tr>
<td style="text-align:left;">
[Evaluation of a series of serum mesothelin in patients with pleural malignant mesothelioma].
</td>
<td style="text-align:left;">
G Ital Med Lav Ergon
</td>
</tr>
<tr>
<td style="text-align:left;">
Pharmacokinetic analysis of malignant pleural mesothelioma-initial results of tumor microcirculation and its correlation to microvessel density (CD-34).
</td>
<td style="text-align:left;">
Acad Radiol
</td>
</tr>
<tr>
<td style="text-align:left;">
Individual versus standard quality of life assessment in a phase II clinical trial in mesothelioma patients: feasibility and responsiveness to clinical changes.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Efficacy and safety of pemetrexed in combination with cisplatin for malignant pleural mesothelioma: a phase I/II study in Japanese patients.
</td>
<td style="text-align:left;">
Jpn. J. Clin. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
[Video-assisted thoracoscopic surgery in diagnostic and treatment of non-operable malignant pleural mesothelioma].
</td>
<td style="text-align:left;">
Khirurgiia (Sofiia)
</td>
</tr>
<tr>
<td style="text-align:left;">
Trimodality treatment of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Molecular targets and targeted therapies for malignant mesothelioma.
</td>
<td style="text-align:left;">
Curr. Med. Chem.
</td>
</tr>
<tr>
<td style="text-align:left;">
MR imaging of benign and malignant pleural disease.
</td>
<td style="text-align:left;">
Magn Reson Imaging Clin N Am
</td>
</tr>
<tr>
<td style="text-align:left;">
The efficacy and safety of weekly vinorelbine in relapsed malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Active symptom control with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma (MS01): a multicentre randomised trial.
</td>
<td style="text-align:left;">
Lancet
</td>
</tr>
<tr>
<td style="text-align:left;">
[Autopsy case of diffuse pleural thickening presenting respiratory impairment and benign asbestos pleurisy].
</td>
<td style="text-align:left;">
Nihon Kokyuki Gakkai Zasshi
</td>
</tr>
<tr>
<td style="text-align:left;">
Pulmonary paragonimiasis with coincidental malignant mesothelioma.
</td>
<td style="text-align:left;">
Intern. Med.
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma 2008.
</td>
<td style="text-align:left;">
Curr Opin Pulm Med
</td>
</tr>
<tr>
<td style="text-align:left;">
Prophylactic radiotherapy for pleural puncture sites in mesothelioma: the controversy continues.
</td>
<td style="text-align:left;">
Curr Opin Pulm Med
</td>
</tr>
<tr>
<td style="text-align:left;">
Response of a patient with pleural and peritoneal mesothelioma after second-line chemotherapy with lipoplatin and gemcitabine.
</td>
<td style="text-align:left;">
Oncology
</td>
</tr>
<tr>
<td style="text-align:left;">
Clinical activity of vinflunine in transitional cell carcinoma of the urothelium and other solid tumors.
</td>
<td style="text-align:left;">
Semin. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Pemetrexed plus carboplatin in elderly patients with malignant pleural mesothelioma: combined analysis of two phase II trials.
</td>
<td style="text-align:left;">
Br. J. Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Cisplatin and vinorelbine first-line chemotherapy in non-resectable malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Br. J. Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Erlotinib plus bevacizumab in previously treated patients with malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Measles virus induces oncolysis of mesothelioma cells and allows dendritic cells to cross-prime tumor-specific CD8 response.
</td>
<td style="text-align:left;">
Cancer Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
Schedule-dependent synergistic effect of pemetrexed combined with gemcitabine against malignant pleural mesothelioma and non-small cell lung cancer cell lines.
</td>
<td style="text-align:left;">
Chemotherapy
</td>
</tr>
<tr>
<td style="text-align:left;">
Asbestos burden predicts survival in pleural mesothelioma.
</td>
<td style="text-align:left;">
Environ. Health Perspect.
</td>
</tr>
<tr>
<td style="text-align:left;">
[Multimodal therapy for malignant pleural mesothelioma including extrapleural pneumonectomy].
</td>
<td style="text-align:left;">
Zentralbl Chir
</td>
</tr>
<tr>
<td style="text-align:left;">
[Chemotherapy of malignant pleural mesothelioma: have we made any progress?].
</td>
<td style="text-align:left;">
Zentralbl Chir
</td>
</tr>
<tr>
<td style="text-align:left;">
Piroxicam and intracavitary platinum-based chemotherapy for the treatment of advanced mesothelioma in pets: preliminary observations.
</td>
<td style="text-align:left;">
J. Exp. Clin. Cancer Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
Induction of apoptosis by intrapleural perfusion hyperthermo-chemotherapy for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Ann Thorac Cardiovasc Surg
</td>
</tr>
<tr>
<td style="text-align:left;">
Radiation associated malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Thorax
</td>
</tr>
<tr>
<td style="text-align:left;">
Morbidity, mortality, mean survival, and the impact of histology on survival after pleurectomy in 64 patients with malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Int J Surg
</td>
</tr>
<tr>
<td style="text-align:left;">
Multiple mechanisms of telomere maintenance exist and differentially affect clinical outcome in diffuse malignant peritoneal mesothelioma.
</td>
<td style="text-align:left;">
Clin. Cancer Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
Pemetrexed plus cisplatin or pemetrexed plus carboplatin for chemonaïve patients with malignant pleural mesothelioma: results of the International Expanded Access Program.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Single-agent pemetrexed for chemonaïve and pretreated patients with malignant pleural mesothelioma: results of an International Expanded Access Program.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Primary pleural neoplasia: entities other than diffuse malignant mesothelioma.
</td>
<td style="text-align:left;">
Arch. Pathol. Lab. Med.
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma: current status and perspective in Japan and the world.
</td>
<td style="text-align:left;">
Gen Thorac Cardiovasc Surg
</td>
</tr>
<tr>
<td style="text-align:left;">
Incidence of atrial fibrillation after extrapleural pneumonectomy vs. pleurectomy in patients with malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Interact Cardiovasc Thorac Surg
</td>
</tr>
<tr>
<td style="text-align:left;">
[Involvement of zinc in taste disturbance occurring during treatment for malignant tumor in the chest and the effects of polaprezinc oral disintegrating tablets (a retrospective study)].
</td>
<td style="text-align:left;">
Gan To Kagaku Ryoho
</td>
</tr>
<tr>
<td style="text-align:left;">
[Pemetrexed].
</td>
<td style="text-align:left;">
Gan To Kagaku Ryoho
</td>
</tr>
<tr>
<td style="text-align:left;">
A phase II trial of tetrathiomolybdate after surgery for malignant mesothelioma: final results.
</td>
<td style="text-align:left;">
Ann. Thorac. Surg.
</td>
</tr>
<tr>
<td style="text-align:left;">
Prevalence and pattern of lymph node metastasis in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Ann. Thorac. Surg.
</td>
</tr>
<tr>
<td style="text-align:left;">
Pemetrexed plus gemcitabine as first-line chemotherapy for patients with peritoneal mesothelioma: final report of a phase II trial.
</td>
<td style="text-align:left;">
J. Clin. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Long-term indwelling pleural catheter (PleurX) for malignant pleural effusion unsuitable for talc pleurodesis.
</td>
<td style="text-align:left;">
Eur J Surg Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
A novel concept of treatment of diffuse or multiple pleural tumors by boron neutron capture therapy (BNCT).
</td>
<td style="text-align:left;">
Radiother Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
[A case of malignant pleural mesothelioma presenting as pneumothorax].
</td>
<td style="text-align:left;">
Nihon Kyobu Shikkan Gakkai Zasshi
</td>
</tr>
<tr>
<td style="text-align:left;">
Open lung-sparing surgery for malignant pleural mesothelioma: the benefits of a radical approach within multimodality therapy.
</td>
<td style="text-align:left;">
Eur J Cardiothorac Surg
</td>
</tr>
<tr>
<td style="text-align:left;">
Pathogenesis of malignant pleural mesothelioma and the role of environmental and genetic factors.
</td>
<td style="text-align:left;">
J Carcinog
</td>
</tr>
<tr>
<td style="text-align:left;">
Acute generalized exanthematous pustulosis after pemetrexed, and recurrence after re-introduction.
</td>
<td style="text-align:left;">
Clin. Exp. Dermatol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Successful palliation of malignant ascites from peritoneal mesothelioma by laparoscopic intraperitoneal hyperthermic chemotherapy.
</td>
<td style="text-align:left;">
Surg Laparosc Endosc Percutan Tech
</td>
</tr>
<tr>
<td style="text-align:left;">
Targeting alpha7-nicotinic receptor for the treatment of pleural mesothelioma.
</td>
<td style="text-align:left;">
Eur. J. Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Review of pemetrexed in combination with cisplatin for the treatment of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Ther Clin Risk Manag
</td>
</tr>
<tr>
<td style="text-align:left;">
Novel oncolytic agent GLV-1h68 is effective against malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Hum. Gene Ther.
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma-targeted CREBBP/EP300 inhibitory protein 1 promoter system for gene therapy and virotherapy.
</td>
<td style="text-align:left;">
Cancer Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
Recent advances in the treatment of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Diagnosis, staging, and surgical treatment of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Curr Treat Options Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
[Therapy of malignant pleural mesothelioma].
</td>
<td style="text-align:left;">
Pneumologie
</td>
</tr>
<tr>
<td style="text-align:left;">
Protein kinase C beta in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Anticancer Drugs
</td>
</tr>
<tr>
<td style="text-align:left;">
Acquisition of cisplatin-resistance in malignant mesothelioma cells abrogates Na+,K+,2Cl(-)-cotransport activity and cisplatin-induced early membrane blebbing.
</td>
<td style="text-align:left;">
Cell. Physiol. Biochem.
</td>
</tr>
<tr>
<td style="text-align:left;">
Prevention of malignant seeding at drain sites after invasive procedures (surgery and/or thoracoscopy) by hypofractionated radiotherapy in patients with pleural mesothelioma.
</td>
<td style="text-align:left;">
Acta Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Clinical consequences of asbestos-related diffuse pleural thickening: A review.
</td>
<td style="text-align:left;">
J Occup Med Toxicol
</td>
</tr>
<tr>
<td style="text-align:left;">
Pathogenesis of malignant pleural mesothelioma and the role of environmental and genetic factors.
</td>
<td style="text-align:left;">
J. Cancer Res. Clin. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Computed tomography, positron emission tomography, positron emission tomography/computed tomography, and magnetic resonance imaging for staging of limited pleural mesothelioma: initial results.
</td>
<td style="text-align:left;">
Invest Radiol
</td>
</tr>
<tr>
<td style="text-align:left;">
Survival of pleural malignant mesothelioma in Italy: a population-based study.
</td>
<td style="text-align:left;">
Int. J. Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Survival of peritoneal malignant mesothelioma in Italy: a population-based study.
</td>
<td style="text-align:left;">
Int. J. Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Proteasome Inhibitor MG132 Induces Apoptosis and Inhibits Invasion of Human Malignant Pleural Mesothelioma Cells.
</td>
<td style="text-align:left;">
Transl Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Inhibition of Hsp90 leads to cell cycle arrest and apoptosis in human malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Transesophageal endoscopic ultrasound with fine needle aspiration in the preoperative staging of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Clin. Cancer Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
Assessment of Survival and Clinical Benefit in Malignant Pleural Mesothelioma (MPM) Patients Treated with Gemcitabine and Carboplatin.
</td>
<td style="text-align:left;">
J Egypt Natl Canc Inst
</td>
</tr>
<tr>
<td style="text-align:left;">
Peritoneal mesothelioma.
</td>
<td style="text-align:left;">
Curr Treat Options Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Pulmonary epithelioid hemangioendothelioma mimicking mesothelioma.
</td>
<td style="text-align:left;">
Pathol. Int.
</td>
</tr>
<tr>
<td style="text-align:left;">
Histologic assessment and prognostic factors of malignant pleural mesothelioma treated with extrapleural pneumonectomy.
</td>
<td style="text-align:left;">
Am. J. Clin. Pathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
A useful antibody panel for differential diagnosis between peritoneal mesothelioma and ovarian serous carcinoma in Japanese cases.
</td>
<td style="text-align:left;">
Am. J. Clin. Pathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Tranexamic acid treatment of hemothorax in two patients with malignant mesothelioma.
</td>
<td style="text-align:left;">
Chest
</td>
</tr>
<tr>
<td style="text-align:left;">
Down-regulation of inhibition of differentiation-1 via activation of activating transcription factor 3 and Smad regulates REIC/Dickkopf-3-induced apoptosis.
</td>
<td style="text-align:left;">
Cancer Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
Carboplatin and pemetrexed in the management of malignant pleural mesothelioma: a realistic treatment option?
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
The aberrant promoter methylation of BMP3b and BMP6 in malignant pleural mesotheliomas.
</td>
<td style="text-align:left;">
Oncol. Rep.
</td>
</tr>
<tr>
<td style="text-align:left;">
Diffuse malignant pleural mesothelioma: a multi-institutional clinicopathological study.
</td>
<td style="text-align:left;">
Surg. Today
</td>
</tr>
<tr>
<td style="text-align:left;">
[Other thoracic cancers. Malignant pleural mesothelioma: biology and diagnosis].
</td>
<td style="text-align:left;">
Rev Mal Respir
</td>
</tr>
<tr>
<td style="text-align:left;">
[Other thoracic cancers. Mesothelioma: treatment].
</td>
<td style="text-align:left;">
Rev Mal Respir
</td>
</tr>
<tr>
<td style="text-align:left;">
Diagnostic and prognostic value of soluble mesothelin-related proteins in patients with malignant pleural mesothelioma in comparison with benign asbestosis and lung cancer.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Treatment of malignant pleural mesothelioma with carboplatin, liposomized doxorubicin, and gemcitabine: a phase II study.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
A case report of malignant pleural mesothelioma with long-term disease control after chemotherapy.
</td>
<td style="text-align:left;">
Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Effective chemotherapy based on a chemosensitivity test for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Ann Thorac Cardiovasc Surg
</td>
</tr>
<tr>
<td style="text-align:left;">
Outcomes with first-line platinum-based combination chemotherapy for malignant pleural mesothelioma: a review of practice in British Columbia.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma of the tunica vaginalis of the testis without exposure to asbestos.
</td>
<td style="text-align:left;">
Cases J
</td>
</tr>
<tr>
<td style="text-align:left;">
Compensator-based intensity-modulated radiation therapy for malignant pleural mesothelioma post extrapleural pneumonectomy.
</td>
<td style="text-align:left;">
J Appl Clin Med Phys
</td>
</tr>
<tr>
<td style="text-align:left;">
Biomarkers for malignant pleural mesothelioma: current status.
</td>
<td style="text-align:left;">
Mol Diagn Ther
</td>
</tr>
<tr>
<td style="text-align:left;">
Monitoring of chemotherapy response in malignant pleural mesothelioma using fluorodeoxyglucose positron emission tomography.
</td>
<td style="text-align:left;">
Intern. Med.
</td>
</tr>
<tr>
<td style="text-align:left;">
Expression of GATA-6 transcription factor in pleural malignant mesothelioma and metastatic pulmonary adenocarcinoma.
</td>
<td style="text-align:left;">
J. Clin. Pathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
[An autopsy case of sarcomatoid malignant mesothelioma mimicking adenocarcinoma with sarcomatoid elements of lung].
</td>
<td style="text-align:left;">
Nihon Kokyuki Gakkai Zasshi
</td>
</tr>
<tr>
<td style="text-align:left;">
Diffuse malignant peritoneal mesothelioma: Failure analysis following cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC).
</td>
<td style="text-align:left;">
Ann. Surg. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Asbestos-related occupational lung diseases in NSW, Australia and potential exposure of the general population.
</td>
<td style="text-align:left;">
Ind Health
</td>
</tr>
<tr>
<td style="text-align:left;">
[Medical thoracoscopic talc pleurodesis for malignant pleural effusion: an analysis of 27 cases].
</td>
<td style="text-align:left;">
Beijing Da Xue Xue Bao
</td>
</tr>
<tr>
<td style="text-align:left;">
Gemcitabine combined with oxaliplatin in pretreated patients with malignant pleural mesothelioma: an observational study.
</td>
<td style="text-align:left;">
J Occup Med Toxicol
</td>
</tr>
<tr>
<td style="text-align:left;">
Phase II study of belinostat (PXD101), a histone deacetylase inhibitor, for second line therapy of advanced malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma.
</td>
<td style="text-align:left;">
Orphanet J Rare Dis
</td>
</tr>
<tr>
<td style="text-align:left;">
Phase I and pharmacokinetic study of pemetrexed plus cisplatin in chemonaive patients with locally advanced or metastatic malignant pleural mesothelioma or non-small cell lung cancer.
</td>
<td style="text-align:left;">
Clin. Cancer Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma treated in Clinic for Pulmonary Diseases and Tuberculosis “Podhrastovi” in ten-year period (from 1998 to 2007).
</td>
<td style="text-align:left;">
Bosn J Basic Med Sci
</td>
</tr>
<tr>
<td style="text-align:left;">
A feasibility study of induction pemetrexed plus cisplatin followed by extrapleural pneumonectomy and postoperative hemithoracic radiation for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Jpn. J. Clin. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
In vitro-chemosensitivity test using the collagen gel droplet embedded culture drug test (CD-DST) for malignant pleural mesothelioma: possibility of clinical application.
</td>
<td style="text-align:left;">
Ann Thorac Cardiovasc Surg
</td>
</tr>
<tr>
<td style="text-align:left;">
Pemetrexed disodium for the treatment of NSCLC: an update.
</td>
<td style="text-align:left;">
Drugs Today
</td>
</tr>
<tr>
<td style="text-align:left;">
[Malignant pleural diseases: diagnosis and treatment].
</td>
<td style="text-align:left;">
Medicina (Kaunas)
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesenterial mesothelioma in stroke patients.
</td>
<td style="text-align:left;">
Acta Med Indones
</td>
</tr>
<tr>
<td style="text-align:left;">
Tryptase mast cells in malignant pleural mesothelioma as an independent favorable prognostic factor.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Immuno-chemotherapy reduces recurrence of malignant pleural mesothelioma: an experimental setting.
</td>
<td style="text-align:left;">
Eur J Cardiothorac Surg
</td>
</tr>
<tr>
<td style="text-align:left;">
Induction of multiple-drug resistance during anti-neoplastic chemotherapy in vitro.
</td>
<td style="text-align:left;">
Int. J. Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Inhibition of the insulin-like growth factor 1 receptor pathway enhances the antitumor effect of cisplatin in human malignant mesothelioma cell lines.
</td>
<td style="text-align:left;">
Cancer Lett.
</td>
</tr>
<tr>
<td style="text-align:left;">
Gene therapy for malignant pleural mesothelioma: present and future.
</td>
<td style="text-align:left;">
Oncol. Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
Kinetics of soluble mesothelin in patients with malignant pleural mesothelioma during treatment.
</td>
<td style="text-align:left;">
Am. J. Respir. Crit. Care Med.
</td>
</tr>
<tr>
<td style="text-align:left;">
Early detection of malignant pleural mesothelioma through measurement of soluble mesothelin-related protein and positron emission tomography.
</td>
<td style="text-align:left;">
Med. J. Aust.
</td>
</tr>
<tr>
<td style="text-align:left;">
Trimodality therapy with induction chemotherapy followed by extrapleural pneumonectomy and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J. Clin. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Decitabine, differently from DNMT1 silencing, exerts its antiproliferative activity through p21 upregulation in malignant pleural mesothelioma (MPM) cells.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Chemotherapy of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Expert Opin Pharmacother
</td>
</tr>
<tr>
<td style="text-align:left;">
Intrapleural administration of pemetrexed: a pharmacokinetic study in an animal model.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
[Remission of malignant pleural mesothelioma using high-dose cisplatin in monochemotherapy].
</td>
<td style="text-align:left;">
Rev Mal Respir
</td>
</tr>
<tr>
<td style="text-align:left;">
Hyperthermic chemoperfusion for the treatment of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Semin. Thorac. Cardiovasc. Surg.
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J. Clin. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Establishment of novel mAb to human ERC/mesothelin useful for study and diagnosis of ERC/mesothelin-expressing cancers.
</td>
<td style="text-align:left;">
Pathol. Int.
</td>
</tr>
<tr>
<td style="text-align:left;">
Is FDG-PET/CT useful for managing malignant pleural mesothelioma?
</td>
<td style="text-align:left;">
J. Med. Invest.
</td>
</tr>
<tr>
<td style="text-align:left;">
Chrysotile biopersistence: the misuse of biased studies.
</td>
<td style="text-align:left;">
Int J Occup Environ Health
</td>
</tr>
<tr>
<td style="text-align:left;">
Three-dimensional evaluation of chemotherapy response in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Eur J Radiol
</td>
</tr>
<tr>
<td style="text-align:left;">
Pemetrexed in first-line treatment of non-small cell lung cancer.
</td>
<td style="text-align:left;">
Cancer Treat. Rev.
</td>
</tr>
<tr>
<td style="text-align:left;">
Symptomatic and quality of life changes after extrapleural pneumonectomy for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J Surg Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Neoadjuvant and intrapleural therapies for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Clin Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Diagnostic and therapeutic strategy in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Eur J Cardiothorac Surg
</td>
</tr>
<tr>
<td style="text-align:left;">
Growth inhibition by tyrosine kinase inhibitors in mesothelioma cell lines.
</td>
<td style="text-align:left;">
Eur. J. Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Impact of accelerator-based boron neutron capture therapy (AB-BNCT) on the treatment of multiple liver tumors and malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Radiother Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Protumorigenic role of HAPLN1 and its IgV domain in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Clin. Cancer Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
Updated clinical information on multitargeted antifolates in lung cancer.
</td>
<td style="text-align:left;">
Clin Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Pulmonary toxicity following IMRT after extrapleural pneumonectomy for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Radiother Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Multicenter phase II trial of neoadjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy and radiation for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J. Clin. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Fine-needle aspiration biopsy of pleural metastases from a carcinosarcoma or true malignant mixed tumor of the parotid gland mimicking a mesothelioma.
</td>
<td style="text-align:left;">
Diagn. Cytopathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Future Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Future developments in the management of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Expert Rev Anticancer Ther
</td>
</tr>
<tr>
<td style="text-align:left;">
[First-line treatment with pemetrexed in association with cisplatin in patients with non-operable malignant pleural mesothelioma].
</td>
<td style="text-align:left;">
Rev Pneumol Clin
</td>
</tr>
<tr>
<td style="text-align:left;">
Prognostic features of long-term survivors after surgical management of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Ann. Thorac. Surg.
</td>
</tr>
<tr>
<td style="text-align:left;">
Extrapleural pneumonectomy with reconstruction of diaphragm and pericardium using autologous materials.
</td>
<td style="text-align:left;">
Ann. Thorac. Surg.
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma: genome-wide expression patterns reflecting general resistance mechanisms and a proposal of novel targets.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Combined inhibition of MET and EGFR suppresses proliferation of malignant mesothelioma cells.
</td>
<td style="text-align:left;">
Carcinogenesis
</td>
</tr>
<tr>
<td style="text-align:left;">
Four-gene expression ratio test for survival in patients undergoing surgery for mesothelioma.
</td>
<td style="text-align:left;">
J. Natl. Cancer Inst.
</td>
</tr>
<tr>
<td style="text-align:left;">
Patterns of local and nodal failure in malignant pleural mesothelioma after extrapleural pneumonectomy and photon-electron radiotherapy.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Effect of citrate on malignant pleural mesothelioma cells: a synergistic effect with cisplatin.
</td>
<td style="text-align:left;">
Anticancer Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
Can “steroid switching” improve steroid-induced psychosis in a patient with advanced cancer?
</td>
<td style="text-align:left;">
J Palliat Med
</td>
</tr>
<tr>
<td style="text-align:left;">
Comparison of conventional and novel PET tracers for imaging mesothelioma in nude mice with subcutaneous and intrapleural xenografts.
</td>
<td style="text-align:left;">
Nucl. Med. Biol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Asbestos–a legacy and a persistent problem.
</td>
<td style="text-align:left;">
J R Nav Med Serv
</td>
</tr>
<tr>
<td style="text-align:left;">
Expanded applications of diagnostic and therapeutic thoracoscopy.
</td>
<td style="text-align:left;">
J. Thorac. Cardiovasc. Surg.
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma-associated antigens recognized by tumor-infiltrating B cells and the clinical significance of the antibody titers.
</td>
<td style="text-align:left;">
Cancer Sci.
</td>
</tr>
<tr>
<td style="text-align:left;">
All-trans-retinoic acid inhibits tumour growth of malignant pleural mesothelioma in mice.
</td>
<td style="text-align:left;">
Eur. Respir. J.
</td>
</tr>
<tr>
<td style="text-align:left;">
COX-2 specific inhibitors enhance the cytotoxic effects of pemetrexed in mesothelioma cell lines.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Imaging a Genetically Engineered Oncolytic Vaccinia Virus (GLV-1h99) Using a Human Norepinephrine Transporter Reporter Gene.
</td>
<td style="text-align:left;">
Clin. Cancer Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
Combined FDG-PET/CT in response evaluation of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Estrogen receptor-beta affects the prognosis of human malignant mesothelioma.
</td>
<td style="text-align:left;">
Cancer Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
[Laparoscopic intraperitoneal hyperthermic perfusion in palliation of malignant ascites. Case report].
</td>
<td style="text-align:left;">
G Chir
</td>
</tr>
<tr>
<td style="text-align:left;">
[Twenty-one patients of malignant pleural mesothelioma in the Senshu district].
</td>
<td style="text-align:left;">
Nihon Kokyuki Gakkai Zasshi
</td>
</tr>
<tr>
<td style="text-align:left;">
[Case of malignant pleural mesothelioma with long-term disease control after 4 different lines of systemic chemotherapy and pleurodesis].
</td>
<td style="text-align:left;">
Nihon Kokyuki Gakkai Zasshi
</td>
</tr>
<tr>
<td style="text-align:left;">
[Case of pemetrexed-induced acute lung injury].
</td>
<td style="text-align:left;">
Nihon Kokyuki Gakkai Zasshi
</td>
</tr>
<tr>
<td style="text-align:left;">
Clinical utility of diagnostic markers for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Monaldi Arch Chest Dis
</td>
</tr>
<tr>
<td style="text-align:left;">
Is malignant pleural mesothelioma a surgical disease? A review of 83 consecutive extra-pleural pneumonectomies.
</td>
<td style="text-align:left;">
Eur J Cardiothorac Surg
</td>
</tr>
<tr>
<td style="text-align:left;">
18F-fluoro-2-deoxy-D-glucose positron emission tomography and positron emission tomography/computed tomography imaging of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J Med Imaging Radiat Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Improving the outcome in malignant pleural mesothelioma: nonaggressive or aggressive approach?
</td>
<td style="text-align:left;">
Curr Opin Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Pleurodesis in follow-up and treatment of malignant pleural mesothelioma patients.
</td>
<td style="text-align:left;">
Tuberk Toraks
</td>
</tr>
<tr>
<td style="text-align:left;">
Outcome for patients with malignant pleural mesothelioma referred for Trimodality therapy in Western Australia.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Pleural well-differentiated papillary mesothelioma: a case report.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Mesothelioma cells escape heat stress by upregulating Hsp40/Hsp70 expression via mitogen-activated protein kinases.
</td>
<td style="text-align:left;">
J. Biomed. Biotechnol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma: current treatments and emerging drugs.
</td>
<td style="text-align:left;">
Expert Opin Emerg Drugs
</td>
</tr>
<tr>
<td style="text-align:left;">
Current therapies for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Environ Health Prev Med
</td>
</tr>
<tr>
<td style="text-align:left;">
Pemetrexed in the treatment of advanced non-squamous lung cancer.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
[Early malignant pleural mesothelioma; report of a case].
</td>
<td style="text-align:left;">
Kyobu Geka
</td>
</tr>
<tr>
<td style="text-align:left;">
Use of totally implantable central venous access port via the basilic vein in patients with thoracic malignancies.
</td>
<td style="text-align:left;">
Int. J. Clin. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Isolated pancreatic metastasis of a malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Kaohsiung J. Med. Sci.
</td>
</tr>
<tr>
<td style="text-align:left;">
Lung cancer gene expression database analysis incorporating prior knowledge with support vector machine-based classification method.
</td>
<td style="text-align:left;">
J. Exp. Clin. Cancer Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
Lymphangiomatoid pattern in diffuse malignant mesothelioma of the pleura: a report of six cases.
</td>
<td style="text-align:left;">
Virchows Arch.
</td>
</tr>
<tr>
<td style="text-align:left;">
Extrapleural pneumonectomy followed by intracavitary intraoperative hyperthermic cisplatin with pharmacologic cytoprotection for treatment of malignant pleural mesothelioma: a phase II prospective study.
</td>
<td style="text-align:left;">
J. Thorac. Cardiovasc. Surg.
</td>
</tr>
<tr>
<td style="text-align:left;">
Prophylactic radiotherapy to intervention sites in mesothelioma: a systematic review and survey of UK practice.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Placenta growth factor expression has prognostic value in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Ann. Thorac. Surg.
</td>
</tr>
<tr>
<td style="text-align:left;">
Localized malignant pleural mesothelioma: report of two cases.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
The urokinase receptor supports tumorigenesis of human malignant pleural mesothelioma cells.
</td>
<td style="text-align:left;">
Am. J. Respir. Cell Mol. Biol.
</td>
</tr>
<tr>
<td style="text-align:left;">
[Malignant mesothelioma].
</td>
<td style="text-align:left;">
Rev Prat
</td>
</tr>
<tr>
<td style="text-align:left;">
The role of surgery in the management of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J BUON
</td>
</tr>
<tr>
<td style="text-align:left;">
Venous thromboembolism in patients receiving multimodality therapy for thoracic malignancies.
</td>
<td style="text-align:left;">
J. Thorac. Cardiovasc. Surg.
</td>
</tr>
<tr>
<td style="text-align:left;">
Docetaxel plus gemcitabine as first-line treatment in malignant pleural mesothelioma: a single institution phase II study.
</td>
<td style="text-align:left;">
Anticancer Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
The Mesothelioma and Radical surgery randomized controlled trial: the Mars feasibility study.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Extrapleural pneumonectomy for malignant pleural mesothelioma: outcomes of treatment and prognostic factors.
</td>
<td style="text-align:left;">
J. Thorac. Cardiovasc. Surg.
</td>
</tr>
<tr>
<td style="text-align:left;">
Trimodality therapy for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Ann. Thorac. Surg.
</td>
</tr>
<tr>
<td style="text-align:left;">
[C-arm computed tomography for transarterial chemoperfusion and chemo-embolization of thoracic lesions].
</td>
<td style="text-align:left;">
Radiologe
</td>
</tr>
<tr>
<td style="text-align:left;">
[Epidermal growth factor receptor aberrations in malignant mesotheliomas].
</td>
<td style="text-align:left;">
Rinsho Byori
</td>
</tr>
<tr>
<td style="text-align:left;">
Solitary fibrous tumor of the pleura: surgery and clinical course in 18 cases.
</td>
<td style="text-align:left;">
Asian Cardiovasc Thorac Ann
</td>
</tr>
<tr>
<td style="text-align:left;">
Evaluation of an attenuated vesicular stomatitis virus vector expressing interferon-beta for use in malignant pleural mesothelioma: heterogeneity in interferon responsiveness defines potential efficacy.
</td>
<td style="text-align:left;">
Hum. Gene Ther.
</td>
</tr>
<tr>
<td style="text-align:left;">
Three decades of experience in the surgical multi-modality management of pleural mesothelioma.
</td>
<td style="text-align:left;">
Eur J Cardiothorac Surg
</td>
</tr>
<tr>
<td style="text-align:left;">
Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Eur. Respir. J.
</td>
</tr>
<tr>
<td style="text-align:left;">
Update on pleural diseases–2007.
</td>
<td style="text-align:left;">
Ann Thorac Med
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma: an update on biomarkers and treatment.
</td>
<td style="text-align:left;">
Chest
</td>
</tr>
<tr>
<td style="text-align:left;">
Hemithoracic radiotherapy after extrapleural pneumonectomy for malignant pleural mesothelioma: a dosimetric comparison of two well-described techniques.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Prognostic factors according to the treatment schedule in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Comparison of CT and integrated PET-CT based radiation therapy planning in patients with malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Radiat Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Pemetrexed for the treatment of non-small-cell lung cancer.
</td>
<td style="text-align:left;">
Expert Rev Anticancer Ther
</td>
</tr>
<tr>
<td style="text-align:left;">
Survival after trimodality therapy for malignant pleural mesothelioma: Radical Pleurectomy, chemotherapy with Cisplatin/Pemetrexed and radiotherapy.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Intrapleural polymeric films containing cisplatin for malignant pleural mesothelioma in a rat tumour model: a preliminary study.
</td>
<td style="text-align:left;">
Eur J Cardiothorac Surg
</td>
</tr>
<tr>
<td style="text-align:left;">
Prognostic significance of epithelial-mesenchymal transition in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Eur J Cardiothorac Surg
</td>
</tr>
<tr>
<td style="text-align:left;">
Pemetrexed-induced pneumonitis: a case report.
</td>
<td style="text-align:left;">
Clin Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Activated cAMP response element binding protein is overexpressed in human mesotheliomas and inhibits apoptosis.
</td>
<td style="text-align:left;">
Am. J. Pathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Pemetrexed in the treatment of malignant mesothelioma: results from an expanded access program in Germany.
</td>
<td style="text-align:left;">
Respir Med
</td>
</tr>
<tr>
<td style="text-align:left;">
Current status of screening for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Semin. Thorac. Cardiovasc. Surg.
</td>
</tr>
<tr>
<td style="text-align:left;">
Recent advances in mesothelioma staging.
</td>
<td style="text-align:left;">
Semin. Thorac. Cardiovasc. Surg.
</td>
</tr>
<tr>
<td style="text-align:left;">
Current trends in radiologic management of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Semin. Thorac. Cardiovasc. Surg.
</td>
</tr>
<tr>
<td style="text-align:left;">
Pathologic evaluation of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Semin. Thorac. Cardiovasc. Surg.
</td>
</tr>
<tr>
<td style="text-align:left;">
Mesothelioma: path to multimodality treatment.
</td>
<td style="text-align:left;">
Semin. Thorac. Cardiovasc. Surg.
</td>
</tr>
<tr>
<td style="text-align:left;">
Surgical techniques for multimodality treatment of malignant pleural mesothelioma: extrapleural pneumonectomy and pleurectomy/decortication.
</td>
<td style="text-align:left;">
Semin. Thorac. Cardiovasc. Surg.
</td>
</tr>
<tr>
<td style="text-align:left;">
Surgical options in malignant pleural mesothelioma: extrapleural pneumonectomy or pleurectomy/decortication.
</td>
<td style="text-align:left;">
Semin. Thorac. Cardiovasc. Surg.
</td>
</tr>
<tr>
<td style="text-align:left;">
Radiation therapy options for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Semin. Thorac. Cardiovasc. Surg.
</td>
</tr>
<tr>
<td style="text-align:left;">
Palliative care for the patient with mesothelioma.
</td>
<td style="text-align:left;">
Semin. Thorac. Cardiovasc. Surg.
</td>
</tr>
<tr>
<td style="text-align:left;">
Multimodality strategies in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Semin. Thorac. Cardiovasc. Surg.
</td>
</tr>
<tr>
<td style="text-align:left;">
Photodynamic therapy as an innovative treatment for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Semin. Thorac. Cardiovasc. Surg.
</td>
</tr>
<tr>
<td style="text-align:left;">
Making the case for molecular staging of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Semin. Thorac. Cardiovasc. Surg.
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma with long-term tumor disappearance of a local relapse after surgery: a case report.
</td>
<td style="text-align:left;">
J Med Case Rep
</td>
</tr>
<tr>
<td style="text-align:left;">
Staging algorithm for diffuse malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Interact Cardiovasc Thorac Surg
</td>
</tr>
<tr>
<td style="text-align:left;">
High-dose-rate surface brachytherapy to boost elongated, curvilinear incisional scars after extrapleural pneumonectomy for malignant pleural mesothelioma treated with adjuvant intensity-modulated radiation therapy.
</td>
<td style="text-align:left;">
Brachytherapy
</td>
</tr>
<tr>
<td style="text-align:left;">
Combined treatment with cisplatin and sirolimus to enhance cell death in human mesothelioma.
</td>
<td style="text-align:left;">
J. Thorac. Cardiovasc. Surg.
</td>
</tr>
<tr>
<td style="text-align:left;">
Primary small cell carcinoma of the pleura: a case report with immunohistochemical and molecular genetic analyses of KIT and PDGFRA genes.
</td>
<td style="text-align:left;">
Med. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Porcelain factory worker with asbestos-related mesothelioma.
</td>
<td style="text-align:left;">
J. Formos. Med. Assoc.
</td>
</tr>
<tr>
<td style="text-align:left;">
Second-line treatment for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Cancer Treat. Rev.
</td>
</tr>
<tr>
<td style="text-align:left;">
Estimation of pulmonary motion in healthy subjects and patients with intrathoracic tumors using 3D-dynamic MRI: initial results.
</td>
<td style="text-align:left;">
Korean J Radiol
</td>
</tr>
<tr>
<td style="text-align:left;">
Intrapleural cisplatin and cytarabine in the management of malignant pleural effusions: a Lung Cancer Study Group trial.
</td>
<td style="text-align:left;">
J. Clin. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Epigenetic profiles distinguish malignant pleural mesothelioma from lung adenocarcinoma.
</td>
<td style="text-align:left;">
Cancer Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
Late cutaneous metastases to the face from malignant pleural mesothelioma: a case report and review of the literature.
</td>
<td style="text-align:left;">
World J Surg Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Survival and relapse pattern after trimodality therapy for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Gen Thorac Cardiovasc Surg
</td>
</tr>
<tr>
<td style="text-align:left;">
Molecular targets in malignant pleural mesothelioma treatment.
</td>
<td style="text-align:left;">
Curr Drug Targets
</td>
</tr>
<tr>
<td style="text-align:left;">
Neurotensin expression and outcome of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Biochimie
</td>
</tr>
<tr>
<td style="text-align:left;">
E7080, a multi-tyrosine kinase inhibitor, suppresses the progression of malignant pleural mesothelioma with different proangiogenic cytokine production profiles.
</td>
<td style="text-align:left;">
Clin. Cancer Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
A novel translational approach for human malignant pleural mesothelioma: heparanase-assisted dual virotherapy.
</td>
<td style="text-align:left;">
Oncogene
</td>
</tr>
<tr>
<td style="text-align:left;">
Treatment with interleukin-2 in malignant pleural mesothelioma: immunological and angiogenetic assessment and prognostic impact.
</td>
<td style="text-align:left;">
Br. J. Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Targeted proteasome inhibition by Velcade induces apoptosis in human mesothelioma and breast cancer cell lines.
</td>
<td style="text-align:left;">
Cancer Chemother. Pharmacol.
</td>
</tr>
<tr>
<td style="text-align:left;">
[Diagnosis of malignant pleural mesothelioma–thoracoscopic biopsy and tumor marker].
</td>
<td style="text-align:left;">
Nihon Geka Gakkai Zasshi
</td>
</tr>
<tr>
<td style="text-align:left;">
[Therapeutic strategies for resectable malignant pleural mesothelioma].
</td>
<td style="text-align:left;">
Nihon Geka Gakkai Zasshi
</td>
</tr>
<tr>
<td style="text-align:left;">
[What is the role of pleuropneumonectomy in malignant pleural mesothelioma?].
</td>
<td style="text-align:left;">
Nihon Geka Gakkai Zasshi
</td>
</tr>
<tr>
<td style="text-align:left;">
[Intrapleural perfusion hyperthermo-chemotherapy with cisplatin in patients with malignant pleural mesothelioma].
</td>
<td style="text-align:left;">
Nihon Geka Gakkai Zasshi
</td>
</tr>
<tr>
<td style="text-align:left;">
Cisplatin-induced expression of Gb3 enables verotoxin-1 treatment of cisplatin resistance in malignant pleural mesothelioma cells.
</td>
<td style="text-align:left;">
Br. J. Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma: biology, diagnosis and therapeutic approaches.
</td>
<td style="text-align:left;">
Curr Mol Pharmacol
</td>
</tr>
<tr>
<td style="text-align:left;">
Comparison of diagnostic quality and accuracy in color-coded versus gray-scale DCE-MR imaging display.
</td>
<td style="text-align:left;">
Int J Comput Assist Radiol Surg
</td>
</tr>
<tr>
<td style="text-align:left;">
Histone deacetylase inhibitors in malignant pleural mesothelioma: preclinical rationale and clinical trials.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Sorafenib inhibits ERK1/2 and MCL-1(L) phosphorylation levels resulting in caspase-independent cell death in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Cancer Biol. Ther.
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma.
</td>
<td style="text-align:left;">
Br. Med. Bull.
</td>
</tr>
<tr>
<td style="text-align:left;">
The role of folate receptor alpha (FRalpha) in the response of malignant pleural mesothelioma to pemetrexed-containing chemotherapy.
</td>
<td style="text-align:left;">
Br. J. Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Multimodality treatment of malignant pleural mesothelioma with or without immunotherapy: does it change anything?
</td>
<td style="text-align:left;">
Interact Cardiovasc Thorac Surg
</td>
</tr>
<tr>
<td style="text-align:left;">
Asbestos, lung cancers, and mesotheliomas: from molecular approaches to targeting tumor survival pathways.
</td>
<td style="text-align:left;">
Am. J. Respir. Cell Mol. Biol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Cold-plasma coagulation in the treatment of malignant pleural mesothelioma: results of a combined approach.
</td>
<td style="text-align:left;">
Interact Cardiovasc Thorac Surg
</td>
</tr>
<tr>
<td style="text-align:left;">
Carboplatin plus pemetrexed as first-line treatment of patients with malignant pleural mesothelioma: a phase II study.
</td>
<td style="text-align:left;">
Clin Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Role of integrated 18-fluorodeoxyglucose position emission tomography-computed tomography in patients surveillance after multimodality therapy of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Gefitinib targets EGFR dimerization and ERK1/2 phosphorylation to inhibit pleural mesothelioma cell proliferation.
</td>
<td style="text-align:left;">
Curr Cancer Drug Targets
</td>
</tr>
<tr>
<td style="text-align:left;">
Primary pleural epithelioid angiosarcoma. A case report and review of the literature.
</td>
<td style="text-align:left;">
Pathol. Res. Pract.
</td>
</tr>
<tr>
<td style="text-align:left;">
Osteopontin-mediated enhanced hyaluronan binding induces multidrug resistance in mesothelioma cells.
</td>
<td style="text-align:left;">
Oncogene
</td>
</tr>
<tr>
<td style="text-align:left;">
Second surgery for recurrence of malignant pleural mesothelioma after extrapleural pneumonectomy.
</td>
<td style="text-align:left;">
Ann. Thorac. Surg.
</td>
</tr>
<tr>
<td style="text-align:left;">
Inhibition of Met/HGF receptor and angiogenesis by NK4 leads to suppression of tumor growth and migration in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Int. J. Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Arginine deprivation and argininosuccinate synthetase expression in the treatment of cancer.
</td>
<td style="text-align:left;">
Int. J. Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Proposed adjustments to pathologic staging of epithelial malignant pleural mesothelioma based on analysis of 354 cases.
</td>
<td style="text-align:left;">
Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Primary malignant mesothelioma of the pericardium.
</td>
<td style="text-align:left;">
Cardiovasc. Pathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Downregulation of Bcl-xL and Mcl-1 is sufficient to induce cell death in mesothelioma cells highly refractory to conventional chemotherapy.
</td>
<td style="text-align:left;">
Carcinogenesis
</td>
</tr>
<tr>
<td style="text-align:left;">
Phase II study of gemcitabine plus docetaxel as second-line treatment in malignant pleural mesothelioma: a single institution study.
</td>
<td style="text-align:left;">
Am. J. Clin. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Knockdown of COPA, identified by loss-of-function screen, induces apoptosis and suppresses tumor growth in mesothelioma mouse model.
</td>
<td style="text-align:left;">
Genomics
</td>
</tr>
<tr>
<td style="text-align:left;">
Effect of induction chemotherapy on lung function and exercise capacity in patients affected by malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Eur J Cardiothorac Surg
</td>
</tr>
<tr>
<td style="text-align:left;">
hsa-miR-29c* is linked to the prognosis of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Cancer Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
Gene therapy for mesothelioma and lung cancer.
</td>
<td style="text-align:left;">
Am. J. Respir. Cell Mol. Biol.
</td>
</tr>
<tr>
<td style="text-align:left;">
[Two cases of pulmonary sarcomatoid carcinoma mimicking malignant mesothelioma].
</td>
<td style="text-align:left;">
Nihon Kokyuki Gakkai Zasshi
</td>
</tr>
<tr>
<td style="text-align:left;">
Consolidative dendritic cell-based immunotherapy elicits cytotoxicity against malignant mesothelioma.
</td>
<td style="text-align:left;">
Am. J. Respir. Crit. Care Med.
</td>
</tr>
<tr>
<td style="text-align:left;">
Therapeutic surgery for nonepithelioid malignant pleural mesothelioma: is it really worthwhile?
</td>
<td style="text-align:left;">
Ann. Thorac. Surg.
</td>
</tr>
<tr>
<td style="text-align:left;">
Thymidylate synthase but not excision repair cross-complementation group 1 tumor expression predicts outcome in patients with malignant pleural mesothelioma treated with pemetrexed-based chemotherapy.
</td>
<td style="text-align:left;">
J. Clin. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
What’s the place of immunotherapy in malignant mesothelioma treatments?
</td>
<td style="text-align:left;">
Cell Adh Migr
</td>
</tr>
<tr>
<td style="text-align:left;">
A novel clinical role for angiopoietin-1 in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Eur. Respir. J.
</td>
</tr>
<tr>
<td style="text-align:left;">
Deciduoid mesothelioma of the pleura in an adolescent boy.
</td>
<td style="text-align:left;">
Pediatr Hematol Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Clinical investigation of malignant mesothelioma in Japan.
</td>
<td style="text-align:left;">
J. Cancer Res. Clin. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Retreatment of recurrent malignant pleural mesothelioma with cisplatin and pemetrexed.
</td>
<td style="text-align:left;">
Int. J. Clin. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Current concepts in chemotherapy for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Clin Respir J
</td>
</tr>
<tr>
<td style="text-align:left;">
Treatment of malignant pleural mesothelioma with liposomized doxorubicine: prolonged time to progression and good survival. A Nordic study.
</td>
<td style="text-align:left;">
Clin Respir J
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma.
</td>
<td style="text-align:left;">
Intern Med J
</td>
</tr>
<tr>
<td style="text-align:left;">
[A case of malignant pleural mesothelioma that responded to cisplatin plus pemetrexed rechallenge].
</td>
<td style="text-align:left;">
Gan To Kagaku Ryoho
</td>
</tr>
<tr>
<td style="text-align:left;">
May cyclooxygenase-2 (COX-2), p21 and p27 expression affect prognosis and therapeutic strategy of patients with malignant pleural mesothelioma?
</td>
<td style="text-align:left;">
Eur J Cardiothorac Surg
</td>
</tr>
<tr>
<td style="text-align:left;">
Life after first-line chemotherapy in malignant pleural mesothelioma: a North-East England experience.
</td>
<td style="text-align:left;">
Clin Oncol (R Coll Radiol)
</td>
</tr>
<tr>
<td style="text-align:left;">
Tissue and serum EGFR as prognostic factors in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Obtaining an upper estimate of the survival benefit associated with surgery for mesothelioma.
</td>
<td style="text-align:left;">
Eur J Cardiothorac Surg
</td>
</tr>
<tr>
<td style="text-align:left;">
Clinical significance of serum vascular endothelial growth factor in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
In vitro anti-mesothelioma activity of cisplatin-gemcitabine combinations: evidence for sequence-dependent effects.
</td>
<td style="text-align:left;">
Cancer Chemother. Pharmacol.
</td>
</tr>
<tr>
<td style="text-align:left;">
A novel prognostic model for malignant mesothelioma incorporating quantitative FDG-PET imaging with clinical parameters.
</td>
<td style="text-align:left;">
Clin. Cancer Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
Volumetric modulation arc radiotherapy compared with static gantry intensity-modulated radiotherapy for malignant pleural mesothelioma tumor: a feasibility study.
</td>
<td style="text-align:left;">
Int. J. Radiat. Oncol. Biol. Phys.
</td>
</tr>
<tr>
<td style="text-align:left;">
Proton therapy for malignant pleural mesothelioma after extrapleural pleuropneumonectomy.
</td>
<td style="text-align:left;">
Int. J. Radiat. Oncol. Biol. Phys.
</td>
</tr>
<tr>
<td style="text-align:left;">
[Surgical treatment of primary pleural tumours in our department].
</td>
<td style="text-align:left;">
Magy Seb
</td>
</tr>
<tr>
<td style="text-align:left;">
Early and late morbidity and mortality and life expectancy following thoracoscopic talc insufflation for control of malignant pleural effusions: a review of 400 cases.
</td>
<td style="text-align:left;">
J Cardiothorac Surg
</td>
</tr>
<tr>
<td style="text-align:left;">
Translational therapies for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Expert Rev Respir Med
</td>
</tr>
<tr>
<td style="text-align:left;">
Expert opinions of the first italian consensus conference on the management of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Am. J. Clin. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Assessment of therapy responses and prediction of survival in malignant pleural mesothelioma through computer-aided volumetric measurement on computed tomography scans.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Soluble mesothelin-related protein in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J Egypt Natl Canc Inst
</td>
</tr>
<tr>
<td style="text-align:left;">
Chemotherapy induced pathologic complete response in malignant pleural mesothelioma: a review and case report.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Prognostic factors for 100 patients with malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Arch Environ Occup Health
</td>
</tr>
<tr>
<td style="text-align:left;">
Activity of doxorubicin and cisplatin combination chemotherapy in patients with diffuse malignant pleural mesothelioma. An Italian Lung Cancer Task Force (FONICAP) Phase II study.
</td>
<td style="text-align:left;">
Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
[Malignant peritoneal mesothelioma].
</td>
<td style="text-align:left;">
Rev Gastroenterol Peru
</td>
</tr>
<tr>
<td style="text-align:left;">
Pemetrexed safety and pharmacokinetics in patients with third-space fluid.
</td>
<td style="text-align:left;">
Clin. Cancer Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
Volume-based parameter of 18)F-FDG PET/CT in malignant pleural mesothelioma: prediction of therapeutic response and prognostic implications.
</td>
<td style="text-align:left;">
Ann. Surg. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Pro-tumorigenic effects of miR-31 loss in mesothelioma.
</td>
<td style="text-align:left;">
J. Biol. Chem.
</td>
</tr>
<tr>
<td style="text-align:left;">
[Monitoring the effectiveness of surgical treatment of malignant pleural effusions].
</td>
<td style="text-align:left;">
Klin Onkol
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma: the standard of care and challenges for future management.
</td>
<td style="text-align:left;">
Crit. Rev. Oncol. Hematol.
</td>
</tr>
<tr>
<td style="text-align:left;">
A new technique of diaphragmatic patch fixation in extrapleural pneumonectomy.
</td>
<td style="text-align:left;">
Eur J Cardiothorac Surg
</td>
</tr>
<tr>
<td style="text-align:left;">
Soluble mesothelin-related Peptide and osteopontin as markers of response in malignant mesothelioma.
</td>
<td style="text-align:left;">
J. Clin. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Integrated positron emission tomography-computed tomography does not accurately stage intrathoracic disease of patients undergoing trimodality therapy for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Thorac Cardiovasc Surg
</td>
</tr>
<tr>
<td style="text-align:left;">
Surgery for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Expert Rev Respir Med
</td>
</tr>
<tr>
<td style="text-align:left;">
Trimodality therapy for malignant pleural mesothelioma: results from an EORTC phase II multicentre trial.
</td>
<td style="text-align:left;">
Eur. Respir. J.
</td>
</tr>
<tr>
<td style="text-align:left;">
Valproate-doxorubicin: promising therapy for progressing mesothelioma. A phase II study.
</td>
<td style="text-align:left;">
Eur. Respir. J.
</td>
</tr>
<tr>
<td style="text-align:left;">
WT1 peptide vaccinations induce CD4 and CD8 T cell immune responses in patients with mesothelioma and non-small cell lung cancer.
</td>
<td style="text-align:left;">
Cancer Immunol. Immunother.
</td>
</tr>
<tr>
<td style="text-align:left;">
The efficacy of the frontline platinum-based combination chemotherapy in malignant peritoneal mesothelioma.
</td>
<td style="text-align:left;">
Jpn. J. Clin. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Imaging in pleural mesothelioma: a review of imaging research presented at the 9th International Meeting of the International Mesothelioma Interest Group.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
CD8+ tumor-infiltrating lymphocytes predict favorable prognosis in malignant pleural mesothelioma after resection.
</td>
<td style="text-align:left;">
Cancer Immunol. Immunother.
</td>
</tr>
<tr>
<td style="text-align:left;">
Integrin-linked kinase, phosphorylated AKT and the prognosis of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Eur J Cardiothorac Surg
</td>
</tr>
<tr>
<td style="text-align:left;">
Vinflunine: review of a new vinca alkaloid and its potential role in oncology.
</td>
<td style="text-align:left;">
J Oncol Pharm Pract
</td>
</tr>
<tr>
<td style="text-align:left;">
Multimodality approach to malignant pleural mesothelioma. A case report.
</td>
<td style="text-align:left;">
Ann Ital Chir
</td>
</tr>
<tr>
<td style="text-align:left;">
Establishment of in vivo fluorescence imaging in mouse models of malignant mesothelioma.
</td>
<td style="text-align:left;">
Int. J. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Putative cancer stem cells in malignant pleural mesothelioma show resistance to cisplatin and pemetrexed.
</td>
<td style="text-align:left;">
Int. J. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Successful salvage chemotherapy with gemcitabine and vinorelbine in a malignant pleural mesothelioma patient previously treated with pemetrexed.
</td>
<td style="text-align:left;">
Jpn. J. Clin. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
In vitro and in vivo therapeutic efficacy of the PPAR-γ agonist troglitazone in combination with cisplatin against malignant pleural mesothelioma cell growth.
</td>
<td style="text-align:left;">
Cancer Sci.
</td>
</tr>
<tr>
<td style="text-align:left;">
Predominantly fibrous malignant mesothelioma in a cat.
</td>
<td style="text-align:left;">
Vet Med Int
</td>
</tr>
<tr>
<td style="text-align:left;">
Usefulness of the nude mouse model in mesothelioma based on a direct patient-xenograft comparison.
</td>
<td style="text-align:left;">
Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Prevalence of in vitro chemotherapeutic drug resistance in primary malignant pleural mesothelioma: result in a cohort of 203 resection specimens.
</td>
<td style="text-align:left;">
J. Thorac. Cardiovasc. Surg.
</td>
</tr>
<tr>
<td style="text-align:left;">
[Effect of cigarette smoking and/or N-bis(2-hydroxypropyl)nitrosamine (DHPN) on the development of lung and pleural tumors in rats induced by administration of asbestos].
</td>
<td style="text-align:left;">
Sangyo Igaku
</td>
</tr>
<tr>
<td style="text-align:left;">
Analysis of the effect of radiotherapy on malignant pleural mesothelioma when given on adjuvant or palliative basis.
</td>
<td style="text-align:left;">
Zhongguo Fei Ai Za Zhi
</td>
</tr>
<tr>
<td style="text-align:left;">
[A case of localized malignant pleural mesothelioma].
</td>
<td style="text-align:left;">
Nihon Kokyuki Gakkai Zasshi
</td>
</tr>
<tr>
<td style="text-align:left;">
Receptor tyrosine kinase and downstream signalling analysis in diffuse malignant peritoneal mesothelioma.
</td>
<td style="text-align:left;">
Eur. J. Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
How successful is lung-preserving radical surgery in the mesothelioma and radical surgery-trial environment? A case-controlled analysis.
</td>
<td style="text-align:left;">
Eur J Cardiothorac Surg
</td>
</tr>
<tr>
<td style="text-align:left;">
Extrapleural pneumonectomy, photodynamic therapy and intensity modulated radiation therapy for the treatment of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Cancer Biol. Ther.
</td>
</tr>
<tr>
<td style="text-align:left;">
Pleural mesothelioma.
</td>
<td style="text-align:left;">
Curr Opin Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
The role of extrapleural pneumonectomy in malignant pleural mesothelioma. A Lung Cancer Study Group trial.
</td>
<td style="text-align:left;">
J. Thorac. Cardiovasc. Surg.
</td>
</tr>
<tr>
<td style="text-align:left;">
Extrapleural pneumonectomy, chemotherapy, and radiotherapy in the treatment of diffuse malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J. Thorac. Cardiovasc. Surg.
</td>
</tr>
<tr>
<td style="text-align:left;">
A phase II study of sorafenib in malignant mesothelioma: results of Cancer and Leukemia Group B 30307.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
A case of cardiac herniation after extrapleural pneumonectomy for malignant thymoma.
</td>
<td style="text-align:left;">
J Anesth
</td>
</tr>
<tr>
<td style="text-align:left;">
Primary Pericardial Mesothelioma: Report of a Patient and Literature Review.
</td>
<td style="text-align:left;">
Case Rep Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
A systematic review of extrapleural pneumonectomy for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Prognostic factors for survival after surgical palliation of malignant pleural effusion.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
[Expectations after ban on asbestos].
</td>
<td style="text-align:left;">
Arh Hig Rada Toksikol
</td>
</tr>
<tr>
<td style="text-align:left;">
[Experience in treating patients with malignant pleural mesothelioma].
</td>
<td style="text-align:left;">
J. UOEH
</td>
</tr>
<tr>
<td style="text-align:left;">
[Diagnosis of pleural metastatic carcinoma with fibrous bronchoscope in thoracoscopy].
</td>
<td style="text-align:left;">
Zhonghua Jie He He Hu Xi Za Zhi
</td>
</tr>
<tr>
<td style="text-align:left;">
Genetically engineered oncolytic Newcastle disease virus effectively induces sustained remission of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Mol. Cancer Ther.
</td>
</tr>
<tr>
<td style="text-align:left;">
A clinical, radiographic and laboratory evaluation of prognostic factors in 363 patients with malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Respiration
</td>
</tr>
<tr>
<td style="text-align:left;">
Prevention of malignant seeding at drain sites by hypofractionated radiotherapy in patients with pleural mesothelioma.
</td>
<td style="text-align:left;">
Asia Pac J Clin Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Chemical characterization of exhaled breath to differentiate between patients with malignant plueral mesothelioma from subjects with similar professional asbestos exposure.
</td>
<td style="text-align:left;">
Anal Bioanal Chem
</td>
</tr>
<tr>
<td style="text-align:left;">
[Second-line therapy in patients with malignant pleural mesothelioma. A French retrospective study (2005-2006)].
</td>
<td style="text-align:left;">
Rev Pneumol Clin
</td>
</tr>
<tr>
<td style="text-align:left;">
Acute postoperative cardiac herniation.
</td>
<td style="text-align:left;">
Interact Cardiovasc Thorac Surg
</td>
</tr>
<tr>
<td style="text-align:left;">
Overexpression of SOCS3 exhibits preclinical antitumor activity against malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Int. J. Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Treatment of malignant pleural mesothelioma: current status and future directions.
</td>
<td style="text-align:left;">
Monaldi Arch Chest Dis
</td>
</tr>
<tr>
<td style="text-align:left;">
High blood neutrophil-to-lymphocyte ratio is an indicator of poor prognosis in malignant mesothelioma patients undergoing systemic therapy.
</td>
<td style="text-align:left;">
Clin. Cancer Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
Intensity-modulated radiation therapy with simultaneous integrated boost in unresected left-sided pleural mesothelioma: a case report.
</td>
<td style="text-align:left;">
Tumori
</td>
</tr>
<tr>
<td style="text-align:left;">
MT1-MMP plays an important role in an invasive activity of malignant pleural mesothelioma cell.
</td>
<td style="text-align:left;">
Exp. Mol. Pathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma: a population-based study of survival.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Induction of senescence markers after neo-adjuvant chemotherapy of malignant pleural mesothelioma and association with clinical outcome: an exploratory analysis.
</td>
<td style="text-align:left;">
Eur. J. Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
TS, DHFR and GARFT expression in non-squamous cell carcinoma of NSCLC and malignant pleural mesothelioma patients treated with pemetrexed.
</td>
<td style="text-align:left;">
Anticancer Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pericardial mesothelioma following thoracal radiotherapy; dissemination from pericardium to pleura.
</td>
<td style="text-align:left;">
Tuberk Toraks
</td>
</tr>
<tr>
<td style="text-align:left;">
Pleural effusion VEGF levels as a prognostic factor of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Respir Med
</td>
</tr>
<tr>
<td style="text-align:left;">
Inhibition of activated phosphatidylinositol 3-kinase/AKT pathway in malignant pleural mesothelioma leads to G1 cell cycle arrest.
</td>
<td style="text-align:left;">
Oncol. Rep.
</td>
</tr>
<tr>
<td style="text-align:left;">
Translational advances in pleural malignancies.
</td>
<td style="text-align:left;">
Respirology
</td>
</tr>
<tr>
<td style="text-align:left;">
Cutaneous needle track seeding of mesothelioma diagnosed by fine needle aspiration cytology: a case report.
</td>
<td style="text-align:left;">
Acta Cytol.
</td>
</tr>
<tr>
<td style="text-align:left;">
The therapeutic efficacy of S-1 against orthotopically implanted human pleural mesothelioma cells in severe combined immunodeficient mice.
</td>
<td style="text-align:left;">
Cancer Chemother. Pharmacol.
</td>
</tr>
<tr>
<td style="text-align:left;">
[Malignant peritoneal mesothelioma: a case report].
</td>
<td style="text-align:left;">
Rev Med Liege
</td>
</tr>
<tr>
<td style="text-align:left;">
Premature senescence induced by DNA demethylating agent (Decitabine) as therapeutic option for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Audit of patients with mesothelioma treated with pemetrexed in a single institution in Western Australia.
</td>
<td style="text-align:left;">
Asia Pac J Clin Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Brain metastasis in malignant pleural mesothelioma presenting as intratumoral hemorrhage.
</td>
<td style="text-align:left;">
Neurol. Med. Chir. (Tokyo)
</td>
</tr>
<tr>
<td style="text-align:left;">
Estrogen receptor β exerts tumor repressive functions in human malignant pleural mesothelioma via EGFR inactivation and affects response to gefitinib.
</td>
<td style="text-align:left;">
PLoS ONE
</td>
</tr>
<tr>
<td style="text-align:left;">
Continued pemetrexed and platin-based chemotherapy in patients with malignant pleural mesothelioma (MPM): value of 18F-FDG-PET/CT.
</td>
<td style="text-align:left;">
Eur J Radiol
</td>
</tr>
<tr>
<td style="text-align:left;">
Delayed bronchial stump dehiscence following trimodality treatment for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J Egypt Natl Canc Inst
</td>
</tr>
<tr>
<td style="text-align:left;">
Current evidence base of FDG-PET/CT imaging in the clinical management of malignant pleural mesothelioma: emerging significance of image segmentation and global disease assessment.
</td>
<td style="text-align:left;">
Mol Imaging Biol
</td>
</tr>
<tr>
<td style="text-align:left;">
[Case of benign asbestos pleurisy with diffuse pleural thickening confirmed on autopsy].
</td>
<td style="text-align:left;">
Nihon Kokyuki Gakkai Zasshi
</td>
</tr>
<tr>
<td style="text-align:left;">
Physical aspects of external beam radiotherapy for the treatment of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Int. J. Radiat. Oncol. Biol. Phys.
</td>
</tr>
<tr>
<td style="text-align:left;">
Can “steroid switching” improve steroid-induced musical hallucinations in a patient with terminal cancer?
</td>
<td style="text-align:left;">
J Palliat Med
</td>
</tr>
<tr>
<td style="text-align:left;">
Identification of cancer stem cell markers in human malignant mesothelioma cells.
</td>
<td style="text-align:left;">
Biochem. Biophys. Res. Commun.
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma: a clinical study of 238 cases.
</td>
<td style="text-align:left;">
Ind Health
</td>
</tr>
<tr>
<td style="text-align:left;">
[Treatment of malignant mesothelioma using intrapleural gamma interferon].
</td>
<td style="text-align:left;">
Bull. Acad. Natl. Med.
</td>
</tr>
<tr>
<td style="text-align:left;">
Serum soluble mesothelin concentrations in malignant pleural mesothelioma: relationship to tumor volume, clinical stage and changes in tumor burden.
</td>
<td style="text-align:left;">
Clin. Cancer Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
European guidelines for the management of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Pol. Arch. Med. Wewn.
</td>
</tr>
<tr>
<td style="text-align:left;">
Targeted epidermal growth factor receptor therapy in malignant pleural mesothelioma: where do we stand?
</td>
<td style="text-align:left;">
Cancer Treat. Rev.
</td>
</tr>
<tr>
<td style="text-align:left;">
Antiangiogenic therapies for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Front Biosci (Landmark Ed)
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma: CT manifestations in 50 cases.
</td>
<td style="text-align:left;">
AJR Am J Roentgenol
</td>
</tr>
<tr>
<td style="text-align:left;">
FDG PET/CT patterns of treatment failure of malignant pleural mesothelioma: relationship to histologic type, treatment algorithm, and survival.
</td>
<td style="text-align:left;">
Eur. J. Nucl. Med. Mol. Imaging
</td>
</tr>
<tr>
<td style="text-align:left;">
Retreatment with pemetrexed-based chemotherapy in patients with malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Dasatinib: an anti-tumour agent via Src inhibition.
</td>
<td style="text-align:left;">
Curr Drug Targets
</td>
</tr>
<tr>
<td style="text-align:left;">
Rat mesothelioma cell proliferation requires p38δ mitogen activated protein kinase and C/EBP-α.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Computed tomography-guided interstitial high-dose-rate brachytherapy in the local treatment of primary and secondary intrathoracic malignancies.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Thymidylate synthase and excision repair cross-complementing group-1 as predictors of responsiveness in mesothelioma patients treated with pemetrexed/carboplatin.
</td>
<td style="text-align:left;">
Clin. Cancer Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
Targeted therapies in malignant pleural mesothelioma: a review of clinical studies.
</td>
<td style="text-align:left;">
Anticancer Drugs
</td>
</tr>
<tr>
<td style="text-align:left;">
Does positron emission tomography offer prognostic information in malignant pleural mesothelioma?
</td>
<td style="text-align:left;">
Interact Cardiovasc Thorac Surg
</td>
</tr>
<tr>
<td style="text-align:left;">
Accuracy of diagnostic biopsy for the histological subtype of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
A practical guide of the Southwest Oncology Group to measure malignant pleural mesothelioma tumors by RECIST and modified RECIST criteria.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Volumetry: an alternative to assess therapy response for malignant pleural mesothelioma?
</td>
<td style="text-align:left;">
Eur. Respir. J.
</td>
</tr>
<tr>
<td style="text-align:left;">
Telomerase activity in pleural malignant mesotheliomas.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Advances in the biology of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Cancer Treat. Rev.
</td>
</tr>
<tr>
<td style="text-align:left;">
Platinum-based doublet chemotherapy in pre-treated malignant pleural mesothelioma (MPM) patients: a mono-institutional experience.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Staging of patients after extrapleural pneumonectomy for malignant pleural mesothelioma–institutional review and current update.
</td>
<td style="text-align:left;">
Interact Cardiovasc Thorac Surg
</td>
</tr>
<tr>
<td style="text-align:left;">
Clinical and pathological features of three-year survivors of malignant pleural mesothelioma following extrapleural pneumonectomy.
</td>
<td style="text-align:left;">
Eur J Cardiothorac Surg
</td>
</tr>
<tr>
<td style="text-align:left;">
Onconase mediated NFKβ downregulation in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Oncogene
</td>
</tr>
<tr>
<td style="text-align:left;">
Peritoneal mesothelioma: description of a case and review of literature.
</td>
<td style="text-align:left;">
Int J Immunopathol Pharmacol
</td>
</tr>
<tr>
<td style="text-align:left;">
Platinum-bisphosphonate complexes have proven to be inactive chemotherapeutics targeted for malignant mesothelioma because of inappropriate hydrolysis.
</td>
<td style="text-align:left;">
J. Inorg. Biochem.
</td>
</tr>
<tr>
<td style="text-align:left;">
Is pleurectomy and decortication superior to palliative care in the treatment of malignant pleural mesothelioma?
</td>
<td style="text-align:left;">
Interact Cardiovasc Thorac Surg
</td>
</tr>
<tr>
<td style="text-align:left;">
What is the role of radiotherapy in malignant pleural mesothelioma?
</td>
<td style="text-align:left;">
Oncologist
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma risk among nuclear workers: a review.
</td>
<td style="text-align:left;">
J Radiol Prot
</td>
</tr>
<tr>
<td style="text-align:left;">
Photodynamic therapy for malignant pleural mesothelioma: the future of treatment?
</td>
<td style="text-align:left;">
Expert Rev Respir Med
</td>
</tr>
<tr>
<td style="text-align:left;">
Downregulated microRNAs in the differential diagnosis of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Int. J. Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Temsirolimus inhibits malignant pleural mesothelioma growth in vitro and in vivo: synergism with chemotherapy.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Computerized segmentation and measurement of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Med Phys
</td>
</tr>
<tr>
<td style="text-align:left;">
Pathology of the pleura: what the pulmonologists need to know.
</td>
<td style="text-align:left;">
Respirology
</td>
</tr>
<tr>
<td style="text-align:left;">
Resistance to caspase-8 and -9 fragments in a malignant pleural mesothelioma cell line with acquired cisplatin-resistance.
</td>
<td style="text-align:left;">
Cell Death Dis
</td>
</tr>
<tr>
<td style="text-align:left;">
[A case of coexisting malignant mesothelioma and squamous cell carcinoma of the lung].
</td>
<td style="text-align:left;">
Gan To Kagaku Ryoho
</td>
</tr>
<tr>
<td style="text-align:left;">
Is serum thioredoxin-1 a useful clinical marker for malignant pleural mesothelioma?
</td>
<td style="text-align:left;">
Antioxid. Redox Signal.
</td>
</tr>
<tr>
<td style="text-align:left;">
Role of protein kinase C β and vascular endothelial growth factor receptor in malignant pleural mesothelioma: Therapeutic implications and the usefulness of Caenorhabditis elegans model organism.
</td>
<td style="text-align:left;">
J Carcinog
</td>
</tr>
<tr>
<td style="text-align:left;">
An unusually large pleural mesothelioma with an outstanding clinical response and long lasting survival: a case report and literature review.
</td>
<td style="text-align:left;">
Tumori
</td>
</tr>
<tr>
<td style="text-align:left;">
Extrapleural pneumonectomy or supportive care: treatment of malignant pleural mesothelioma?
</td>
<td style="text-align:left;">
Interact Cardiovasc Thorac Surg
</td>
</tr>
<tr>
<td style="text-align:left;">
The evolution of multimodality therapy for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Curr Treat Options Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Synergistic effect of non-transmissible Sendai virus vector encoding the c-myc suppressor FUSE-binding protein-interacting repressor plus cisplatin in the treatment of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Cancer Sci.
</td>
</tr>
<tr>
<td style="text-align:left;">
Pemetrexed in the treatment of thoracic malignancies: a single centre experience in Singapore.
</td>
<td style="text-align:left;">
Singapore Med J
</td>
</tr>
<tr>
<td style="text-align:left;">
An extracellular signal-regulated kinase 2 survival pathway mediates resistance of human mesothelioma cells to asbestos-induced injury.
</td>
<td style="text-align:left;">
Am. J. Respir. Cell Mol. Biol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Surgical treatment of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Curr Treat Options Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Chemotherapy for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Curr Treat Options Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Cytopathologic diagnosis in pleural effusion and cyto-histopathologic correlation.
</td>
<td style="text-align:left;">
Turk Patoloji Derg
</td>
</tr>
<tr>
<td style="text-align:left;">
Antiproliferative effects of novel aliphatic acetogenin analogs against aggressive solid tumor cell lines.
</td>
<td style="text-align:left;">
In Vivo
</td>
</tr>
<tr>
<td style="text-align:left;">
Soluble markers for diagnosis of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Biomark Med
</td>
</tr>
<tr>
<td style="text-align:left;">
Imaging of mesothelioma.
</td>
<td style="text-align:left;">
Recent Results Cancer Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
Surgical therapy of mesothelioma.
</td>
<td style="text-align:left;">
Recent Results Cancer Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
Chemotherapy and radiotherapy for mesothelioma.
</td>
<td style="text-align:left;">
Recent Results Cancer Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
Association of MiR-126 with soluble mesothelin-related peptides, a marker for malignant mesothelioma.
</td>
<td style="text-align:left;">
PLoS ONE
</td>
</tr>
<tr>
<td style="text-align:left;">
Update on malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Semin Respir Crit Care Med
</td>
</tr>
<tr>
<td style="text-align:left;">
Medical treatment of mesothelioma: anything new?
</td>
<td style="text-align:left;">
Curr Oncol Rep
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma: when is radiation therapy indicated?
</td>
<td style="text-align:left;">
Expert Rev Anticancer Ther
</td>
</tr>
<tr>
<td style="text-align:left;">
Summary of prognostic factors and patient selection for extrapleural pneumonectomy in the treatment of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Ann. Surg. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Circulating and tumor-infiltrating myeloid cells predict survival in human pleural mesothelioma.
</td>
<td style="text-align:left;">
Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Intensity-modulated radiotherapy after extrapleural pneumonectomy in the combined-modality treatment of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
The diminishing role of surgery in pleural disease.
</td>
<td style="text-align:left;">
Curr Opin Pulm Med
</td>
</tr>
<tr>
<td style="text-align:left;">
Recognition of pleural mesothelioma by mucin-1(950-958)/human leukocyte antigen A*0201-specific CD8+ T-cells.
</td>
<td style="text-align:left;">
Eur. Respir. J.
</td>
</tr>
<tr>
<td style="text-align:left;">
A 5-aza-2’-deoxycytidine/valproate combination induces cytotoxic T-cell response against mesothelioma.
</td>
<td style="text-align:left;">
Eur. Respir. J.
</td>
</tr>
<tr>
<td style="text-align:left;">
Review on clinical trials of targeted treatments in malignant mesothelioma.
</td>
<td style="text-align:left;">
Cancer Chemother. Pharmacol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Natural-killer cell-mediated cytotoxicity of blood-lymphocytes from patients with malignant mesothelioma treated by intrapleural interleukin-2.
</td>
<td style="text-align:left;">
Int. J. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Genes associated with prognosis after surgery for malignant pleural mesothelioma promote tumor cell survival in vitro.
</td>
<td style="text-align:left;">
BMC Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Curr Oncol Rep
</td>
</tr>
<tr>
<td style="text-align:left;">
A patient-like human malignant pleural mesothelioma nude-mouse model.
</td>
<td style="text-align:left;">
Oncol. Rep.
</td>
</tr>
<tr>
<td style="text-align:left;">
Pleurectomy, intrapleural cisplatin and interferon followed by systemic carboplatin plus interferon in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Oncol. Rep.
</td>
</tr>
<tr>
<td style="text-align:left;">
Curcumin suppresses growth of mesothelioma cells in vitro and in vivo, in part, by stimulating apoptosis.
</td>
<td style="text-align:left;">
Mol. Cell. Biochem.
</td>
</tr>
<tr>
<td style="text-align:left;">
Expression of a functional CCR2 receptor enhances tumor localization and tumor eradication by retargeted human T cells expressing a mesothelin-specific chimeric antibody receptor.
</td>
<td style="text-align:left;">
Clin. Cancer Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
Inactivation of Merlin in malignant mesothelioma cells and the Hippo signaling cascade dysregulation.
</td>
<td style="text-align:left;">
Pathol. Int.
</td>
</tr>
<tr>
<td style="text-align:left;">
Photodynamic therapy and the evolution of a lung-sparing surgical treatment for mesothelioma.
</td>
<td style="text-align:left;">
Ann. Thorac. Surg.
</td>
</tr>
<tr>
<td style="text-align:left;">
Combined chemotherapy with cytotoxic and targeted compounds for the management of human malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Trends Pharmacol. Sci.
</td>
</tr>
<tr>
<td style="text-align:left;">
[Usefulness of 18F-FDG PET-CT in the presurgical assessment of malignant pleural mesothelioma treated with neoadjuvant chemotherapy].
</td>
<td style="text-align:left;">
Rev Esp Med Nucl
</td>
</tr>
<tr>
<td style="text-align:left;">
Tumor cell repopulation between cycles of chemotherapy is inhibited by regulatory T-cell depletion in a murine mesothelioma model.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
[Value of tomotherapy in malignant pleural mesothelioma: first clinical results].
</td>
<td style="text-align:left;">
Rev Mal Respir
</td>
</tr>
<tr>
<td style="text-align:left;">
Pemetrexed in malignant pleural mesothelioma and the clinical outcome.
</td>
<td style="text-align:left;">
Clin Respir J
</td>
</tr>
<tr>
<td style="text-align:left;">
Cell-growth and migration inhibition of human mesothelioma cells induced by 3-O-methylfunicone from Penicillium pinophilum and cisplatin.
</td>
<td style="text-align:left;">
Invest New Drugs
</td>
</tr>
<tr>
<td style="text-align:left;">
Re-evaluating the role of palliative radiotherapy in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Eur. J. Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Mesothelioma at era of helical tomotherapy: results of two institutions in combining chemotherapy, surgery and radiotherapy.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Lovastatin and valproic acid additively attenuate cell invasion in ACC-MESO-1 cells.
</td>
<td style="text-align:left;">
Biochem. Biophys. Res. Commun.
</td>
</tr>
<tr>
<td style="text-align:left;">
Epigenetic silencing of microRNA-34b/c plays an important role in the pathogenesis of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Clin. Cancer Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
Intrathoracic chemo-thermotherapy with radiofrequency waves after extrapleural pneumonectomy for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Interact Cardiovasc Thorac Surg
</td>
</tr>
<tr>
<td style="text-align:left;">
Clinical significance of pleural effusion mesothelin in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Clin. Chem. Lab. Med.
</td>
</tr>
<tr>
<td style="text-align:left;">
Establishing locoregional control of malignant pleural mesothelioma using high-dose radiotherapy and (18) F-FDG PET/CT scan correlation.
</td>
<td style="text-align:left;">
J Med Imaging Radiat Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Improving survival results after surgical management of malignant pleural mesothelioma: an Australian institution experience.
</td>
<td style="text-align:left;">
Ann Thorac Cardiovasc Surg
</td>
</tr>
<tr>
<td style="text-align:left;">
[Exploratory study on the detection of markers for diagnosing early-stage malignant mesothelioma].
</td>
<td style="text-align:left;">
Nihon Eiseigaku Zasshi
</td>
</tr>
<tr>
<td style="text-align:left;">
[Current status and future direction of Japan’s clinical trial for malignant pleural mesothelioma].
</td>
<td style="text-align:left;">
Nihon Eiseigaku Zasshi
</td>
</tr>
<tr>
<td style="text-align:left;">
Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study.
</td>
<td style="text-align:left;">
Lancet Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Death receptor 5 and cellular FLICE-inhibitory protein regulate pemetrexed-induced apoptosis in human lung cancer cells.
</td>
<td style="text-align:left;">
Eur. J. Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Pleural mesothelioma side populations have a precursor phenotype.
</td>
<td style="text-align:left;">
Carcinogenesis
</td>
</tr>
<tr>
<td style="text-align:left;">
Predicting survival in malignant mesothelioma.
</td>
<td style="text-align:left;">
Eur. Respir. J.
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma: clinicopathologic and survival characteristic in a consecutive series of 40 patients.
</td>
<td style="text-align:left;">
Ann Thorac Cardiovasc Surg
</td>
</tr>
<tr>
<td style="text-align:left;">
Validity of procalcitonin and C-reactive protein measurement when differentiating between benign and malignant pleural effusion.
</td>
<td style="text-align:left;">
Clin. Lab.
</td>
</tr>
<tr>
<td style="text-align:left;">
Chronic inflammation in tumor stroma is an independent predictor of prolonged survival in epithelioid malignant pleural mesothelioma patients.
</td>
<td style="text-align:left;">
Cancer Immunol. Immunother.
</td>
</tr>
<tr>
<td style="text-align:left;">
Coactivation of receptor tyrosine kinases in malignant mesothelioma as a rationale for combination targeted therapy.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Receptor tyrosine kinase inhibitors and cytotoxic drugs affect pleural mesothelioma cell proliferation: insight into EGFR and ERK1/2 as antitumor targets.
</td>
<td style="text-align:left;">
Biochem. Pharmacol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Expression and regulation of B7-H3 immunoregulatory receptor, in human mesothelial and mesothelioma cells: immunotherapeutic implications.
</td>
<td style="text-align:left;">
J. Cell. Physiol.
</td>
</tr>
<tr>
<td style="text-align:left;">
The cytostatic effects of lovastatin on ACC-MESO-1 cells.
</td>
<td style="text-align:left;">
J. Surg. Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
SEOM guidelines for the treatment of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Clin Transl Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
CBP501-calmodulin binding contributes to sensitizing tumor cells to cisplatin and bleomycin.
</td>
<td style="text-align:left;">
Mol. Cancer Ther.
</td>
</tr>
<tr>
<td style="text-align:left;">
Soluble mesothelin, megakaryocyte potentiating factor, and osteopontin as markers of patient response and outcome in mesothelioma.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Tissue factor pathway inhibitor attenuates the progression of malignant pleural mesothelioma in nude mice.
</td>
<td style="text-align:left;">
Am. J. Respir. Cell Mol. Biol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Expression of the Ets transcription factor EHF in serous ovarian carcinoma effusions is a marker of poor survival.
</td>
<td style="text-align:left;">
Hum. Pathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Helical tomotherapy for resected malignant pleural mesothelioma: dosimetric evaluation and toxicity.
</td>
<td style="text-align:left;">
Radiother Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma in Singapore.
</td>
<td style="text-align:left;">
Asian Pac. J. Cancer Prev.
</td>
</tr>
<tr>
<td style="text-align:left;">
Pleurectomy/decortication, hyperthermic pleural lavage with povidone-iodine followed by adjuvant chemotherapy in patients with malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Safety and effectiveness of pemetrexed in patients with malignant pleural mesothelioma based on all-case drug-registry study.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Effects of the demethylating agent, 5-azacytidine, on expression of the kallikrein-kinin genes in carcinoma cells of the lung and pleura.
</td>
<td style="text-align:left;">
Patholog Res Int
</td>
</tr>
<tr>
<td style="text-align:left;">
Immune responses and immunotherapeutic interventions in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Cancer Immunol. Immunother.
</td>
</tr>
<tr>
<td style="text-align:left;">
[Current status of surgical treatment for malignant pleural mesothelioma].
</td>
<td style="text-align:left;">
Kyobu Geka
</td>
</tr>
<tr>
<td style="text-align:left;">
Miliary mesothelioma: a new clinical and radiological presentation in mesothelioma patients with prolonged survival after trimodality therapy.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Biomarkers in malignant mesothelioma: diagnostic and prognostic role of soluble mesothelin-related peptide.
</td>
<td style="text-align:left;">
Int. J. Biol. Markers
</td>
</tr>
<tr>
<td style="text-align:left;">
Raltitrexed plus cisplatin is cost-effective compared with pemetrexed plus cisplatin in patients with malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Second-line chemotherapy in malignant pleural mesothelioma: results of a retrospective multicenter survey.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Automated ERCC1 immunochemistry on hybrid cytology/tissue microarray of malignant effusions: evaluation of antibodies 8F1 and D-10.
</td>
<td style="text-align:left;">
J Clin Bioinforma
</td>
</tr>
<tr>
<td style="text-align:left;">
Phase II study of cediranib in patients with malignant pleural mesothelioma: SWOG S0509.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Prophylactic irradiation of intervention sites in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Radiother Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Strong anti-tumor effect of NVP-AUY922, a novel Hsp90 inhibitor, on non-small cell lung cancer.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Periostin expression and epithelial-mesenchymal transition in cancer: a review and an update.
</td>
<td style="text-align:left;">
Virchows Arch.
</td>
</tr>
<tr>
<td style="text-align:left;">
Raltitrexed in mesothelioma.
</td>
<td style="text-align:left;">
Expert Rev Anticancer Ther
</td>
</tr>
<tr>
<td style="text-align:left;">
Brief report: a phase II study of sunitinib in malignant pleural mesothelioma. the NCIC Clinical Trials Group.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Aquaporin 1 is an independent prognostic factor in pleural malignant mesothelioma.
</td>
<td style="text-align:left;">
Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Clinical implications of 18F-fluorodeoxyglucose positron emission tomography/computed tomography at delayed phase for diagnosis and prognosis of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Oncol. Rep.
</td>
</tr>
<tr>
<td style="text-align:left;">
Evaluation of platinum-ethacrynic acid conjugates in the treatment of mesothelioma.
</td>
<td style="text-align:left;">
ChemMedChem
</td>
</tr>
<tr>
<td style="text-align:left;">
A phase II trial of low-dose gemcitabine in a prolonged infusion and cisplatin for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Anticancer Drugs
</td>
</tr>
<tr>
<td style="text-align:left;">
Polycomb repressor complex-2 is a novel target for mesothelioma therapy.
</td>
<td style="text-align:left;">
Clin. Cancer Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
Low ERCC1 expression in malignant pleural mesotheliomas treated with cisplatin and vinorelbine predicts prolonged progression-free survival.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
PET-guided dose escalation tomotherapy in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Strahlenther Onkol
</td>
</tr>
<tr>
<td style="text-align:left;">
An in vivo platform for tumor biomarker assessment.
</td>
<td style="text-align:left;">
PLoS ONE
</td>
</tr>
<tr>
<td style="text-align:left;">
Metastasis of pleural mesothelioma presenting as bleeding colonic polyp.
</td>
<td style="text-align:left;">
Ann. Thorac. Surg.
</td>
</tr>
<tr>
<td style="text-align:left;">
Gene therapy for lung neoplasms.
</td>
<td style="text-align:left;">
Clin. Chest Med.
</td>
</tr>
<tr>
<td style="text-align:left;">
Eosinophil colony-stimulating factor induced by administration of interleukin-2 into the pleural cavity of patients with malignant pleurisy.
</td>
<td style="text-align:left;">
Am. J. Respir. Cell Mol. Biol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Diffuse malignant peritoneal mesothelioma–an update on treatment.
</td>
<td style="text-align:left;">
Cancer Treat. Rev.
</td>
</tr>
<tr>
<td style="text-align:left;">
[Pleuro-pulmonary metastases from a malignant mesothelioma of the tunica vaginalis].
</td>
<td style="text-align:left;">
Rev Mal Respir
</td>
</tr>
<tr>
<td style="text-align:left;">
Population-based survival for malignant mesothelioma after introduction of novel chemotherapy.
</td>
<td style="text-align:left;">
Eur. Respir. J.
</td>
</tr>
<tr>
<td style="text-align:left;">
Downregulation of MUC1 expression and its recognition by CD8⁺ T cells on the surface of malignant pleural mesothelioma cells treated with HDACi.
</td>
<td style="text-align:left;">
Eur. J. Immunol.
</td>
</tr>
<tr>
<td style="text-align:left;">
[Anti-angiogenic factors in thoracic oncology: successes, failures and prospects].
</td>
<td style="text-align:left;">
Rev Mal Respir
</td>
</tr>
<tr>
<td style="text-align:left;">
[Follow-up of subjects occupationally exposed to asbestos, what are the objectives, the benefits, and the possible risks?].
</td>
<td style="text-align:left;">
Rev Mal Respir
</td>
</tr>
<tr>
<td style="text-align:left;">
Vorinostat/SAHA-induced apoptosis in malignant mesothelioma is FLIP/caspase 8-dependent and HR23B-independent.
</td>
<td style="text-align:left;">
Eur. J. Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
[Treatment of pleural tumors].
</td>
<td style="text-align:left;">
Rev Prat
</td>
</tr>
<tr>
<td style="text-align:left;">
Butein impairs the protumorigenic activity of malignant pleural mesothelioma cells.
</td>
<td style="text-align:left;">
Cell Cycle
</td>
</tr>
<tr>
<td style="text-align:left;">
BRCA1 is an essential mediator of vinorelbine-induced apoptosis in mesothelioma.
</td>
<td style="text-align:left;">
J. Pathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Clinical impact of extrapleural pneumonectomy for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Ann. Surg. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
The application of cold-plasma coagulation on the visceral pleura results in a predictable depth of necrosis without fistula generation.
</td>
<td style="text-align:left;">
Interact Cardiovasc Thorac Surg
</td>
</tr>
<tr>
<td style="text-align:left;">
Long-term survival after lung-sparing total pleurectomy for locally advanced (International Mesothelioma Interest Group Stage T3-T4) non-sarcomatoid malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Eur J Cardiothorac Surg
</td>
</tr>
<tr>
<td style="text-align:left;">
Novel therapies in phase II and III trials for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J Natl Compr Canc Netw
</td>
</tr>
<tr>
<td style="text-align:left;">
Extrapleural pneumonectomy for early stage malignant pleural mesothelioma: a harmful procedure.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
CD26 overexpression is associated with prolonged survival and enhanced chemosensitivity in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Clin. Cancer Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
Treatment failure after extrapleural pneumonectomy for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J Thorac Dis
</td>
</tr>
<tr>
<td style="text-align:left;">
A pathological complete response after preoperative chemotherapy with carboplatin and pemetrexed in malignant pleural mesothelioma: A case report.
</td>
<td style="text-align:left;">
J Thorac Dis
</td>
</tr>
<tr>
<td style="text-align:left;">
Epithelial malignant pleural mesothelioma after extrapleural pneumonectomy: stratification of survival with CT-derived tumor volume.
</td>
<td style="text-align:left;">
AJR Am J Roentgenol
</td>
</tr>
<tr>
<td style="text-align:left;">
Synthesis, characterization and antiproliferative activity on mesothelioma cell lines of bis(carboxylato)platinum(IV) complexes based on picoplatin.
</td>
<td style="text-align:left;">
Dalton Trans
</td>
</tr>
<tr>
<td style="text-align:left;">
Mechanisms of pleurodesis.
</td>
<td style="text-align:left;">
Respiration
</td>
</tr>
<tr>
<td style="text-align:left;">
A retrospective study of chemotherapy with and without pemetrexed in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Anticancer Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
Preclinical studies identify novel targeted pharmacological strategies for treatment of human malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Br. J. Pharmacol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Photodynamic drug delivery enhancement in tumours does not depend on leukocyte-endothelial interaction in a human mesothelioma xenograft model.
</td>
<td style="text-align:left;">
Eur J Cardiothorac Surg
</td>
</tr>
<tr>
<td style="text-align:left;">
Cyberknife radiosurgery for focal paravertebral recurrence after radical pleurectomy/decortication in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Eur J Cardiothorac Surg
</td>
</tr>
<tr>
<td style="text-align:left;">
Inflammation-based prognostic indices in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
BioKnife, a uPA activity-dependent oncolytic Sendai virus, eliminates pleural spread of malignant mesothelioma via simultaneous stimulation of uPA expression.
</td>
<td style="text-align:left;">
Mol. Ther.
</td>
</tr>
<tr>
<td style="text-align:left;">
Adjuvant intensity-modulated proton therapy in malignant pleural mesothelioma. A comparison with intensity-modulated radiotherapy and a spot size variation assessment.
</td>
<td style="text-align:left;">
Strahlenther Onkol
</td>
</tr>
<tr>
<td style="text-align:left;">
¹⁸F-FDG uptake on PET could be a predictive marker of excision repair cross-complementation group 1 (ERCC1) expression in patients with thoracic neoplasms?
</td>
<td style="text-align:left;">
Neoplasma
</td>
</tr>
<tr>
<td style="text-align:left;">
Relationship between 18F-FDG uptake on positron emission tomography and molecular biology in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Eur. J. Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
[Clinical analysis of 45 patients with malignant pleural mesothelioma].
</td>
<td style="text-align:left;">
Zhongguo Fei Ai Za Zhi
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Am J Health Syst Pharm
</td>
</tr>
<tr>
<td style="text-align:left;">
[An autopsied case of primary malignant pericardial mesothelioma diagnosed antemortally].
</td>
<td style="text-align:left;">
Nihon Kokyuki Gakkai Zasshi
</td>
</tr>
<tr>
<td style="text-align:left;">
[Malignant pleural mesothelioma with multiple nodules].
</td>
<td style="text-align:left;">
Nihon Kokyuki Gakkai Zasshi
</td>
</tr>
<tr>
<td style="text-align:left;">
First-line chemotherapy with liposomal doxorubicin plus cisplatin for patients with advanced malignant pleural mesothelioma: phase II trial.
</td>
<td style="text-align:left;">
Br. J. Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Diagnosis and treatment of pleural mesothelioma.
</td>
<td style="text-align:left;">
Semin Surg Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Hemithoracic intensity-modulated radiotherapy using helical tomotherapy for patients after extrapleural pneumonectomy for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J. Radiat. Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
[Malignant pleural mesothelioma].
</td>
<td style="text-align:left;">
Dtsch. Med. Wochenschr.
</td>
</tr>
<tr>
<td style="text-align:left;">
Soluble mesothelin-related peptides levels in patients with malignant mesothelioma.
</td>
<td style="text-align:left;">
Dis. Markers
</td>
</tr>
<tr>
<td style="text-align:left;">
Is there a single spot size and grid for intensity modulated proton therapy? Simulation of head and neck, prostate and mesothelioma cases.
</td>
<td style="text-align:left;">
Med Phys
</td>
</tr>
<tr>
<td style="text-align:left;">
Curcumin induces autophagy in ACC-MESO-1 cells.
</td>
<td style="text-align:left;">
Phytother Res
</td>
</tr>
<tr>
<td style="text-align:left;">
Immunity and malignant mesothelioma: from mesothelial cell damage to tumor development and immune response-based therapies.
</td>
<td style="text-align:left;">
Cancer Lett.
</td>
</tr>
<tr>
<td style="text-align:left;">
Systemic treatment of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Future Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Pleurectomy/decortication is superior to extrapleural pneumonectomy in the multimodality management of patients with malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Phase II study of dasatinib in patients with previously treated malignant mesothelioma (cancer and leukemia group B 30601): a brief report.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Epidemiology of mesothelioma in Egypt. A ten-year (1998-2007) multicentre study.
</td>
<td style="text-align:left;">
Arch Med Sci
</td>
</tr>
<tr>
<td style="text-align:left;">
Advances in malignant pleural mesothelioma therapy: targeting EphA2 a novel approach.
</td>
<td style="text-align:left;">
Am J Cancer Res
</td>
</tr>
<tr>
<td style="text-align:left;">
Mesothelioma: a review.
</td>
<td style="text-align:left;">
Ochsner J
</td>
</tr>
<tr>
<td style="text-align:left;">
Induction chemotherapy, extrapleural pneumonectomy, and adjuvant radiotherapy for malignant pleural mesothelioma: experience of Guy’s and St Thomas’ hospitals.
</td>
<td style="text-align:left;">
Gen Thorac Cardiovasc Surg
</td>
</tr>
<tr>
<td style="text-align:left;">
Novel intrapleural therapies for malignant diseases.
</td>
<td style="text-align:left;">
Respiration
</td>
</tr>
<tr>
<td style="text-align:left;">
An overview of neoadjuvant chemotherapy in the multimodality treatment of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Cancer Treat. Rev.
</td>
</tr>
<tr>
<td style="text-align:left;">
[A case of malignant mesothelioma of the pleura].
</td>
<td style="text-align:left;">
Nihon Kyobu Geka Gakkai Zasshi
</td>
</tr>
<tr>
<td style="text-align:left;">
Prognostic factors in malignant pleural mesothelioma: a retrospective study.
</td>
<td style="text-align:left;">
Intern. Med.
</td>
</tr>
<tr>
<td style="text-align:left;">
18F-FDG PET/CT in a recurrent diffuse malignant peritoneal mesothelioma.
</td>
<td style="text-align:left;">
Clin Nucl Med
</td>
</tr>
<tr>
<td style="text-align:left;">
Complete response and long-term survival in malignant pleural mesothelioma: case report.
</td>
<td style="text-align:left;">
Anticancer Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
[‘Malignant peritoneal mesothelioma’: a condition difficult to diagnose].
</td>
<td style="text-align:left;">
Ned Tijdschr Geneeskd
</td>
</tr>
<tr>
<td style="text-align:left;">
Overexpression and potential targeting of the oncofoetal antigen 5T4 in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
[A diffuse, pleural, malignant mesothelioma kept in long remission by chemotherapy combining pirarubicin and cisplatin].
</td>
<td style="text-align:left;">
Gan No Rinsho
</td>
</tr>
<tr>
<td style="text-align:left;">
Estimating treatment effects from a randomized clinical trial in the presence of a secondary treatment.
</td>
<td style="text-align:left;">
Biostatistics
</td>
</tr>
<tr>
<td style="text-align:left;">
The circadian clock gene BMAL1 is a novel therapeutic target for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Int. J. Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Effect of increasing experience on dosimetric and clinical outcomes in the management of malignant pleural mesothelioma with intensity-modulated radiation therapy.
</td>
<td style="text-align:left;">
Int. J. Radiat. Oncol. Biol. Phys.
</td>
</tr>
<tr>
<td style="text-align:left;">
Anti-angiogenic therapies for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Expert Opin Investig Drugs
</td>
</tr>
<tr>
<td style="text-align:left;">
What is the optimum strategy for thromboembolic prophylaxis following extrapleural pneumonectomy in patients with malignant pleural mesothelioma?
</td>
<td style="text-align:left;">
Interact Cardiovasc Thorac Surg
</td>
</tr>
<tr>
<td style="text-align:left;">
SOCS-1 gene delivery cooperates with cisplatin plus pemetrexed to exhibit preclinical antitumor activity against malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Int. J. Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Radical pleurectomy and intraoperative photodynamic therapy for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Ann. Thorac. Surg.
</td>
</tr>
<tr>
<td style="text-align:left;">
Laparoscopic thoracic duct clipping for persistent chylothorax after extrapleural pneumonectomy.
</td>
<td style="text-align:left;">
Ann. Thorac. Surg.
</td>
</tr>
<tr>
<td style="text-align:left;">
Nitric oxide (NO) enhances pemetrexed cytotoxicity via NO‑cGMP signaling in lung adenocarcinoma cells in vitro and in vivo.
</td>
<td style="text-align:left;">
Int. J. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
The flavonoid resveratrol suppresses growth of human malignant pleural mesothelioma cells through direct inhibition of specificity protein 1.
</td>
<td style="text-align:left;">
Int. J. Mol. Med.
</td>
</tr>
<tr>
<td style="text-align:left;">
Interaction and cross-resistance of cisplatin and pemetrexed in malignant pleural mesothelioma cell lines.
</td>
<td style="text-align:left;">
Oncol. Rep.
</td>
</tr>
<tr>
<td style="text-align:left;">
Huge malignant solitary fibrous tumor of the pleura.
</td>
<td style="text-align:left;">
Gen Thorac Cardiovasc Surg
</td>
</tr>
<tr>
<td style="text-align:left;">
SU6668, a multiple tyrosine kinase inhibitor, inhibits progression of human malignant pleural mesothelioma in an orthotopic model.
</td>
<td style="text-align:left;">
Respirology
</td>
</tr>
<tr>
<td style="text-align:left;">
Radiation-induced malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Can Assoc Radiol J
</td>
</tr>
<tr>
<td style="text-align:left;">
Topotecan and pegylated liposomal doxorubicin combination as palliative treatment in patients with pretreated advanced malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Int J Clin Pharmacol Ther
</td>
</tr>
<tr>
<td style="text-align:left;">
Antitumor activity of MEK and PI3K inhibitors against malignant pleural mesothelioma cells in vitro and in vivo.
</td>
<td style="text-align:left;">
Int. J. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
[The chemotherapy of peritoneal malignant mesothelioma].
</td>
<td style="text-align:left;">
Gan To Kagaku Ryoho
</td>
</tr>
<tr>
<td style="text-align:left;">
Perifosine as a potential novel anti-cancer agent inhibits EGFR/MET-AKT axis in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
PLoS ONE
</td>
</tr>
<tr>
<td style="text-align:left;">
Pleural intensity-modulated radiotherapy for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Int. J. Radiat. Oncol. Biol. Phys.
</td>
</tr>
<tr>
<td style="text-align:left;">
Salvage therapy with topical antifungal for Aspergillus fumigatus empyema complicating extrapleural pneumonectomy.
</td>
<td style="text-align:left;">
Interact Cardiovasc Thorac Surg
</td>
</tr>
<tr>
<td style="text-align:left;">
Asbestos-related pleural disease.
</td>
<td style="text-align:left;">
Curr Opin Pulm Med
</td>
</tr>
<tr>
<td style="text-align:left;">
Molecular pathogenesis of malignant mesothelioma.
</td>
<td style="text-align:left;">
Expert Rev Mol Med
</td>
</tr>
<tr>
<td style="text-align:left;">
Validation of prognostic factors in malignant pleural mesothelioma: a retrospective analysis of data from patients seeking compensation from the New South Wales Dust Diseases Board.
</td>
<td style="text-align:left;">
Clin Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Multicenter, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma.
</td>
<td style="text-align:left;">
J. Clin. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Investigational approaches for mesothelioma.
</td>
<td style="text-align:left;">
Front Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
FDG PET/CT Response Evaluation in Malignant Pleural Mesothelioma Patients Treated with Talc Pleurodesis and Chemotherapy.
</td>
<td style="text-align:left;">
J Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Effects of combined therapies on the survival of pleural mesothelioma patients treated in Brescia, 1982-2006.
</td>
<td style="text-align:left;">
Tumori
</td>
</tr>
<tr>
<td style="text-align:left;">
[Mesothelioma and mesothelial hyperplasia].
</td>
<td style="text-align:left;">
Zhonghua Nei Ke Za Zhi
</td>
</tr>
<tr>
<td style="text-align:left;">
Response to chemotherapy is predictive in relation to longer overall survival in an individual patient combined-analysis with pleural mesothelioma.
</td>
<td style="text-align:left;">
Eur. J. Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma: from the bench to the bedside.
</td>
<td style="text-align:left;">
Respiration
</td>
</tr>
<tr>
<td style="text-align:left;">
Prospective study on functional results after lung-sparing radical pleurectomy in the management of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Multicentric study on malignant pleural mesothelioma in Turkey: clinicopathologic and survival characteristics of 282 patients.
</td>
<td style="text-align:left;">
Med. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Role of hedgehog signaling in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Clin. Cancer Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
Natural diterpenes from coffee, cafestol and kahweol induce apoptosis through regulation of specificity protein 1 expression in human malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J. Biomed. Sci.
</td>
</tr>
<tr>
<td style="text-align:left;">
Gallium-67 scanning in patients with malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Jpn. J. Med.
</td>
</tr>
<tr>
<td style="text-align:left;">
Clinical role of pleural effusion MMP-3 levels in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Oncol Lett
</td>
</tr>
<tr>
<td style="text-align:left;">
Pretreatment serum C-reactive protein levels predict benefit from multimodality treatment including radical surgery in malignant pleural mesothelioma: a retrospective multicenter analysis.
</td>
<td style="text-align:left;">
Ann. Surg.
</td>
</tr>
<tr>
<td style="text-align:left;">
[Malignant pleural mesothelioma].
</td>
<td style="text-align:left;">
Ther Umsch
</td>
</tr>
<tr>
<td style="text-align:left;">
[Chemotherapy for malignant tumors of lung and pleura].
</td>
<td style="text-align:left;">
Ther Umsch
</td>
</tr>
<tr>
<td style="text-align:left;">
A multicenter phase II study of cisplatin, pemetrexed, and bevacizumab in patients with advanced malignant mesothelioma.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
An open-label phase I pilot study of continuous intrapleural infusion of escalated doses of methotrexate in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Am. J. Clin. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
A case report of an extremely rare and aggressive tumor: primary malignant pericardial mesothelioma.
</td>
<td style="text-align:left;">
Rare Tumors
</td>
</tr>
<tr>
<td style="text-align:left;">
Effectiveness of mesothelin family proteins and osteopontin for malignant mesothelioma.
</td>
<td style="text-align:left;">
Eur. Respir. J.
</td>
</tr>
<tr>
<td style="text-align:left;">
Inhibition of phosphoinositide-3 kinase pathway down regulates ABCG2 function and sensitizes malignant pleural mesothelioma to chemotherapy.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
[Cisplatin and cytosine arabinoside (ARA-C) for the therapy of primary and secondary pleural neoplasms].
</td>
<td style="text-align:left;">
G Ital Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Revisiting cutaneous adverse reactions to pemetrexed.
</td>
<td style="text-align:left;">
Oncol Lett
</td>
</tr>
<tr>
<td style="text-align:left;">
Asbestos-related disease: screening and diagnosis.
</td>
<td style="text-align:left;">
Adv Clin Chem
</td>
</tr>
<tr>
<td style="text-align:left;">
Prognostic factors in malignant pleural mesothelioma: role of talc pleurodesis.
</td>
<td style="text-align:left;">
Asian Cardiovasc Thorac Ann
</td>
</tr>
<tr>
<td style="text-align:left;">
Cytoreductive surgery and hyperthermic intrathoracic chemotherapy perfusion for malignant pleural tumours: perioperative management and clinical experience.
</td>
<td style="text-align:left;">
Eur J Cardiothorac Surg
</td>
</tr>
<tr>
<td style="text-align:left;">
Effects of hyaluronic acid and CD44 interaction on the proliferation and invasiveness of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Tumour Biol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Folylpoly-glutamate synthetase expression is associated with tumor response and outcome from pemetrexed-based chemotherapy in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
A phase II study of intermittent sunitinib malate as second-line therapy in progressive malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Phase II clinical trial of first or second-line treatment with bortezomib in patients with malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
‘It’s all bad news’: the first 3 months following a diagnosis of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Psychooncology
</td>
</tr>
<tr>
<td style="text-align:left;">
Molecular resistance fingerprint of pemetrexed and platinum in a long-term survivor of mesothelioma.
</td>
<td style="text-align:left;">
PLoS ONE
</td>
</tr>
<tr>
<td style="text-align:left;">
Patterns of care for malignant pleural mesothelioma patients compensated by the Dust Diseases Board in New South Wales, Australia.
</td>
<td style="text-align:left;">
Intern Med J
</td>
</tr>
<tr>
<td style="text-align:left;">
Withaferin A inhibits the proteasome activity in mesothelioma in vitro and in vivo.
</td>
<td style="text-align:left;">
PLoS ONE
</td>
</tr>
<tr>
<td style="text-align:left;">
Convergent signaling in the regulation of connective tissue growth factor in malignant mesothelioma: TGFβ signaling and defects in the Hippo signaling cascade.
</td>
<td style="text-align:left;">
Cell Cycle
</td>
</tr>
<tr>
<td style="text-align:left;">
Quality of life after radical pleurectomy decortication for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Ann. Thorac. Surg.
</td>
</tr>
<tr>
<td style="text-align:left;">
Therapeutic antitumor efficacy of anti-epidermal growth factor receptor antibody, cetuximab, against malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Int. J. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Histone deacetylase inhibitors as potential therapeutic agents for the treatment of malignant mesothelioma.
</td>
<td style="text-align:left;">
Anticancer Agents Med Chem
</td>
</tr>
<tr>
<td style="text-align:left;">
3T MRI in evaluation of asbestos-related thoracic diseases - preliminary results.
</td>
<td style="text-align:left;">
Radiol Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Health-related quality of life and inflammatory markers in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Support Care Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Paraneoplastic leukocytoclastic vasculitis as an initial presentation of malignant pleural mesothelioma: a case report.
</td>
<td style="text-align:left;">
J Med Case Rep
</td>
</tr>
<tr>
<td style="text-align:left;">
Comprehensive treatment of malignant mesothelioma patients after the failure of systemic chemotherapy.
</td>
<td style="text-align:left;">
Cryobiology
</td>
</tr>
<tr>
<td style="text-align:left;">
A biomarker profile for predicting efficacy of cisplatin-vinorelbine therapy in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Cancer Chemother. Pharmacol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Intratumoral Wnt2B expression affects tumor proliferation and survival in malignant pleural mesothelioma patients.
</td>
<td style="text-align:left;">
Exp Ther Med
</td>
</tr>
<tr>
<td style="text-align:left;">
DNA repair polymorphisms and treatment outcomes of patients with malignant mesothelioma treated with gemcitabine-platinum combination chemotherapy.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Role of conservative (palliative) care-only in the management of advanced malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Anticancer Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
Asbestos exposure and survival in malignant mesothelioma: a description of 122 consecutive cases at an occupational clinic.
</td>
<td style="text-align:left;">
Int J Occup Environ Med
</td>
</tr>
<tr>
<td style="text-align:left;">
Sphingosine kinase 1 is required for mesothelioma cell proliferation: role of histone acetylation.
</td>
<td style="text-align:left;">
PLoS ONE
</td>
</tr>
<tr>
<td style="text-align:left;">
Carbonic anhydrase IX in malignant pleural mesotheliomas: a potential target for anti-cancer therapy.
</td>
<td style="text-align:left;">
Bioorg. Med. Chem.
</td>
</tr>
<tr>
<td style="text-align:left;">
Heterozygous loss of NF2 is an early molecular alteration in well-differentiated papillary mesothelioma of the peritoneum.
</td>
<td style="text-align:left;">
Cancer Genet
</td>
</tr>
<tr>
<td style="text-align:left;">
Toxic epidermal necrolysis related to Cisplatin and pemetrexed for metastatic non-small cell lung cancer.
</td>
<td style="text-align:left;">
Onkologie
</td>
</tr>
<tr>
<td style="text-align:left;">
Recombinant human endostatin (endostar) decreased recurrent ascites, pleural fluid and ascitic VEGF in a case of advanced mesothelioma.
</td>
<td style="text-align:left;">
J Chemother
</td>
</tr>
<tr>
<td style="text-align:left;">
Fibulin-3 as a blood and effusion biomarker for pleural mesothelioma.
</td>
<td style="text-align:left;">
N. Engl. J. Med.
</td>
</tr>
<tr>
<td style="text-align:left;">
Photodynamic therapy for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J Natl Compr Canc Netw
</td>
</tr>
<tr>
<td style="text-align:left;">
Pegylated liposomal doxorubicin in malignant pleural mesothelioma: a possible guardian for long-term survival.
</td>
<td style="text-align:left;">
Onco Targets Ther
</td>
</tr>
<tr>
<td style="text-align:left;">
Optimization of response classification criteria for patients with malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Tunneling Nanotubes: A new paradigm for studying intercellular communication and therapeutics in cancer.
</td>
<td style="text-align:left;">
Commun Integr Biol
</td>
</tr>
<tr>
<td style="text-align:left;">
[One case of malignant mesothelioma that developed right pneumothorax after a diagnosis with left pneumothorax].
</td>
<td style="text-align:left;">
Gan To Kagaku Ryoho
</td>
</tr>
<tr>
<td style="text-align:left;">
High prevalence of serum antibodies reacting with simian virus 40 capsid protein mimotopes in patients affected by malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Proc. Natl. Acad. Sci. U.S.A.
</td>
</tr>
<tr>
<td style="text-align:left;">
Outcome and prognostic factors of pleural mesothelioma after surgical diagnosis and/or pleurodesis.
</td>
<td style="text-align:left;">
J. Thorac. Cardiovasc. Surg.
</td>
</tr>
<tr>
<td style="text-align:left;">
Improved survival after introduction of chemotherapy for malignant pleural mesothelioma in Slovenia: Population-based survey of 444 patients.
</td>
<td style="text-align:left;">
Radiol Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Excision repair cross complementation group 1 and thymidylate synthase expression in patients with mesothelioma.
</td>
<td style="text-align:left;">
Clin Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Utilisation of a thoracic oncology database to capture radiological and pathological images for evaluation of response to chemotherapy in patients with malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
BMJ Open
</td>
</tr>
<tr>
<td style="text-align:left;">
CD9 expression as a favorable prognostic marker for patients with malignant mesothelioma.
</td>
<td style="text-align:left;">
Oncol. Rep.
</td>
</tr>
<tr>
<td style="text-align:left;">
Long term survival after trimodal therapy in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Swiss Med Wkly
</td>
</tr>
<tr>
<td style="text-align:left;">
Prognostic significance of metabolic response by positron emission tomography after neoadjuvant chemotherapy for resectable malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Ann. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Clinical utility of 18-fluorodeoxyglucose positron emission tomography/computed tomography in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Exp Ther Med
</td>
</tr>
<tr>
<td style="text-align:left;">
Disease volumes as a marker for patient response in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Ann. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Nonselective transarterial chemoperfusion: a palliative treatment for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Radiology
</td>
</tr>
<tr>
<td style="text-align:left;">
Incidence and survival of malignant pleural mesothelioma in norway: a population-based study of 1686 cases.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Tomotherapy after pleurectomy/decortication or biopsy for malignant pleural mesothelioma allows the delivery of high dose of radiation in patients with intact lung.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
MicroRNA miR-34b/c enhances cellular radiosensitivity of malignant pleural mesothelioma cells.
</td>
<td style="text-align:left;">
Anticancer Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
Improved quality of life in patients with malignant pleural effusion following videoassisted thoracoscopic talc pleurodesis. Preliminary results.
</td>
<td style="text-align:left;">
Anticancer Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
Suppression of activin A signals inhibits growth of malignant pleural mesothelioma cells.
</td>
<td style="text-align:left;">
Br. J. Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Multimodal therapy of malignant pleural mesothelioma: is the replacement of radical surgery imminent?
</td>
<td style="text-align:left;">
Interact Cardiovasc Thorac Surg
</td>
</tr>
<tr>
<td style="text-align:left;">
Intraoperative hyperthermic chemotherapy perfusion for malignant pleural mesothelioma: an in vitro evaluation.
</td>
<td style="text-align:left;">
J. Thorac. Cardiovasc. Surg.
</td>
</tr>
<tr>
<td style="text-align:left;">
Diagnosis of malignant pericarditis: a single centre experience.
</td>
<td style="text-align:left;">
Kardiol Pol
</td>
</tr>
<tr>
<td style="text-align:left;">
NK cells from malignant pleural effusions are not anergic but produce cytokines and display strong antitumor activity on short-term IL-2 activation.
</td>
<td style="text-align:left;">
Eur. J. Immunol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Surgical management of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Thorac Surg Clin
</td>
</tr>
<tr>
<td style="text-align:left;">
18F-fluoro-2-deoxy-d-glucose positron emission tomography/computed tomography fused imaging in malignant mesothelioma patients: looking from outside is not enough.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Mesothelioma: a soon to be forgotten disease in the United States?
</td>
<td style="text-align:left;">
J Bronchology Interv Pulmonol
</td>
</tr>
<tr>
<td style="text-align:left;">
Pemetrexed plus carboplatin or cisplatin as neoadjuvant treatment of operable malignant pleural mesothelioma (MPM).
</td>
<td style="text-align:left;">
Anticancer Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
Mechanisms of cisplatin-induced cell death in malignant mesothelioma cells: role of inhibitor of apoptosis proteins (IAPs) and caspases.
</td>
<td style="text-align:left;">
Int. J. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
PTEN protein expression in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Tumour Biol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Factors predicting poor survival after lung-sparing radical pleurectomy of IMIG stage III malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Eur J Cardiothorac Surg
</td>
</tr>
<tr>
<td style="text-align:left;">
Second Italian consensus conference on malignant pleural mesothelioma: state of the art and recommendations.
</td>
<td style="text-align:left;">
Cancer Treat. Rev.
</td>
</tr>
<tr>
<td style="text-align:left;">
Patterns of failure, toxicity, and survival after extrapleural pneumonectomy and hemithoracic intensity-modulated radiation therapy for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
[Antibody therapy for malignant mesothelioma: humanized anti-cD26 mAb therapy].
</td>
<td style="text-align:left;">
Nippon Rinsho
</td>
</tr>
<tr>
<td style="text-align:left;">
Re-directed T cells for the treatment of fibroblast activation protein (FAP)-positive malignant pleural mesothelioma (FAPME-1).
</td>
<td style="text-align:left;">
BMC Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
A seven-year disease-free survivor of malignant pleural mesothelioma treated with hyperthermia and chemotherapy: a case report.
</td>
<td style="text-align:left;">
J Med Case Rep
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma: new insights into a rare disease.
</td>
<td style="text-align:left;">
Cancer Treat. Rev.
</td>
</tr>
<tr>
<td style="text-align:left;">
Podoplanin overexpression in human mesothelioma cell lines enhances the tumorigenic phenotype.
</td>
<td style="text-align:left;">
Oncol. Rep.
</td>
</tr>
<tr>
<td style="text-align:left;">
PARP1 inhibition affects pleural mesothelioma cell viability and uncouples AKT/mTOR axis via SIRT1.
</td>
<td style="text-align:left;">
J. Cell. Mol. Med.
</td>
</tr>
<tr>
<td style="text-align:left;">
Asymptomatic primary tuberculous pleurisy with intense 18-fluorodeoxyglucose uptake mimicking malignant mesothelioma.
</td>
<td style="text-align:left;">
BMC Infect. Dis.
</td>
</tr>
<tr>
<td style="text-align:left;">
Clinical characteristics, treatment and survival outcomes in malignant mesothelioma: eighteen years’ experience in Turkey.
</td>
<td style="text-align:left;">
Asian Pac. J. Cancer Prev.
</td>
</tr>
<tr>
<td style="text-align:left;">
Phase II trial of neoadjuvant pemetrexed plus cisplatin followed by surgery and radiation in the treatment of pleural mesothelioma.
</td>
<td style="text-align:left;">
BMC Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
What is the survival after surgery for localized malignant pleural mesothelioma?
</td>
<td style="text-align:left;">
Interact Cardiovasc Thorac Surg
</td>
</tr>
<tr>
<td style="text-align:left;">
Effects of treatment regimens on survival in patients with malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Eur Rev Med Pharmacol Sci
</td>
</tr>
<tr>
<td style="text-align:left;">
[Malignant pleural mesothelioma: diagnosis and treatment].
</td>
<td style="text-align:left;">
Rev Pneumol Clin
</td>
</tr>
<tr>
<td style="text-align:left;">
Changes in pulmonary function tests predict radiological response to chemotherapy in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Eur J Cardiothorac Surg
</td>
</tr>
<tr>
<td style="text-align:left;">
Is survivin expression prognostic or predictive in malignant pleural mesothelioma?
</td>
<td style="text-align:left;">
Virchows Arch.
</td>
</tr>
<tr>
<td style="text-align:left;">
The expression of Axl receptor tyrosine kinase influences the tumour phenotype and clinical outcome of patients with malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Br. J. Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
SMO expression level correlates with overall survival in patients with malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J. Exp. Clin. Cancer Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
Local and systemic exposure of cisplatin during hyperthermic intrathoracic chemotherapy perfusion after pleurectomy and decortication for treatment of pleural malignancies.
</td>
<td style="text-align:left;">
J Surg Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Gene therapy for malignant mesothelioma: current prospects and challenges.
</td>
<td style="text-align:left;">
Cancer Gene Ther.
</td>
</tr>
<tr>
<td style="text-align:left;">
[Expression of thrombomodulin in malignant pleural mesothelioma].
</td>
<td style="text-align:left;">
G Ital Med Lav Ergon
</td>
</tr>
<tr>
<td style="text-align:left;">
[A case report: an university professor suffering from malignant mesothelioma].
</td>
<td style="text-align:left;">
G Ital Med Lav Ergon
</td>
</tr>
<tr>
<td style="text-align:left;">
[Identification and characterization of microRNA involving in malignant pleural mesothelioma].
</td>
<td style="text-align:left;">
G Ital Med Lav Ergon
</td>
</tr>
<tr>
<td style="text-align:left;">
[Malignant mesothelioma: analysis of a hospital case series].
</td>
<td style="text-align:left;">
G Ital Med Lav Ergon
</td>
</tr>
<tr>
<td style="text-align:left;">
Surgery in mesothelioma–where do we go after MARS?
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Use of cancer therapy at the end of life in patients with malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Support Care Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Chemotherapy management of malignant pleural mesothelioma: a phase II study comparing two popular chemotherapy regimens.
</td>
<td style="text-align:left;">
Clin Transl Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma: update on treatment options with a focus on novel therapies.
</td>
<td style="text-align:left;">
Clin. Chest Med.
</td>
</tr>
<tr>
<td style="text-align:left;">
Rare pleural tumors.
</td>
<td style="text-align:left;">
Clin. Chest Med.
</td>
</tr>
<tr>
<td style="text-align:left;">
Therapeutic targeting malignant mesothelioma with a novel 6-substituted pyrrolo[2,3-d]pyrimidine thienoyl antifolate via its selective uptake by the proton-coupled folate transporter.
</td>
<td style="text-align:left;">
Cancer Chemother. Pharmacol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma: factors influencing the prognosis.
</td>
<td style="text-align:left;">
Oncology (Williston Park, N.Y.)
</td>
</tr>
<tr>
<td style="text-align:left;">
Laparoscopic repair of secondary parahiatal hernia with incarceration of the stomach: a case report.
</td>
<td style="text-align:left;">
J Med Case Rep
</td>
</tr>
<tr>
<td style="text-align:left;">
M14K and M38K malignant pleural mesothelioma cell lines preserve the same claudin-based phenotype in vivo.
</td>
<td style="text-align:left;">
In Vivo
</td>
</tr>
<tr>
<td style="text-align:left;">
Hypoxia affects in vitro growth of newly established cell lines from patients with malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Biomed. Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
Hyperthermic intraoperative pleural cisplatin chemotherapy extends interval to recurrence and survival among low-risk patients with malignant pleural mesothelioma undergoing surgical macroscopic complete resection.
</td>
<td style="text-align:left;">
J. Thorac. Cardiovasc. Surg.
</td>
</tr>
<tr>
<td style="text-align:left;">
Reduced folate carrier and folylpolyglutamate synthetase, but not thymidylate synthase predict survival in pemetrexed-treated patients suffering from malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Multimodality treatment of pleural mesothelioma.
</td>
<td style="text-align:left;">
Surg. Oncol. Clin. N. Am.
</td>
</tr>
<tr>
<td style="text-align:left;">
Snail expression is associated with a poor prognosis in malignant pleural mesotheliomas.
</td>
<td style="text-align:left;">
Ann. Thorac. Surg.
</td>
</tr>
<tr>
<td style="text-align:left;">
Oestrogen receptors are prognostic factors in malignant peritoneal mesothelioma.
</td>
<td style="text-align:left;">
J. Cancer Res. Clin. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Anti-Yo antibody-mediated paraneoplastic cerebellar degeneration in a female patient with pleural malignant mesothelioma.
</td>
<td style="text-align:left;">
Jpn. J. Clin. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Circulating tumor cells as a diagnostic test for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Expert Opin Med Diagn
</td>
</tr>
<tr>
<td style="text-align:left;">
Gli as a novel therapeutic target in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
PLoS ONE
</td>
</tr>
<tr>
<td style="text-align:left;">
Thymidylate synthase and folyl-polyglutamate synthase are not clinically useful markers of response to pemetrexed in patients with malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Lung volume measurements as a surrogate marker for patient response in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
A feasibility study of induction pemetrexed plus cisplatin followed by pleurectomy/decortication aimed at macroscopic complete resection for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Jpn. J. Clin. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
TRAIL and proteasome inhibitors combination induces a robust apoptosis in human malignant pleural mesothelioma cells through Mcl-1 and Akt protein cleavages.
</td>
<td style="text-align:left;">
BMC Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Pemetrexed-induced neutropenic enteritis and severe cutaneous hyperpigmentation in a patient with malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Downregulation of Sp1 is involved in honokiol-induced cell cycle arrest and apoptosis in human malignant pleural mesothelioma cells.
</td>
<td style="text-align:left;">
Oncol. Rep.
</td>
</tr>
<tr>
<td style="text-align:left;">
Preclinical demonstration of synergistic Active Nutrients/Drug (AND) combination as a potential treatment for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
PLoS ONE
</td>
</tr>
<tr>
<td style="text-align:left;">
Current and future options for the diagnosis of malignant pleural effusion.
</td>
<td style="text-align:left;">
Expert Opin Med Diagn
</td>
</tr>
<tr>
<td style="text-align:left;">
Phase 2 study of sorafenib in malignant mesothelioma previously treated with platinum-containing chemotherapy.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Thalidomide versus active supportive care for maintenance in patients with malignant mesothelioma after first-line chemotherapy (NVALT 5): an open-label, multicentre, randomised phase 3 study.
</td>
<td style="text-align:left;">
Lancet Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
The N-ERC index is a novel monitoring and prognostic marker for advanced malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J Thorac Dis
</td>
</tr>
<tr>
<td style="text-align:left;">
Bone metastases with nerve root compression as a late complication in patient with epithelial pleural mesothelioma.
</td>
<td style="text-align:left;">
J Thorac Dis
</td>
</tr>
<tr>
<td style="text-align:left;">
Calretinin is essential for mesothelioma cell growth/survival in vitro: a potential new target for malignant mesothelioma therapy?
</td>
<td style="text-align:left;">
Int. J. Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
[Intraoperative chemotherapy after radical pleurectomy or extrapleural pneumonectomy].
</td>
<td style="text-align:left;">
Chirurg
</td>
</tr>
<tr>
<td style="text-align:left;">
Serum HMGB1 as a prognostic marker for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
BMC Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Survival of mesothelioma in a palliative medical care unit in egypt.
</td>
<td style="text-align:left;">
Asian Pac. J. Cancer Prev.
</td>
</tr>
<tr>
<td style="text-align:left;">
Overexpression of Numb suppresses tumor cell growth and enhances sensitivity to cisplatin in epithelioid malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Oncol. Rep.
</td>
</tr>
<tr>
<td style="text-align:left;">
Good response of malignant pleural effusion from carcinoma of unknown primary site to the anti-tuberculosis therapy: a case report.
</td>
<td style="text-align:left;">
Int J Clin Exp Pathol
</td>
</tr>
<tr>
<td style="text-align:left;">
Proton magnetic resonance metabolomic characterization of ovarian serous carcinoma effusions: chemotherapy-related effects and comparison with malignant mesothelioma and breast carcinoma.
</td>
<td style="text-align:left;">
Hum. Pathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Thymidylate synthase expression determines pemetrexed targets and resistance development in tumour cells.
</td>
<td style="text-align:left;">
PLoS ONE
</td>
</tr>
<tr>
<td style="text-align:left;">
Management of malignant pleural mesothelioma: have we made any progress?
</td>
<td style="text-align:left;">
Panminerva Med
</td>
</tr>
<tr>
<td style="text-align:left;">
Secondary malignant peritoneal mesothelioma of the greater omentum after therapy for primary pleural mesothelioma.
</td>
<td style="text-align:left;">
Case Rep Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Radical pleurectomy and chemoradiation for malignant pleural mesothelioma: the outcome of incomplete resections.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Relationship between 18 FDG PET-CT findings and the survival of 177 patients with malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Eur Rev Med Pharmacol Sci
</td>
</tr>
<tr>
<td style="text-align:left;">
A novel targeting therapy of malignant mesothelioma using anti-podoplanin antibody.
</td>
<td style="text-align:left;">
J. Immunol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Peritoneal mesothelioma: the site of origin matters.
</td>
<td style="text-align:left;">
Am Soc Clin Oncol Educ Book
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma: incidence, etiology, diagnosis, treatment, and occupational health.
</td>
<td style="text-align:left;">
Dtsch Arztebl Int
</td>
</tr>
<tr>
<td style="text-align:left;">
EphB4 as a therapeutic target in mesothelioma.
</td>
<td style="text-align:left;">
BMC Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Cyclooxygenase-2, epidermal growth factor receptor, and aromatase signaling in inflammation and mesothelioma.
</td>
<td style="text-align:left;">
Mol. Cancer Ther.
</td>
</tr>
<tr>
<td style="text-align:left;">
[Regional treatment of malignant pleural mesothelioma: results from the tumor centre Regensburg].
</td>
<td style="text-align:left;">
Chirurg
</td>
</tr>
<tr>
<td style="text-align:left;">
Up-regulation of DDX39 in human malignant pleural mesothelioma cell lines compared to normal pleural mesothelial cells.
</td>
<td style="text-align:left;">
Anticancer Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
Effusion cytology in the diagnosis of malignant epithelioid and biphasic pleural mesothelioma.
</td>
<td style="text-align:left;">
Arch. Pathol. Lab. Med.
</td>
</tr>
<tr>
<td style="text-align:left;">
Surgery in the treatment of malignant pleural mesothelioma: recruitment into trials should be the default position.
</td>
<td style="text-align:left;">
Thorax
</td>
</tr>
<tr>
<td style="text-align:left;">
Systematic review of pleurectomy in the treatment of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
A phase II clinical trial of the vascular disrupting agent BNC105P as second line chemotherapy for advanced Malignant Pleural Mesothelioma.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
The role of epigenetics in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Phase II study of first-line bortezomib and cisplatin in malignant pleural mesothelioma and prospective validation of progression free survival rate as a primary end-point for mesothelioma clinical trials (European Organisation for Research and Treatment of Cancer 08052).
</td>
<td style="text-align:left;">
Eur. J. Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Meta-analysis of microRNA-183 family expression in human cancer studies comparing cancer tissues with noncancerous tissues.
</td>
<td style="text-align:left;">
Gene
</td>
</tr>
<tr>
<td style="text-align:left;">
[Malignant pleural mesothelioma after radiation treatment for Hodgkin lymphoma].
</td>
<td style="text-align:left;">
Rev Pneumol Clin
</td>
</tr>
<tr>
<td style="text-align:left;">
Diffuse intrapulmonary malignant mesothelioma masquerading as interstitial lung disease: a distinctive variant of mesothelioma.
</td>
<td style="text-align:left;">
Am. J. Surg. Pathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
ERCC1, MLH1, MSH2, MSH6, and βIII-tubulin: resistance proteins associated with response and outcome to platinum-based chemotherapy in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Clin Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Therapies currently in Phase II trials for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Expert Opin Investig Drugs
</td>
</tr>
<tr>
<td style="text-align:left;">
Defect in recruiting effector memory CD8+ T-cells in malignant pleural effusions compared to normal pleural fluid.
</td>
<td style="text-align:left;">
BMC Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
The challenge of prognostic markers in pleural mesothelioma.
</td>
<td style="text-align:left;">
J Thorac Dis
</td>
</tr>
<tr>
<td style="text-align:left;">
Intensity-modulated radiotherapy and volumetric-modulated arc therapy for malignant pleural mesothelioma after extrapleural pleuropneumonectomy.
</td>
<td style="text-align:left;">
J Appl Clin Med Phys
</td>
</tr>
<tr>
<td style="text-align:left;">
Primary pericardial mesothelioma: a rare entity.
</td>
<td style="text-align:left;">
Case Rep Oncol Med
</td>
</tr>
<tr>
<td style="text-align:left;">
Diffuse mesothelioma of the peritoneum: a pathological study of 64 tumours treated with cytoreductive therapy.
</td>
<td style="text-align:left;">
Pathology
</td>
</tr>
<tr>
<td style="text-align:left;">
Tsc1-Tp53 loss induces mesothelioma in mice, and evidence for this mechanism in human mesothelioma.
</td>
<td style="text-align:left;">
Oncogene
</td>
</tr>
<tr>
<td style="text-align:left;">
Pemetrexed-induced eyelid edema in lung cancer.
</td>
<td style="text-align:left;">
J Craniofac Surg
</td>
</tr>
<tr>
<td style="text-align:left;">
[Prognosis related clinical and molecular factors in malignant pleural mesothelioma].
</td>
<td style="text-align:left;">
Zhonghua Jie He He Hu Xi Za Zhi
</td>
</tr>
<tr>
<td style="text-align:left;">
SAHA overcomes FLIP-mediated inhibition of SMAC mimetic-induced apoptosis in mesothelioma.
</td>
<td style="text-align:left;">
Cell Death Dis
</td>
</tr>
<tr>
<td style="text-align:left;">
A phase II study of pirarubicin in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
FDG PET/CT in the management of primary pleural tumors and pleural metastases.
</td>
<td style="text-align:left;">
AJR Am J Roentgenol
</td>
</tr>
<tr>
<td style="text-align:left;">
Secondline chemotherapy versus best supportive care in patient with malignant pleural mesothelioma: a retrospective study.
</td>
<td style="text-align:left;">
Asian Pac. J. Cancer Prev.
</td>
</tr>
<tr>
<td style="text-align:left;">
The use of indwelling pleural catheters for the management of malignant pleural effusion–direct costs in a Dutch hospital.
</td>
<td style="text-align:left;">
Respiration
</td>
</tr>
<tr>
<td style="text-align:left;">
Overexpression of EPH receptor B2 in malignant mesothelioma correlates with oncogenic behavior.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
An oncolytic vaccinia virus expressing the human sodium iodine symporter prolongs survival and facilitates SPECT/CT imaging in an orthotopic model of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Surgery
</td>
</tr>
<tr>
<td style="text-align:left;">
Identification of pregnancy-associated plasma protein A as a migration-promoting gene in malignant pleural mesothelioma cells: a potential therapeutic target.
</td>
<td style="text-align:left;">
Oncotarget
</td>
</tr>
<tr>
<td style="text-align:left;">
Up-regulation of DDX39 in human pancreatic cancer cells with acquired gemcitabine resistance compared to gemcitabine-sensitive parental cells.
</td>
<td style="text-align:left;">
Anticancer Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
Epidemiology of malignant pleural mesothelioma in the province of Sassari (Sardinia, Italy). A population-based report.
</td>
<td style="text-align:left;">
Ann Ital Chir
</td>
</tr>
<tr>
<td style="text-align:left;">
Negative modulation of mitochondrial oxidative phosphorylation by epigallocatechin-3 gallate leads to growth arrest and apoptosis in human malignant pleural mesothelioma cells.
</td>
<td style="text-align:left;">
Biochim. Biophys. Acta
</td>
</tr>
<tr>
<td style="text-align:left;">
Risk factors associated with asbestos-related diseases: a community-based case-control study.
</td>
<td style="text-align:left;">
BMC Public Health
</td>
</tr>
<tr>
<td style="text-align:left;">
Variability of tumor area measurements for response assessment in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Med Phys
</td>
</tr>
<tr>
<td style="text-align:left;">
18F-FDG PET/CT in suspected recurrences of epithelial malignant pleural mesothelioma in asbestos-fibers-exposed patients (comparison to standard diagnostic follow-up).
</td>
<td style="text-align:left;">
Clin Imaging
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma in a clerk working in an asbestos factory.
</td>
<td style="text-align:left;">
Ann. Acad. Med. Singap.
</td>
</tr>
<tr>
<td style="text-align:left;">
Treatment of malignant pleural mesothelioma by fibroblast activation protein-specific re-directed T cells.
</td>
<td style="text-align:left;">
J Transl Med
</td>
</tr>
<tr>
<td style="text-align:left;">
Characterization of a French series of female cases of mesothelioma.
</td>
<td style="text-align:left;">
Am. J. Ind. Med.
</td>
</tr>
<tr>
<td style="text-align:left;">
Giant malignant mesothelioma in the upper mediastinum: A case report.
</td>
<td style="text-align:left;">
Oncol Lett
</td>
</tr>
<tr>
<td style="text-align:left;">
Patterns of disease progression on 18F-fluorodeoxyglucose positron emission tomography-computed tomography in patients with malignant pleural mesothelioma undergoing multimodality therapy with pleurectomy/decortication.
</td>
<td style="text-align:left;">
Nucl Med Commun
</td>
</tr>
<tr>
<td style="text-align:left;">
BAP1 protein is a progression factor in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Pathol. Oncol. Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
Overexpression and promoter mutation of the TERT gene in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Oncogene
</td>
</tr>
<tr>
<td style="text-align:left;">
Long non coding RNAs (lncRNAs) are dysregulated in Malignant Pleural Mesothelioma (MPM).
</td>
<td style="text-align:left;">
PLoS ONE
</td>
</tr>
<tr>
<td style="text-align:left;">
Systematic review of trimodality therapy for patients with malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Ann Cardiothorac Surg
</td>
</tr>
<tr>
<td style="text-align:left;">
Do we need a revised staging system for malignant pleural mesothelioma? Analysis of the IASLC database.
</td>
<td style="text-align:left;">
Ann Cardiothorac Surg
</td>
</tr>
<tr>
<td style="text-align:left;">
Gremlin-1 associates with fibrillin microfibrils in vivo and regulates mesothelioma cell survival through transcription factor slug.
</td>
<td style="text-align:left;">
Oncogenesis
</td>
</tr>
<tr>
<td style="text-align:left;">
Existing models, but not neutrophil-to-lymphocyte ratio, are prognostic in malignant mesothelioma.
</td>
<td style="text-align:left;">
Br. J. Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Which type of surgery should become the preferred procedure for malignant pleural mesothelioma: extrapleural pneumonectomy or extended pleurectomy?
</td>
<td style="text-align:left;">
J Thorac Dis
</td>
</tr>
<tr>
<td style="text-align:left;">
Imaging in pleural mesothelioma: a review of the 11th International Conference of the International Mesothelioma Interest Group.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
The value of pemetrexed for the treatment of malignant pleural mesothelioma: a comprehensive review.
</td>
<td style="text-align:left;">
Anticancer Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
Cytoreductive surgery and post-operative heated pleural chemotherapy for the management of pleural surface malignancy.
</td>
<td style="text-align:left;">
Int J Hyperthermia
</td>
</tr>
<tr>
<td style="text-align:left;">
Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial.
</td>
<td style="text-align:left;">
Lancet Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Pulmonary mucinous cystadenocarcinoma presenting as a pleural mesothelioma.
</td>
<td style="text-align:left;">
Int J Surg Case Rep
</td>
</tr>
<tr>
<td style="text-align:left;">
The association of 18F-FDG PET/CT parameters with survival in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Eur. J. Nucl. Med. Mol. Imaging
</td>
</tr>
<tr>
<td style="text-align:left;">
Estrogen receptor β activation impairs mitochondrial oxidative metabolism and affects malignant mesothelioma cell growth in vitro and in vivo.
</td>
<td style="text-align:left;">
Oncogenesis
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma with bone metastases.
</td>
<td style="text-align:left;">
Med. Pediatr. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma presenting as acute empyema with severe leukocytosis.
</td>
<td style="text-align:left;">
Ann Thorac Cardiovasc Surg
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma: current and future perspectives.
</td>
<td style="text-align:left;">
J Thorac Dis
</td>
</tr>
<tr>
<td style="text-align:left;">
Clinical indications and results after chest wall resection for recurrent mesothelioma.
</td>
<td style="text-align:left;">
J. Thorac. Cardiovasc. Surg.
</td>
</tr>
<tr>
<td style="text-align:left;">
Treatment of malignant pleural effusion.
</td>
<td style="text-align:left;">
Chest
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant transformation of well-differentiated papillary mesothelioma 13 years after the diagnosis: a case report.
</td>
<td style="text-align:left;">
Clin Respir J
</td>
</tr>
<tr>
<td style="text-align:left;">
Intracavitary chemotherapy.
</td>
<td style="text-align:left;">
Crit. Rev. Oncol. Hematol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Clinical characteristics of patients with malignant pleural mesothelioma harboring somatic BAP1 mutations.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Lymph node involvement and metastatic lymph node ratio influence the survival of malignant pleural mesothelioma: a French multicenter retrospective study.
</td>
<td style="text-align:left;">
Oncol. Rep.
</td>
</tr>
<tr>
<td style="text-align:left;">
Restoring expression of miR-16: a novel approach to therapy for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Ann. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Prognostic nutritional index predicts outcomes of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J. Cancer Res. Clin. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Gemcitabine and vinorelbine as second-line or beyond treatment in patients with malignant pleural mesothelioma pretreated with platinum plus pemetrexed chemotherapy.
</td>
<td style="text-align:left;">
Int. J. Clin. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
¹⁸F-FDG uptake on PET is a predictive marker of thymidylate synthase expression in patients with thoracic neoplasms.
</td>
<td style="text-align:left;">
Oncol. Rep.
</td>
</tr>
<tr>
<td style="text-align:left;">
Immunological effects of the TGFβ-blocking antibody GC1008 in malignant pleural mesothelioma patients.
</td>
<td style="text-align:left;">
Oncoimmunology
</td>
</tr>
<tr>
<td style="text-align:left;">
Diffuse malignant peritoneal mesothelioma.
</td>
<td style="text-align:left;">
Kaohsiung J. Med. Sci.
</td>
</tr>
<tr>
<td style="text-align:left;">
Identification of a seven glycopeptide signature for malignant pleural mesothelioma in human serum by selected reaction monitoring.
</td>
<td style="text-align:left;">
Clin Proteomics
</td>
</tr>
<tr>
<td style="text-align:left;">
Radical pleurectomy/decortication followed by high dose of radiation therapy for malignant pleural mesothelioma. Final results with long-term follow-up.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
The state of the art in the technical performance of lung-sparing operations for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Semin. Thorac. Cardiovasc. Surg.
</td>
</tr>
<tr>
<td style="text-align:left;">
[Malignant pleural mesothelioma: 2013 state of the art].
</td>
<td style="text-align:left;">
Bull Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Antigenic phenotype of malignant mesotheliomas and pulmonary adenocarcinomas. An immunohistologic analysis demonstrating the value of Leu M1 antigen.
</td>
<td style="text-align:left;">
Am. J. Pathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Protumorigenic effects of mir-145 loss in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Oncogene
</td>
</tr>
<tr>
<td style="text-align:left;">
Clinicopathologic characteristics of malignant mesotheliomas arising in patients with a history of radiation for Hodgkin and non-Hodgkin lymphoma.
</td>
<td style="text-align:left;">
J. Clin. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Surgical pathology of lung cancer.
</td>
<td style="text-align:left;">
Semin Respir Crit Care Med
</td>
</tr>
<tr>
<td style="text-align:left;">
[Helical tomotherapy in the treatment of malignant pleural mesothelioma: The impact of low doses on pulmonary and oesophageal toxicity].
</td>
<td style="text-align:left;">
Cancer Radiother
</td>
</tr>
<tr>
<td style="text-align:left;">
FDG PET/CT is useful for detecting infiltration to the port site in patients with malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Gen Thorac Cardiovasc Surg
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant cardiac tamponade.
</td>
<td style="text-align:left;">
Acta Cardiol
</td>
</tr>
<tr>
<td style="text-align:left;">
Targeted delivery of let-7a microRNA encapsulated ephrin-A1 conjugated liposomal nanoparticles inhibit tumor growth in lung cancer.
</td>
<td style="text-align:left;">
Int J Nanomedicine
</td>
</tr>
<tr>
<td style="text-align:left;">
Effects of cisplatin and panobinostat on human mesothelial (Met-5A) and malignant pleural mesothelioma (MSTO-211H) cells.
</td>
<td style="text-align:left;">
Genet. Mol. Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
Radiotherapy for the treatment of pain in malignant pleural mesothelioma: a systematic review.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Extrapleural pneumonectomy for diffuse, malignant mesothelioma.
</td>
<td style="text-align:left;">
Ann. Thorac. Surg.
</td>
</tr>
<tr>
<td style="text-align:left;">
Vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Solitary fibrous tumors of the pleura: a case report and review of the literature.
</td>
<td style="text-align:left;">
Tumori
</td>
</tr>
<tr>
<td style="text-align:left;">
An RNAi-based screen reveals PLK1, CDK1 and NDC80 as potential therapeutic targets in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Br. J. Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Current readings: improvements in intensity-modulated radiation therapy for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Semin. Thorac. Cardiovasc. Surg.
</td>
</tr>
<tr>
<td style="text-align:left;">
Pharmacological targeting of p53 through RITA is an effective antitumoral strategy for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Cell Cycle
</td>
</tr>
<tr>
<td style="text-align:left;">
Pleural mesothelioma in a young male patient.
</td>
<td style="text-align:left;">
Monaldi Arch Chest Dis
</td>
</tr>
<tr>
<td style="text-align:left;">
A systematic review and meta-analysis of surgical treatments for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Antitumor effect and antiangiogenic potential of the mTOR inhibitor temsirolimus against malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Oncol. Rep.
</td>
</tr>
<tr>
<td style="text-align:left;">
Antineoplastic activity of povidone-iodine on different mesothelioma cell lines: results of in vitro study.
</td>
<td style="text-align:left;">
Eur J Cardiothorac Surg
</td>
</tr>
<tr>
<td style="text-align:left;">
Pemetrexed combined with platinum-based chemotherapy for advanced malignant peritoneal mesothelioma: retrospective analysis of six cases.
</td>
<td style="text-align:left;">
Anticancer Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
Extrapleural pneumonectomy for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Multimed Man Cardiothorac Surg
</td>
</tr>
<tr>
<td style="text-align:left;">
Comparative proteomic analysis of malignant pleural mesothelioma evidences an altered expression of nuclear lamin and filament-related proteins.
</td>
<td style="text-align:left;">
Proteomics Clin Appl
</td>
</tr>
<tr>
<td style="text-align:left;">
Radiotherapy applications of patients with malignant mesothelioma: A single center experience.
</td>
<td style="text-align:left;">
Rep Pract Oncol Radiother
</td>
</tr>
<tr>
<td style="text-align:left;">
PI3K/mTOR signaling in mesothelioma patients treated with induction chemotherapy followed by extrapleural pneumonectomy.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Circulating fibrinogen is a prognostic and predictive biomarker in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Br. J. Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Systemic treatment of malignant pleural mesothelioma: new agents in clinical trials raise hope of relevant improvements.
</td>
<td style="text-align:left;">
Curr Opin Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Molecular classification of malignant pleural mesothelioma: identification of a poor prognosis subgroup linked to the epithelial-to-mesenchymal transition.
</td>
<td style="text-align:left;">
Clin. Cancer Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
A feasibility study evaluating Surgery for Mesothelioma After Radiation Therapy: the “SMART” approach for resectable malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Immunotherapy for malignant pleural mesothelioma. Current status and future prospects.
</td>
<td style="text-align:left;">
Am. J. Respir. Cell Mol. Biol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Clinical outcome of postoperative highly conformal versus 3D conformal radiotherapy in patients with malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Radiat Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
ZIC1 is silenced and has tumor suppressor function in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Prognostic factors in patients presenting with pleural effusion revealing malignancy.
</td>
<td style="text-align:left;">
Respiration
</td>
</tr>
<tr>
<td style="text-align:left;">
Expression of carbonic anhydrase IX (CAIX) in malignant mesothelioma. An immunohistochemical and immunocytochemical study.
</td>
<td style="text-align:left;">
Neoplasma
</td>
</tr>
<tr>
<td style="text-align:left;">
Predictors of long-term survival following radical surgery for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Eur J Cardiothorac Surg
</td>
</tr>
<tr>
<td style="text-align:left;">
Differences in lectin binding of malignant pleural mesothelioma and adenocarcinoma of the lung.
</td>
<td style="text-align:left;">
Am. J. Pathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Phase I trial of cisplatin, pemetrexed, and imatinib mesylate in chemonaive patients with unresectable malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Clin Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Diffuse malignant epithelioid mesothelioma in a background of benign multicystic peritoneal mesothelioma: a case report and review of the literature.
</td>
<td style="text-align:left;">
BMJ Case Rep
</td>
</tr>
<tr>
<td style="text-align:left;">
[Clinicopathological characteristics and prognosis of malignant pleural mesothelioma].
</td>
<td style="text-align:left;">
Zhonghua Jie He He Hu Xi Za Zhi
</td>
</tr>
<tr>
<td style="text-align:left;">
The journey of mesothelioma: from postmortem to FNA.
</td>
<td style="text-align:left;">
BMJ Case Rep
</td>
</tr>
<tr>
<td style="text-align:left;">
Does surgery improve survival of patients with malignant pleural mesothelioma?: a multicenter retrospective analysis of 1365 consecutive patients.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
A Case Report of IgG4-Related Disease Clinically Mimicking Pleural Mesothelioma.
</td>
<td style="text-align:left;">
Tuberc Respir Dis (Seoul)
</td>
</tr>
<tr>
<td style="text-align:left;">
Multimodal management of malignant pleural mesothelioma: where are we today?
</td>
<td style="text-align:left;">
Eur. Respir. J.
</td>
</tr>
<tr>
<td style="text-align:left;">
CEA, AFP, CA125, CA153 and CA199 in malignant pleural effusions predict the cause.
</td>
<td style="text-align:left;">
Asian Pac. J. Cancer Prev.
</td>
</tr>
<tr>
<td style="text-align:left;">
Intrapleural natural beta interferon in the treatment of malignant pleural effusions.
</td>
<td style="text-align:left;">
Oncology
</td>
</tr>
<tr>
<td style="text-align:left;">
Pleural resection and pleural infusion chemotherapy for therapy of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Genet. Mol. Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma.
</td>
<td style="text-align:left;">
Pak J Med Sci
</td>
</tr>
<tr>
<td style="text-align:left;">
Preclinical evaluation of microRNA-34b/c delivery for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Acta Med. Okayama
</td>
</tr>
<tr>
<td style="text-align:left;">
Systemic but not topical TRAIL-expressing mesenchymal stem cells reduce tumour growth in malignant mesothelioma.
</td>
<td style="text-align:left;">
Thorax
</td>
</tr>
<tr>
<td style="text-align:left;">
Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies.
</td>
<td style="text-align:left;">
Cancer Immunol Res
</td>
</tr>
<tr>
<td style="text-align:left;">
Pathologic complete remission of malignant pleural mesothelioma after combined modality treatment: a case report.
</td>
<td style="text-align:left;">
Acta Clin Belg
</td>
</tr>
<tr>
<td style="text-align:left;">
Lymphohistiocytoid mesothelioma: a rare lymphomatoid variant of predominantly sarcomatoid mesothelioma.
</td>
<td style="text-align:left;">
Ultrastruct Pathol
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant intraperitoneal mesothelioma-Başkent University experience.
</td>
<td style="text-align:left;">
J Turk Ger Gynecol Assoc
</td>
</tr>
<tr>
<td style="text-align:left;">
Cilengitide inhibits attachment and invasion of malignant pleural mesothelioma cells through antagonism of integrins αvβ3 and αvβ5.
</td>
<td style="text-align:left;">
PLoS ONE
</td>
</tr>
<tr>
<td style="text-align:left;">
CARP-1 functional mimetics are a novel class of small molecule inhibitors of malignant pleural mesothelioma cells.
</td>
<td style="text-align:left;">
PLoS ONE
</td>
</tr>
<tr>
<td style="text-align:left;">
Surgery for malignant pleural mesothelioma: why, when and what?
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
[Malignant pleural mesothelioma: new aspects of medical therapy].
</td>
<td style="text-align:left;">
Pneumologie
</td>
</tr>
<tr>
<td style="text-align:left;">
Biomolecular and clinical practice in malignant pleural mesothelioma and lung cancer: what thoracic surgeons should know.
</td>
<td style="text-align:left;">
Eur J Cardiothorac Surg
</td>
</tr>
<tr>
<td style="text-align:left;">
Surgical management of malignant pleural mesothelioma: impact of surgery on survival and quality of life-relation to chemotherapy, radiotherapy, and alternative therapies.
</td>
<td style="text-align:left;">
ISRN Surg
</td>
</tr>
<tr>
<td style="text-align:left;">
[Peritoneal malignant mesothelioma: review and recent data].
</td>
<td style="text-align:left;">
Ann Pathol
</td>
</tr>
<tr>
<td style="text-align:left;">
Small cell carcinoma presenting with massive pleural spread mimicking malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Intern. Med.
</td>
</tr>
<tr>
<td style="text-align:left;">
Prognostic factors influencing survival in 35 patients with malignant peritoneal mesothelioma.
</td>
<td style="text-align:left;">
Neoplasma
</td>
</tr>
<tr>
<td style="text-align:left;">
Methotrexate and gemcitabine combination chemotherapy for the treatment of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Mol Clin Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Clinical characteristics, treatment and survival outcomes in malignant pleural mesothelioma: an institutional experience in Turkey.
</td>
<td style="text-align:left;">
J BUON
</td>
</tr>
<tr>
<td style="text-align:left;">
Expression profiling stratifies mesothelioma tumors and signifies deregulation of spindle checkpoint pathway and microtubule network with therapeutic implications.
</td>
<td style="text-align:left;">
Ann. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Prognostic factors affecting survival in malignant pleural mesothelioma: analysis of 125 subjects.
</td>
<td style="text-align:left;">
Tumori
</td>
</tr>
<tr>
<td style="text-align:left;">
Catheter tract metastasis associated with indwelling pleural catheters.
</td>
<td style="text-align:left;">
Chest
</td>
</tr>
<tr>
<td style="text-align:left;">
A phase II trial of prolonged, continuous infusion of low-dose gemcitabine plus cisplatin in patients with advanced malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Cancer Chemother. Pharmacol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Vinorelbine and gemcitabine as second- or third-line therapy for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Disulfiram suppresses growth of the malignant pleural mesothelioma cells in part by inducing apoptosis.
</td>
<td style="text-align:left;">
PLoS ONE
</td>
</tr>
<tr>
<td style="text-align:left;">
Significance of osteopontin in the sensitivity of malignant pleural mesothelioma to pemetrexed.
</td>
<td style="text-align:left;">
Int. J. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant peritoneal mesothelioma: clinicopathological characteristics of two cases.
</td>
<td style="text-align:left;">
Case Rep Surg
</td>
</tr>
<tr>
<td style="text-align:left;">
Relationship between prognosis and neutrophil: lymphocyte and platelet:lymphocyte ratios in patients with malignant pleural mesotheliomas.
</td>
<td style="text-align:left;">
Asian Pac. J. Cancer Prev.
</td>
</tr>
<tr>
<td style="text-align:left;">
Autocrine CSF-1R signaling drives mesothelioma chemoresistance via AKT activation.
</td>
<td style="text-align:left;">
Cell Death Dis
</td>
</tr>
<tr>
<td style="text-align:left;">
Extrapleural pneumonectomy for malignant mesothelioma: an Italian multicenter retrospective study.
</td>
<td style="text-align:left;">
Ann. Thorac. Surg.
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma and the Society of Thoracic Surgeons Database: an analysis of surgical morbidity and mortality.
</td>
<td style="text-align:left;">
J. Thorac. Cardiovasc. Surg.
</td>
</tr>
<tr>
<td style="text-align:left;">
Clinical utility of 18F-FDG positron emission tomography in malignant peritoneal mesothelioma.
</td>
<td style="text-align:left;">
Q J Nucl Med Mol Imaging
</td>
</tr>
<tr>
<td style="text-align:left;">
Regulation of somatostatin receptor 4-mediated cytostatic effects by CD26 in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Br. J. Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Newly synthesized anticancer drug HUHS1015 is effective on malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Cancer Sci.
</td>
</tr>
<tr>
<td style="text-align:left;">
Wide complex ventricular tachycardia presenting sign of metastatic pleural mesothelioma.
</td>
<td style="text-align:left;">
BMJ Case Rep
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma metastatic to the submandibular salivary gland, simulating glandular hypertrophy, diagnosed by fine-needle aspiration biopsy: a case report and literature review.
</td>
<td style="text-align:left;">
World J Surg Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Supplementary prognostic variables for pleural mesothelioma: a report from the IASLC staging committee.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Signal transducer and activator of transcription 1 (STAT1) acts like an oncogene in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Virchows Arch.
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma: a single-center experience in Turkey.
</td>
<td style="text-align:left;">
Med. Sci. Monit.
</td>
</tr>
<tr>
<td style="text-align:left;">
Merlin deficiency predicts FAK inhibitor sensitivity: a synthetic lethal relationship.
</td>
<td style="text-align:left;">
Sci Transl Med
</td>
</tr>
<tr>
<td style="text-align:left;">
Autofluorescence thoracoscopy in pleural disease: does it have clinical relevance?
</td>
<td style="text-align:left;">
Expert Rev Respir Med
</td>
</tr>
<tr>
<td style="text-align:left;">
EUS-guided fine needle tissue acquisition for the diagnosis of pleural metastases from endometrial cancer.
</td>
<td style="text-align:left;">
Eur Rev Med Pharmacol Sci
</td>
</tr>
<tr>
<td style="text-align:left;">
Assessing the function of homologous recombination DNA repair in malignant pleural effusion (MPE) samples.
</td>
<td style="text-align:left;">
Br. J. Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Management of malignant pleural mesothelioma-The European experience.
</td>
<td style="text-align:left;">
J Thorac Dis
</td>
</tr>
<tr>
<td style="text-align:left;">
Recurring loss involving chromosomes 1, 3, and 22 in malignant mesothelioma: possible sites of tumor suppressor genes.
</td>
<td style="text-align:left;">
Genes Chromosomes Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Assessment of cisplatin concentration and depth of penetration in human lung tissue after hyperthermic exposure.
</td>
<td style="text-align:left;">
Eur J Cardiothorac Surg
</td>
</tr>
<tr>
<td style="text-align:left;">
Efficacy of phase 1 trials in malignant pleural mesothelioma: description of a series of patients at a single institution.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Cisplatin-resistant cells in malignant pleural mesothelioma cell lines show ALDH(high)CD44(+) phenotype and sphere-forming capacity.
</td>
<td style="text-align:left;">
BMC Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Diagnostic potential of miR-126, miR-143, miR-145, and miR-652 in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J Mol Diagn
</td>
</tr>
<tr>
<td style="text-align:left;">
Prognostic factors in elderly patients with malignant pleural mesothelioma: results of a multicenter survey.
</td>
<td style="text-align:left;">
Br. J. Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Synergistic antitumor activity of recombinant human Apo2L/tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) in combination with carboplatin and pemetrexed in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Frequent coamplification and cooperation between C-MYC and PVT1 oncogenes promote malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
B7-H1 expression in malignant pleural mesothelioma is associated with sarcomatoid histology and poor prognosis.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Women with malignant pleural mesothelioma have a threefold better survival rate than men.
</td>
<td style="text-align:left;">
Ann. Thorac. Surg.
</td>
</tr>
<tr>
<td style="text-align:left;">
Third-space fluid distribution of pemetrexed in non-small cell lung cancer patients.
</td>
<td style="text-align:left;">
Cancer Chemother. Pharmacol.
</td>
</tr>
<tr>
<td style="text-align:left;">
ERCC1 as a biological marker guiding management in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Asian Pac. J. Cancer Prev.
</td>
</tr>
<tr>
<td style="text-align:left;">
Efficacy and cost of video-assisted thoracoscopic partial pleurectomy versus talc pleurodesis in patients with malignant pleural mesothelioma (MesoVATS): an open-label, randomised, controlled trial.
</td>
<td style="text-align:left;">
Lancet
</td>
</tr>
<tr>
<td style="text-align:left;">
Interventional therapies for malignant pleural effusions: the present and the future.
</td>
<td style="text-align:left;">
Respirology
</td>
</tr>
<tr>
<td style="text-align:left;">
Second-line gemcitabine-based chemotherapy regimens improve overall 3-year survival rate in patients with malignant pleural mesothelioma: a multicenter retrospective study.
</td>
<td style="text-align:left;">
Med. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Nonamplified FGFR1 is a growth driver in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Mol. Cancer Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
Synchronous pleural and peritoneal malignant mesothelioma: a case report and review of literature.
</td>
<td style="text-align:left;">
Int J Clin Exp Pathol
</td>
</tr>
<tr>
<td style="text-align:left;">
New histone deacetylase inhibitors improve cisplatin antitumor properties against thoracic cancer cells.
</td>
<td style="text-align:left;">
Oncotarget
</td>
</tr>
<tr>
<td style="text-align:left;">
Metastatic mesothelioma to the thyroid.
</td>
<td style="text-align:left;">
Cytojournal
</td>
</tr>
<tr>
<td style="text-align:left;">
Phase 1 study of the antimesothelin immunotoxin SS1P in combination with pemetrexed and cisplatin for front-line therapy of pleural mesothelioma and correlation of tumor response with serum mesothelin, megakaryocyte potentiating factor, and cancer antigen 125.
</td>
<td style="text-align:left;">
Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Polymorphisms in folate pathway and pemetrexed treatment outcome in patients with malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Radiol Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Usp9x- and Noxa-mediated Mcl-1 downregulation contributes to pemetrexed-induced apoptosis in human non-small-cell lung cancer cells.
</td>
<td style="text-align:left;">
Cell Death Dis
</td>
</tr>
<tr>
<td style="text-align:left;">
Prognostic coronary surgery in a case of malignant mesothelioma previously managed with trimodality treatment.
</td>
<td style="text-align:left;">
Heart Lung Circ
</td>
</tr>
<tr>
<td style="text-align:left;">
The homeobox gene EMX2 is a prognostic and predictive marker in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
CD157 enhances malignant pleural mesothelioma aggressiveness and predicts poor clinical outcome.
</td>
<td style="text-align:left;">
Oncotarget
</td>
</tr>
<tr>
<td style="text-align:left;">
EF24 and RAD001 potentiates the anticancer effect of platinum-based agents in human malignant pleural mesothelioma (MSTO-211H) cells and protects nonmalignant mesothelial (MET-5A) cells.
</td>
<td style="text-align:left;">
Hum Exp Toxicol
</td>
</tr>
<tr>
<td style="text-align:left;">
Newly established ELISA for N-ERC/mesothelin improves diagnostic accuracy in patients with suspected pleural mesothelioma.
</td>
<td style="text-align:left;">
Cancer Med
</td>
</tr>
<tr>
<td style="text-align:left;">
Randomized phase II trial of pemetrexed/cisplatin with or without CBP501 in patients with advanced malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Photodynamic therapy enhanced by hyperbaric oxygenation in palliation of malignant pleural mesothelioma: clinical experience.
</td>
<td style="text-align:left;">
Photodiagnosis Photodyn Ther
</td>
</tr>
<tr>
<td style="text-align:left;">
The role of microRNAs in the diagnosis and treatment of malignant pleural mesothelioma–a short review.
</td>
<td style="text-align:left;">
Microrna
</td>
</tr>
<tr>
<td style="text-align:left;">
Photodynamic therapy in the management of malignant pleural mesothelioma: A review.
</td>
<td style="text-align:left;">
Photodiagnosis Photodyn Ther
</td>
</tr>
<tr>
<td style="text-align:left;">
Serum albumin as a significant prognostic factor in patients with malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Tumour Biol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Activation of Nrf2 pathways correlates with resistance of NSCLC cell lines to CBP501 in vitro.
</td>
<td style="text-align:left;">
Mol. Cancer Ther.
</td>
</tr>
<tr>
<td style="text-align:left;">
Sarcomatoid malignant mesothelioma presenting with intramedullary spinal cord metastasis: a case report and literature review.
</td>
<td style="text-align:left;">
Global Spine J
</td>
</tr>
<tr>
<td style="text-align:left;">
Predictive value of systemic and local inflammation parameters in talc pleurodesis assessment.
</td>
<td style="text-align:left;">
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub
</td>
</tr>
<tr>
<td style="text-align:left;">
Diagnosis and treatment of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Arch. Bronconeumol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Current issues in malignant pleural mesothelioma evaluation and management.
</td>
<td style="text-align:left;">
Oncologist
</td>
</tr>
<tr>
<td style="text-align:left;">
Failure patterns after hemithoracic pleural intensity modulated radiation therapy for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Int. J. Radiat. Oncol. Biol. Phys.
</td>
</tr>
<tr>
<td style="text-align:left;">
Phrenic nerve paralysis as the initial presentation in pleural sarcomatoid mesothelioma.
</td>
<td style="text-align:left;">
Case Rep Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma and central nervous system metastases. Report of two cases, pooled analysis, and systematic review.
</td>
<td style="text-align:left;">
Ann Am Thorac Soc
</td>
</tr>
<tr>
<td style="text-align:left;">
Extrapleural pneumonectomy after induction chemotherapy: perioperative outcome in 251 mesothelioma patients from three high-volume institutions.
</td>
<td style="text-align:left;">
Ann. Thorac. Surg.
</td>
</tr>
<tr>
<td style="text-align:left;">
Metastasis of mesothelioma to the maxillary gingiva.
</td>
<td style="text-align:left;">
Oncol Lett
</td>
</tr>
<tr>
<td style="text-align:left;">
A commercially available preparation of Staphylococcus aureus bio-products potently inhibits tumour growth in a murine model of mesothelioma.
</td>
<td style="text-align:left;">
Respirology
</td>
</tr>
<tr>
<td style="text-align:left;">
Gamma knife radiosurgery of brain metastasis from malignant pleural mesothelioma–report of three cases with autopsy study in a case.
</td>
<td style="text-align:left;">
Nagoya J Med Sci
</td>
</tr>
<tr>
<td style="text-align:left;">
Absence of amplification of the FGFR1-gene in human malignant mesothelioma of the pleura: a pilot study.
</td>
<td style="text-align:left;">
BMC Res Notes
</td>
</tr>
<tr>
<td style="text-align:left;">
Hyponatraemia is a predictor of clinical outcome for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Support Care Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Progression free survival rate at 9 and 18 weeks predict overall survival in patients with malignant pleural mesothelioma: an individual patient pooled analysis of 10 European Organisation for Research and Treatment of Cancer Lung Cancer Group studies and an independent study validation.
</td>
<td style="text-align:left;">
Eur. J. Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Gingival metastasis as first sign of multiorgan dissemination of epithelioid malignant mesothelioma.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Identification of actionable mutations in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Should we continue to offer extrapleural pneumonectomy to selected mesothelioma patients? A single center experience comparing surgical and non-surgical management.
</td>
<td style="text-align:left;">
Jpn. J. Clin. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Factors associated with survival in a large series of patients with malignant pleural mesothelioma in New South Wales.
</td>
<td style="text-align:left;">
Br. J. Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Fibroblast growth factor receptor inhibition is active against mesothelioma and synergizes with radio- and chemotherapy.
</td>
<td style="text-align:left;">
Am. J. Respir. Crit. Care Med.
</td>
</tr>
<tr>
<td style="text-align:left;">
Ratio of intratumoral macrophage phenotypes is a prognostic factor in epithelioid malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
PLoS ONE
</td>
</tr>
<tr>
<td style="text-align:left;">
Extrapleural pneumonectomy in the treatment of epithelioid malignant pleural mesothelioma: novel prognostic implications of combined N1 and N2 nodal involvement based on experience in 529 patients.
</td>
<td style="text-align:left;">
Ann. Surg.
</td>
</tr>
<tr>
<td style="text-align:left;">
Systematic review of response rates of sarcomatoid malignant pleural mesotheliomas in clinical trials.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Phase II clinical trial of amatuximab, a chimeric antimesothelin antibody with pemetrexed and cisplatin in advanced unresectable pleural mesothelioma.
</td>
<td style="text-align:left;">
Clin. Cancer Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
A multicentre non-blinded randomised controlled trial to assess the impact of regular early specialist symptom control treatment on quality of life in malignant mesothelioma (RESPECT-MESO): study protocol for a randomised controlled trial.
</td>
<td style="text-align:left;">
Trials
</td>
</tr>
<tr>
<td style="text-align:left;">
Correlation between TS, MTHFR, and ERCC1 gene polymorphisms and the efficacy of platinum in combination with pemetrexed first-line chemotherapy in mesothelioma patients.
</td>
<td style="text-align:left;">
Clin Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Characterization and drug sensitivity profiling of primary malignant mesothelioma cells from pleural effusions.
</td>
<td style="text-align:left;">
BMC Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Local and systemic therapies for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Curr Treat Options Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Agonist activation of estrogen receptor beta (ERβ) sensitizes malignant pleural mesothelioma cells to cisplatin cytotoxicity.
</td>
<td style="text-align:left;">
Mol. Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Rechallenge with pemetrexed-based chemotherapy improves the survival of patients with advanced non-squamous non-small-cell lung cancer.
</td>
<td style="text-align:left;">
Mol Clin Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Naftopidil is useful for the treatment of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Pharmacology
</td>
</tr>
<tr>
<td style="text-align:left;">
Multimodality imaging for characterization, classification, and staging of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Radiographics
</td>
</tr>
<tr>
<td style="text-align:left;">
Impact of New Chemotherapeutic agents on the outcome of Egyptian patients with Advanced Malignant Pleural Mesothelioma.
</td>
<td style="text-align:left;">
Gulf J Oncolog
</td>
</tr>
<tr>
<td style="text-align:left;">
Long progression-free survival by pemetrexed continuation maintenance therapy following cisplatin-based chemotherapy in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Intern. Med.
</td>
</tr>
<tr>
<td style="text-align:left;">
Pseudo-tumor mimicking indwelling pleural catheter tract metastasis in mesothelioma.
</td>
<td style="text-align:left;">
J Bronchology Interv Pulmonol
</td>
</tr>
<tr>
<td style="text-align:left;">
Advances in malignant peritoneal mesothelioma.
</td>
<td style="text-align:left;">
Int J Colorectal Dis
</td>
</tr>
<tr>
<td style="text-align:left;">
Downregulation of thymidylate synthase and E2F1 by arsenic trioxide in mesothelioma.
</td>
<td style="text-align:left;">
Int. J. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Use of computed tomography and positron emission tomography/computed tomography for staging of local extent in patients with malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J Comput Assist Tomogr
</td>
</tr>
<tr>
<td style="text-align:left;">
Cisplatin in combination with Phenethyl Isothiocyanate (PEITC), a potential new therapeutic strategy for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Oncotarget
</td>
</tr>
<tr>
<td style="text-align:left;">
Oral cyclophosphamide and etoposide in treatment of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Asian Pac. J. Cancer Prev.
</td>
</tr>
<tr>
<td style="text-align:left;">
Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity.
</td>
<td style="text-align:left;">
Sci Transl Med
</td>
</tr>
<tr>
<td style="text-align:left;">
Estimation of an optimal chemotherapy utilization rate for malignant pleural mesothelioma: an evidence-based benchmark for cancer care.
</td>
<td style="text-align:left;">
Asia Pac J Clin Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Combination effect of photodynamic therapy using NPe6 with pemetrexed for human malignant pleural mesothelioma cells.
</td>
<td style="text-align:left;">
Int. J. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Quantitative analyses at baseline and interim PET evaluation for response assessment and outcome definition in patients with malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Eur. J. Nucl. Med. Mol. Imaging
</td>
</tr>
<tr>
<td style="text-align:left;">
Therapeutic activity of glycoengineered anti-GM2 antibodies against malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Cancer Sci.
</td>
</tr>
<tr>
<td style="text-align:left;">
CK2α, over-expressed in human malignant pleural mesothelioma, regulates the Hedgehog signaling pathway in mesothelioma cells.
</td>
<td style="text-align:left;">
J. Exp. Clin. Cancer Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
Caring for patients with malignant pleural mesothelioma in Japan: evaluation of a Palliative Care Educational Program.
</td>
<td style="text-align:left;">
Asian Pac. J. Cancer Prev.
</td>
</tr>
<tr>
<td style="text-align:left;">
FISH analysis of intrapulmonary malignant mesothelioma without a clinically detectable primary pleural lesion: an autopsy case.
</td>
<td style="text-align:left;">
Jpn. J. Clin. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Extrapleural pneumonectomy for pleural malignancies.
</td>
<td style="text-align:left;">
Thorac Surg Clin
</td>
</tr>
<tr>
<td style="text-align:left;">
Hemithoracic intensity modulated radiation therapy after pleurectomy/decortication for malignant pleural mesothelioma: toxicity, patterns of failure, and a matched survival analysis.
</td>
<td style="text-align:left;">
Int. J. Radiat. Oncol. Biol. Phys.
</td>
</tr>
<tr>
<td style="text-align:left;">
Current controversies in the management of malignant pleural effusions.
</td>
<td style="text-align:left;">
Semin Respir Crit Care Med
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma: new hope in the horizon with novel therapeutic strategies.
</td>
<td style="text-align:left;">
Cancer Treat. Rev.
</td>
</tr>
<tr>
<td style="text-align:left;">
Predictors of clinical use of pleurodesis and/or indwelling pleural catheter therapy for malignant pleural effusion.
</td>
<td style="text-align:left;">
Chest
</td>
</tr>
<tr>
<td style="text-align:left;">
[A clinical study of six surgically treated patients with malignant tumors arising from chronic pleuritis and pyothorax].
</td>
<td style="text-align:left;">
Nihon Kyobu Geka Gakkai Zasshi
</td>
</tr>
<tr>
<td style="text-align:left;">
MiR-score: a novel 6-microRNA signature that predicts survival outcomes in patients with malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Mol Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Photodynamic therapy for lung cancer and malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Semin. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Combination of arginine deprivation with TRAIL treatment as a targeted-therapy for mesothelioma.
</td>
<td style="text-align:left;">
Anticancer Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
Clinicopathologic and survival characteristics of malignant pleural mesothelioma registered in hospital cancer registry.
</td>
<td style="text-align:left;">
Tanaffos
</td>
</tr>
<tr>
<td style="text-align:left;">
Detection of circulating tumour cells in peripheral blood of patients with malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Cancer Biomark
</td>
</tr>
<tr>
<td style="text-align:left;">
Novel induction therapies for pleural mesothelioma.
</td>
<td style="text-align:left;">
Semin. Thorac. Cardiovasc. Surg.
</td>
</tr>
<tr>
<td style="text-align:left;">
1-[2-(2-Methoxyphenylamino)ethylamino]-3-(naphthalene-1- yloxy)propan-2-ol may be a promising anticancer drug.
</td>
<td style="text-align:left;">
Molecules
</td>
</tr>
<tr>
<td style="text-align:left;">
Adenosine deaminase inhibitor EHNA exhibits a potent anticancer effect against malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Cell. Physiol. Biochem.
</td>
</tr>
<tr>
<td style="text-align:left;">
[Hyperthermic chemoperfusion of the pleural cavity in the combined treatment for malignant pleural mesothelioma].
</td>
<td style="text-align:left;">
Vopr Onkol
</td>
</tr>
<tr>
<td style="text-align:left;">
[Pemetrexed-induced scleroderma-like changes in the lower legs].
</td>
<td style="text-align:left;">
Ann Dermatol Venereol
</td>
</tr>
<tr>
<td style="text-align:left;">
Early experience with intensity modulated proton therapy for lung-intact mesothelioma: A case series.
</td>
<td style="text-align:left;">
Pract Radiat Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Third-line chemotherapy with carboplatin, gemcitabine and liposomised doxorubicin for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Med. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Protocol for the surgical and large bore procedures in malignant pleural mesothelioma and radiotherapy trial (SMART Trial): an RCT evaluating whether prophylactic radiotherapy reduces the incidence of procedure tract metastases.
</td>
<td style="text-align:left;">
BMJ Open
</td>
</tr>
<tr>
<td style="text-align:left;">
Acute lower limb ischemia complicating pemetrexed and carboplatin combination chemotherapy for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Ann Ital Chir
</td>
</tr>
<tr>
<td style="text-align:left;">
Fluoro deoxyglucose positron emission tomography-computerized tomography in primary staging and response assessment of a rare case of primary pleural synovial sarcoma.
</td>
<td style="text-align:left;">
Indian J Nucl Med
</td>
</tr>
<tr>
<td style="text-align:left;">
[Current surgical therapy for malignant pleural mesothelioma].
</td>
<td style="text-align:left;">
Kyobu Geka
</td>
</tr>
<tr>
<td style="text-align:left;">
Clinical experience of volumetric modulated arc therapy for malignant pleural mesothelioma after extrapleural pneumonectomy.
</td>
<td style="text-align:left;">
J. Radiat. Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
SWOG S0722: phase II study of mTOR inhibitor everolimus (RAD001) in advanced malignant pleural mesothelioma (MPM).
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Testing mapping algorithms of the cancer-specific EORTC QLQ-C30 onto EQ-5D in malignant mesothelioma.
</td>
<td style="text-align:left;">
Health Qual Life Outcomes
</td>
</tr>
<tr>
<td style="text-align:left;">
Fast neutron radiotherapy in the treatment of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Am. J. Clin. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Wnt7A is a putative prognostic and chemosensitivity marker in human malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Oncol. Rep.
</td>
</tr>
<tr>
<td style="text-align:left;">
Ki67 index is an independent prognostic factor in epithelioid but not in non-epithelioid malignant pleural mesothelioma: a multicenter study.
</td>
<td style="text-align:left;">
Br. J. Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
A case of advanced malignant pleural mesothelioma treatment with chemotherapy and photodynamic therapy.
</td>
<td style="text-align:left;">
Tuberc Respir Dis (Seoul)
</td>
</tr>
<tr>
<td style="text-align:left;">
Is Radiotherapy Useful for Treating Pain in Mesothelioma?: A Phase II Trial.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Cytoreductive surgery and hyperthermic intrapleural chemotherapy for malignant pleural diseases: preliminary experience.
</td>
<td style="text-align:left;">
Future Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
MDM2 is an important prognostic and predictive factor for platin-pemetrexed therapy in malignant pleural mesotheliomas and deregulation of P14/ARF (encoded by CDKN2A) seems to contribute to an MDM2-driven inactivation of P53.
</td>
<td style="text-align:left;">
Br. J. Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Persistent lung expansion after pleural talc poudrage in non-surgically resected malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Ann. Thorac. Surg.
</td>
</tr>
<tr>
<td style="text-align:left;">
Itraconazole therapy in a pancreatic adenocarcinoma patient: A case report.
</td>
<td style="text-align:left;">
J Oncol Pharm Pract
</td>
</tr>
<tr>
<td style="text-align:left;">
New and emerging therapeutic options for malignant pleural mesothelioma: review of early clinical trials.
</td>
<td style="text-align:left;">
Cancer Manag Res
</td>
</tr>
<tr>
<td style="text-align:left;">
Feasibility and performance of an adaptive contrast-oriented FDG PET/CT quantification technique for global disease assessment of malignant pleural mesothelioma and a brief review of the literature.
</td>
<td style="text-align:left;">
Hell J Nucl Med
</td>
</tr>
<tr>
<td style="text-align:left;">
Clinical and prognostic features of erionite-induced malignant mesothelioma.
</td>
<td style="text-align:left;">
Yonsei Med. J.
</td>
</tr>
<tr>
<td style="text-align:left;">
New biomarkers in the selection of patients for talcage of pleural cavity in the palliative therapy of malign pleural exudate.
</td>
<td style="text-align:left;">
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub
</td>
</tr>
<tr>
<td style="text-align:left;">
Searching for targets for the systemic therapy of mesothelioma.
</td>
<td style="text-align:left;">
Ann. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma: history, controversy and future of a manmade epidemic.
</td>
<td style="text-align:left;">
Eur Respir Rev
</td>
</tr>
<tr>
<td style="text-align:left;">
Pleurectomy/decortication, hyperthermic pleural lavage with povidone-iodine, prophylactic radiotherapy, and systemic chemotherapy in patients with malignant pleural mesothelioma: a 10-year experience.
</td>
<td style="text-align:left;">
J. Thorac. Cardiovasc. Surg.
</td>
</tr>
<tr>
<td style="text-align:left;">
Evaluation of androgen receptor and GATA binding protein 3 as immunohistochemical markers in the diagnosis of metastatic breast carcinoma to the lung.
</td>
<td style="text-align:left;">
Pathol. Int.
</td>
</tr>
<tr>
<td style="text-align:left;">
[A case of malignant peritoneal mesothelioma without deletion of p16].
</td>
<td style="text-align:left;">
Gan To Kagaku Ryoho
</td>
</tr>
<tr>
<td style="text-align:left;">
Intrapleural Fibrinolysis for the Treatment of Indwelling Pleural Catheter-Related Symptomatic Loculations: A Multicenter Observational Study.
</td>
<td style="text-align:left;">
Chest
</td>
</tr>
<tr>
<td style="text-align:left;">
Changing pattern in malignant mesothelioma survival.
</td>
<td style="text-align:left;">
Transl Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Interim results of pleurectomy/decortication and intraoperative intrapleural hyperthermic cisplatin perfusion for patients with malignant pleural mesothelioma intolerable to extrapleural pneumonectomy.
</td>
<td style="text-align:left;">
Gen Thorac Cardiovasc Surg
</td>
</tr>
<tr>
<td style="text-align:left;">
Hemithoracic radiation therapy after extrapleural pneumonectomy for malignant pleural mesothelioma: Toxicity and outcomes at an Australian institution.
</td>
<td style="text-align:left;">
J Med Imaging Radiat Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
The effect of chemotherapy on health-related quality of life in mesothelioma: results from the SWAMP trial.
</td>
<td style="text-align:left;">
Br. J. Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
The South West Area Mesothelioma and Pemetrexed trial: a multicentre prospective observational study evaluating novel markers of chemotherapy response and prognostication.
</td>
<td style="text-align:left;">
Br. J. Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Diffuse intrapulmonary malignant mesothelioma presenting with miliary pulmonary nodules: A case report.
</td>
<td style="text-align:left;">
Pathol. Int.
</td>
</tr>
<tr>
<td style="text-align:left;">
Updated patterns of failure after multimodality therapy for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J. Thorac. Cardiovasc. Surg.
</td>
</tr>
<tr>
<td style="text-align:left;">
Analysis of expression of programmed cell death 1 ligand 1 (PD-L1) in malignant pleural mesothelioma (MPM).
</td>
<td style="text-align:left;">
PLoS ONE
</td>
</tr>
<tr>
<td style="text-align:left;">
Impact of mesothelioma histologic subtype on outcomes in the Surveillance, Epidemiology, and End Results database.
</td>
<td style="text-align:left;">
J. Surg. Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
Unusual appearance of malignant peritoneal mesothelioma.
</td>
<td style="text-align:left;">
J Comput Assist Tomogr
</td>
</tr>
<tr>
<td style="text-align:left;">
[Role of the Sonic Hedgehog pathway in thoracic cancers].
</td>
<td style="text-align:left;">
Rev Mal Respir
</td>
</tr>
<tr>
<td style="text-align:left;">
Vorinostat in patients with advanced malignant pleural mesothelioma who have progressed on previous chemotherapy (VANTAGE-014): a phase 3, double-blind, randomised, placebo-controlled trial.
</td>
<td style="text-align:left;">
Lancet Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
The efficacy of pemetrexed and bevacizumab intrapleural injection for malignant pleural mesothelioma-mediated malignant pleural effusion.
</td>
<td style="text-align:left;">
Indian J Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Efficacy and safety of an intensified schedule of tremelimumab for chemotherapy-resistant malignant mesothelioma: an open-label, single-arm, phase 2 study.
</td>
<td style="text-align:left;">
Lancet Respir Med
</td>
</tr>
<tr>
<td style="text-align:left;">
Blockade of aquaporin 1 inhibits proliferation, motility, and metastatic potential of mesothelioma in vitro but not in an in vivo model.
</td>
<td style="text-align:left;">
Dis. Markers
</td>
</tr>
<tr>
<td style="text-align:left;">
NF2 blocks Snail-mediated p53 suppression in mesothelioma.
</td>
<td style="text-align:left;">
Oncotarget
</td>
</tr>
<tr>
<td style="text-align:left;">
Prognostic factors in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Hum. Pathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Effects of extended pleurectomy and decortication on quality of life and pulmonary function in patients with malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Ann. Thorac. Surg.
</td>
</tr>
<tr>
<td style="text-align:left;">
A new prognostic index for overall survival in malignant pleural mesothelioma: the rPHS (regimen, PS, histology or stage) index.
</td>
<td style="text-align:left;">
Jpn. J. Clin. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Importance of excision repair cross-complementation group 1 and ribonucleotide reductase M1 as prognostic biomarkers in malignant pleural mesothelioma treated with platinum-based induction chemotherapy followed by surgery.
</td>
<td style="text-align:left;">
J. Thorac. Cardiovasc. Surg.
</td>
</tr>
<tr>
<td style="text-align:left;">
[A case of malignant pleural mesothelioma with infectious bronchogenic cyst].
</td>
<td style="text-align:left;">
Nihon Kyobu Shikkan Gakkai Zasshi
</td>
</tr>
<tr>
<td style="text-align:left;">
Demographics, management and survival of patients with malignant pleural mesothelioma in the National Lung Cancer Audit in England and Wales.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
A STAT3-NFkB/DDIT3/CEBPβ axis modulates ALDH1A3 expression in chemoresistant cell subpopulations.
</td>
<td style="text-align:left;">
Oncotarget
</td>
</tr>
<tr>
<td style="text-align:left;">
Prognostic factors in malignant pleural mesothelioma: a retrospective study of 60 Turkish patients.
</td>
<td style="text-align:left;">
J Cancer Res Ther
</td>
</tr>
<tr>
<td style="text-align:left;">
BAP1 mutation is a frequent somatic event in peritoneal malignant mesothelioma.
</td>
<td style="text-align:left;">
J Transl Med
</td>
</tr>
<tr>
<td style="text-align:left;">
Single-dose dexamethasone for the prevention of pemetrexed associated cutaneous adverse reactions.
</td>
<td style="text-align:left;">
J Oncol Pharm Pract
</td>
</tr>
<tr>
<td style="text-align:left;">
Intrapleural Photodynamic Therapy for Mesothelioma: What Place and Which Future?
</td>
<td style="text-align:left;">
Ann. Thorac. Surg.
</td>
</tr>
<tr>
<td style="text-align:left;">
Claudin 3, 4, and 15 expression in solid tumors of lung adenocarcinoma versus malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Ann Diagn Pathol
</td>
</tr>
<tr>
<td style="text-align:left;">
Local treatment of a pleural mesothelioma tumor with ONCOS-102 induces a systemic antitumor CD8<sup>+</sup> T-cell response, prominent infiltration of CD8<sup>+</sup> lymphocytes and Th1 type polarization.
</td>
<td style="text-align:left;">
Oncoimmunology
</td>
</tr>
<tr>
<td style="text-align:left;">
Inhibition of autophagy sensitizes malignant pleural mesothelioma cells to dual PI3K/mTOR inhibitors.
</td>
<td style="text-align:left;">
Cell Death Dis
</td>
</tr>
<tr>
<td style="text-align:left;">
The combination of sorafenib and everolimus shows antitumor activity in preclinical models of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
BMC Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Randomized Trials of Systemic Medically-treated Malignant Mesothelioma: A Systematic Review.
</td>
<td style="text-align:left;">
Anticancer Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
Mesothelioma treatment.
</td>
<td style="text-align:left;">
Rev Port Pneumol
</td>
</tr>
<tr>
<td style="text-align:left;">
Loss of the deubiquitylase BAP1 alters class I histone deacetylase expression and sensitivity of mesothelioma cells to HDAC inhibitors.
</td>
<td style="text-align:left;">
Oncotarget
</td>
</tr>
<tr>
<td style="text-align:left;">
The established and future biomarkers of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Cancer Treat. Rev.
</td>
</tr>
<tr>
<td style="text-align:left;">
Amplatzer Device in Bronchial Stump Fistula after Extrapleural Pneumonectomy.
</td>
<td style="text-align:left;">
Thorac Cardiovasc Surg
</td>
</tr>
<tr>
<td style="text-align:left;">
Localized malignant pleural mesothelioma with renal metastasis.
</td>
<td style="text-align:left;">
Oxf Med Case Reports
</td>
</tr>
<tr>
<td style="text-align:left;">
An IR Navigation System for Pleural PDT.
</td>
<td style="text-align:left;">
Front Phys
</td>
</tr>
<tr>
<td style="text-align:left;">
Surgical cytoreduction restores the antitumor efficacy of a Listeria monocytogenes vaccine in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Immunol. Lett.
</td>
</tr>
<tr>
<td style="text-align:left;">
Monte Carlo simulation of light fluence calculation during pleural PDT.
</td>
<td style="text-align:left;">
Proc SPIE Int Soc Opt Eng
</td>
</tr>
<tr>
<td style="text-align:left;">
Targeting glucosylceramide synthase induction of cell surface globotriaosylceramide (Gb3) in acquired cisplatin-resistance of lung cancer and malignant pleural mesothelioma cells.
</td>
<td style="text-align:left;">
Exp. Cell Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
Surgical treatment for malignant pleural mesothelioma: extrapleural pneumonectomy, pleurectomy/decortication or extended pleurectomy?
</td>
<td style="text-align:left;">
J BUON
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant Pleural Mesothelioma : Rationale for a New TNM Classification.
</td>
<td style="text-align:left;">
Acta Chir. Belg.
</td>
</tr>
<tr>
<td style="text-align:left;">
An unusual cause of an anterior mediastinal mass.
</td>
<td style="text-align:left;">
Respir Med Case Rep
</td>
</tr>
<tr>
<td style="text-align:left;">
Treatment patterns and survival analysis in 9014 patients with malignant pleural mesothelioma from Belgium, the Netherlands and England.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Differential p16/INK4A cyclin-dependent kinase inhibitor expression correlates with chemotherapy efficacy in a cohort of 88 malignant pleural mesothelioma patients.
</td>
<td style="text-align:left;">
Br. J. Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma in the southwestern part of The Netherlands.
</td>
<td style="text-align:left;">
Eur. Respir. J.
</td>
</tr>
<tr>
<td style="text-align:left;">
Frequency of Surgery in Black Patients with Malignant Pleural Mesothelioma.
</td>
<td style="text-align:left;">
Dis. Markers
</td>
</tr>
<tr>
<td style="text-align:left;">
Clinical Evaluation of ErbB-Targeted CAR T-Cells, Following Intracavity Delivery in Patients with ErbB-Expressing Solid Tumors.
</td>
<td style="text-align:left;">
Methods Mol. Biol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Combinatorial anti-angiogenic gene therapy in a human malignant mesothelioma model.
</td>
<td style="text-align:left;">
Oncol. Rep.
</td>
</tr>
<tr>
<td style="text-align:left;">
[Prognostic factors in diffuse malignant mesothelioma of the pleura].
</td>
<td style="text-align:left;">
Pneumologie
</td>
</tr>
<tr>
<td style="text-align:left;">
Drug fever after cancer chemotherapy is most commonly observed on posttreatment days 3 and 4.
</td>
<td style="text-align:left;">
Support Care Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Research priorities in mesothelioma: A James Lind Alliance Priority Setting Partnership.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Prophylactic Radiotherapy to Intervention Sites in Malignant Pleural Mesothelioma–Single-institution Experience and Literature Review.
</td>
<td style="text-align:left;">
Anticancer Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant peritoneal mesothelioma: a series of 19 cases.
</td>
<td style="text-align:left;">
Digestion
</td>
</tr>
<tr>
<td style="text-align:left;">
Cynara scolymus affects malignant pleural mesothelioma by promoting apoptosis and restraining invasion.
</td>
<td style="text-align:left;">
Oncotarget
</td>
</tr>
<tr>
<td style="text-align:left;">
Medical and oncological management of malignant mesothelioma.
</td>
<td style="text-align:left;">
Br J Hosp Med (Lond)
</td>
</tr>
<tr>
<td style="text-align:left;">
Pleural mesothelial cells in pleural and lung diseases.
</td>
<td style="text-align:left;">
J Thorac Dis
</td>
</tr>
<tr>
<td style="text-align:left;">
The tumoral and stromal immune microenvironment in malignant pleural mesothelioma: A comprehensive analysis reveals prognostic immune markers.
</td>
<td style="text-align:left;">
Oncoimmunology
</td>
</tr>
<tr>
<td style="text-align:left;">
The endoplasmic reticulum mitochondrial calcium cross talk is downregulated in malignant pleural mesothelioma cells and plays a critical role in apoptosis inhibition.
</td>
<td style="text-align:left;">
Oncotarget
</td>
</tr>
<tr>
<td style="text-align:left;">
The effectiveness and safety of platinum-based pemetrexed and platinum-based gemcitabine treatment in patients with malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
BMC Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Second line therapy in malignant pleural mesothelioma: A systematic review.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Prognostic Score of Long-Term Survival After Surgery for Malignant Pleural Mesothelioma: A Multicenter Analysis.
</td>
<td style="text-align:left;">
Ann. Thorac. Surg.
</td>
</tr>
<tr>
<td style="text-align:left;">
Cerebral Metastasis of a Malignant Pleural Mesothelioma: A Case Report and Review of the Literature.
</td>
<td style="text-align:left;">
Cureus
</td>
</tr>
<tr>
<td style="text-align:left;">
Survival from malignant mesothelioma: where are we now?
</td>
<td style="text-align:left;">
J R Coll Physicians Edinb
</td>
</tr>
<tr>
<td style="text-align:left;">
A clinical protocol to inhibit the HGF/c-Met pathway for malignant mesothelioma with an intrapleural injection of adenoviruses expressing the NK4 gene.
</td>
<td style="text-align:left;">
Springerplus
</td>
</tr>
<tr>
<td style="text-align:left;">
Intracellular lactate-mediated induction of estrogen receptor beta (ERβ) in biphasic malignant pleural mesothelioma cells.
</td>
<td style="text-align:left;">
Oncotarget
</td>
</tr>
<tr>
<td style="text-align:left;">
Downregulation of TBXAS1 in an iron-induced malignant mesothelioma model.
</td>
<td style="text-align:left;">
Cancer Sci.
</td>
</tr>
<tr>
<td style="text-align:left;">
Cul4A overexpression associated with Gli1 expression in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J. Cell. Mol. Med.
</td>
</tr>
<tr>
<td style="text-align:left;">
Primary Peritoneal Mesothelioma Resulting in Small Bowel Obstruction: A Case Report and Review of Literature.
</td>
<td style="text-align:left;">
Am J Case Rep
</td>
</tr>
<tr>
<td style="text-align:left;">
Inhibition of NADPH oxidase 4 induces apoptosis in malignant mesothelioma: Role of reactive oxygen species.
</td>
<td style="text-align:left;">
Oncol. Rep.
</td>
</tr>
<tr>
<td style="text-align:left;">
Molecular Pharmacology of Malignant Pleural Mesothelioma: Challenges and Perspectives From Preclinical and Clinical Studies.
</td>
<td style="text-align:left;">
Curr Drug Targets
</td>
</tr>
<tr>
<td style="text-align:left;">
[MULTIMODAL APPROACH IN THE TREATMENT OF PATIENTS WITH MALIGNANT PLEURAL LESIONS].
</td>
<td style="text-align:left;">
Vopr Onkol
</td>
</tr>
<tr>
<td style="text-align:left;">
Mesothelioma treatment: Are we on target? A review.
</td>
<td style="text-align:left;">
J Adv Res
</td>
</tr>
<tr>
<td style="text-align:left;">
Characterization of hypoxia in malignant pleural mesothelioma with FMISO PET-CT.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Prognostic significance of morphological growth patterns and mitotic index of epithelioid malignant peritoneal mesothelioma.
</td>
<td style="text-align:left;">
Histopathology
</td>
</tr>
<tr>
<td style="text-align:left;">
Radical Radiation Therapy After Lung-Sparing Surgery for Malignant Pleural Mesothelioma: Survival, Pattern of Failure, and Prognostic Factors.
</td>
<td style="text-align:left;">
Int. J. Radiat. Oncol. Biol. Phys.
</td>
</tr>
<tr>
<td style="text-align:left;">
Autophagy Correlates with the Therapeutic Responsiveness of Malignant Pleural Mesothelioma in 3D Models.
</td>
<td style="text-align:left;">
PLoS ONE
</td>
</tr>
<tr>
<td style="text-align:left;">
Akt Kinase-Interacting Protein 1 Signals through CREB to Drive Diffuse Malignant Mesothelioma.
</td>
<td style="text-align:left;">
Cancer Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
Imaging in pleural mesothelioma: A review of the 12th International Conference of the International Mesothelioma Interest Group.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Improvement of malignant pleural mesothelioma immunotherapy by epigenetic modulators.
</td>
<td style="text-align:left;">
Curr Top Med Chem
</td>
</tr>
<tr>
<td style="text-align:left;">
Latest developments in our understanding of the pathogenesis of mesothelioma and the design of targeted therapies.
</td>
<td style="text-align:left;">
Expert Rev Respir Med
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant Pleural Mesothelioma Outcomes in the Era of Combined Platinum and Folate Antimetabolite Chemotherapy.
</td>
<td style="text-align:left;">
Lung Cancer Int
</td>
</tr>
<tr>
<td style="text-align:left;">
A New Prognostic Score Supporting Treatment Allocation for Multimodality Therapy for Malignant Pleural Mesothelioma: A Review of 12 Years’ Experience.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Extended Pleurectomy and Decortication for Malignant Pleural Mesothelioma Is an Effective and Safe Cytoreductive Surgery in the Elderly.
</td>
<td style="text-align:left;">
Ann. Thorac. Surg.
</td>
</tr>
<tr>
<td style="text-align:left;">
[Localized Malignant Mesothelioma of the Pleura].
</td>
<td style="text-align:left;">
Kyobu Geka
</td>
</tr>
<tr>
<td style="text-align:left;">
Trimodality Treatment of Malignant Pleural Mesothelioma: An Institutional Review.
</td>
<td style="text-align:left;">
Am. J. Clin. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Critical review about MDM2 in cancer: Possible role in malignant mesothelioma and implications for treatment.
</td>
<td style="text-align:left;">
Crit. Rev. Oncol. Hematol.
</td>
</tr>
<tr>
<td style="text-align:left;">
The diagnosis, therapy and prognosis of diffuse malignant mesothelioma.
</td>
<td style="text-align:left;">
Eur J Cardiothorac Surg
</td>
</tr>
<tr>
<td style="text-align:left;">
Prognostic value of several biomarkers for the patients with malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Tumour Biol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Advances in the diagnosis, treatment and prognosis of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Ann Transl Med
</td>
</tr>
<tr>
<td style="text-align:left;">
Systemic therapy options for malignant pleural mesothelioma beyond first-line therapy: a systematic review.
</td>
<td style="text-align:left;">
Expert Rev Respir Med
</td>
</tr>
<tr>
<td style="text-align:left;">
Epithelioid pleural mesothelioma concurrently associated with miliary pulmonary metastases and minimal change nephrotic syndrome - A hitherto undescribed case.
</td>
<td style="text-align:left;">
Pathol. Res. Pract.
</td>
</tr>
<tr>
<td style="text-align:left;">
Successful palliation for an aged patient with primary pericardial mesothelioma.
</td>
<td style="text-align:left;">
World J Surg Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
A phase 1b clinical trial of the CD40-activating antibody CP-870,893 in combination with cisplatin and pemetrexed in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Ann. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Which is the Role of Pneumonectomy in the Era of Parenchymal-Sparing Procedures? Early/Long-Term Survival and Functional Results of a Single-Center Experience.
</td>
<td style="text-align:left;">
Lung
</td>
</tr>
<tr>
<td style="text-align:left;">
Identification of circulating miRNAs profiles that distinguish malignant pleural mesothelioma from lung adenocarcinoma.
</td>
<td style="text-align:left;">
EXCLI J
</td>
</tr>
<tr>
<td style="text-align:left;">
Expression of the Stem Cell Factor Nestin in Malignant Pleural Mesothelioma Is Associated with Poor Prognosis.
</td>
<td style="text-align:left;">
PLoS ONE
</td>
</tr>
<tr>
<td style="text-align:left;">
Tomotherapy improves local control and changes failure patterns in locally advanced malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Pract Radiat Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Targeting immune checkpoints: New opportunity for mesothelioma treatment?
</td>
<td style="text-align:left;">
Cancer Treat. Rev.
</td>
</tr>
<tr>
<td style="text-align:left;">
Response evaluation in mesothelioma: Beyond RECIST.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Tomotherapy PET-guided dose escalation: A dosimetric feasibility study for patients with malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Strahlenther Onkol
</td>
</tr>
<tr>
<td style="text-align:left;">
Mithramycin Depletes Specificity Protein 1 and Activates p53 to Mediate Senescence and Apoptosis of Malignant Pleural Mesothelioma Cells.
</td>
<td style="text-align:left;">
Clin. Cancer Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
Expression and activity of eIF6 trigger malignant pleural mesothelioma growth in vivo.
</td>
<td style="text-align:left;">
Oncotarget
</td>
</tr>
<tr>
<td style="text-align:left;">
Advanced therapeutic approach for the treatment of malignant pleural mesothelioma via the intrapleural administration of liposomal pemetrexed.
</td>
<td style="text-align:left;">
J Control Release
</td>
</tr>
<tr>
<td style="text-align:left;">
Systemic approach to malignant pleural mesothelioma: what news of chemotherapy, targeted agents and immunotherapy?
</td>
<td style="text-align:left;">
Tumori
</td>
</tr>
<tr>
<td style="text-align:left;">
Orthotopic Implantation and Peripheral Immune Cell Monitoring in the II-45 Syngeneic Rat Mesothelioma Model.
</td>
<td style="text-align:left;">
J Vis Exp
</td>
</tr>
<tr>
<td style="text-align:left;">
The prognostic significance of BAP1, NF2, and CDKN2A in malignant peritoneal mesothelioma.
</td>
<td style="text-align:left;">
Mod. Pathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Lapatinib enhances trastuzumab-mediated antibody-dependent cellular cytotoxicity via upregulation of HER2 in malignant mesothelioma cells.
</td>
<td style="text-align:left;">
Oncol. Rep.
</td>
</tr>
<tr>
<td style="text-align:left;">
Rapidly progressive sarcomatoid malignant mesothelioma of the pleura mimicking pulmonary empyema.
</td>
<td style="text-align:left;">
Clin Case Rep
</td>
</tr>
<tr>
<td style="text-align:left;">
Pemetrexed-Induced Rash May Be Prevented by Supplementary Corticosteroids.
</td>
<td style="text-align:left;">
Biol. Pharm. Bull.
</td>
</tr>
<tr>
<td style="text-align:left;">
Vinca alkaloids in the therapeutic management of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Cancer Treat. Rev.
</td>
</tr>
<tr>
<td style="text-align:left;">
Neoadjuvant chemotherapy and extrapleural pneumonectomy of malignant pleural mesothelioma with or without hemithoracic radiotherapy (SAKK 17/04): a randomised, international, multicentre phase 2 trial.
</td>
<td style="text-align:left;">
Lancet Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
MDM2 and HIF1alpha expression levels in different histologic subtypes of malignant pleural mesothelioma: correlation with pathological and clinical data.
</td>
<td style="text-align:left;">
Oncotarget
</td>
</tr>
<tr>
<td style="text-align:left;">
Erratum to: Tomotherapy PET-guided dose escalation–A dosimetric feasibility study for patients with malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Strahlenther Onkol
</td>
</tr>
<tr>
<td style="text-align:left;">
Management of malignant pleural mesothelioma: a French multicenter retrospective study (GFPC 0802 study).
</td>
<td style="text-align:left;">
BMC Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Tremelimumab for the treatment of malignant mesothelioma.
</td>
<td style="text-align:left;">
Expert Opin Biol Ther
</td>
</tr>
<tr>
<td style="text-align:left;">
An Autopsy Case Report of Malignant Pleural Mesothelioma with Deciduoid Features.
</td>
<td style="text-align:left;">
Intern. Med.
</td>
</tr>
<tr>
<td style="text-align:left;">
Trimodality strategy for treating malignant pleural mesothelioma: results of a feasibility study of induction pemetrexed plus cisplatin followed by extrapleural pneumonectomy and postoperative hemithoracic radiation (Japan Mesothelioma Interest Group 0601 Trial).
</td>
<td style="text-align:left;">
Int. J. Clin. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Brain metastases in malignant pleural mesothelioma. Case report and review of the literature.
</td>
<td style="text-align:left;">
Am. J. Clin. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Relapse pattern and second-line treatment following multimodality treatment for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Eur J Cardiothorac Surg
</td>
</tr>
<tr>
<td style="text-align:left;">
Current surgical strategies for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Surg. Today
</td>
</tr>
<tr>
<td style="text-align:left;">
Biologic therapy and gene therapy in the multimodality treatment of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Ann Transl Med
</td>
</tr>
<tr>
<td style="text-align:left;">
Isolation of Chemoresistant Cell Subpopulations.
</td>
<td style="text-align:left;">
Methods Mol. Biol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Adoption of pleurectomy and decortication for malignant mesothelioma leads to similar survival as extrapleural pneumonectomy.
</td>
<td style="text-align:left;">
J. Thorac. Cardiovasc. Surg.
</td>
</tr>
<tr>
<td style="text-align:left;">
Accelerated hemithoracic radiation followed by extrapleural pneumonectomy for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J. Thorac. Cardiovasc. Surg.
</td>
</tr>
<tr>
<td style="text-align:left;">
Pembrolizumab for the treatment of thoracic malignancies: current landscape and future directions.
</td>
<td style="text-align:left;">
Future Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Fibrocyte-like cells mediate acquired resistance to anti-angiogenic therapy with bevacizumab.
</td>
<td style="text-align:left;">
Nat Commun
</td>
</tr>
<tr>
<td style="text-align:left;">
High RRM1 Expression Is Associated with Adverse Outcome in Patients with Cisplatin/Vinorelbine-treated Malignant Pleural Mesothelioma.
</td>
<td style="text-align:left;">
Anticancer Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
Extrapleural pneumonectomy for malignant pleural mesothelioma: is this an operation that should now be consigned to history?
</td>
<td style="text-align:left;">
Future Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
The MesoVATS trial: is there a future for video-assisted thoracoscopic surgery partial pleurectomy?
</td>
<td style="text-align:left;">
Future Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Pleurectomy/decortication and hyperthermic intrapleural chemotherapy for malignant pleural mesothelioma: initial experience.
</td>
<td style="text-align:left;">
Future Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Management of recurrence after initial surgery for malignant pleural mesothelioma: a mini-review.
</td>
<td style="text-align:left;">
Future Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Biomarkers and prognostic factors for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Future Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Clinically occult primary fallopian tube carcinoma presenting as a malignant pleural effusion.
</td>
<td style="text-align:left;">
Clin Respir J
</td>
</tr>
<tr>
<td style="text-align:left;">
Extended Tumor Control after Dendritic Cell Vaccination with Low-Dose Cyclophosphamide as Adjuvant Treatment in Patients with Malignant Pleural Mesothelioma.
</td>
<td style="text-align:left;">
Am. J. Respir. Crit. Care Med.
</td>
</tr>
<tr>
<td style="text-align:left;">
[Analysis of the clinical diagnosis of asbestosis complicated with malignant mesothelioma].
</td>
<td style="text-align:left;">
Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi
</td>
</tr>
<tr>
<td style="text-align:left;">
Determinants of Survival in Malignant Pleural Mesothelioma: A Surveillance, Epidemiology, and End Results (SEER) Study of 14,228 Patients.
</td>
<td style="text-align:left;">
PLoS ONE
</td>
</tr>
<tr>
<td style="text-align:left;">
Pleural epitheliod hemangioendothelioma: What started as a liver fluke and ended up being almost mistaken for malignant mesothelioma.
</td>
<td style="text-align:left;">
Ann Thorac Med
</td>
</tr>
<tr>
<td style="text-align:left;">
Diffuse malignant mesothelioma of the pleura in Ontario and Quebec: a retrospective study of 332 patients.
</td>
<td style="text-align:left;">
J. Clin. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Closing faucets: the role of anti-angiogenic therapies in malignant pleural diseases.
</td>
<td style="text-align:left;">
Clin Transl Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
[Analysis of misdiagnosis of 38 cases of solitary fibrous tumor of the pleura].
</td>
<td style="text-align:left;">
Zhonghua Jie He He Hu Xi Za Zhi
</td>
</tr>
<tr>
<td style="text-align:left;">
Patterns in the incidence, mortality and survival of malignant pleural and peritoneal mesothelioma, New South Wales, 1972-2009.
</td>
<td style="text-align:left;">
Aust N Z J Public Health
</td>
</tr>
<tr>
<td style="text-align:left;">
Long-term results in malignant pleural mesothelioma treated with neoadjuvant chemotherapy, extrapleural pneumonectomy and intensity-modulated radiotherapy.
</td>
<td style="text-align:left;">
Radiat Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Non-islet Cell Tumour Hypoglycaemia (NICTH) in Malignant Mesothelioma: Case Report.
</td>
<td style="text-align:left;">
Malays J Med Sci
</td>
</tr>
<tr>
<td style="text-align:left;">
Clinical role of a new prognostic score using platelet-to-lymphocyte ratio in patients with malignant pleural mesothelioma undergoing extrapleural pneumonectomy.
</td>
<td style="text-align:left;">
J Thorac Dis
</td>
</tr>
<tr>
<td style="text-align:left;">
Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial.
</td>
<td style="text-align:left;">
Lancet
</td>
</tr>
<tr>
<td style="text-align:left;">
Infant pleuropulmonary blastoma: report of a rare case and review of literature.
</td>
<td style="text-align:left;">
Int J Clin Exp Pathol
</td>
</tr>
<tr>
<td style="text-align:left;">
Functional Analysis of the Adrenomedullin Pathway in Malignant Pleural Mesothelioma.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Massive localized malignant pleural mesothelioma (LMPM): manifestations on computed tomography in 6 cases.
</td>
<td style="text-align:left;">
Int J Clin Exp Med
</td>
</tr>
<tr>
<td style="text-align:left;">
Efficacy of medical thoracoscopic talc pleurodesis in malignant pleural effusion caused by different types of tumors and different pathological classifications of lung cancer.
</td>
<td style="text-align:left;">
Int J Clin Exp Med
</td>
</tr>
<tr>
<td style="text-align:left;">
KAT5 (Tip60) is a potential therapeutic target in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Int. J. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Non-coding RNA repertoires in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Specimen weight and volume: important predictors of survival in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Eur J Cardiothorac Surg
</td>
</tr>
<tr>
<td style="text-align:left;">
Retrospective analysis of unknown primary cancers with malignant pleural effusion at initial diagnosis.
</td>
<td style="text-align:left;">
Thorac Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Prognostic and Therapeutic Implications of MicroRNA in Malignant Pleural Mesothelioma.
</td>
<td style="text-align:left;">
Microrna
</td>
</tr>
<tr>
<td style="text-align:left;">
Protocol for PIT: a phase III trial of prophylactic irradiation of tracts in patients with malignant pleural mesothelioma following invasive chest wall intervention.
</td>
<td style="text-align:left;">
BMJ Open
</td>
</tr>
<tr>
<td style="text-align:left;">
[Asbestos and respiratory diseases].
</td>
<td style="text-align:left;">
Presse Med
</td>
</tr>
<tr>
<td style="text-align:left;">
Antagonizing the Hedgehog Pathway with Vismodegib Impairs Malignant Pleural Mesothelioma Growth In Vivo by Affecting Stroma.
</td>
<td style="text-align:left;">
Mol. Cancer Ther.
</td>
</tr>
<tr>
<td style="text-align:left;">
Repetitive responses to nanoparticle albumin-bound paclitaxel and carboplatin in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Respirol Case Rep
</td>
</tr>
<tr>
<td style="text-align:left;">
Contemporary Analysis of Prognostic Factors in Patients with Unresectable Malignant Pleural Mesothelioma.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
A Randomized Phase II Study Adding Axitinib to Pemetrexed-Cisplatin in Patients with Malignant Pleural Mesothelioma: A Single-Center Trial Combining Clinical and Translational Outcomes.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Downregulation of thymidylate synthase by RNAi molecules enhances the antitumor effect of pemetrexed in an orthotopic malignant mesothelioma xenograft mouse model.
</td>
<td style="text-align:left;">
Int. J. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Identification of cis- and trans-acting elements regulating calretinin expression in mesothelioma cells.
</td>
<td style="text-align:left;">
Oncotarget
</td>
</tr>
<tr>
<td style="text-align:left;">
Human lung-derived mesenchymal stem cell-conditioned medium exerts in vitro antitumor effects in malignant pleural mesothelioma cell lines.
</td>
<td style="text-align:left;">
Stem Cell Res Ther
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma: an update on diagnosis and treatment options.
</td>
<td style="text-align:left;">
Ther Adv Respir Dis
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Oncol Nurs Forum
</td>
</tr>
<tr>
<td style="text-align:left;">
Clinical and pathologic predictors of clinical outcome of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Tumori
</td>
</tr>
<tr>
<td style="text-align:left;">
Cutaneous Metastases From Malignant Mesothelioma of the Tunica Vaginalis Testis.
</td>
<td style="text-align:left;">
Am J Dermatopathol
</td>
</tr>
<tr>
<td style="text-align:left;">
Population pharmacokinetics and exposure-response relationship of amatuximab, an anti-mesothelin monoclonal antibody, in patients with malignant pleural mesothelioma and its application in dose selection.
</td>
<td style="text-align:left;">
Cancer Chemother. Pharmacol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Peritoneal mesothelioma metastasis to the tongue - Comparison with 8 pleural mesothelioma reports with tongue metastases.
</td>
<td style="text-align:left;">
Ann Med Surg (Lond)
</td>
</tr>
<tr>
<td style="text-align:left;">
Plasma Biomarker Enrichment of Clinical Prognostic Indices in Malignant Pleural Mesothelioma.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Anaesthetic management of extra-pleural pneumonectomy and hyperthermic intrathoracic chemotherapy procedure.
</td>
<td style="text-align:left;">
Indian J Anaesth
</td>
</tr>
<tr>
<td style="text-align:left;">
Evaluation of Machine Learning Algorithm Utilization for Lung Cancer Classification Based on Gene Expression Levels.
</td>
<td style="text-align:left;">
Asian Pac. J. Cancer Prev.
</td>
</tr>
<tr>
<td style="text-align:left;">
Asbestos Induces Oxidative Stress and Activation of Nrf2 Signaling in Murine Macrophages: Chemopreventive Role of the Synthetic Lignan Secoisolariciresinol Diglucoside (LGM2605).
</td>
<td style="text-align:left;">
Int J Mol Sci
</td>
</tr>
<tr>
<td style="text-align:left;">
A catalogue of treatment and technologies for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Expert Rev Anticancer Ther
</td>
</tr>
<tr>
<td style="text-align:left;">
Icmt inhibition exerts anti-angiogenic and anti-hyperpermeability activities impeding malignant pleural effusion.
</td>
<td style="text-align:left;">
Oncotarget
</td>
</tr>
<tr>
<td style="text-align:left;">
Pilot and Feasibility Trial Evaluating Immuno-Gene Therapy of Malignant Mesothelioma Using Intrapleural Delivery of Adenovirus-IFNα Combined with Chemotherapy.
</td>
<td style="text-align:left;">
Clin. Cancer Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
Safety of indwelling pleural catheter use in patients undergoing chemotherapy: a five-year retrospective evaluation.
</td>
<td style="text-align:left;">
BMC Pulm Med
</td>
</tr>
<tr>
<td style="text-align:left;">
Novel Hyaluronan Formulation Enhances the Efficacy of Boron Neutron Capture Therapy for Murine Mesothelioma.
</td>
<td style="text-align:left;">
Anticancer Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
Immune biomarkers PD-1/PD-L1 and TLR3 in malignant pleural mesotheliomas.
</td>
<td style="text-align:left;">
Hum. Pathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Advanced epithelioid pleural mesothelioma, long lasting disease stabilization and long term survival with cisplatin-pemetrexed chemotherapy re-challenge: a case report.
</td>
<td style="text-align:left;">
Clin Ter
</td>
</tr>
<tr>
<td style="text-align:left;">
The management of the diaphragm during radical surgery for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Eur J Cardiothorac Surg
</td>
</tr>
<tr>
<td style="text-align:left;">
Impact of induction therapy on postoperative outcome after extrapleural pneumonectomy for malignant pleural mesothelioma: does induction-accelerated hemithoracic radiation increase the surgical risk?
</td>
<td style="text-align:left;">
Eur J Cardiothorac Surg
</td>
</tr>
<tr>
<td style="text-align:left;">
The role of thoracic surgery in the management of mesothelioma: an expert opinion on the limited evidence.
</td>
<td style="text-align:left;">
Expert Rev Respir Med
</td>
</tr>
<tr>
<td style="text-align:left;">
An intrapleural administration of zoledronic acid for inoperable malignant mesothelioma patients: a phase I clinical study protocol.
</td>
<td style="text-align:left;">
Springerplus
</td>
</tr>
<tr>
<td style="text-align:left;">
Primary Malignant Neuroendocrine Tumour of Pleura: First Case Report.
</td>
<td style="text-align:left;">
Case Rep Oncol Med
</td>
</tr>
<tr>
<td style="text-align:left;">
Deformable medical image registration of pleural cavity for photodynamic therapy by using finite-element based method.
</td>
<td style="text-align:left;">
Proc SPIE Int Soc Opt Eng
</td>
</tr>
<tr>
<td style="text-align:left;">
Advances in treatment of mesothelioma.
</td>
<td style="text-align:left;">
Expert Opin Pharmacother
</td>
</tr>
<tr>
<td style="text-align:left;">
Pemetrexed Maintenance Therapy Following Bevacizumab-Containing First-Line Chemotherapy in Advanced Malignant Pleural Mesothelioma: A Case Report and Literatures Review.
</td>
<td style="text-align:left;">
Medicine (Baltimore)
</td>
</tr>
<tr>
<td style="text-align:left;">
A pilot study of volumetric-modulated arc therapy for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J Appl Clin Med Phys
</td>
</tr>
<tr>
<td style="text-align:left;">
[Localized Malignant Mesothelioma of the Pleura with Hemothorax].
</td>
<td style="text-align:left;">
Kyobu Geka
</td>
</tr>
<tr>
<td style="text-align:left;">
Chronic mesothelial reaction and toxicity of potassium octatitanate fibers in the pleural cavity in mice and F344 rats.
</td>
<td style="text-align:left;">
Cancer Sci.
</td>
</tr>
<tr>
<td style="text-align:left;">
A phase Ia/Ib clinical trial of metronomic chemotherapy based on a mathematical model of oral vinorelbine in metastatic non-small cell lung cancer and malignant pleural mesothelioma: rationale and study protocol.
</td>
<td style="text-align:left;">
BMC Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Multiwalled carbon nanotubes intratracheally instilled into the rat lung induce development of pleural malignant mesothelioma and lung tumors.
</td>
<td style="text-align:left;">
Cancer Sci.
</td>
</tr>
<tr>
<td style="text-align:left;">
Pain in Malignant Pleural Mesothelioma: A Prospective Characterization Study.
</td>
<td style="text-align:left;">
Pain Med
</td>
</tr>
<tr>
<td style="text-align:left;">
Predictive value of BRCA1 expression on the efficacy of chemotherapy based on anti-microtubule agents: a pooled analysis across different malignancies and agents.
</td>
<td style="text-align:left;">
Ann Transl Med
</td>
</tr>
<tr>
<td style="text-align:left;">
Massive chest wall resection and reconstruction for malignant disease.
</td>
<td style="text-align:left;">
Onco Targets Ther
</td>
</tr>
<tr>
<td style="text-align:left;">
Geometric dose prediction model for hemithoracic intensity-modulated radiation therapy in mesothelioma patients with two intact lungs.
</td>
<td style="text-align:left;">
J Appl Clin Med Phys
</td>
</tr>
<tr>
<td style="text-align:left;">
Precision immunotherapy; dynamics in the cellular profile of pleural effusions in malignant mesothelioma patients.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
[Surgical therapy of malignant pleural mesothelioma].
</td>
<td style="text-align:left;">
Chirurg
</td>
</tr>
<tr>
<td style="text-align:left;">
The role of “closed abdomen” hyperthermic intraperitoneal chemotherapy (HIPEC) in the palliative treatment of neoplastic ascites from peritoneal carcinomatosis: report of a single-center experience.
</td>
<td style="text-align:left;">
Support Care Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Conjunctival Metastasis from Pleural Mesothelioma.
</td>
<td style="text-align:left;">
Ocul Oncol Pathol
</td>
</tr>
<tr>
<td style="text-align:left;">
Thoracoscopy in malignant mesothelioma.
</td>
<td style="text-align:left;">
Pneumologie
</td>
</tr>
<tr>
<td style="text-align:left;">
Genomic copy number alterations in 33 malignant peritoneal mesothelioma analyzed by comparative genomic hybridization array.
</td>
<td style="text-align:left;">
Hum. Pathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Clinical development of TargomiRs, a miRNA mimic-based treatment for patients with recurrent thoracic cancer.
</td>
<td style="text-align:left;">
Epigenomics
</td>
</tr>
<tr>
<td style="text-align:left;">
Inhibition of PAI-1 Limits Tumor Angiogenesis Regardless of Angiogenic Stimuli in Malignant Pleural Mesothelioma.
</td>
<td style="text-align:left;">
Cancer Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
[Clinical Pathological Diagnosis, and Treatment for Pleural Mesothelioma].
</td>
<td style="text-align:left;">
Gan To Kagaku Ryoho
</td>
</tr>
<tr>
<td style="text-align:left;">
Present and future roles of FDG-PET/CT imaging in the management of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Jpn J Radiol
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma in a 17-year old boy: A case report and literature review.
</td>
<td style="text-align:left;">
Respir Med Case Rep
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma: initial experience in integrated (18)F-FDG PET/MR imaging.
</td>
<td style="text-align:left;">
Clin Imaging
</td>
</tr>
<tr>
<td style="text-align:left;">
Impact of Age on Long-Term Outcomes of Surgery for Malignant Pleural Mesothelioma.
</td>
<td style="text-align:left;">
Clin Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
KCa1.1, a calcium-activated potassium channel subunit alpha 1, is targeted by miR-17-5p and modulates cell migration in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Mol. Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
[Diagnosis and prognosis of malignant mesothelioma. A description of 8 clinical cases].
</td>
<td style="text-align:left;">
Minerva Med.
</td>
</tr>
<tr>
<td style="text-align:left;">
[Drug carrier nanosystems in malignant pleural mesothelioma].
</td>
<td style="text-align:left;">
Tuberk Toraks
</td>
</tr>
<tr>
<td style="text-align:left;">
Orotate phosphoribosyltransferase is overexpressed in malignant pleural mesothelioma: Dramatically responds one case in high OPRT expression.
</td>
<td style="text-align:left;">
Rare Dis
</td>
</tr>
<tr>
<td style="text-align:left;">
Kinesin family members KIF11 and KIF23 as potential therapeutic targets in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Int. J. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
The Genetic Landscape of Malignant Pleural Mesothelioma: Results from Massively Parallel Sequencing.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
The Third Italian Consensus Conference for Malignant Pleural Mesothelioma: State of the art and recommendations.
</td>
<td style="text-align:left;">
Crit. Rev. Oncol. Hematol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Effect of renal function on pemetrexed-induced haematotoxicity.
</td>
<td style="text-align:left;">
Cancer Chemother. Pharmacol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Synergistic anti-tumor efficacy of immunogenic adenovirus ONCOS-102 (Ad5/3-D24-GM-CSF) and standard of care chemotherapy in preclinical mesothelioma model.
</td>
<td style="text-align:left;">
Int. J. Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Moving Immune Checkpoint Blockade in Thoracic Tumors beyond NSCLC.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Nanoparticle-based targeted gene therapy for lung cancer.
</td>
<td style="text-align:left;">
Am J Cancer Res
</td>
</tr>
<tr>
<td style="text-align:left;">
Antitumor effect of novel anti-podoplanin antibody NZ-12 against malignant pleural mesothelioma in an orthotopic xenograft model.
</td>
<td style="text-align:left;">
Cancer Sci.
</td>
</tr>
<tr>
<td style="text-align:left;">
A longitudinal study of the hyaluronan level in the serum of patients with malignant mesothelioma under treatment. Hyaluronan as an indicator of progressive disease.
</td>
<td style="text-align:left;">
Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Circulating epigenetic biomarkers in lung malignancies: From early diagnosis to therapy.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
A phase II study of vincristine in malignant mesothelioma–a negative report.
</td>
<td style="text-align:left;">
Cancer Chemother. Pharmacol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Reduction of estradiol in human malignant pleural mesothelioma tissues may prevent tumour growth, as implied by in in-vivo and in-vitro models.
</td>
<td style="text-align:left;">
Oncotarget
</td>
</tr>
<tr>
<td style="text-align:left;">
Phase II Study of Hemithoracic Intensity-Modulated Pleural Radiation Therapy (IMPRINT) As Part of Lung-Sparing Multimodality Therapy in Patients With Malignant Pleural Mesothelioma.
</td>
<td style="text-align:left;">
J. Clin. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Comorbidity, postoperative morbidity and survival in patients undergoing radical surgery for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Eur J Cardiothorac Surg
</td>
</tr>
<tr>
<td style="text-align:left;">
Prophylactic radiotherapy for the prevention of procedure-tract metastases after surgical and large-bore pleural procedures in malignant pleural mesothelioma (SMART): a multicentre, open-label, phase 3, randomised controlled trial.
</td>
<td style="text-align:left;">
Lancet Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Positive response of a primary malignant pericardial mesothelioma to pemetrexed plus cisplatin followed by pemetrexed maintenance chemotherapy: A case report.
</td>
<td style="text-align:left;">
Oncol Lett
</td>
</tr>
<tr>
<td style="text-align:left;">
[Thoracoscopy using flexible fiberoptic bronchoscopy–a preliminary report of experimental and clinical studies].
</td>
<td style="text-align:left;">
Zhonghua Nei Ke Za Zhi
</td>
</tr>
<tr>
<td style="text-align:left;">
A case of pseudoachalasia hiding a malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Tumori
</td>
</tr>
<tr>
<td style="text-align:left;">
Low Merlin expression and high Survivin labeling index are indicators for poor prognosis in patients with malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Mol Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Protocol of the Australasian Malignant Pleural Effusion-2 (AMPLE-2) trial: a multicentre randomised study of aggressive versus symptom-guided drainage via indwelling pleural catheters.
</td>
<td style="text-align:left;">
BMJ Open
</td>
</tr>
<tr>
<td style="text-align:left;">
P2X7 targeting inhibits growth of human mesothelioma.
</td>
<td style="text-align:left;">
Oncotarget
</td>
</tr>
<tr>
<td style="text-align:left;">
Dasatinib modulates sensitivity to pemetrexed in malignant pleural mesothelioma cell lines.
</td>
<td style="text-align:left;">
Oncotarget
</td>
</tr>
<tr>
<td style="text-align:left;">
NCCN Guidelines Insights: Malignant Pleural Mesothelioma, Version 3.2016.
</td>
<td style="text-align:left;">
J Natl Compr Canc Netw
</td>
</tr>
<tr>
<td style="text-align:left;">
MicroRNA gene expression signatures in long-surviving malignant pleural mesothelioma patients.
</td>
<td style="text-align:left;">
Genom Data
</td>
</tr>
<tr>
<td style="text-align:left;">
Safety and Complications of Medical Thoracoscopy.
</td>
<td style="text-align:left;">
Adv Med
</td>
</tr>
<tr>
<td style="text-align:left;">
Pleural Effusions from Patients with Mesothelioma Induce Recruitment of Monocytes and Their Differentiation into M2 Macrophages.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Pleural Effusion of Patients with Malignant Mesothelioma Induces Macrophage-Mediated T Cell Suppression.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Cochrane corner: interventions for the management of malignant pleural effusions.
</td>
<td style="text-align:left;">
Thorax
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma with lacrimal gland metastasis.
</td>
<td style="text-align:left;">
Acta Ophthalmol
</td>
</tr>
<tr>
<td style="text-align:left;">
Current Treatment of Mesothelioma: Extrapleural Pneumonectomy Versus Pleurectomy/Decortication.
</td>
<td style="text-align:left;">
Thorac Surg Clin
</td>
</tr>
<tr>
<td style="text-align:left;">
New therapeutic strategies for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Biochem. Pharmacol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Silencing Receptor EphA2 Enhanced Sensitivity to Lipoplatin™ in Lung Tumor and MPM Cells.
</td>
<td style="text-align:left;">
Cancer Invest.
</td>
</tr>
<tr>
<td style="text-align:left;">
Combination of cisplatin and lurbinectedin as palliative chemotherapy in progressive malignant pleural mesothelioma: Report of two cases.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
A Phase II Study of PF-03446962 in Patients with Advanced Malignant Pleural Mesothelioma. CCTG Trial IND.207.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Inhibition of the Polyamine Synthesis Pathway Is Synthetically Lethal with Loss of Argininosuccinate Synthase 1.
</td>
<td style="text-align:left;">
Cell Rep
</td>
</tr>
<tr>
<td style="text-align:left;">
Management of malignant pleural mesothelioma-part 2: therapeutic approaches : Consensus of the Austrian Mesothelioma Interest Group (AMIG).
</td>
<td style="text-align:left;">
Wien. Klin. Wochenschr.
</td>
</tr>
<tr>
<td style="text-align:left;">
Management of malignant pleural mesothelioma - part 3 : Data from the Austrian Mesothelioma Interest Group (AMIG) database.
</td>
<td style="text-align:left;">
Wien. Klin. Wochenschr.
</td>
</tr>
<tr>
<td style="text-align:left;">
Genomic Landscape of Malignant Mesotheliomas.
</td>
<td style="text-align:left;">
Mol. Cancer Ther.
</td>
</tr>
<tr>
<td style="text-align:left;">
Calpeptin Prevents Malignant Pleural Mesothelioma Cell Proliferation via the Angiopoietin1/Tie2 System.
</td>
<td style="text-align:left;">
Asian Pac. J. Cancer Prev.
</td>
</tr>
<tr>
<td style="text-align:left;">
Trabectedin Is Active against Malignant Pleural Mesothelioma Cell and Xenograft Models and Synergizes with Chemotherapy and Bcl-2 Inhibition In Vitro.
</td>
<td style="text-align:left;">
Mol. Cancer Ther.
</td>
</tr>
<tr>
<td style="text-align:left;">
Quercetin and Cisplatin combined treatment altered cell cycle and mitogen activated protein kinase expressions in malignant mesotelioma cells.
</td>
<td style="text-align:left;">
BMC Complement Altern Med
</td>
</tr>
<tr>
<td style="text-align:left;">
Treatment offers hope in mesothelioma.
</td>
<td style="text-align:left;">
Nurs Stand
</td>
</tr>
<tr>
<td style="text-align:left;">
Pembrolizumab-associated minimal change disease in a patient with malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
BMC Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Co-existing tuberculosis and malignant mesothelioma with multiple sites venous thrombosis: a case report.
</td>
<td style="text-align:left;">
BMC Res Notes
</td>
</tr>
<tr>
<td style="text-align:left;">
Metformin and survival of people with type 2 diabetes and pleural mesothelioma: A population-based retrospective cohort study.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Promising in vivo efficacy of the BET bromodomain inhibitor OTX015/MK-8628 in malignant pleural mesothelioma xenografts.
</td>
<td style="text-align:left;">
Int. J. Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
How does the timing of chemotherapy affect outcome following radical surgery for malignant pleural mesothelioma?
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma of the pleura with desmoplastic histology: a case series and literature review.
</td>
<td style="text-align:left;">
BMC Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
[Malignant Pleural Mesotheliomas].
</td>
<td style="text-align:left;">
Zentralbl Chir
</td>
</tr>
<tr>
<td style="text-align:left;">
Validation of EORTC and CALGB prognostic models in surgical patients submitted to diagnostic, palliative or curative surgery for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J Thorac Dis
</td>
</tr>
<tr>
<td style="text-align:left;">
PI3 Kinase Pathway and MET Inhibition is Efficacious in Malignant Pleural Mesothelioma.
</td>
<td style="text-align:left;">
Sci Rep
</td>
</tr>
<tr>
<td style="text-align:left;">
Mesotheliomas in Lebanon: Witnessing a Change in Epidemiology.
</td>
<td style="text-align:left;">
Asian Pac. J. Cancer Prev.
</td>
</tr>
<tr>
<td style="text-align:left;">
Serum mesothelin, osteopontin and vimentin: useful markers for clinical monitoring of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Int. J. Biol. Markers
</td>
</tr>
<tr>
<td style="text-align:left;">
Intensity-modulated radiotherapy for relapsed malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Future Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Patient-Derived Xenograft Establishment from Human Malignant Pleural Mesothelioma.
</td>
<td style="text-align:left;">
Clin. Cancer Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
Targeting the vasculature: anti-angiogenic agents for malignant mesothelioma.
</td>
<td style="text-align:left;">
Expert Rev Anticancer Ther
</td>
</tr>
<tr>
<td style="text-align:left;">
Screening of Pleural Mesotheliomas for DNA-damage Repair Players by Digital Gene Expression Analysis Can Enhance Clinical Management of Patients Receiving Platin-Based Chemotherapy.
</td>
<td style="text-align:left;">
J Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Five years update on relationships between malignant pleural mesothelioma and exposure to asbestos and other elongated mineral particles.
</td>
<td style="text-align:left;">
J Toxicol Environ Health B Crit Rev
</td>
</tr>
<tr>
<td style="text-align:left;">
Epithelioid peritoneal mesothelioma: a hybrid phenotype within a mesenchymal-epithelial/epithelial-mesenchymal transition framework.
</td>
<td style="text-align:left;">
Oncotarget
</td>
</tr>
<tr>
<td style="text-align:left;">
Glycodelin is a potential novel follow-up biomarker for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Oncotarget
</td>
</tr>
<tr>
<td style="text-align:left;">
Circulating microRNAs found dysregulated in ex-exposed asbestos workers and pleural mesothelioma patients as potential new biomarkers.
</td>
<td style="text-align:left;">
Oncotarget
</td>
</tr>
<tr>
<td style="text-align:left;">
MicroRNA-302b targets Mcl-1 and inhibits cell proliferation and induces apoptosis in malignant pleural mesothelioma cells.
</td>
<td style="text-align:left;">
Am J Cancer Res
</td>
</tr>
<tr>
<td style="text-align:left;">
Systemically Administered RNAi Molecule Sensitizes Malignant Pleural Mesotheliomal Cells to Pemetrexed Therapy.
</td>
<td style="text-align:left;">
Mol. Pharm.
</td>
</tr>
<tr>
<td style="text-align:left;">
Management of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Thorac Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma: A retrospective analysis of clinicopathological and survival data.
</td>
<td style="text-align:left;">
Thorac Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Amount of Epithelioid Differentiation Is a Predictor of Survival in Malignant Pleural Mesothelioma.
</td>
<td style="text-align:left;">
Ann. Thorac. Surg.
</td>
</tr>
<tr>
<td style="text-align:left;">
Relation between neutrophil/lymphocyte ratio and primary tumor metabolic activity in patients with malign pleural mesothelioma.
</td>
<td style="text-align:left;">
Clin Respir J
</td>
</tr>
<tr>
<td style="text-align:left;">
Current best practice in the evaluation and management of malignant pleural effusions.
</td>
<td style="text-align:left;">
Ther Adv Respir Dis
</td>
</tr>
<tr>
<td style="text-align:left;">
Calretinin but not caveolin-1 correlates with tumour histology and survival in malignant mesothelioma.
</td>
<td style="text-align:left;">
Pathology
</td>
</tr>
<tr>
<td style="text-align:left;">
Vascular endothelial growth factor promoter-based conditionally replicative adenoviruses effectively suppress growth of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Cancer Sci.
</td>
</tr>
<tr>
<td style="text-align:left;">
Tamoxifen Suppresses the Growth of Malignant Pleural Mesothelioma Cells.
</td>
<td style="text-align:left;">
Anticancer Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
Sarcomatoid Type Primary Pericardial Mesothelioma with a Long-term Survival after the Onset of Cardiac Tamponade.
</td>
<td style="text-align:left;">
Intern. Med.
</td>
</tr>
<tr>
<td style="text-align:left;">
In Vitro and In Vivo Antitumor Activity of [Pt(O,O’-acac)(γ-acac)(DMS)] in Malignant Pleural Mesothelioma.
</td>
<td style="text-align:left;">
PLoS ONE
</td>
</tr>
<tr>
<td style="text-align:left;">
Genomic profiling of malignant peritoneal mesothelioma reveals recurrent alterations in epigenetic regulatory genes BAP1, SETD2, and DDX3X.
</td>
<td style="text-align:left;">
Mod. Pathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
[Update on epidemiology, pathophysiology, diagnosis and treatment of malignant pleural mesothelioma].
</td>
<td style="text-align:left;">
Rev Med Inst Mex Seguro Soc
</td>
</tr>
<tr>
<td style="text-align:left;">
Mesothelioma in the United States: a Surveillance, Epidemiology, and End Results (SEER)-Medicare investigation of treatment patterns and overall survival.
</td>
<td style="text-align:left;">
Clin Epidemiol
</td>
</tr>
<tr>
<td style="text-align:left;">
The resistance related to targeted therapy in malignant pleural mesothelioma: Why has not the target been hit yet?
</td>
<td style="text-align:left;">
Crit. Rev. Oncol. Hematol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Extended Pleurectomy-Decortication-Based Treatment for Advanced Stage Epithelial Mesothelioma Yielding a Median Survival of Nearly Three Years.
</td>
<td style="text-align:left;">
Ann. Thorac. Surg.
</td>
</tr>
<tr>
<td style="text-align:left;">
Intrapleural Adenoviral-mediated Endothelial Cell Protein C Receptor Gene Transfer Suppresses the Progression of Malignant Pleural Mesothelioma in a Mouse Model.
</td>
<td style="text-align:left;">
Sci Rep
</td>
</tr>
<tr>
<td style="text-align:left;">
SORORIN and PLK1 as potential therapeutic targets in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Int. J. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
FAS and FASL genetic polymorphisms impact on clinical outcome of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Onco Targets Ther
</td>
</tr>
<tr>
<td style="text-align:left;">
Cytotoxic T Cells in PD-L1-Positive Malignant Pleural Mesotheliomas Are Counterbalanced by Distinct Immunosuppressive Factors.
</td>
<td style="text-align:left;">
Cancer Immunol Res
</td>
</tr>
<tr>
<td style="text-align:left;">
Lysis of human malignant mesothelioma cells by natural killer (NK) and lymphokine-activated killer (LAK) cells.
</td>
<td style="text-align:left;">
Am. Rev. Respir. Dis.
</td>
</tr>
<tr>
<td style="text-align:left;">
Trametinib plus 4-Methylumbelliferone Exhibits Antitumor Effects by ERK Blockade and CD44 Downregulation and Affects PD-1 and PD-L1 in Malignant Pleural Mesothelioma.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Diagnostic Utility of Pleural Fluid Cell Block versus Pleural Biopsy Collected by Flex-Rigid Pleuroscopy for Malignant Pleural Disease: A Single Center Retrospective Analysis.
</td>
<td style="text-align:left;">
PLoS ONE
</td>
</tr>
<tr>
<td style="text-align:left;">
Elevated aspartate aminotransferase and monocyte counts predict unfavorable prognosis in patients with malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Neoplasma
</td>
</tr>
<tr>
<td style="text-align:left;">
Indomethacin augments lymphokine-activated killer cell generation by patients with malignant mesothelioma.
</td>
<td style="text-align:left;">
Clin. Immunol. Immunopathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Fluoro-edenite induces fibulin-3 overexpression in non-malignant human mesothelial cells.
</td>
<td style="text-align:left;">
Oncol Lett
</td>
</tr>
<tr>
<td style="text-align:left;">
Primary malignant pericardial mesothelioma with increased serum mesothelin diagnosed by surgical pericardial resection: A case report.
</td>
<td style="text-align:left;">
Mol Clin Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma: an update on investigation, diagnosis and treatment.
</td>
<td style="text-align:left;">
Eur Respir Rev
</td>
</tr>
<tr>
<td style="text-align:left;">
A specific inhibitor of lactate dehydrogenase overcame the resistance toward gemcitabine in hypoxic mesothelioma cells, and modulated the expression of the human equilibrative transporter-1.
</td>
<td style="text-align:left;">
Nucleosides Nucleotides Nucleic Acids
</td>
</tr>
<tr>
<td style="text-align:left;">
Extrapleural Pneumonectomy for Malignant Pleural Mesothelioma: A Novel Mini-Invasive Technique.
</td>
<td style="text-align:left;">
Innovations (Phila)
</td>
</tr>
<tr>
<td style="text-align:left;">
A Comparison of Singlet Oxygen Explicit Dosimetry (SOED) and Singlet Oxygen Luminescence Dosimetry (SOLD) for Photofrin-Mediated Photodynamic Therapy.
</td>
<td style="text-align:left;">
Cancers (Basel)
</td>
</tr>
<tr>
<td style="text-align:left;">
The evolution of the diminishing role of extrapleural pneumonectomy in the surgical management of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Onco Targets Ther
</td>
</tr>
<tr>
<td style="text-align:left;">
The role of surgical intervention in lung cancer with carcinomatous pleuritis.
</td>
<td style="text-align:left;">
J Thorac Dis
</td>
</tr>
<tr>
<td style="text-align:left;">
Open access phone triage for veterans with suspected malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J. Surg. Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
Percutaneous Cryoablation for the Treatment of Recurrent Malignant Pleural Mesothelioma: Safety, Early-Term Efficacy, and Predictors of Local Recurrence.
</td>
<td style="text-align:left;">
J Vasc Interv Radiol
</td>
</tr>
<tr>
<td style="text-align:left;">
Minimal change disease associated with malignant pleural mesothelioma: case report and review of the literature.
</td>
<td style="text-align:left;">
BMJ Case Rep
</td>
</tr>
<tr>
<td style="text-align:left;">
Advances in pleuroscopy.
</td>
<td style="text-align:left;">
Clin Respir J
</td>
</tr>
<tr>
<td style="text-align:left;">
Co-occurring Mutations of Tumor Suppressor Genes, <i>LATS2</i> and <i>NF2</i>, in Malignant Pleural Mesothelioma.
</td>
<td style="text-align:left;">
Clin. Cancer Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
Pericardial Effusion due to Primary Malignant Pericardial Mesothelioma: A Common Finding but an Uncommon Cause.
</td>
<td style="text-align:left;">
Case Rep Med
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant Mesothelioma Biomarkers: From Discovery to Use in Clinical Practice for Diagnosis, Monitoring, Screening, and Treatment.
</td>
<td style="text-align:left;">
Chest
</td>
</tr>
<tr>
<td style="text-align:left;">
Deciduoid mesothelioma of the thorax: A comprehensive review of the scientific literature.
</td>
<td style="text-align:left;">
Clin Respir J
</td>
</tr>
<tr>
<td style="text-align:left;">
Prognostic value of pretreatment volume-based quantitative <sup>18</sup>F-FDG PET/CT parameters in patients with malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Eur J Radiol
</td>
</tr>
<tr>
<td style="text-align:left;">
Metabolic response assessment with 18F-FDG-PET/CT is superior to modified RECIST for the evaluation of response to platinum-based doublet chemotherapy in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Eur J Radiol
</td>
</tr>
<tr>
<td style="text-align:left;">
Pemetrexed for epithelioid haemangioendothelioma of the pleura.
</td>
<td style="text-align:left;">
Respirol Case Rep
</td>
</tr>
<tr>
<td style="text-align:left;">
BAP1 Is Altered by Copy Number Loss, Mutation, and/or Loss of Protein Expression in More Than 70% of Malignant Peritoneal Mesotheliomas.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Chromosomal abnormalities and their correlations with asbestos exposure and survival in patients with mesothelioma.
</td>
<td style="text-align:left;">
Br. J. Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Role of postoperative radiotherapy in the management of malignant pleural mesothelioma : A propensity score matching of the SEER database.
</td>
<td style="text-align:left;">
Strahlenther Onkol
</td>
</tr>
<tr>
<td style="text-align:left;">
Turning back the Wheel: Inducing Mesenchymal to Epithelial Transition via Wilms Tumor 1 Knockdown in Human Mesothelioma Cell Lines to Influence Proliferation, Invasiveness, and Chemotaxis.
</td>
<td style="text-align:left;">
Pathol. Oncol. Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
Blockage of epithelial to mesenchymal transition and upregulation of let 7b are critically involved in ursolic acid induced apoptosis in malignant mesothelioma cell.
</td>
<td style="text-align:left;">
Int. J. Biol. Sci.
</td>
</tr>
<tr>
<td style="text-align:left;">
[Problems of diagnosis and surgical treatment in pleural mesothelioma].
</td>
<td style="text-align:left;">
Nihon Kyobu Geka Gakkai Zasshi
</td>
</tr>
<tr>
<td style="text-align:left;">
Small bowel metastasis from pancreatic cancer in a long-term survival patient with synchronous advanced malignant pleural mesothelioma: A case report and literature review.
</td>
<td style="text-align:left;">
Oncol Lett
</td>
</tr>
<tr>
<td style="text-align:left;">
[Prognostic factors in cases of diffuse malignant pleural mesothelioma].
</td>
<td style="text-align:left;">
Nihon Kyobu Shikkan Gakkai Zasshi
</td>
</tr>
<tr>
<td style="text-align:left;">
Long-term outcomes of intensity-modulated radiotherapy following extra-pleural pneumonectomy for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Acta Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Identification of MiR-21-5p as a Functional Regulator of Mesothelin Expression Using MicroRNA Capture Affinity Coupled with Next Generation Sequencing.
</td>
<td style="text-align:left;">
PLoS ONE
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pericardial mesothelioma : A systematic review of current practice.
</td>
<td style="text-align:left;">
Herz
</td>
</tr>
<tr>
<td style="text-align:left;">
[Malignant Pleural Mesothelioma with Excessive Inflammation and High Level of Interleukin 6 - A Case Report].
</td>
<td style="text-align:left;">
Gan To Kagaku Ryoho
</td>
</tr>
<tr>
<td style="text-align:left;">
Geographic and socioeconomic factors in patients with malignant pleural mesothelioma in New South Wales and their impact upon clinical outcomes.
</td>
<td style="text-align:left;">
Respirology
</td>
</tr>
<tr>
<td style="text-align:left;">
Clinical Experience With Pemetrexed in Breast Cancer.
</td>
<td style="text-align:left;">
Semin. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Tissue transglutaminase (TG2) enables survival of human malignant pleural mesothelioma cells in hypoxia.
</td>
<td style="text-align:left;">
Cell Death Dis
</td>
</tr>
<tr>
<td style="text-align:left;">
Stent Implantation for Superior Vena Cava Syndrome of Malignant Cause.
</td>
<td style="text-align:left;">
Rofo
</td>
</tr>
<tr>
<td style="text-align:left;">
Paclitaxel-releasing mesenchymal stromal cells inhibit in vitro proliferation of human mesothelioma cells.
</td>
<td style="text-align:left;">
Biomed. Pharmacother.
</td>
</tr>
<tr>
<td style="text-align:left;">
Pemetrexed-related interstitial lung disease reported from post marketing surveillance (malignant pleural mesothelioma/non-small cell lung cancer).
</td>
<td style="text-align:left;">
Jpn. J. Clin. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Prognostication and monitoring of mesothelioma using biomarkers: a systematic review.
</td>
<td style="text-align:left;">
Br. J. Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
[A case of remission induced in diffuse pleural malignant mesothelioma by the treatment with cisplatin and doxorubicin].
</td>
<td style="text-align:left;">
Gan To Kagaku Ryoho
</td>
</tr>
<tr>
<td style="text-align:left;">
Switching off malignant mesothelioma: exploiting the hypoxic microenvironment.
</td>
<td style="text-align:left;">
Genes Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Prognostic and predictive aspects of the tumor immune microenvironment and immune checkpoints in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Oncoimmunology
</td>
</tr>
<tr>
<td style="text-align:left;">
Kdm6a and Kdm6b: Altered expression in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Int. J. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Does selective pleural irradiation of malignant pleural mesothelioma allow radiation dose escalation? : A planning study.
</td>
<td style="text-align:left;">
Strahlenther Onkol
</td>
</tr>
<tr>
<td style="text-align:left;">
Large primary pleural synovial sarcoma with severe dyspnea: a case report.
</td>
<td style="text-align:left;">
Surg Case Rep
</td>
</tr>
<tr>
<td style="text-align:left;">
Modern management of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Lung Cancer (Auckl)
</td>
</tr>
<tr>
<td style="text-align:left;">
A phase II trial of dovitinib in previously-treated advanced pleural mesothelioma: The Ontario Clinical Oncology Group.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Pharmacokinetic evaluation of intrapleural perfusion with hyperthermic chemotherapy using cisplatin in patients with malignant pleural effusion.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Pleural carcinogenic potency of mineral fibers (asbestos, attapulgite) and their cytotoxicity on cultured cells.
</td>
<td style="text-align:left;">
J. Natl. Cancer Inst.
</td>
</tr>
<tr>
<td style="text-align:left;">
Intracavitary ‘T4 immunotherapy’ of malignant mesothelioma using pan-ErbB re-targeted CAR T-cells.
</td>
<td style="text-align:left;">
Cancer Lett.
</td>
</tr>
<tr>
<td style="text-align:left;">
Radiation therapy for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Cancer Radiother
</td>
</tr>
<tr>
<td style="text-align:left;">
Real-time light dosimetry for intra-cavity photodynamic therapy: Application for pleural mesothelioma treatment.
</td>
<td style="text-align:left;">
Photodiagnosis Photodyn Ther
</td>
</tr>
<tr>
<td style="text-align:left;">
The Immune Microenvironment, Genome-wide Copy Number Aberrations, and Survival in Mesothelioma.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Non-Hodgkin Lymphoma and Pleural Mesothelioma in a Person Exposed to Asbestos.
</td>
<td style="text-align:left;">
Turk Patoloji Derg
</td>
</tr>
<tr>
<td style="text-align:left;">
Is less also better? A single-institution experience on treatment of early stage Malignant Pleural Mesothelioma.
</td>
<td style="text-align:left;">
Eur J Surg Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
The Controlling Nutritional Status Score Is a Significant Independent Predictor of Poor Prognosis in Patients With Malignant Pleural Mesothelioma.
</td>
<td style="text-align:left;">
Clin Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Mesothelin promotes epithelial-to-mesenchymal transition and tumorigenicity of human lung cancer and mesothelioma cells.
</td>
<td style="text-align:left;">
Mol. Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
The PD-L1/PD-1 pathway promotes dysfunction, but not “exhaustion”, in tumor-responding T cells from pleural effusions in lung cancer patients.
</td>
<td style="text-align:left;">
Cancer Immunol. Immunother.
</td>
</tr>
<tr>
<td style="text-align:left;">
Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial.
</td>
<td style="text-align:left;">
Lancet Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Pembrolizumab in the treatment of metastatic non-small-cell lung cancer: patient selection and perspectives.
</td>
<td style="text-align:left;">
Lung Cancer (Auckl)
</td>
</tr>
<tr>
<td style="text-align:left;">
Impact of tumour thickness on survival after radical radiation and surgery in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Eur. Respir. J.
</td>
</tr>
<tr>
<td style="text-align:left;">
Midkine is a potential novel marker for malignant mesothelioma with different prognostic and diagnostic values from mesothelin.
</td>
<td style="text-align:left;">
BMC Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Combinational therapy of crizotinib and afatinib for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Am J Cancer Res
</td>
</tr>
<tr>
<td style="text-align:left;">
Improved Outcomes with Modern Lung-Sparing Trimodality Therapy in Patients with Malignant Pleural Mesothelioma.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Targeting BAP1: a new paradigm for mesothelioma.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
A Novel Panel of Serum Biomarkers for MPM Diagnosis.
</td>
<td style="text-align:left;">
Dis. Markers
</td>
</tr>
<tr>
<td style="text-align:left;">
Intensity modulated radiation therapy after extra-pleural pneumonectomy for malignant pleural mesothelioma is feasible without fatal pulmonary toxicity and provides good survival.
</td>
<td style="text-align:left;">
Asia Pac J Clin Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Phase 1 Dose-Escalation Study of Pegylated Arginine Deiminase, Cisplatin, and Pemetrexed in Patients With Argininosuccinate Synthetase 1-Deficient Thoracic Cancers.
</td>
<td style="text-align:left;">
J. Clin. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
A Novel BRCA1-Associated Protein-1 Isoform Affects Response of Mesothelioma Cells to Drugs Impairing BRCA1-Mediated DNA Repair.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma: single-institution experience of 101 patients over a 15-year period.
</td>
<td style="text-align:left;">
Acta Chir. Belg.
</td>
</tr>
<tr>
<td style="text-align:left;">
The case for performing pleural biopsies for the aetiological diagnosis of exudates. Yes.
</td>
<td style="text-align:left;">
Rev Clin Esp
</td>
</tr>
<tr>
<td style="text-align:left;">
Folic acid phenotype (FAP) is a superior biomarker predicting response to pemetrexed-based chemotherapy in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Oncotarget
</td>
</tr>
<tr>
<td style="text-align:left;">
Pleurectomy-decortication in malignant pleural mesothelioma: are different surgical techniques associated with different outcomes? Results from a multicentre study.
</td>
<td style="text-align:left;">
Eur J Cardiothorac Surg
</td>
</tr>
<tr>
<td style="text-align:left;">
Three-dimensional finite-element based deformable image registration for evaluation of pleural cavity irradiation during photodynamic therapy.
</td>
<td style="text-align:left;">
Med Phys
</td>
</tr>
<tr>
<td style="text-align:left;">
Prophylactic radiotherapy for procedure tract metastases in mesothelioma: a review.
</td>
<td style="text-align:left;">
Curr Opin Pulm Med
</td>
</tr>
<tr>
<td style="text-align:left;">
Spotlight on bevacizumab and its potential in the treatment of malignant pleural mesothelioma: the evidence to date.
</td>
<td style="text-align:left;">
Onco Targets Ther
</td>
</tr>
<tr>
<td style="text-align:left;">
Inhibition of the platelet-derived growth factor receptor beta (PDGFRB) using gene silencing, crenolanib besylate, or imatinib mesylate hampers the malignant phenotype of mesothelioma cell lines.
</td>
<td style="text-align:left;">
Genes Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Post-recurrence chemotherapy for mesothelioma patients undergoing extrapleural pneumonectomy.
</td>
<td style="text-align:left;">
Int. J. Clin. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Comprehensive immunohistochemical study of mesothelin (MSLN) using different monoclonal antibodies 5B2 and MN-1 in 1562 tumors with evaluation of its prognostic value in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Oncotarget
</td>
</tr>
<tr>
<td style="text-align:left;">
Intensity-Modulated Radiation Therapy Improves the Target Coverage Over 3-D Planning While Meeting Lung Tolerance Doses for All Patients With Malignant Pleural Mesothelioma.
</td>
<td style="text-align:left;">
Technol. Cancer Res. Treat.
</td>
</tr>
<tr>
<td style="text-align:left;">
Growth suppressive effect of pegylated arginase in malignant pleural mesothelioma xenografts.
</td>
<td style="text-align:left;">
Respir. Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
Combined Inhibition of NEDD8-Activating Enzyme and mTOR Suppresses <i>NF2</i> Loss-Driven Tumorigenesis.
</td>
<td style="text-align:left;">
Mol. Cancer Ther.
</td>
</tr>
<tr>
<td style="text-align:left;">
Significant Clinical Benefit of Pemetrexed-based Chemotherapy for Advanced Diffuse Malignant Peritoneal Mesothelioma: A Case Presentation.
</td>
<td style="text-align:left;">
Indian J Med Paediatr Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Targeting YAP in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J. Cell. Mol. Med.
</td>
</tr>
<tr>
<td style="text-align:left;">
Clinical Features and Treatment Outcome of Malignant Pleural Mesothelioma.
</td>
<td style="text-align:left;">
Oncol Res Treat
</td>
</tr>
<tr>
<td style="text-align:left;">
Pleural mesothelioma in household members of asbestos-exposed workers in Friuli Venezia Giulia, Italy.
</td>
<td style="text-align:left;">
Int J Occup Med Environ Health
</td>
</tr>
<tr>
<td style="text-align:left;">
Induction chemotherapy, extrapleural pneumonectomy and adjuvant radiotherapy for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Eur J Cardiothorac Surg
</td>
</tr>
<tr>
<td style="text-align:left;">
[Malignant Pleural Mesothelioma Presenting Refractory Pneumothorax Successfully Treated by Intrapleural Administration of Diluted Fibrin Glue;Report of a Case].
</td>
<td style="text-align:left;">
Kyobu Geka
</td>
</tr>
<tr>
<td style="text-align:left;">
CAR T-cell therapy for lung cancer and malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Transl Res
</td>
</tr>
<tr>
<td style="text-align:left;">
Prognostic significance of soluble mesothelin in malignant pleural mesothelioma: a meta-analysis.
</td>
<td style="text-align:left;">
Oncotarget
</td>
</tr>
<tr>
<td style="text-align:left;">
SU-E-T-595: Comparison of Volumetric Modulated Arc Therapy (VMAT) and Static Intensity Modulated Radiotherapy (IMRT) for Malignant Pleural Mesothelioma in Patients with Intact Lungs/Post Pleurectomy.
</td>
<td style="text-align:left;">
Med Phys
</td>
</tr>
<tr>
<td style="text-align:left;">
Diode-Pumped Laser for Lung-Sparing Surgical Treatment of Malignant Pleural Mesothelioma.
</td>
<td style="text-align:left;">
Ann. Thorac. Surg.
</td>
</tr>
<tr>
<td style="text-align:left;">
Immunotherapy and radiation therapy for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Transl Lung Cancer Res
</td>
</tr>
<tr>
<td style="text-align:left;">
Viroimmunotherapy of Thoracic Cancers.
</td>
<td style="text-align:left;">
Biomedicines
</td>
</tr>
<tr>
<td style="text-align:left;">
The inhibition of FGF receptor 1 activity mediates sorafenib antiproliferative effects in human malignant pleural mesothelioma tumor-initiating cells.
</td>
<td style="text-align:left;">
Stem Cell Res Ther
</td>
</tr>
<tr>
<td style="text-align:left;">
Calretinin as a blood-based biomarker for mesothelioma.
</td>
<td style="text-align:left;">
BMC Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
DCLK1 is correlated with MET and ERK5 expression, and associated with prognosis in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Int. J. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Synergistic targeting of malignant pleural mesothelioma cells by MDM2 inhibitors and TRAIL agonists.
</td>
<td style="text-align:left;">
Oncotarget
</td>
</tr>
<tr>
<td style="text-align:left;">
Induction chemotherapy vs post-operative adjuvant therapy for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Expert Rev Respir Med
</td>
</tr>
<tr>
<td style="text-align:left;">
Surgery as part of radical treatment for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Curr Opin Pulm Med
</td>
</tr>
<tr>
<td style="text-align:left;">
First-line chemotherapy with pemetrexed plus cisplatin for malignant peritoneal mesothelioma.
</td>
<td style="text-align:left;">
Expert Rev Anticancer Ther
</td>
</tr>
<tr>
<td style="text-align:left;">
Deregulation of miRNAs in malignant pleural mesothelioma is associated with prognosis and suggests an alteration of cell metabolism.
</td>
<td style="text-align:left;">
Sci Rep
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant Pleural Mesothelioma with Marked Lymphatic Involvement: A Report of Two Autopsy Cases.
</td>
<td style="text-align:left;">
Case Rep Oncol Med
</td>
</tr>
<tr>
<td style="text-align:left;">
A pilot study of zoledronic acid in the treatment of patients with advanced malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Lung Cancer (Auckl)
</td>
</tr>
<tr>
<td style="text-align:left;">
JQ1, a BET Inhibitor, Synergizes with Cisplatin and Induces Apoptosis in Highly Chemoresistant Malignant Pleural Mesothelioma Cells.
</td>
<td style="text-align:left;">
Curr Cancer Drug Targets
</td>
</tr>
<tr>
<td style="text-align:left;">
Cost-effectiveness analysis of additional bevacizumab to pemetrexed plus cisplatin for malignant pleural mesothelioma based on the MAPS trial.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Promising investigational drug candidates in phase I and phase II clinical trials for mesothelioma.
</td>
<td style="text-align:left;">
Expert Opin Investig Drugs
</td>
</tr>
<tr>
<td style="text-align:left;">
Optimal Therapy of Advanced Stage Mesothelioma.
</td>
<td style="text-align:left;">
Curr Treat Options Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Guidelines for Pathologic Diagnosis of Malignant Mesothelioma 2017 Update of the Consensus Statement From the International Mesothelioma Interest Group.
</td>
<td style="text-align:left;">
Arch. Pathol. Lab. Med.
</td>
</tr>
<tr>
<td style="text-align:left;">
Germline mutations in DNA repair genes predispose asbestos-exposed patients to malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Cancer Lett.
</td>
</tr>
<tr>
<td style="text-align:left;">
LUME-Meso: Design and Rationale of the Phase III Part of a Placebo-Controlled Study of Nintedanib and Pemetrexed/Cisplatin Followed by Maintenance Nintedanib in Patients With Unresectable Malignant Pleural Mesothelioma.
</td>
<td style="text-align:left;">
Clin Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Antimetabolites in the treatment of advanced pleural mesothelioma: a network meta-analysis of randomized clinical trials.
</td>
<td style="text-align:left;">
J Chemother
</td>
</tr>
<tr>
<td style="text-align:left;">
Apoptosis by [Pt(O,O’-acac)(γ-acac)(DMS)] requires PKC-δ mediated p53 activation in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
PLoS ONE
</td>
</tr>
<tr>
<td style="text-align:left;">
Combined Inhibition of CDK4/6 and PI3K/AKT/mTOR Pathways Induces a Synergistic Anti-Tumor Effect in Malignant Pleural Mesothelioma Cells.
</td>
<td style="text-align:left;">
Neoplasia
</td>
</tr>
<tr>
<td style="text-align:left;">
The impact of surgical approach on quality of life for pleural malignant mesothelioma.
</td>
<td style="text-align:left;">
Ann Transl Med
</td>
</tr>
<tr>
<td style="text-align:left;">
Intra-abdominal manifestations of pleural mesothelioma.
</td>
<td style="text-align:left;">
Ann Transl Med
</td>
</tr>
<tr>
<td style="text-align:left;">
Extrapleural pneumonectomy (EPP) <i>vs.</i> pleurectomy decortication (P/D).
</td>
<td style="text-align:left;">
Ann Transl Med
</td>
</tr>
<tr>
<td style="text-align:left;">
Intraoperative intracavitary hyperthermic chemotherapy for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Ann Transl Med
</td>
</tr>
<tr>
<td style="text-align:left;">
Overview of treatment related complications in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Ann Transl Med
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant peritoneal mesothelioma: a review.
</td>
<td style="text-align:left;">
Ann Transl Med
</td>
</tr>
<tr>
<td style="text-align:left;">
A nuanced view of extrapleural pneumonectomy for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Ann Transl Med
</td>
</tr>
<tr>
<td style="text-align:left;">
Volumetric assessment in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Ann Transl Med
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma: adjuvant therapy with radiation therapy.
</td>
<td style="text-align:left;">
Ann Transl Med
</td>
</tr>
<tr>
<td style="text-align:left;">
Novel immunotherapy clinical trials in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Ann Transl Med
</td>
</tr>
<tr>
<td style="text-align:left;">
<i>In vitro</i> experimental models of mesothelioma revisited.
</td>
<td style="text-align:left;">
Transl Lung Cancer Res
</td>
</tr>
<tr>
<td style="text-align:left;">
Intraoperative adjuncts for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Transl Lung Cancer Res
</td>
</tr>
<tr>
<td style="text-align:left;">
Novel systemic therapy against malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Transl Lung Cancer Res
</td>
</tr>
<tr>
<td style="text-align:left;">
Immunotherapy for malignant pleural mesothelioma: current status and future directions.
</td>
<td style="text-align:left;">
Transl Lung Cancer Res
</td>
</tr>
<tr>
<td style="text-align:left;">
Radio-immunotherapy and chemo-immunotherapy as a novel treatment paradigm in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Transl Lung Cancer Res
</td>
</tr>
<tr>
<td style="text-align:left;">
Drug development against the hippo pathway in mesothelioma.
</td>
<td style="text-align:left;">
Transl Lung Cancer Res
</td>
</tr>
<tr>
<td style="text-align:left;">
Targeting the epigenome in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Transl Lung Cancer Res
</td>
</tr>
<tr>
<td style="text-align:left;">
Tumor suppressor candidate 2 (TUSC2, FUS-1) and human cancers.
</td>
<td style="text-align:left;">
Discov Med
</td>
</tr>
<tr>
<td style="text-align:left;">
High-dose palliative radiotherapy for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J Med Imaging Radiat Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial.
</td>
<td style="text-align:left;">
Lancet Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Magnetic nanoparticles-based therapy for malignant mesothelioma.
</td>
<td style="text-align:left;">
Rom J Morphol Embryol
</td>
</tr>
<tr>
<td style="text-align:left;">
Functional image guided radiation therapy planning in volumetric modulated arc therapy for patients with malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Adv Radiat Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Synthetic lethality in malignant pleural mesothelioma with PARP1 inhibition.
</td>
<td style="text-align:left;">
Cancer Chemother. Pharmacol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma segmentation for photodynamic therapy planning.
</td>
<td style="text-align:left;">
Comput Med Imaging Graph
</td>
</tr>
<tr>
<td style="text-align:left;">
Isolated thoracic perfusion with chemofiltration for progressive malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Onco Targets Ther
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant Pleural Mesothelioma: State of the art and advanced cell therapy.
</td>
<td style="text-align:left;">
Eur J Med Chem
</td>
</tr>
<tr>
<td style="text-align:left;">
Expression of ALCAM (CD166) and PD-L1 (CD274) independently predicts shorter survival in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Hum. Pathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Heart Dosimetry is Correlated With Risk of Radiation Pneumonitis After Lung-Sparing Hemithoracic Pleural Intensity Modulated Radiation Therapy for Malignant Pleural Mesothelioma.
</td>
<td style="text-align:left;">
Int. J. Radiat. Oncol. Biol. Phys.
</td>
</tr>
<tr>
<td style="text-align:left;">
Long-Term Survival Outcomes of Cancer-Directed Surgery for Malignant Pleural Mesothelioma: Propensity Score Matching Analysis.
</td>
<td style="text-align:left;">
J. Clin. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Radiological predictors of complete cytoreduction in 59 patients with peritoneal mesothelioma treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy at a UK referral centre.
</td>
<td style="text-align:left;">
Br J Radiol
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma - Pleural cavity irradiation after decortication with helical tomotherapy.
</td>
<td style="text-align:left;">
Rep Pract Oncol Radiother
</td>
</tr>
<tr>
<td style="text-align:left;">
Pathological complete response in malignant pleural mesothelioma patients following induction chemotherapy: Predictive factors and outcomes.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Survival in Good Performance Malignant Pleural Mesothelioma Patients; Prognostic Factors and Predictors of Response
</td>
<td style="text-align:left;">
Asian Pac. J. Cancer Prev.
</td>
</tr>
<tr>
<td style="text-align:left;">
National Cancer Database Report on Pneumonectomy Versus Lung-Sparing Surgery for Malignant Pleural Mesothelioma.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Near-Infrared Intraoperative Imaging Can Successfully Identify Malignant Pleural Mesothelioma After Neoadjuvant Chemotherapy.
</td>
<td style="text-align:left;">
Mol Imaging
</td>
</tr>
<tr>
<td style="text-align:left;">
The role of radical radiotherapy in the management of malignant pleural mesothelioma: A systematic review.
</td>
<td style="text-align:left;">
Radiother Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Clinical staging of malignant pleural mesothelioma: current perspectives.
</td>
<td style="text-align:left;">
Lung Cancer (Auckl)
</td>
</tr>
<tr>
<td style="text-align:left;">
Chimeric Antigen Receptor (CAR) T Cell Therapy for Malignant Pleural Mesothelioma (MPM).
</td>
<td style="text-align:left;">
Cancers (Basel)
</td>
</tr>
<tr>
<td style="text-align:left;">
Safety and activity of microRNA-loaded minicells in patients with recurrent malignant pleural mesothelioma: a first-in-man, phase 1, open-label, dose-escalation study.
</td>
<td style="text-align:left;">
Lancet Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Biomarkers for early diagnosis of malignant mesothelioma: Do we need another moonshot?
</td>
<td style="text-align:left;">
Oncotarget
</td>
</tr>
<tr>
<td style="text-align:left;">
Oncolytic Viral Therapy for Mesothelioma.
</td>
<td style="text-align:left;">
Front Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Radiotherapy for the treatment of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Lancet Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
The epithelioid BAP1-negative and p16-positive phenotype predicts prolonged survival in pleural mesothelioma.
</td>
<td style="text-align:left;">
Histopathology
</td>
</tr>
<tr>
<td style="text-align:left;">
Nintedanib Plus Pemetrexed/Cisplatin in Patients With Malignant Pleural Mesothelioma: Phase II Results From the Randomized, Placebo-Controlled LUME-Meso Trial.
</td>
<td style="text-align:left;">
J. Clin. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Identification of ALK Rearrangements in Malignant Peritoneal Mesothelioma.
</td>
<td style="text-align:left;">
JAMA Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
MicroRNA-31 Regulates Chemosensitivity in Malignant Pleural Mesothelioma.
</td>
<td style="text-align:left;">
Mol Ther Nucleic Acids
</td>
</tr>
<tr>
<td style="text-align:left;">
Role of new radiation techniques in the treatment of pleural mesothelioma.
</td>
<td style="text-align:left;">
Thorac Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Clinical and biologic prognostic factors in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Thorac Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Treatment for recurrence after extrapleural pneumonectomy for malignant pleural mesothelioma: A single institution experience.
</td>
<td style="text-align:left;">
Thorac Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Determination of PD-L1 expression in effusions from mesothelioma by immuno-cytochemical staining.
</td>
<td style="text-align:left;">
Cancer Cytopathol
</td>
</tr>
<tr>
<td style="text-align:left;">
The value of delayed phase enhanced imaging in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J Thorac Dis
</td>
</tr>
<tr>
<td style="text-align:left;">
Prognostic and predictive role of [<sup>18</sup> F]fluorodeoxyglucose positron emission tomography (FDG-PET) in patients with unresectable malignant pleural mesothelioma (MPM) treated with up-front pemetrexed-based chemotherapy.
</td>
<td style="text-align:left;">
Cancer Med
</td>
</tr>
<tr>
<td style="text-align:left;">
Role of proton-coupled folate transporter in pemetrexed resistance of mesothelioma: clinical evidence and new pharmacological tools.
</td>
<td style="text-align:left;">
Ann. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
A Case Report of Primary Pericardial Malignant Mesothelioma Treated with Pemetrexed and Cisplatin.
</td>
<td style="text-align:left;">
J. Korean Med. Sci.
</td>
</tr>
<tr>
<td style="text-align:left;">
Novel ATP-competitive Akt inhibitor afuresertib suppresses the proliferation of malignant pleural mesothelioma cells.
</td>
<td style="text-align:left;">
Cancer Med
</td>
</tr>
<tr>
<td style="text-align:left;">
Soluble Mesothelin-Related Peptides to Monitor Recurrence After Resection of Pleural Mesothelioma.
</td>
<td style="text-align:left;">
Ann. Thorac. Surg.
</td>
</tr>
<tr>
<td style="text-align:left;">
A Randomized Phase II Trial of Adjuvant Galinpepimut-S, WT-1 Analogue Peptide Vaccine, After Multimodality Therapy for Patients with Malignant Pleural Mesothelioma.
</td>
<td style="text-align:left;">
Clin. Cancer Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
Low-dose photon irradiation induces invasiveness through the SDF-1α/CXCR4 pathway in malignant mesothelioma cells.
</td>
<td style="text-align:left;">
Oncotarget
</td>
</tr>
<tr>
<td style="text-align:left;">
Application of 3D Mass Spectrometry Imaging to TKIs.
</td>
<td style="text-align:left;">
Clin. Pharmacol. Ther.
</td>
</tr>
<tr>
<td style="text-align:left;">
New Concepts in the Treatment of Malignant Pleural Mesothelioma.
</td>
<td style="text-align:left;">
Annu. Rev. Med.
</td>
</tr>
<tr>
<td style="text-align:left;">
Estimating past inhalation exposure to asbestos: A tool for risk attribution and disease screening.
</td>
<td style="text-align:left;">
Int J Hyg Environ Health
</td>
</tr>
<tr>
<td style="text-align:left;">
Extended pleurectomy decortication for malignant pleural mesothelioma in the elderly: the need for an inclusive yet selective approach.
</td>
<td style="text-align:left;">
Interact Cardiovasc Thorac Surg
</td>
</tr>
<tr>
<td style="text-align:left;">
Comprehensive Pharmacogenomic Profiling of Malignant Pleural Mesothelioma Identifies a Subgroup Sensitive to FGFR Inhibition.
</td>
<td style="text-align:left;">
Clin. Cancer Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
Chemical Profiling of Primary Mesothelioma Cultures Defines Subtypes with Different Expression Profiles and Clinical Responses.
</td>
<td style="text-align:left;">
Clin. Cancer Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
Loss of BAP1 Expression in Atypical Mesothelial Proliferations Helps to Predict Malignant Mesothelioma.
</td>
<td style="text-align:left;">
Am. J. Surg. Pathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Role of thoracoscopy, mediastinoscopy and laparoscopy in the diagnosis and staging of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J Vis Surg
</td>
</tr>
<tr>
<td style="text-align:left;">
Video assisted thoracoscopic and open chest surgery in diagnosis and treatment of malignant pleural diseases.
</td>
<td style="text-align:left;">
J Vis Surg
</td>
</tr>
<tr>
<td style="text-align:left;">
Molecular and Histopathological Characterization of the Tumor Immune Microenvironment in Advanced Stage of Malignant Pleural Mesothelioma.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
A review of bevacizumab in the treatment of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Future Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Retrospective study of hypersensitivity reactions to chemotherapeutic agents in a thoracic oncology service.
</td>
<td style="text-align:left;">
J Clin Pharm Ther
</td>
</tr>
<tr>
<td style="text-align:left;">
A link between the fibroblast growth factor axis and the miR-16 family reveals potential new treatment combinations in mesothelioma.
</td>
<td style="text-align:left;">
Mol Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Cancer antigen profiling for malignant pleural mesothelioma immunotherapy: expression and coexpression of mesothelin, cancer antigen 125, and Wilms tumor 1.
</td>
<td style="text-align:left;">
Oncotarget
</td>
</tr>
<tr>
<td style="text-align:left;">
Targeting microRNA to improve diagnostic and therapeutic approaches for malignant mesothelioma.
</td>
<td style="text-align:left;">
Oncotarget
</td>
</tr>
<tr>
<td style="text-align:left;">
PD-L1 expression associated with worse survival outcome in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Asia Pac J Clin Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Chimeric Antigen Receptor (CAR) T-Cell Therapy for Thoracic Malignancies.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
External validation of prognostic indices for overall survival of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Surgical and non-surgical management of malignant pleural effusions.
</td>
<td style="text-align:left;">
Expert Rev Respir Med
</td>
</tr>
<tr>
<td style="text-align:left;">
Dysregulated Expression of the MicroRNA miR-137 and Its Target YBX1 Contribute to the Invasive Characteristics of Malignant Pleural Mesothelioma.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
4EGI-1 represses cap-dependent translation and regulates genome-wide translation in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Invest New Drugs
</td>
</tr>
<tr>
<td style="text-align:left;">
Mesothelioma in Australia: a review.
</td>
<td style="text-align:left;">
Med. J. Aust.
</td>
</tr>
<tr>
<td style="text-align:left;">
[Prophylactic radiotherapy in a single fraction of 10Gy at intervention pleural site in patient with malignant pleural mesothelioma: A retrospective monocentric cohort study].
</td>
<td style="text-align:left;">
Cancer Radiother
</td>
</tr>
<tr>
<td style="text-align:left;">
High dose irradiation after pleurectomy/decortication or biopsy for pleural mesothelioma treatment.
</td>
<td style="text-align:left;">
Cancer Radiother
</td>
</tr>
<tr>
<td style="text-align:left;">
<i>Ex vivo</i> evaluation of tumor cell specific drug responses in malignant pleural effusions.
</td>
<td style="text-align:left;">
Oncotarget
</td>
</tr>
<tr>
<td style="text-align:left;">
Efficacy of Cell-Free and Concentrated Ascites Reinfusion Therapy for Palliative Care in a Patient with Malignant Pleural Mesothelioma: A Case Report.
</td>
<td style="text-align:left;">
J Nippon Med Sch
</td>
</tr>
<tr>
<td style="text-align:left;">
Temporal and spatial heterogeneity of programmed cell death 1-Ligand 1 expression in malignant mesothelioma.
</td>
<td style="text-align:left;">
Oncoimmunology
</td>
</tr>
<tr>
<td style="text-align:left;">
The analysis of novel microRNA mimic sequences in cancer cells reveals lack of specificity in stem-loop RT-qPCR-based microRNA detection.
</td>
<td style="text-align:left;">
BMC Res Notes
</td>
</tr>
<tr>
<td style="text-align:left;">
Proton Therapy for Malignant Pleural Mesothelioma: A Three Case Series Describing the Clinical and Dosimetric Advantages of Proton-Based Therapy.
</td>
<td style="text-align:left;">
Cureus
</td>
</tr>
<tr>
<td style="text-align:left;">
Abundant expression of TIM-3, LAG-3, PD-1 and PD-L1 as immunotherapy checkpoint targets in effusions of mesothelioma patients.
</td>
<td style="text-align:left;">
Oncotarget
</td>
</tr>
<tr>
<td style="text-align:left;">
Effect of an Indwelling Pleural Catheter vs Talc Pleurodesis on Hospitalization Days in Patients With Malignant Pleural Effusion: The AMPLE Randomized Clinical Trial.
</td>
<td style="text-align:left;">
JAMA
</td>
</tr>
<tr>
<td style="text-align:left;">
Activity of pirarubicin (4’-0-tetrahydropyranyladriamycin) in malignant mesothelioma.
</td>
<td style="text-align:left;">
Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant Pleural Mesothelioma: Diagnosis, Staging, Pitfalls and Follow-up.
</td>
<td style="text-align:left;">
Semin. Ultrasound CT MR
</td>
</tr>
<tr>
<td style="text-align:left;">
Circulating complement component 4d (C4d) correlates with tumor volume, chemotherapeutic response and survival in patients with malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Sci Rep
</td>
</tr>
<tr>
<td style="text-align:left;">
Patterns of care and survival among patients with malignant mesothelioma in the United States.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Diaphragm and lung-preserving surgery with hyperthermic chemotherapy for malignant pleural mesothelioma: A 10-year experience.
</td>
<td style="text-align:left;">
J. Thorac. Cardiovasc. Surg.
</td>
</tr>
<tr>
<td style="text-align:left;">
CAR T-cell immunotherapy of MET-expressing malignant mesothelioma.
</td>
<td style="text-align:left;">
Oncoimmunology
</td>
</tr>
<tr>
<td style="text-align:left;">
Predictors of trimodality therapy and trends in therapy for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Eur J Cardiothorac Surg
</td>
</tr>
<tr>
<td style="text-align:left;">
Hyaluronic acid enhances cell migration and invasion via the YAP1/TAZ-RHAMM axis in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Oncotarget
</td>
</tr>
<tr>
<td style="text-align:left;">
National Trends in the Epidemiology of Malignant Pleural Mesothelioma: A National Cancer Data Base Study.
</td>
<td style="text-align:left;">
Ann. Thorac. Surg.
</td>
</tr>
<tr>
<td style="text-align:left;">
Targeting CXCR4 with [<sup>68</sup>Ga]Pentixafor: a suitable theranostic approach in pleural mesothelioma?
</td>
<td style="text-align:left;">
Oncotarget
</td>
</tr>
<tr>
<td style="text-align:left;">
Pseudomesotheliomatous carcinoma of the pleura: an autopsy case of metastasis from a G-CSF-producing anaplastic carcinoma of the pancreas.
</td>
<td style="text-align:left;">
APMIS
</td>
</tr>
<tr>
<td style="text-align:left;">
Effect of hyperthermic intrathoracic chemotherapy on the malignant pleural mesothelioma: a systematic review and meta-analysis.
</td>
<td style="text-align:left;">
Oncotarget
</td>
</tr>
<tr>
<td style="text-align:left;">
A Nomogram to Predict Prognosis in Malignant Pleural Mesothelioma.
</td>
<td style="text-align:left;">
World J Surg
</td>
</tr>
<tr>
<td style="text-align:left;">
18F-Fluorodeoxyglucose PET/CT and dynamic contrast-enhanced MRI as imaging biomarkers in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Nucl Med Commun
</td>
</tr>
<tr>
<td style="text-align:left;">
[Malign pleural mesothelioma - so far an undefeated tumor].
</td>
<td style="text-align:left;">
Vnitr Lek
</td>
</tr>
<tr>
<td style="text-align:left;">
Focal adhesion kinase a potential therapeutic target for pancreatic cancer and malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Cancer Biol. Ther.
</td>
</tr>
<tr>
<td style="text-align:left;">
Radical multimodality therapy for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Cochrane Database Syst Rev
</td>
</tr>
<tr>
<td style="text-align:left;">
Cisplatin-induced sudden cardiac death with hemodynamic collapse: a severe adverse drug reaction: Case report.
</td>
<td style="text-align:left;">
Medicine (Baltimore)
</td>
</tr>
<tr>
<td style="text-align:left;">
HSP90 inhibition alters the chemotherapy-driven rearrangement of the oncogenic secretome.
</td>
<td style="text-align:left;">
Oncogene
</td>
</tr>
<tr>
<td style="text-align:left;">
Review of malignant pleural mesothelioma survival after talc pleurodesis or surgery.
</td>
<td style="text-align:left;">
J Thorac Dis
</td>
</tr>
<tr>
<td style="text-align:left;">
Minor regression and long-time survival (56 months) in a patient with malignant pleural mesothelioma under Viscum album and Helleborus niger extracts-a case report.
</td>
<td style="text-align:left;">
J Thorac Dis
</td>
</tr>
<tr>
<td style="text-align:left;">
Biomarker-Integrated Neoadjuvant Dasatinib Trial in Resectable Malignant Pleural Mesothelioma.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Success rate of medical thoracoscopy and talc pleurodesis in malignant pleurisy: A single-centre experience.
</td>
<td style="text-align:left;">
Respirology
</td>
</tr>
<tr>
<td style="text-align:left;">
Pseudomesotheliomatous carcinoma of the lung.
</td>
<td style="text-align:left;">
Vojnosanit Pregl
</td>
</tr>
<tr>
<td style="text-align:left;">
Heterogeneous Contributing Factors in MPM Disease Development and Progression: Biological Advances and Clinical Implications.
</td>
<td style="text-align:left;">
Int J Mol Sci
</td>
</tr>
<tr>
<td style="text-align:left;">
Treatment of Malignant Pleural Mesothelioma: American Society of Clinical Oncology Clinical Practice Guideline.
</td>
<td style="text-align:left;">
J. Clin. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma as a difficult interdisciplinary problem.
</td>
<td style="text-align:left;">
Kardiochir Torakochirurgia Pol
</td>
</tr>
<tr>
<td style="text-align:left;">
Mesothelioma With a Large Prevascular Lymph Node: N1 Involvement or Something Different?
</td>
<td style="text-align:left;">
Ann. Thorac. Surg.
</td>
</tr>
<tr>
<td style="text-align:left;">
[Systemic Treatment of Malignant Pleural Mesothelioma].
</td>
<td style="text-align:left;">
Gan To Kagaku Ryoho
</td>
</tr>
<tr>
<td style="text-align:left;">
Therapeutic potential of targeting S100A11 in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Oncogenesis
</td>
</tr>
<tr>
<td style="text-align:left;">
Is Pleurectomy/Decortication Superior to Extrapleural Pneumonectomy for Patients with Malignant Pleural Mesothelioma? A Single-Institutional Experience.
</td>
<td style="text-align:left;">
Ann Thorac Cardiovasc Surg
</td>
</tr>
<tr>
<td style="text-align:left;">
<i>SFRP</i> Tumour Suppressor Genes Are Potential Plasma-Based Epigenetic Biomarkers for Malignant Pleural Mesothelioma.
</td>
<td style="text-align:left;">
Dis. Markers
</td>
</tr>
<tr>
<td style="text-align:left;">
Multiple intracranial metastases from postoperative giant sarcomatoid malignant pleural mesothelioma: A case report and literature review.
</td>
<td style="text-align:left;">
Mol Clin Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Bromodomain inhibition exerts its therapeutic potential in malignant pleural mesothelioma by promoting immunogenic cell death and changing the tumor immune-environment.
</td>
<td style="text-align:left;">
Oncoimmunology
</td>
</tr>
<tr>
<td style="text-align:left;">
Single-institution experience of intensity-modulated radiotherapy for malignant pleural mesothelioma at University of Catania.
</td>
<td style="text-align:left;">
Future Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Evaluating quality of life and cost implications of prophylactic radiotherapy in mesothelioma: Health economic analysis of the SMART trial.
</td>
<td style="text-align:left;">
PLoS ONE
</td>
</tr>
<tr>
<td style="text-align:left;">
Radiofrequency Ablation Effectively Treated Focal Recurrence of Mesothelioma.
</td>
<td style="text-align:left;">
Ann. Thorac. Surg.
</td>
</tr>
<tr>
<td style="text-align:left;">
Computed tomography in the evaluation of malignant pleural mesothelioma-Association of tumor size to a sarcomatoid histology, a more advanced TNM stage and poor survival.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Progress and challenges in Mesothelioma: From bench to bedside.
</td>
<td style="text-align:left;">
Respir Med
</td>
</tr>
<tr>
<td style="text-align:left;">
[Anti-tumor immunotherapy in malignant pleural mesothelioma].
</td>
<td style="text-align:left;">
Rev Mal Respir
</td>
</tr>
<tr>
<td style="text-align:left;">
Outcomes of the Multimodal Treatment of Malignant Pleural Mesiothelioma: The Role of Surgery.
</td>
<td style="text-align:left;">
Korean J Thorac Cardiovasc Surg
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma with squamous differentiation.
</td>
<td style="text-align:left;">
Histopathology
</td>
</tr>
<tr>
<td style="text-align:left;">
Real-life feasibility of home-based pulmonary rehabilitation in chemotherapy-treated patients with thoracic cancers: a pilot study.
</td>
<td style="text-align:left;">
BMC Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
A prospective study to investigate the role of serial serum mesothelin in monitoring mesothelioma.
</td>
<td style="text-align:left;">
BMC Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Prognostic Impact of Inflammation-related Biomarkers on Overall Survival of Patients with Inoperable Malignant Pleural Mesothelioma.
</td>
<td style="text-align:left;">
In Vivo
</td>
</tr>
<tr>
<td style="text-align:left;">
Determinants of malignant pleural mesothelioma survival and burden of disease in France: a national cohort analysis.
</td>
<td style="text-align:left;">
Cancer Med
</td>
</tr>
<tr>
<td style="text-align:left;">
Stem Cells Application in Thoracic Surgery: Current Perspective and Future Directions.
</td>
<td style="text-align:left;">
Adv. Exp. Med. Biol.
</td>
</tr>
<tr>
<td style="text-align:left;">
<sup>18</sup>F-FDG PET/CT in the management of patients with malignant pleural mesothelioma being considered for multimodality therapy: experience of a tertiary referral center.
</td>
<td style="text-align:left;">
Br J Radiol
</td>
</tr>
<tr>
<td style="text-align:left;">
The C-Reactive Protein/Albumin Ratio is a Novel Significant Prognostic Factor in Patients with Malignant Pleural Mesothelioma: A Retrospective Multi-institutional Study.
</td>
<td style="text-align:left;">
Ann. Surg. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Mesothelin and osteopontin as circulating markers of diffuse malignant peritoneal mesothelioma: A preliminary study.
</td>
<td style="text-align:left;">
Eur J Surg Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Physicochemical and pharmacokinetic properties of polymeric films loaded with cisplatin for the treatment of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J Thorac Dis
</td>
</tr>
<tr>
<td style="text-align:left;">
Polymeric films loaded with cisplatin for malignant pleural mesothelioma: a pharmacokinetic study in an ovine model.
</td>
<td style="text-align:left;">
J Thorac Dis
</td>
</tr>
<tr>
<td style="text-align:left;">
Hyperthermic intrathoracic chemotherapy after extended pleurectomy and decortication for malignant pleura mesothelioma: an observational study on outcome and microcirculatory changes.
</td>
<td style="text-align:left;">
J Thorac Dis
</td>
</tr>
<tr>
<td style="text-align:left;">
Clinical diagnosis of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J Thorac Dis
</td>
</tr>
<tr>
<td style="text-align:left;">
Surgery for malignant pleural mesothelioma: an international guidelines review.
</td>
<td style="text-align:left;">
J Thorac Dis
</td>
</tr>
<tr>
<td style="text-align:left;">
The role of intracavitary therapies in the treatment of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J Thorac Dis
</td>
</tr>
<tr>
<td style="text-align:left;">
Chemotherapy treatment in malignant pleural mesothelioma: a difficult history.
</td>
<td style="text-align:left;">
J Thorac Dis
</td>
</tr>
<tr>
<td style="text-align:left;">
Target therapy: new drugs or new combinations of drugs in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J Thorac Dis
</td>
</tr>
<tr>
<td style="text-align:left;">
New horizons from immunotherapy in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J Thorac Dis
</td>
</tr>
<tr>
<td style="text-align:left;">
Medical treatment of malignant pleural mesothelioma relapses.
</td>
<td style="text-align:left;">
J Thorac Dis
</td>
</tr>
<tr>
<td style="text-align:left;">
Serum mesothelin and other biomarkers: what have we learned in the last decade?
</td>
<td style="text-align:left;">
J Thorac Dis
</td>
</tr>
<tr>
<td style="text-align:left;">
Overexpressed genes in malignant pleural mesothelioma: implications in clinical management.
</td>
<td style="text-align:left;">
J Thorac Dis
</td>
</tr>
<tr>
<td style="text-align:left;">
Novel therapies for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Lancet Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Macroscopic complete resection is not associated with improved survival in patients with malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J. Thorac. Cardiovasc. Surg.
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma immune microenvironment and checkpoint expression: correlation with clinical-pathological features and intratumor heterogeneity over time.
</td>
<td style="text-align:left;">
Ann. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Aminopeptidase N/CD13 as a potential therapeutic target in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Eur. Respir. J.
</td>
</tr>
<tr>
<td style="text-align:left;">
DNA methylation profiling of asbestos-treated MeT5A cell line reveals novel pathways implicated in asbestos response.
</td>
<td style="text-align:left;">
Arch. Toxicol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Progress in the Management of Malignant Pleural Mesothelioma in 2017.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Live-Cell Mesothelioma Biobank to Explore Mechanisms of Tumor Progression.
</td>
<td style="text-align:left;">
Front Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
[Implementation of Hyperthermic Intrathoracic Chemotherapy (HITHOC) in Germany].
</td>
<td style="text-align:left;">
Zentralbl Chir
</td>
</tr>
<tr>
<td style="text-align:left;">
Drug repurposing in malignant pleural mesothelioma: a breath of fresh air?
</td>
<td style="text-align:left;">
Eur Respir Rev
</td>
</tr>
<tr>
<td style="text-align:left;">
Post-irradiation pericardial malignant mesothelioma with deletion of p16: a case report.
</td>
<td style="text-align:left;">
Cancer Biol Med
</td>
</tr>
<tr>
<td style="text-align:left;">
Phase I Study of Intrapleural Gene-Mediated Cytotoxic Immunotherapy in Patients with Malignant Pleural Effusion.
</td>
<td style="text-align:left;">
Mol. Ther.
</td>
</tr>
<tr>
<td style="text-align:left;">
Updates in the diagnosis and treatment of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Curr Opin Pulm Med
</td>
</tr>
<tr>
<td style="text-align:left;">
Targeting the Hippo Pathway Is a New Potential Therapeutic Modality for Malignant Mesothelioma.
</td>
<td style="text-align:left;">
Cancers (Basel)
</td>
</tr>
<tr>
<td style="text-align:left;">
Inhibition of yes-associated protein down-regulates PD-L1 (CD274) expression in human malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J. Cell. Mol. Med.
</td>
</tr>
<tr>
<td style="text-align:left;">
Involvement of Heparanase in the Pathogenesis of Mesothelioma: Basic Aspects and Clinical Applications.
</td>
<td style="text-align:left;">
J. Natl. Cancer Inst.
</td>
</tr>
<tr>
<td style="text-align:left;">
Quality of life of survivors of malignant pleural mesothelioma in Japan: a cross sectional study.
</td>
<td style="text-align:left;">
BMC Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Primary Spinal Malignant Mesothelioma: A Case Report and Literature Review.
</td>
<td style="text-align:left;">
World Neurosurg
</td>
</tr>
<tr>
<td style="text-align:left;">
SYSTEMS-2: A randomised phase II study of radiotherapy dose escalation for pain control in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Clin Transl Radiat Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Heterogeneity in Immune Cell Content in Malignant Pleural Mesothelioma.
</td>
<td style="text-align:left;">
Int J Mol Sci
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant Pleural Mesothelioma with Bone Marrow Metastases.
</td>
<td style="text-align:left;">
Intern. Med.
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma: diagnostic value of medical thoracoscopy and long-term prognostic analysis.
</td>
<td style="text-align:left;">
BMC Pulm Med
</td>
</tr>
<tr>
<td style="text-align:left;">
Poor Prognostic Factors in Patients with Malignant Pleural Mesothelioma Classified as Pathological Stage IB According to the Eighth Edition TNM Classification.
</td>
<td style="text-align:left;">
Ann. Surg. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
FGF2 and EGF induce epithelial-mesenchymal transition in malignant pleural mesothelioma cells via a MAPKinase/MMP1 signal.
</td>
<td style="text-align:left;">
Carcinogenesis
</td>
</tr>
<tr>
<td style="text-align:left;">
Carbon Nanotubes and Other Engineered Nanoparticles Induced Pathophysiology on Mesothelial Cells and Mesothelial Membranes.
</td>
<td style="text-align:left;">
Front Physiol
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant cells from pleural fluids in malignant mesothelioma patients reveal novel mutations.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) for the treatment of malignant mesothelioma.
</td>
<td style="text-align:left;">
BMC Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Video-assisted thoracoscopic PlasmaJet ablation for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J Vis Surg
</td>
</tr>
<tr>
<td style="text-align:left;">
[Malignant pleural mesothelioma].
</td>
<td style="text-align:left;">
Ugeskr. Laeg.
</td>
</tr>
<tr>
<td style="text-align:left;">
In Silico and In Vitro Analyses of LncRNAs as Potential Regulators in the Transition from the Epithelioid to Sarcomatoid Histotype of Malignant Pleural Mesothelioma (MPM).
</td>
<td style="text-align:left;">
Int J Mol Sci
</td>
</tr>
<tr>
<td style="text-align:left;">
Prospective registry database of patients with malignant mesothelioma: directions for a future Japanese registry-based lung cancer study.
</td>
<td style="text-align:left;">
J Thorac Dis
</td>
</tr>
<tr>
<td style="text-align:left;">
Prognostic factors and treatment outcomes of malignant pleural mesothelioma in Eastern Asian patients - A Taiwanese study.
</td>
<td style="text-align:left;">
J. Formos. Med. Assoc.
</td>
</tr>
<tr>
<td style="text-align:left;">
Nintedanib Is Active in Malignant Pleural Mesothelioma Cell Models and Inhibits Angiogenesis and Tumor Growth <i>In Vivo</i>.
</td>
<td style="text-align:left;">
Clin. Cancer Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
Ipilimumab/Nivolumab-related Opsoclonus-Myoclonus-Ataxia Syndrome Variant in a Patient with Malignant Pleural Mesothelioma.
</td>
<td style="text-align:left;">
J. Immunother.
</td>
</tr>
<tr>
<td style="text-align:left;">
Loss of C/EBP-β LIP drives cisplatin resistance in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Facility volume and postoperative outcomes for malignant pleural mesothelioma: A National Cancer Data Base analysis.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Aberrant Lck Signal via CD28 Costimulation Augments Antigen-Specific Functionality and Tumor Control by Redirected T Cells with PD-1 Blockade in Humanized Mice.
</td>
<td style="text-align:left;">
Clin. Cancer Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
A Phase I Trial of Surgical Resection and Intraoperative Hyperthermic Cisplatin and Gemcitabine for Pleural Mesothelioma.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
NGR-hTNF in combination with best investigator choice in previously treated malignant pleural mesothelioma (NGR015): a randomised, double-blind, placebo-controlled phase 3 trial.
</td>
<td style="text-align:left;">
Lancet Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Four immunohistochemical assays to measure the PD-L1 expression in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Oncotarget
</td>
</tr>
<tr>
<td style="text-align:left;">
A subgroup of pleural mesothelioma expresses ALK protein and may be targetable by combined rapamycin and crizotinib therapy.
</td>
<td style="text-align:left;">
Oncotarget
</td>
</tr>
<tr>
<td style="text-align:left;">
Tremelimumab combined with durvalumab in patients with mesothelioma (NIBIT-MESO-1): an open-label, non-randomised, phase 2 study.
</td>
<td style="text-align:left;">
Lancet Respir Med
</td>
</tr>
<tr>
<td style="text-align:left;">
Targeting Tie-2/angiopoietin axis in experimental mesothelioma confers differential responses and raises predictive implications.
</td>
<td style="text-align:left;">
Oncotarget
</td>
</tr>
<tr>
<td style="text-align:left;">
A preclinical model to investigate the role of surgically-induced inflammation in tumor responses to intraoperative photodynamic therapy.
</td>
<td style="text-align:left;">
Lasers Surg Med
</td>
</tr>
<tr>
<td style="text-align:left;">
Utilization of Intensity-Modulated Radiation Therapy for Malignant Pleural Mesothelioma in the United States.
</td>
<td style="text-align:left;">
Clin Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Effects of Reduction in Tumor Burden on Survival in Epithelioid Malignant Pleural Mesothelioma.
</td>
<td style="text-align:left;">
Mayo Clin. Proc.
</td>
</tr>
<tr>
<td style="text-align:left;">
<sup>18</sup>F-fluorodeoxyglucose imaging of primary malignant pericardial mesothelioma with concurrent pericardial and pleural effusions and bone metastasis: A case report.
</td>
<td style="text-align:left;">
Mol Clin Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Is there a role for immunotherapy in malignant pleural mesothelioma?
</td>
<td style="text-align:left;">
Med. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Heterogeneity in Malignant Pleural Mesothelioma.
</td>
<td style="text-align:left;">
Int J Mol Sci
</td>
</tr>
<tr>
<td style="text-align:left;">
A Phase II Trial of First-Line Combination Chemotherapy With Cisplatin, Pemetrexed, and Nivolumab for Unresectable Malignant Pleural Mesothelioma: A Study Protocol.
</td>
<td style="text-align:left;">
Clin Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Immunohistochemically detectable metallothionein expression in malignant pleural mesotheliomas is strongly associated with early failure to platin-based chemotherapy.
</td>
<td style="text-align:left;">
Oncotarget
</td>
</tr>
<tr>
<td style="text-align:left;">
Surgical Options for Malignant Mesothelioma: A Single-Center Experience.
</td>
<td style="text-align:left;">
Korean J Thorac Cardiovasc Surg
</td>
</tr>
<tr>
<td style="text-align:left;">
Proton beam therapy for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Transl Lung Cancer Res
</td>
</tr>
<tr>
<td style="text-align:left;">
FDG PET-derived parameters as prognostic tool in progressive malignant pleural mesothelioma treated patients.
</td>
<td style="text-align:left;">
Eur. J. Nucl. Med. Mol. Imaging
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma following radiotherapy in a 16-year-old boy.
</td>
<td style="text-align:left;">
Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Inactivation of Tp53 and Pten drives rapid development of pleural and peritoneal malignant mesotheliomas.
</td>
<td style="text-align:left;">
J. Cell. Physiol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Pleural mesothelioma: is the surgeon still there?
</td>
<td style="text-align:left;">
Ann. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Programmed Death 1 Blockade With Nivolumab in Patients With Recurrent Malignant Pleural Mesothelioma.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Increased sensitivity to apoptosis upon endoplasmic reticulum stress-induced activation of the unfolded protein response in chemotherapy-resistant malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Br. J. Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Immune checkpoint blockade therapy of mesothelioma: a clinical and radiological challenge.
</td>
<td style="text-align:left;">
Cancer Immunol. Immunother.
</td>
</tr>
<tr>
<td style="text-align:left;">
Assessment of new HDAC inhibitors for immunotherapy of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Clin Epigenetics
</td>
</tr>
<tr>
<td style="text-align:left;">
Experimental Model of Human Malignant Mesothelioma in Athymic Mice.
</td>
<td style="text-align:left;">
Int J Mol Sci
</td>
</tr>
<tr>
<td style="text-align:left;">
Trophoblast Glycoprotein is Associated With a Favorable Outcome for Mesothelioma and a Target for Antibody Drug Conjugates.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Scientific Advances and New Frontiers in Mesothelioma Therapeutics.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Dynamic contrast-enhanced CT for the assessment of tumour response in malignant pleural mesothelioma: a pilot study.
</td>
<td style="text-align:left;">
Eur Radiol
</td>
</tr>
<tr>
<td style="text-align:left;">
Nivolumab Immunotherapy in Malignant Mesothelioma: A Case Report Highlighting a New Opportunity for Exceptional Outcomes.
</td>
<td style="text-align:left;">
Am J Case Rep
</td>
</tr>
<tr>
<td style="text-align:left;">
Chemo-manipulation of tumor blood vessels by a metal-based anticancer complex enhances antitumor therapy.
</td>
<td style="text-align:left;">
Sci Rep
</td>
</tr>
<tr>
<td style="text-align:left;">
The role of pemetrexed in recurrent epithelial ovarian cancer: A scoping review.
</td>
<td style="text-align:left;">
Oncol Rev
</td>
</tr>
<tr>
<td style="text-align:left;">
Combined hyaluronate-based films loaded with pemetrexed and cisplatin for the treatment of malignant pleural mesothelioma: Preliminary evaluation in an orthotopic tumor recurrence model.
</td>
<td style="text-align:left;">
Eur J Pharm Sci
</td>
</tr>
<tr>
<td style="text-align:left;">
Cytopathologic Diagnosis of Epithelioid and Mixed-Type Malignant Mesothelioma: Ten Years of Clinical Experience in Relation to International Guidelines.
</td>
<td style="text-align:left;">
Arch. Pathol. Lab. Med.
</td>
</tr>
<tr>
<td style="text-align:left;">
A systematic review and meta-analysis of second-line therapies for treatment of mesothelioma.
</td>
<td style="text-align:left;">
Respir Med
</td>
</tr>
<tr>
<td style="text-align:left;">
ERS/EACTS statement on the management of malignant pleural effusions.
</td>
<td style="text-align:left;">
Eur. Respir. J.
</td>
</tr>
<tr>
<td style="text-align:left;">
Mismatch Repair Protein Defects and Microsatellite Instability in Malignant Pleural Mesothelioma.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
ERS/EACTS statement on the management of malignant pleural effusions.
</td>
<td style="text-align:left;">
Eur J Cardiothorac Surg
</td>
</tr>
<tr>
<td style="text-align:left;">
The Economic Impact of Clinical Research in an Italian Public Hospital: The Malignant Pleural Mesothelioma Case Study.
</td>
<td style="text-align:left;">
Int J Health Policy Manag
</td>
</tr>
<tr>
<td style="text-align:left;">
Double cancer comprising malignant pleural mesothelioma and squamous cell carcinoma of the lung treated with radiotherapy: A case report.
</td>
<td style="text-align:left;">
Mol Clin Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant Pleural Mesothelioma, Biphasic Type: An Unusual and Insidious Case of Rapidly Progressive Small Blue Cell Tumor.
</td>
<td style="text-align:left;">
Cureus
</td>
</tr>
<tr>
<td style="text-align:left;">
Inhibition of MDM2 via Nutlin-3A: A Potential Therapeutic Approach for Pleural Mesotheliomas with MDM2-Induced Inactivation of Wild-Type P53.
</td>
<td style="text-align:left;">
J Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Surgery in Malignant Pleural Mesothelioma.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Current treatments and trials in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Clin Respir J
</td>
</tr>
<tr>
<td style="text-align:left;">
Pembrolizumab as Palliative Immunotherapy in Malignant Pleural Mesothelioma.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Pemetrexed, Vitamin B12, and Thoracic Tumors: The Times, They Are A-Changin’.
</td>
<td style="text-align:left;">
Clin Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
ADP sensitizes ZL55 cells to the activity of cisplatin.
</td>
<td style="text-align:left;">
J. Cell. Physiol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Early-stage Clinical Characterization of Malignant Pleural Mesothelioma.
</td>
<td style="text-align:left;">
In Vivo
</td>
</tr>
<tr>
<td style="text-align:left;">
Ancillary studies in pleural, pericardial, and peritoneal effusion cytology.
</td>
<td style="text-align:left;">
Cancer Cytopathol
</td>
</tr>
<tr>
<td style="text-align:left;">
BAMLET kills chemotherapy-resistant mesothelioma cells, holding oleic acid in an activated cytotoxic state.
</td>
<td style="text-align:left;">
PLoS ONE
</td>
</tr>
<tr>
<td style="text-align:left;">
Zoledronic acid in the management of mesothelioma - a feasibility study (Zol-A Trial): study protocol for a randomised controlled trial.
</td>
<td style="text-align:left;">
Trials
</td>
</tr>
<tr>
<td style="text-align:left;">
[PLEURECTOMY/DECORTICATION].
</td>
<td style="text-align:left;">
Nihon Geka Gakkai Zasshi
</td>
</tr>
<tr>
<td style="text-align:left;">
Pleural malignant mesothelioma following Wilms’ tumor.
</td>
<td style="text-align:left;">
Am. J. Clin. Pathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Modification of existing patient-reported outcome measures: qualitative development of the MD Anderson Symptom Inventory for malignant pleural mesothelioma (MDASI-MPM).
</td>
<td style="text-align:left;">
Qual Life Res
</td>
</tr>
<tr>
<td style="text-align:left;">
Targeting CD26 suppresses proliferation of malignant mesothelioma cell via downmodulation of ubiquitin-specific protease 22.
</td>
<td style="text-align:left;">
Biochem. Biophys. Res. Commun.
</td>
</tr>
<tr>
<td style="text-align:left;">
Expression of Numb and Gli1 in malignant pleural mesothelioma and their clinical significance.
</td>
<td style="text-align:left;">
J Cancer Res Ther
</td>
</tr>
<tr>
<td style="text-align:left;">
Evaluation of the photon dose calculation accuracy in radiation therapy of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J Cancer Res Ther
</td>
</tr>
<tr>
<td style="text-align:left;">
Adjuvant, neoadjuvant, and definitive radiation therapy for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J Thorac Dis
</td>
</tr>
<tr>
<td style="text-align:left;">
Survival by Histologic Subtype of Malignant Pleural Mesothelioma and the Impact of Surgical Resection on Overall Survival.
</td>
<td style="text-align:left;">
Clin Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Preclinical investigation of folate receptor-targeted nanoparticles for photodynamic therapy of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Int. J. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Intensity-modulated radiotherapy is a safe and effective treatment for localized malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Thorac Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Autologous Dendritic Cell Therapy in Mesothelioma Patients Enhances Frequencies of Peripheral CD4 T Cells Expressing HLA-DR, PD-1, or ICOS.
</td>
<td style="text-align:left;">
Front Immunol
</td>
</tr>
<tr>
<td style="text-align:left;">
Novel platinum agents and mesenchymal stromal cells for thoracic malignancies: state of the art and future perspectives.
</td>
<td style="text-align:left;">
Expert Opin Ther Pat
</td>
</tr>
<tr>
<td style="text-align:left;">
Moderately Hypofractionated Helical IMRT, FDG-PET/CT-guided, for Progressive Malignant Pleural Mesothelioma in Patients With Intact Lungs.
</td>
<td style="text-align:left;">
Clin Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
What’s new in mesothelioma.
</td>
<td style="text-align:left;">
Pathologica
</td>
</tr>
<tr>
<td style="text-align:left;">
Current efforts in research of pleural mesothelioma-An analysis of the ClinicalTrials.gov registry.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Tumor-specific genetic variants can be detected in circulating cell-free DNA of malignant pleural mesothelioma patients.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Antibody drug conjugates in thoracic malignancies.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Curcumin induces apoptosis and inhibits angiogenesis in murine malignant mesothelioma.
</td>
<td style="text-align:left;">
Int. J. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Berberine induces mitochondrial‑mediated apoptosis and protective autophagy in human malignant pleural mesothelioma NCI‑H2452 cells.
</td>
<td style="text-align:left;">
Oncol. Rep.
</td>
</tr>
<tr>
<td style="text-align:left;">
Is There a Role for Cancer-Directed Surgery in Early-Stage Sarcomatoid or Biphasic Mesothelioma?
</td>
<td style="text-align:left;">
Ann. Thorac. Surg.
</td>
</tr>
<tr>
<td style="text-align:left;">
Genomic Deletion of <i>BAP1</i> and <i>CDKN2A</i> Are Useful Markers for Quality Control of Malignant Pleural Mesothelioma (MPM) Primary Cultures.
</td>
<td style="text-align:left;">
Int J Mol Sci
</td>
</tr>
<tr>
<td style="text-align:left;">
Prophylactic procedure tract radiotherapy for malignant pleural mesothelioma: A systematic review and meta-analysis.
</td>
<td style="text-align:left;">
Clin Transl Radiat Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Inhibiting crosstalk between MET signaling and mitochondrial dynamics and morphology: a novel therapeutic approach for lung cancer and mesothelioma.
</td>
<td style="text-align:left;">
Cancer Biol. Ther.
</td>
</tr>
<tr>
<td style="text-align:left;">
Iron addiction with ferroptosis-resistance in asbestos-induced mesothelial carcinogenesis: Toward the era of mesothelioma prevention.
</td>
<td style="text-align:left;">
Free Radic. Biol. Med.
</td>
</tr>
<tr>
<td style="text-align:left;">
p53 modeling as a route to mesothelioma patients stratification and novel therapeutic identification.
</td>
<td style="text-align:left;">
J Transl Med
</td>
</tr>
<tr>
<td style="text-align:left;">
[Malignant pleural mesothelioma: The role of surgery].
</td>
<td style="text-align:left;">
Rev Pneumol Clin
</td>
</tr>
<tr>
<td style="text-align:left;">
Incidence of cutaneous reactions with pemetrexed: Comparison of patients who received three days of oral dexamethasone twice daily to patients who did not.
</td>
<td style="text-align:left;">
J Oncol Pharm Pract
</td>
</tr>
<tr>
<td style="text-align:left;">
Integrative Molecular Characterization of Malignant Pleural Mesothelioma.
</td>
<td style="text-align:left;">
Cancer Discov
</td>
</tr>
<tr>
<td style="text-align:left;">
Mesothelin as a target for cervical cancer therapy.
</td>
<td style="text-align:left;">
Arch. Gynecol. Obstet.
</td>
</tr>
<tr>
<td style="text-align:left;">
Management of recurrent pleural mesothelioma: Successful rechallenge with nintedanib in combination with chemotherapy.
</td>
<td style="text-align:left;">
Clin Case Rep
</td>
</tr>
<tr>
<td style="text-align:left;">
Thoracic aortic endografts used to resect the left subclavian artery infiltrated by malignant tumours.
</td>
<td style="text-align:left;">
Eur J Cardiothorac Surg
</td>
</tr>
<tr>
<td style="text-align:left;">
Prediction modelling using routine clinical parameters to stratify survival in Malignant Pleural Mesothelioma patients undergoing cytoreductive surgery.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Experimental study of the inhibition effect of CXCL12/CXCR4 in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J. Investig. Med.
</td>
</tr>
<tr>
<td style="text-align:left;">
Safety of Same-Day Vitamin B12 Supplementation in Patients Receiving Pemetrexed for the Treatment of Non-Small-Cell Lung Cancer or Pleural Mesothelioma: A Retrospective Analysis.
</td>
<td style="text-align:left;">
Clin Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Metabolic Characterization of Antifolate Responsiveness and Non-responsiveness in Malignant Pleural Mesothelioma Cells.
</td>
<td style="text-align:left;">
Front Pharmacol
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma in Finland: regional and gender variation.
</td>
<td style="text-align:left;">
Acta Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Differential Survival Characteristics of Sarcomatoid Subtype in Biphasic Pleural Mesothelioma.
</td>
<td style="text-align:left;">
Ann. Thorac. Surg.
</td>
</tr>
<tr>
<td style="text-align:left;">
Apatinib for salvage treatment of advanced malignant pleural mesothelioma: A case report.
</td>
<td style="text-align:left;">
Medicine (Baltimore)
</td>
</tr>
<tr>
<td style="text-align:left;">
Peripheral Blood DNA Methylation as Potential Biomarker of Malignant Pleural Mesothelioma in Asbestos-Exposed Subjects.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Multimodality treatment of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
F1000Res
</td>
</tr>
<tr>
<td style="text-align:left;">
Factors influencing malignant mesothelioma survival: a retrospective review of the National Mesothelioma Virtual Bank cohort.
</td>
<td style="text-align:left;">
F1000Res
</td>
</tr>
<tr>
<td style="text-align:left;">
<sup>18</sup>F-FDG PET/CT in therapy response and in predicting responders or non-responders in malignant pleural mesothelioma patients, by using semi-quantitative mRECIST and EORTC criteria.
</td>
<td style="text-align:left;">
Hell J Nucl Med
</td>
</tr>
<tr>
<td style="text-align:left;">
Reactivity of tumor cells in malignant effusions with a panel of monoclonal and polyclonal antibodies.
</td>
<td style="text-align:left;">
Tumour Biol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Establishment and characterization of CRISPR/Cas9-mediated NF2<sup>-/-</sup> human mesothelial cell line: Molecular insight into fibroblast growth factor receptor 2 in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Cancer Sci.
</td>
</tr>
<tr>
<td style="text-align:left;">
Pyruvate Treatment Restores the Effectiveness of Chemotherapeutic Agents in Human Colon Adenocarcinoma and Pleural Mesothelioma Cells.
</td>
<td style="text-align:left;">
Int J Mol Sci
</td>
</tr>
<tr>
<td style="text-align:left;">
Real-life treatment practice for malignant pleural mesothelioma in Belgium.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
[Surgical treatment of pleural mesothelioma].
</td>
<td style="text-align:left;">
Rev Pneumol Clin
</td>
</tr>
<tr>
<td style="text-align:left;">
Soluble AXL is ubiquitously present in malignant serous effusions.
</td>
<td style="text-align:left;">
Gynecol. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Extended pleurectomy decortication for thymoma with pleural dissemination.
</td>
<td style="text-align:left;">
Gen Thorac Cardiovasc Surg
</td>
</tr>
<tr>
<td style="text-align:left;">
Amelanotic Malignant Melanoma with Dense Pleural Thickening Mimicking Malignant Mesothelioma.
</td>
<td style="text-align:left;">
Intern. Med.
</td>
</tr>
<tr>
<td style="text-align:left;">
The use of patient-reported outcome measures (PROMs) in the management of malignant pleural mesothelioma: a descriptive literature survey.
</td>
<td style="text-align:left;">
Transl Lung Cancer Res
</td>
</tr>
<tr>
<td style="text-align:left;">
Breath analysis as a diagnostic and screening tool for malignant pleural mesothelioma: a systematic review.
</td>
<td style="text-align:left;">
Transl Lung Cancer Res
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant peritoneal mesothelioma: a review.
</td>
<td style="text-align:left;">
Transl Lung Cancer Res
</td>
</tr>
<tr>
<td style="text-align:left;">
Extrapleural pneumonectomy: still indicated?
</td>
<td style="text-align:left;">
Transl Lung Cancer Res
</td>
</tr>
<tr>
<td style="text-align:left;">
Combined modality treatment in mesothelioma: a systemic literature review with treatment recommendations.
</td>
<td style="text-align:left;">
Transl Lung Cancer Res
</td>
</tr>
<tr>
<td style="text-align:left;">
Current chemotherapy strategies in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Transl Lung Cancer Res
</td>
</tr>
<tr>
<td style="text-align:left;">
Is there a role for prophylactic radiotherapy to intervention tract sites in patients with malignant pleural mesothelioma?
</td>
<td style="text-align:left;">
Transl Lung Cancer Res
</td>
</tr>
<tr>
<td style="text-align:left;">
A randomized phase II study of pleurectomy/decortication preceded or followed by (neo-)adjuvant chemotherapy in patients with early stage malignant pleural mesothelioma (EORTC 1205).
</td>
<td style="text-align:left;">
Transl Lung Cancer Res
</td>
</tr>
<tr>
<td style="text-align:left;">
Treatment of malignant pleural mesothelioma with chemotherapy preceding versus after surgical resection.
</td>
<td style="text-align:left;">
J. Thorac. Cardiovasc. Surg.
</td>
</tr>
<tr>
<td style="text-align:left;">
Phase-II study with the combination of cisplatin and doxorubicin in advanced malignant mesothelioma of the pleura.
</td>
<td style="text-align:left;">
Onkologie
</td>
</tr>
<tr>
<td style="text-align:left;">
Systemic Therapy Use and Outcomes After Relapse from Preoperative Radiation and Extrapleural Pneumonectomy for Malignant Pleural Mesothelioma.
</td>
<td style="text-align:left;">
Oncologist
</td>
</tr>
<tr>
<td style="text-align:left;">
3D Culture Models of Malignant Mesothelioma Reveal a Powerful Interplay Between Photodynamic Therapy and Kinase Suppression Offering Hope to Reduce Tumor Recurrence.
</td>
<td style="text-align:left;">
Photochem. Photobiol.
</td>
</tr>
<tr>
<td style="text-align:left;">
A Novel Prospective Study Assessing the Combination of Photodynamic Therapy and Proton Radiation Therapy: Safety and Outcomes When Treating Malignant Pleural Mesothelioma.
</td>
<td style="text-align:left;">
Photochem. Photobiol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Systematic review of quality of life following pleurectomy decortication and extrapleural pneumonectomy for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
BMC Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Modeling Epidermal Growth Factor Inhibitor-mediated Enhancement of Photodynamic Therapy Efficacy Using 3D Mesothelioma Cell Culture.
</td>
<td style="text-align:left;">
Photochem. Photobiol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Biodistribution and Tumor Uptake of <sup>67</sup>Ga-Nimotuzumab in a Malignant Pleural Mesothelioma Xenograft.
</td>
<td style="text-align:left;">
Molecules
</td>
</tr>
<tr>
<td style="text-align:left;">
Deciduoid type malignant pleural mesothelioma: a case report.
</td>
<td style="text-align:left;">
AME Case Rep
</td>
</tr>
<tr>
<td style="text-align:left;">
Management of database: European Society of Thoracic Surgeons mesothelioma database-difficulties in improving quality data for rare tumour.
</td>
<td style="text-align:left;">
J Thorac Dis
</td>
</tr>
<tr>
<td style="text-align:left;">
[Malignant pleural mesothelioma: rare and aggressive but with new therapeutic perspectives].
</td>
<td style="text-align:left;">
Rev Prat
</td>
</tr>
<tr>
<td style="text-align:left;">
Whole-Body MRI: Comparison of Its Capability for TNM Staging of Malignant Pleural Mesothelioma With That of Coregistered PET/MRI, Integrated FDG PET/CT, and Conventional Imaging.
</td>
<td style="text-align:left;">
AJR Am J Roentgenol
</td>
</tr>
<tr>
<td style="text-align:left;">
A single centre phase II trial to assess the immunological activity of TroVax® plus pemetrexed/cisplatin in patients with malignant pleural mesothelioma - the SKOPOS trial.
</td>
<td style="text-align:left;">
Oncoimmunology
</td>
</tr>
<tr>
<td style="text-align:left;">
Low-dose cyclophosphamide depletes circulating naïve and activated regulatory T cells in malignant pleural mesothelioma patients synergistically treated with dendritic cell-based immunotherapy.
</td>
<td style="text-align:left;">
Oncoimmunology
</td>
</tr>
<tr>
<td style="text-align:left;">
Assessment of signaling pathway inhibitors and identification of predictive biomarkers in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Simultaneous presence of lung adenocarcinoma and malignant pleural mesothelioma: A case report.
</td>
<td style="text-align:left;">
Respir Med Case Rep
</td>
</tr>
<tr>
<td style="text-align:left;">
Combined modality treatment for malignant pleural mesothelioma: a single-centre long-term survival analysis using extrapleural pneumonectomy.
</td>
<td style="text-align:left;">
Eur J Cardiothorac Surg
</td>
</tr>
<tr>
<td style="text-align:left;">
The FAK inhibitor BI 853520 inhibits spheroid formation and orthotopic tumor growth in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J. Mol. Med.
</td>
</tr>
<tr>
<td style="text-align:left;">
The Role of Yes-Associated Protein (YAP) in Regulating Programmed Death-Ligand 1 (PD-L1) in Thoracic Cancer.
</td>
<td style="text-align:left;">
Biomedicines
</td>
</tr>
<tr>
<td style="text-align:left;">
BAP1 gene mutations in Egyptian patients with advanced sporadic malignant pleural mesothelioma (MPM): relation with clinical outcomes and survival.
</td>
<td style="text-align:left;">
Cancer Genet
</td>
</tr>
<tr>
<td style="text-align:left;">
Pleural thickness after neoadjuvant chemotherapy is a prognostic factor in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J. Thorac. Cardiovasc. Surg.
</td>
</tr>
<tr>
<td style="text-align:left;">
Metachronous Lung Cancer After Pleurectomy/Decortication.
</td>
<td style="text-align:left;">
Ann. Thorac. Surg.
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma of the pleura.
</td>
<td style="text-align:left;">
Mayo Clin. Proc.
</td>
</tr>
<tr>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
Bull Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Case report: Steroid responsive mesothelioma-related pleural effusion.
</td>
<td style="text-align:left;">
Respir Med Case Rep
</td>
</tr>
<tr>
<td style="text-align:left;">
Efficacy and Safety of Avelumab Treatment in Patients With Advanced Unresectable Mesothelioma: Phase 1b Results From the JAVELIN Solid Tumor Trial.
</td>
<td style="text-align:left;">
JAMA Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
MicroRNAs for the Diagnosis and Management of Malignant Pleural Mesothelioma: A Literature Review.
</td>
<td style="text-align:left;">
Front Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Heparanase inhibitors restrain mesothelioma.
</td>
<td style="text-align:left;">
Oncotarget
</td>
</tr>
<tr>
<td style="text-align:left;">
Return to work after surgical treatment for malignant pleural mesothelioma: report of a case.
</td>
<td style="text-align:left;">
Gen Thorac Cardiovasc Surg
</td>
</tr>
<tr>
<td style="text-align:left;">
Surgical Risk and Survival Associated With Less Invasive Surgery for Malignant Pleural Mesothelioma.
</td>
<td style="text-align:left;">
Semin. Thorac. Cardiovasc. Surg.
</td>
</tr>
<tr>
<td style="text-align:left;">
Progress of malignant mesothelioma research in basic science: A review of the 14th international conference of the international mesothelioma interest group (iMig2018).
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Prognostic factors of survival in patients with malignant pleural mesothelioma: an analysis of the National Cancer Database.
</td>
<td style="text-align:left;">
Carcinogenesis
</td>
</tr>
<tr>
<td style="text-align:left;">
ADAM10 mediates malignant pleural mesothelioma invasiveness.
</td>
<td style="text-align:left;">
Oncogene
</td>
</tr>
<tr>
<td style="text-align:left;">
Dosimetric Correlates of Pulmonary Toxicity in Patients with Malignant Pleural Mesothelioma Receiving Radiation Therapy to the Intact Lungs.
</td>
<td style="text-align:left;">
Pract Radiat Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Antagonists of growth hormone-releasing hormone (GHRH) inhibit the growth of human malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Proc. Natl. Acad. Sci. U.S.A.
</td>
</tr>
<tr>
<td style="text-align:left;">
Ipilimumab and nivolumab in the treatment of recurrent malignant pleural mesothelioma (INITIATE): results of a prospective, single-arm, phase 2 trial.
</td>
<td style="text-align:left;">
Lancet Respir Med
</td>
</tr>
<tr>
<td style="text-align:left;">
Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial.
</td>
<td style="text-align:left;">
Lancet Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Early specialist palliative care on quality of life for malignant pleural mesothelioma: a randomised controlled trial.
</td>
<td style="text-align:left;">
Thorax
</td>
</tr>
<tr>
<td style="text-align:left;">
Learning from the past to design better trials in second-line treatment for mesothelioma patients.
</td>
<td style="text-align:left;">
Ecancermedicalscience
</td>
</tr>
<tr>
<td style="text-align:left;">
Managing malignant pleural mesothelioma: experience and perceptions of health care professionals caring for people with mesothelioma.
</td>
<td style="text-align:left;">
Support Care Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Inhibition of collagen production delays malignant mesothelioma tumor growth in a murine model.
</td>
<td style="text-align:left;">
Biochem. Biophys. Res. Commun.
</td>
</tr>
<tr>
<td style="text-align:left;">
MesoTRAP: a feasibility study that includes a pilot clinical trial comparing video-assisted thoracoscopic partial pleurectomy decortication with indwelling pleural catheter in patients with trapped lung due to malignant pleural mesothelioma designed to address recruitment and randomisation uncertainties and sample size requirements for a phase III trial.
</td>
<td style="text-align:left;">
BMJ Open Respir Res
</td>
</tr>
<tr>
<td style="text-align:left;">
Computed tomography features of local pleural recurrence in patients with malignant pleural mesothelioma treated with intensity-modulated pleural radiation therapy.
</td>
<td style="text-align:left;">
Eur Radiol
</td>
</tr>
<tr>
<td style="text-align:left;">
Histomorphological and Immunohistochemical Analysis of Pleural Neoplasms.
</td>
<td style="text-align:left;">
Iran J Pathol
</td>
</tr>
<tr>
<td style="text-align:left;">
Gene expression profiling of homologous recombination repair pathway indicates susceptibility for olaparib treatment in malignant pleural mesothelioma in vitro.
</td>
<td style="text-align:left;">
BMC Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Characteristics and long-term outcomes of advanced pleural mesothelioma in Latin America (MeSO-CLICaP).
</td>
<td style="text-align:left;">
Thorac Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Robust Cell Detection and Segmentation for Image Cytometry Reveal Th17 Cell Heterogeneity.
</td>
<td style="text-align:left;">
Cytometry A
</td>
</tr>
<tr>
<td style="text-align:left;">
Fluorodeoxyglucose versus Choline Positron Emission Tomography/Computed Tomography Response Evaluation in Two Malignant Pleural Mesothelioma Patients Treated with Talc Pleurodesis and Neoadjuvant Chemotherapy.
</td>
<td style="text-align:left;">
Cureus
</td>
</tr>
<tr>
<td style="text-align:left;">
MST1/Hippo promoter gene methylation predicts poor survival in patients with malignant pleural mesothelioma in the IFCT-GFPC-0701 MAPS Phase 3 trial.
</td>
<td style="text-align:left;">
Br. J. Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Use of Immune Checkpoint Inhibitors in Mesothelioma.
</td>
<td style="text-align:left;">
Curr Treat Options Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Pemetrexed-loaded nanoparticles targeted to malignant pleural mesothelioma cells: an in vitro study.
</td>
<td style="text-align:left;">
Int J Nanomedicine
</td>
</tr>
<tr>
<td style="text-align:left;">
Vascular-targeted low dose photodynamic therapy stabilizes tumor vessels by modulating pericyte contractility.
</td>
<td style="text-align:left;">
Lasers Surg Med
</td>
</tr>
<tr>
<td style="text-align:left;">
[Possibilities of cytological diagnosis of the nature of the exudate at the stage of emergency.]
</td>
<td style="text-align:left;">
Klin. Lab. Diagn.
</td>
</tr>
<tr>
<td style="text-align:left;">
Maintenance Defactinib Versus Placebo After First-Line Chemotherapy in Patients With Merlin-Stratified Pleural Mesothelioma: COMMAND-A Double-Blind, Randomized, Phase II Study.
</td>
<td style="text-align:left;">
J. Clin. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Multiple sclerosis outcomes after cancer immunotherapy.
</td>
<td style="text-align:left;">
Clin Transl Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant Pleural Mesothelioma: Is Tailoring the Second-Line Therapy Really “Raising the Bar?”
</td>
<td style="text-align:left;">
Curr Treat Options Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Tumor PD-L1 expression in malignant pleural and peritoneal mesothelioma by Dako PD-L1 22C3 pharmDx and Dako PD-L1 28-8 pharmDx assays.
</td>
<td style="text-align:left;">
Hum. Pathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
The Role of Adjuvant Radiotherapy in the Treatment of Pleural Mesothelioma.
</td>
<td style="text-align:left;">
Ann. Surg. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Relations between approved platinum drugs and non-coding RNAs in mesothelioma.
</td>
<td style="text-align:left;">
Noncoding RNA Res
</td>
</tr>
<tr>
<td style="text-align:left;">
Interplay of non-coding RNAs and approved antimetabolites such as gemcitabine and pemetrexed in mesothelioma.
</td>
<td style="text-align:left;">
Noncoding RNA Res
</td>
</tr>
<tr>
<td style="text-align:left;">
Intrapleural immunotherapy: An update on emerging treatment strategies for pleural malignancy.
</td>
<td style="text-align:left;">
Clin Respir J
</td>
</tr>
<tr>
<td style="text-align:left;">
Dynamic contrast-enhanced MRI of malignant pleural mesothelioma: a comparative study of pharmacokinetic models and correlation with mRECIST criteria.
</td>
<td style="text-align:left;">
Cancer Imaging
</td>
</tr>
<tr>
<td style="text-align:left;">
Deep convolutional neural networks for the automated segmentation of malignant pleural mesothelioma on computed tomography scans.
</td>
<td style="text-align:left;">
J Med Imaging (Bellingham)
</td>
</tr>
<tr>
<td style="text-align:left;">
When RON MET TAM in Mesothelioma: All Druggable for One, and One Drug for All?
</td>
<td style="text-align:left;">
Front Endocrinol (Lausanne)
</td>
</tr>
<tr>
<td style="text-align:left;">
Prolonged post-recurrence survival following pleurectomy/decortication for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Oncol Lett
</td>
</tr>
<tr>
<td style="text-align:left;">
Body composition and nutritional status in malignant pleural mesothelioma: implications for activity levels and quality of life.
</td>
<td style="text-align:left;">
Eur J Clin Nutr
</td>
</tr>
<tr>
<td style="text-align:left;">
Making cold malignant pleural effusions hot: driving novel immunotherapies.
</td>
<td style="text-align:left;">
Oncoimmunology
</td>
</tr>
<tr>
<td style="text-align:left;">
Chemosensitivity and resistance testing in malignant effusions with focus on primary malignant mesothelioma and metastatic adenocarcinoma.
</td>
<td style="text-align:left;">
Pleura Peritoneum
</td>
</tr>
<tr>
<td style="text-align:left;">
Normothermic intraperitoneal chemotherapy long term (NIPEC-LT) in the management of peritoneal surface malignancy, an overview.
</td>
<td style="text-align:left;">
Pleura Peritoneum
</td>
</tr>
<tr>
<td style="text-align:left;">
Tomotherapy in malignant mesothelioma: a planning study to establish dose constraints.
</td>
<td style="text-align:left;">
Strahlenther Onkol
</td>
</tr>
<tr>
<td style="text-align:left;">
Patterns of care and survival of older patients with malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J Geriatr Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Prophylactic Irradiation of Tracts in Patients With Malignant Pleural Mesothelioma: An Open-Label, Multicenter, Phase III Randomized Trial.
</td>
<td style="text-align:left;">
J. Clin. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Thoracic Hyper-IgG4-Related Disease Mimicking Malignant Pleural Mesothelioma.
</td>
<td style="text-align:left;">
Lung
</td>
</tr>
<tr>
<td style="text-align:left;">
The Investigation of Lipoxygenases as Therapeutic Targets in Malignant Pleural Mesothelioma.
</td>
<td style="text-align:left;">
Pathol. Oncol. Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
Pseudomesotheliomatous Carcinoma with a High Pleural Hyaluronic Acid Concentration Arising from a Primary Esophageal Squamous Cell Carcinoma.
</td>
<td style="text-align:left;">
Am J Case Rep
</td>
</tr>
<tr>
<td style="text-align:left;">
A survey of patient and caregiver experience with malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Support Care Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Survival analysis via nomogram of surgical patients with malignant pleural mesothelioma in the Surveillance, Epidemiology, and End Results database.
</td>
<td style="text-align:left;">
Thorac Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Extra-pleural pneumonectomy in the era of image-guided intensity-modulated radiotherapy.
</td>
<td style="text-align:left;">
Radiol Med
</td>
</tr>
<tr>
<td style="text-align:left;">
Inherited predisposition to malignant mesothelioma and overall survival following platinum chemotherapy.
</td>
<td style="text-align:left;">
Proc. Natl. Acad. Sci. U.S.A.
</td>
</tr>
<tr>
<td style="text-align:left;">
The timing of chemotherapy in the management plan for medically operable early-stage malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Expert Rev Respir Med
</td>
</tr>
<tr>
<td style="text-align:left;">
Chemotherapy Versus Supportive Care for Unresected Malignant Pleural Mesothelioma.
</td>
<td style="text-align:left;">
Clin Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Disparities in Compliance With National Guidelines for the Treatment of Malignant Pleural Mesothelioma.
</td>
<td style="text-align:left;">
Ann. Thorac. Surg.
</td>
</tr>
<tr>
<td style="text-align:left;">
Management of Malignant Pleural Mesothelioma in the Elderly Population.
</td>
<td style="text-align:left;">
Ann. Surg. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Pathological evaluation of the visceral pleura in the radical pleurectomy/decortication for malignant pleural mesothelioma patients.
</td>
<td style="text-align:left;">
J Thorac Dis
</td>
</tr>
<tr>
<td style="text-align:left;">
Extra-pleural pneumonectomy.
</td>
<td style="text-align:left;">
J Thorac Dis
</td>
</tr>
<tr>
<td style="text-align:left;">
Physician requests by patients with malignant pleural mesothelioma in Japan.
</td>
<td style="text-align:left;">
BMC Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Pain management in patients with malignant mesothelioma: challenges and solutions.
</td>
<td style="text-align:left;">
Lung Cancer (Auckl)
</td>
</tr>
<tr>
<td style="text-align:left;">
Whole-genome sequencing of human malignant mesothelioma tumours and cell lines.
</td>
<td style="text-align:left;">
Carcinogenesis
</td>
</tr>
<tr>
<td style="text-align:left;">
Metadherin Is a Prognostic Apoptosis Modulator in Mesothelioma Induced via NF-κB-Mediated Signaling.
</td>
<td style="text-align:left;">
Transl Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
First-ever Abscopal Effect after Palliative Radiotherapy and Immuno-gene Therapy for Malignant Pleural Mesothelioma.
</td>
<td style="text-align:left;">
Cureus
</td>
</tr>
<tr>
<td style="text-align:left;">
Metastatic Clear Cell Renal Carcinoma Without Evidence of a Primary Renal Tumour Mimicking Advanced Stage of Malignant Lung Tumour.
</td>
<td style="text-align:left;">
Klin Onkol
</td>
</tr>
<tr>
<td style="text-align:left;">
A phase Ib study of GSK3052230, an FGF ligand trap in combination with pemetrexed and cisplatin in patients with malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Invest New Drugs
</td>
</tr>
<tr>
<td style="text-align:left;">
50 Patients with Malignant Mesothelioma of Both the Pleura and Peritoneum: A Single-Institution Experience.
</td>
<td style="text-align:left;">
Ann. Surg. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Loco-regional staging of malignant pleural mesothelioma by integrated <sup>18</sup>F-FDG PET/MRI.
</td>
<td style="text-align:left;">
Eur J Radiol
</td>
</tr>
<tr>
<td style="text-align:left;">
Advances in pulmonary and pleural malignant disorders.
</td>
<td style="text-align:left;">
Clin Med (Lond)
</td>
</tr>
<tr>
<td style="text-align:left;">
Adjuvant dendritic cell based immunotherapy (DCBI) after cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal mesothelioma, a phase II single centre open-label clinical trial: rationale and design of the MESOPEC trial.
</td>
<td style="text-align:left;">
BMJ Open
</td>
</tr>
<tr>
<td style="text-align:left;">
Lymphangitic carcinomatosis: A common radiographic manifestation of local failure following extended pleurectomy/decortication in patients with malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Role of Immunotherapy in Small Cell Lung Cancer, Thymic Epithelial Tumors, and Mesothelioma.
</td>
<td style="text-align:left;">
Am Soc Clin Oncol Educ Book
</td>
</tr>
<tr>
<td style="text-align:left;">
Fast, Low-Dose Megavoltage-Topogram Localization on TomoTherapy: Initial Clinical Experience With Mesothelioma Patients.
</td>
<td style="text-align:left;">
Pract Radiat Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Nintedanib in combination with pemetrexed and cisplatin for chemotherapy-naive patients with advanced malignant pleural mesothelioma (LUME-Meso): a double-blind, randomised, placebo-controlled phase 3 trial.
</td>
<td style="text-align:left;">
Lancet Respir Med
</td>
</tr>
<tr>
<td style="text-align:left;">
Wnt/IL-1β/IL-8 autocrine circuitries control chemoresistance in mesothelioma initiating cells by inducing ABCB5.
</td>
<td style="text-align:left;">
Int. J. Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
High systemic immune-inflammation index represents an unfavorable prognosis of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Cancer Manag Res
</td>
</tr>
<tr>
<td style="text-align:left;">
The Use of Radiation Therapy for the Treatment of Malignant Pleural Mesothelioma: Expert Opinion from the National Cancer Institute Thoracic Malignancy Steering Committee, International Association for the Study of Lung Cancer, and Mesothelioma Applied Research Foundation.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
A Proposed System Toward Standardizing Surgical-Based Treatments for Malignant Pleural Mesothelioma, From the Joint National Cancer Institute-International Association for the Study of Lung Cancer-Mesothelioma Applied Research Foundation Taskforce.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Inactivation of <i>Bap1</i> Cooperates with Losses of <i>Nf2</i> and <i>Cdkn2a</i> to Drive the Development of Pleural Malignant Mesothelioma in Conditional Mouse Models.
</td>
<td style="text-align:left;">
Cancer Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
Clinical Efficacy and Safety of Nivolumab: Results of a <u>M</u>ulticenter, Op<u>e</u>n-label, Single-a<u>r</u>m, Japanese Phase II study in Mal<u>i</u>gnant Pleural Meso<u>t</u>helioma (MERIT).
</td>
<td style="text-align:left;">
Clin. Cancer Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
[Recent Developments in the Regional Treatment of Peritoneal and Pleural Tumours (incl. HIPEC and HITOC)].
</td>
<td style="text-align:left;">
Zentralbl Chir
</td>
</tr>
<tr>
<td style="text-align:left;">
Advances in pathological diagnosis of mesothelioma: what pulmonologists should know.
</td>
<td style="text-align:left;">
Curr Opin Pulm Med
</td>
</tr>
<tr>
<td style="text-align:left;">
Health-Related Quality of Life Impact from Adding Bevacizumab to Cisplatin-Pemetrexed in Malignant Pleural Mesothelioma in the MAPS IFCT-GFPC-0701 Phase III Trial.
</td>
<td style="text-align:left;">
Clin. Cancer Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
Communication of a mesothelioma diagnosis: developing recommendations to improve the patient experience.
</td>
<td style="text-align:left;">
BMJ Open Respir Res
</td>
</tr>
<tr>
<td style="text-align:left;">
Defining the role of adjuvant radiotherapy for malignant pleural mesothelioma: a propensity-matched landmark analysis of the National Cancer Database.
</td>
<td style="text-align:left;">
J Thorac Dis
</td>
</tr>
<tr>
<td style="text-align:left;">
Expression of estrogen receptor beta (ERβ) and its prognostic value in pleural mesothelioma.
</td>
<td style="text-align:left;">
J Thorac Dis
</td>
</tr>
<tr>
<td style="text-align:left;">
The Prevalence and Clinical Relevance of Nonexpandable Lung in Malignant Pleural Mesothelioma. A Prospective, Single-Center Cohort Study of 229 Patients.
</td>
<td style="text-align:left;">
Ann Am Thorac Soc
</td>
</tr>
<tr>
<td style="text-align:left;">
Evaluation of Matrix Metalloproteinase 9 Serum Concentration as a Biomarker in Malignant Mesothelioma.
</td>
<td style="text-align:left;">
Dis. Markers
</td>
</tr>
<tr>
<td style="text-align:left;">
Development of novel monoclonal antibodies with specific binding affinity for denatured human CD26 in formalin-fixed paraffin-embedded and decalcified specimens.
</td>
<td style="text-align:left;">
PLoS ONE
</td>
</tr>
<tr>
<td style="text-align:left;">
Breath Analysis: A Systematic Review of Volatile Organic Compounds (VOCs) in Diagnostic and Therapeutic Management of Pleural Mesothelioma.
</td>
<td style="text-align:left;">
Cancers (Basel)
</td>
</tr>
<tr>
<td style="text-align:left;">
Evaluation of the psychometric properties and minimally important difference of the MD Anderson Symptom Inventory for malignant pleural mesothelioma (MDASI-MPM).
</td>
<td style="text-align:left;">
J Patient Rep Outcomes
</td>
</tr>
<tr>
<td style="text-align:left;">
miR-625-3p and lncRNA GAS5 in Liquid Biopsies for Predicting the Outcome of Malignant Pleural Mesothelioma Patients Treated with Neo-Adjuvant Chemotherapy and Surgery.
</td>
<td style="text-align:left;">
Noncoding RNA
</td>
</tr>
<tr>
<td style="text-align:left;">
Prolonged retention of liposomes in the pleural cavity of normal mice and high tumor distribution in mice with malignant pleural effusion, after intrapleural injection.
</td>
<td style="text-align:left;">
Int J Nanomedicine
</td>
</tr>
<tr>
<td style="text-align:left;">
[Hyperthermic intrathoracic chemotherapy in thoracic surgery].
</td>
<td style="text-align:left;">
Chirurg
</td>
</tr>
<tr>
<td style="text-align:left;">
Management of Clinically Lymph Node-Positive Malignant Pleural Mesothelioma.
</td>
<td style="text-align:left;">
Semin. Thorac. Cardiovasc. Surg.
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant Pleural Mesothelioma: A Multi-Disciplinary Approach.
</td>
<td style="text-align:left;">
Gulf J Oncolog
</td>
</tr>
<tr>
<td style="text-align:left;">
Pattern of failure after adjuvant radiotherapy following extrapleural pneumonectomy of pleural mesothelioma in the SAKK 17/04 trial.
</td>
<td style="text-align:left;">
Radiother Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Long term survival and perioperative propensity score matched outcomes of diaphragmatic resections compared to stripping in cytoreductive surgery + intra-peritoneal chemotherapy.
</td>
<td style="text-align:left;">
Am. J. Surg.
</td>
</tr>
<tr>
<td style="text-align:left;">
What can independent research for mesothelioma achieve to treat this orphan disease?
</td>
<td style="text-align:left;">
Expert Opin Investig Drugs
</td>
</tr>
<tr>
<td style="text-align:left;">
2-Deoxy-glucose Enhances the Effect of Cisplatin and Pemetrexed in Reducing Malignant Pleural Mesothelioma Cell Proliferation But Not Spheroid Growth.
</td>
<td style="text-align:left;">
Anticancer Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
Clinical Response of Live-Attenuated, <i>Listeria monocytogenes</i> Expressing Mesothelin (CRS-207) with Chemotherapy in Patients with Malignant Pleural Mesothelioma.
</td>
<td style="text-align:left;">
Clin. Cancer Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
Preliminary results of entire pleural intensity-modulated radiotherapy in a neoadjuvant setting for resectable malignant mesothelioma.
</td>
<td style="text-align:left;">
Radiat Oncol J
</td>
</tr>
<tr>
<td style="text-align:left;">
Targeting angiogenesis for patients with unresectable malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Semin. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Efficacy and safety of pemetrexed plus cisplatin as first-line chemotherapy in advanced malignant peritoneal mesothelioma.
</td>
<td style="text-align:left;">
Jpn. J. Clin. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Transcriptional suppression of the miR-15/16 family by c-Myc in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Oncotarget
</td>
</tr>
<tr>
<td style="text-align:left;">
Pemetrexed-conjugated hyaluronan for the treatment of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Eur J Pharm Sci
</td>
</tr>
<tr>
<td style="text-align:left;">
Nivo-lution in Mesothelioma.
</td>
<td style="text-align:left;">
Clin. Cancer Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
Prostate Carcinoma and Pleural Mesothelioma: An Extremely Rare Co-occurrence.
</td>
<td style="text-align:left;">
Cureus
</td>
</tr>
<tr>
<td style="text-align:left;">
Simple and Rapid Quantification of the Multi-Enzyme Targeting Antifolate Pemetrexed in Human Plasma.
</td>
<td style="text-align:left;">
Ther Drug Monit
</td>
</tr>
<tr>
<td style="text-align:left;">
Perioperative anesthetic management of patients with malignant pleural mesothelioma undergoing cytoreductive surgery and intraoperative chemotherapy.
</td>
<td style="text-align:left;">
Rev Esp Anestesiol Reanim
</td>
</tr>
<tr>
<td style="text-align:left;">
The Oncolytic Virus <i>dl</i>922-947 Triggers Immunogenic Cell Death in Mesothelioma and Reduces Xenograft Growth.
</td>
<td style="text-align:left;">
Front Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
A multicenter, randomized, phase II/III study of dendritic cells loaded with allogeneic tumor cell lysate (MesoPher) in subjects with mesothelioma as maintenance therapy after chemotherapy: DENdritic cell Immunotherapy for Mesothelioma (DENIM) trial.
</td>
<td style="text-align:left;">
Transl Lung Cancer Res
</td>
</tr>
<tr>
<td style="text-align:left;">
Molecular characterization of localized pleural mesothelioma.
</td>
<td style="text-align:left;">
Mod. Pathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Heterologous sarcomatoid pleural mesothelioma with osteosarcomatous differentiation: a report of autopsy case that accomplished trimodality therapy and review of the literature.
</td>
<td style="text-align:left;">
Gen Thorac Cardiovasc Surg
</td>
</tr>
<tr>
<td style="text-align:left;">
Mesothelioma of the tunica vaginalis testis.
</td>
<td style="text-align:left;">
Hum. Pathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
The Prognostic Role of TNM Staging Compared With Tumor Volume and Number of Pleural Sites in Malignant Pleural Mesothelioma.
</td>
<td style="text-align:left;">
Clin Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Phase II Trial of Cediranib in Combination With Cisplatin and Pemetrexed in Chemotherapy-Naïve Patients With Unresectable Malignant Pleural Mesothelioma (SWOG S0905).
</td>
<td style="text-align:left;">
J. Clin. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Immune Signature of Malignant Pleural Mesothelioma as Assessed by Transcriptome Analysis.
</td>
<td style="text-align:left;">
Cancer Genomics Proteomics
</td>
</tr>
<tr>
<td style="text-align:left;">
Dropwort-induced metabolic reprogramming restrains YAP/TAZ/TEAD oncogenic axis in mesothelioma.
</td>
<td style="text-align:left;">
J. Exp. Clin. Cancer Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
Targeting the C-terminus of galectin-9 induces mesothelioma apoptosis and M2 macrophage depletion.
</td>
<td style="text-align:left;">
Oncoimmunology
</td>
</tr>
<tr>
<td style="text-align:left;">
MESOTIP: Phase II multicenter randomized trial evaluating the association of PIPAC and systemic chemotherapy vs. systemic chemotherapy alone as 1st-line treatment of malignant peritoneal mesothelioma.
</td>
<td style="text-align:left;">
Pleura Peritoneum
</td>
</tr>
<tr>
<td style="text-align:left;">
Bidirectional chemotherapy allowing surgery and HIPEC for malignant peritoneal mesothelioma.
</td>
<td style="text-align:left;">
Pleura Peritoneum
</td>
</tr>
<tr>
<td style="text-align:left;">
Phase I Study of Lentiviral-Transduced Chimeric Antigen Receptor-Modified T Cells Recognizing Mesothelin in Advanced Solid Cancers.
</td>
<td style="text-align:left;">
Mol. Ther.
</td>
</tr>
<tr>
<td style="text-align:left;">
Multidisciplinary palliative treatment including isolated thoracic perfusion for progressive malignant pleural mesothelioma: a retrospective observational study.
</td>
<td style="text-align:left;">
J BUON
</td>
</tr>
<tr>
<td style="text-align:left;">
Phenotypic and functional analysis of malignant mesothelioma tumor-infiltrating lymphocytes.
</td>
<td style="text-align:left;">
Oncoimmunology
</td>
</tr>
<tr>
<td style="text-align:left;">
Multi-antigen Vaccination With Simultaneous Engagement of the OX40 Receptor Delays Malignant Mesothelioma Growth and Increases Survival in Animal Models.
</td>
<td style="text-align:left;">
Front Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Largely Unchanged Annual Incidence and Overall Survival of Pleural Mesothelioma in the USA.
</td>
<td style="text-align:left;">
World J Surg
</td>
</tr>
<tr>
<td style="text-align:left;">
Return to intended oncologic treatment after surgery for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J. Thorac. Cardiovasc. Surg.
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant Pleural Effusion and Its Current Management: A Review.
</td>
<td style="text-align:left;">
Medicina (Kaunas)
</td>
</tr>
<tr>
<td style="text-align:left;">
Integration of Tumor-Treating Fields into the Multidisciplinary Management of Patients with Solid Malignancies.
</td>
<td style="text-align:left;">
Oncologist
</td>
</tr>
<tr>
<td style="text-align:left;">
Building a Bridge between Chemotherapy and Immunotherapy in Malignant Pleural Mesothelioma: Investigating the Effect of Chemotherapy on Immune Checkpoint Expression.
</td>
<td style="text-align:left;">
Int J Mol Sci
</td>
</tr>
<tr>
<td style="text-align:left;">
EPHA2 mutations with oncogenic characteristics in squamous cell lung cancer and malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Oncogenesis
</td>
</tr>
<tr>
<td style="text-align:left;">
Proceedings of the American Society of Cytopathology companion session at the 2019 United States and Canadian Academy of Pathology Annual meeting, part 2: effusion cytology with focus on theranostics and diagnosis of malignant mesothelioma.
</td>
<td style="text-align:left;">
J Am Soc Cytopathol
</td>
</tr>
<tr>
<td style="text-align:left;">
Determination of Mesothelin Levels in Pleural Effusion Does Not Help Predict Survival of Patients With Malignant Pleural Mesothelioma.
</td>
<td style="text-align:left;">
Anticancer Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
Molecular Testing on Pleural Fluid Samples.
</td>
<td style="text-align:left;">
Semin Respir Crit Care Med
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant Mesothelioma: Has Anything Changed?
</td>
<td style="text-align:left;">
Semin Respir Crit Care Med
</td>
</tr>
<tr>
<td style="text-align:left;">
Expression of FGFR1-4 in Malignant Pleural Mesothelioma Tissue and Corresponding Cell Lines and its Relationship to Patient Survival and FGFR Inhibitor Sensitivity.
</td>
<td style="text-align:left;">
Cells
</td>
</tr>
<tr>
<td style="text-align:left;">
The Role of Immunohistochemistry Studies in Distinguishing Malignant Mesothelioma from Metastatic Lung Carcinoma in Malignant Pleural Effusion.
</td>
<td style="text-align:left;">
Iran J Pathol
</td>
</tr>
<tr>
<td style="text-align:left;">
V-domain Ig-containing suppressor of T-cell activation (VISTA), a potentially targetable immune checkpoint molecule, is highly expressed in epithelioid malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Mod. Pathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Translating mesothelioma molecular genomics and dependencies into precision oncology-based therapies.
</td>
<td style="text-align:left;">
Semin. Cancer Biol.
</td>
</tr>
<tr>
<td style="text-align:left;">
EURACAN/IASLC Proposals for Updating the Histologic Classification of Pleural Mesothelioma: Towards a More Multidisciplinary Approach.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Development of a Novel Prognostic Risk Classification System for Malignant Pleural Mesothelioma.
</td>
<td style="text-align:left;">
Clin Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Phase I study of YS110, a recombinant humanized monoclonal antibody to CD26, in Japanese patients with advanced malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
PFKFB3 inhibition reprograms malignant pleural mesothelioma to nutrient stress-induced macropinocytosis and ER stress as independent binary adaptive responses.
</td>
<td style="text-align:left;">
Cell Death Dis
</td>
</tr>
<tr>
<td style="text-align:left;">
Volumetric Modulated Arc Therapy After Lung Sparing Surgery for Malignant Pleural Mesothelioma: A Single Institution Experience.
</td>
<td style="text-align:left;">
Clin Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
In Vitro Characterization of Cisplatin and Pemetrexed Effects in Malignant Pleural Mesothelioma 3D Culture Phenotypes.
</td>
<td style="text-align:left;">
Cancers (Basel)
</td>
</tr>
<tr>
<td style="text-align:left;">
Bortezomib sensitivity is tissue dependent and high expression of the 20S proteasome precludes good response in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Cancer Manag Res
</td>
</tr>
<tr>
<td style="text-align:left;">
Establishment and characterization of human malignant pleural mesothelioma cell line SMC-1.
</td>
<td style="text-align:left;">
Sci. Sin., Ser. B, Chem. Biol. Agric. Med. Earth Sci.
</td>
</tr>
<tr>
<td style="text-align:left;">
Intracavitary cisplatin-fibrin chemotherapy after surgery for malignant pleural mesothelioma: A phase I trial.
</td>
<td style="text-align:left;">
J. Thorac. Cardiovasc. Surg.
</td>
</tr>
<tr>
<td style="text-align:left;">
Survival results in biphasic malignant pleural mesothelioma patients: A multicentric analysis.
</td>
<td style="text-align:left;">
J. Thorac. Cardiovasc. Surg.
</td>
</tr>
<tr>
<td style="text-align:left;">
Approved and emerging treatments of malignant pleural mesothelioma in elderly patients.
</td>
<td style="text-align:left;">
Expert Rev Respir Med
</td>
</tr>
<tr>
<td style="text-align:left;">
Types of surgery post-neoadjuvant chemotherapy for pleural mesothelioma.
</td>
<td style="text-align:left;">
Expert Rev Respir Med
</td>
</tr>
<tr>
<td style="text-align:left;">
Endoplasmic Reticulum Stress Signaling as a Therapeutic Target in Malignant Pleural Mesothelioma.
</td>
<td style="text-align:left;">
Cancers (Basel)
</td>
</tr>
<tr>
<td style="text-align:left;">
Adequate nephroprotection reduces renal complications after hyperthermic intrathoracic chemotherapy.
</td>
<td style="text-align:left;">
J Surg Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Dual-input tracer kinetic modeling of dynamic contrast-enhanced MRI in thoracic malignancies.
</td>
<td style="text-align:left;">
J Appl Clin Med Phys
</td>
</tr>
<tr>
<td style="text-align:left;">
Treatment of Malignant Peritoneal Mesothelioma.
</td>
<td style="text-align:left;">
Klin Onkol
</td>
</tr>
<tr>
<td style="text-align:left;">
Stereotactic Body Radiation Therapy (SBRT) as Salvage Therapy for Oligorecurrent Pleural Mesothelioma After Multi-Modality Therapy.
</td>
<td style="text-align:left;">
Front Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Functional Genomic Screen in Mesothelioma Reveals that Loss of Function of BRCA1-Associated Protein 1 Induces Chemoresistance to Ribonucleotide Reductase Inhibition.
</td>
<td style="text-align:left;">
Mol. Cancer Ther.
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant Peritoneal Mesothelioma: Patterns of Care and Survival in the Netherlands: A Population-Based Study.
</td>
<td style="text-align:left;">
Ann. Surg. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Tumour Treating Fields in combination with pemetrexed and cisplatin or carboplatin as first-line treatment for unresectable malignant pleural mesothelioma (STELLAR): a multicentre, single-arm phase 2 trial.
</td>
<td style="text-align:left;">
Lancet Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Why Be One Protein When You Can Affect Many? The Multiple Roles of YB-1 in Lung Cancer and Mesothelioma.
</td>
<td style="text-align:left;">
Front Cell Dev Biol
</td>
</tr>
<tr>
<td style="text-align:left;">
Posterior Intercostal Lymph Nodes Double Recurrence and Death Risk in Malignant Pleural Mesothelioma.
</td>
<td style="text-align:left;">
Ann. Thorac. Surg.
</td>
</tr>
<tr>
<td style="text-align:left;">
CD70 expression correlates with a worse prognosis in malignant pleural mesothelioma patients via immune evasion and enhanced invasiveness.
</td>
<td style="text-align:left;">
J. Pathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Detection of Anaplastic Lymphoma Kinase-Rearranged Mesothelioma Cells in Ascites by Companion Diagnostics.
</td>
<td style="text-align:left;">
Acta Cytol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Multicystic peritoneal mesothelioma: a systematic review of the literature.
</td>
<td style="text-align:left;">
Pleura Peritoneum
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma in situ diagnosed by methylthioadenosine phosphorylase loss and homozygous deletion of CDKN2A: a case report.
</td>
<td style="text-align:left;">
Virchows Arch.
</td>
</tr>
<tr>
<td style="text-align:left;">
24-hour cyclophosphamide infusion therapy for malignant mesothelioma of the pleura.
</td>
<td style="text-align:left;">
Br J Dis Chest
</td>
</tr>
<tr>
<td style="text-align:left;">
Emerging therapies in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Crit. Rev. Oncol. Hematol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Extrapleural pneumonectomies for pleural mesothelioma.
</td>
<td style="text-align:left;">
Expert Rev Respir Med
</td>
</tr>
<tr>
<td style="text-align:left;">
Current treatment strategies in malignant pleural mesothelioma with a treatment algorithm.
</td>
<td style="text-align:left;">
Adv Respir Med
</td>
</tr>
<tr>
<td style="text-align:left;">
Globular C1q Receptor (gC1qR/p32/HABP1) Is Overexpressed in Malignant Pleural Mesothelioma and Is Associated With Increased Survival in Surgical Patients Treated With Chemotherapy.
</td>
<td style="text-align:left;">
Front Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
CRISPR Screening Identifies WEE1 as a Combination Target for Standard Chemotherapy in Malignant Pleural Mesothelioma.
</td>
<td style="text-align:left;">
Mol. Cancer Ther.
</td>
</tr>
<tr>
<td style="text-align:left;">
The mTOR Signaling Pathway Is Associated With the Prognosis of Malignant Pleural Mesothelioma After Multimodality Therapy.
</td>
<td style="text-align:left;">
Anticancer Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
The prognostic analysis of the some clinicopathological parameters and gene protein expressions in malignant mesothelioma.
</td>
<td style="text-align:left;">
Tuberk Toraks
</td>
</tr>
<tr>
<td style="text-align:left;">
Elevated Circulating Activin A Levels in Patients With Malignant Pleural Mesothelioma Are Related to Cancer Cachexia and Reduced Response to Platinum-based Chemotherapy.
</td>
<td style="text-align:left;">
Clin Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Secretome of pleural effusions associated with non-small cell lung cancer (NSCLC) and malignant mesothelioma: therapeutic implications.
</td>
<td style="text-align:left;">
Oncotarget
</td>
</tr>
<tr>
<td style="text-align:left;">
Extended pleurectomy decortication for the treatment of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Multimed Man Cardiothorac Surg
</td>
</tr>
<tr>
<td style="text-align:left;">
Pleural small cell carcinoma with massive pleural effusion: A case report.
</td>
<td style="text-align:left;">
Medicine (Baltimore)
</td>
</tr>
<tr>
<td style="text-align:left;">
Anaplastic Lymphoma Kinase Gene Rearrangement in Children and Young Adults With Mesothelioma.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Long-term benefit from immune modulation and anti-inflammatory treatment in metastatic mesothelioma.
</td>
<td style="text-align:left;">
Respir Med Case Rep
</td>
</tr>
<tr>
<td style="text-align:left;">
Correlation of prechemotherapy urinary megalin ectodomain (A-megalin) levels with the development of cisplatin-induced nephrotoxicity: a prospective observational study.
</td>
<td style="text-align:left;">
BMC Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
A Man in His 20s With Cough, Unilateral Pleural Effusion, and Nodular Pleural Thickening.
</td>
<td style="text-align:left;">
Chest
</td>
</tr>
<tr>
<td style="text-align:left;">
Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1-2 trial.
</td>
<td style="text-align:left;">
Lancet Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Prognostic Immune Cell Profiling of Malignant Pleural Effusion Patients by Computerized Immunohistochemical and Transcriptional Analysis.
</td>
<td style="text-align:left;">
Cancers (Basel)
</td>
</tr>
<tr>
<td style="text-align:left;">
Serum levels of the chemokine CCL2 are elevated in malignant pleural mesothelioma patients.
</td>
<td style="text-align:left;">
BMC Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Nivolumab for the treatment of unresectable pleural mesothelioma.
</td>
<td style="text-align:left;">
Expert Opin Biol Ther
</td>
</tr>
<tr>
<td style="text-align:left;">
Clinical utility of FDG-PET/CT for post-surgery surveillance of malignant pleural mesothelioma - Comparison with contrast-enhanced CT.
</td>
<td style="text-align:left;">
Oncotarget
</td>
</tr>
<tr>
<td style="text-align:left;">
<i>In-vitro</i> proliferation assay with recycled ascitic cancer cells in malignant pleural mesothelioma: A case report.
</td>
<td style="text-align:left;">
World J Clin Cases
</td>
</tr>
<tr>
<td style="text-align:left;">
[How I manage… Malignant pleural mesothelioma in 2019].
</td>
<td style="text-align:left;">
Rev Med Liege
</td>
</tr>
<tr>
<td style="text-align:left;">
Cisplatin unleashes Toll-like receptor 3-mediated apoptosis through the downregulation of c-FLIP in malignant mesothelioma.
</td>
<td style="text-align:left;">
Cancer Lett.
</td>
</tr>
<tr>
<td style="text-align:left;">
Prognostic influence of tumor microenvironment after hypofractionated radiation and surgery for mesothelioma.
</td>
<td style="text-align:left;">
J. Thorac. Cardiovasc. Surg.
</td>
</tr>
<tr>
<td style="text-align:left;">
A Phase II Study of Pazopanib in Patients with Malignant Pleural Mesothelioma: NCCTG N0623 (Alliance).
</td>
<td style="text-align:left;">
Oncologist
</td>
</tr>
<tr>
<td style="text-align:left;">
Novel Germline Mutations in DNA Damage Repair in Patients with Malignant Pleural Mesotheliomas.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
A phase II trial of single oral FGF inhibitor, AZD4547, as second or third line therapy in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Implantation and Monitoring by PET/CT of an Orthotopic Model of Human Pleural Mesothelioma in Athymic Mice.
</td>
<td style="text-align:left;">
J Vis Exp
</td>
</tr>
<tr>
<td style="text-align:left;">
Combined MEK and PI3K/p110β Inhibition as a Novel Targeted Therapy for Malignant Mesothelioma Displaying Sarcomatoid Features.
</td>
<td style="text-align:left;">
Cancer Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
Analysis of mismatch repair (MMR) proteins expression in a series of malignant pleural mesothelioma (MPM) patients.
</td>
<td style="text-align:left;">
Clin Transl Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
LOX family and ZFPM2 as novel diagnostic biomarkers for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Biomark Res
</td>
</tr>
<tr>
<td style="text-align:left;">
Screening of Pleural Mesothelioma Cell Lines for Kinase Activity May Identify New Mechanisms of Therapy Resistance in Patients Receiving Platin-Based Chemotherapy.
</td>
<td style="text-align:left;">
J Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Dosimetric Comparison of Lung-Sparing Radiation Therapy between Volumetric Arc Therapy and Helical Tomotherapy for Unresectable Malignant Pleural Mesothelioma.
</td>
<td style="text-align:left;">
Biomed Res Int
</td>
</tr>
<tr>
<td style="text-align:left;">
Frequent Homozygous Deletions of Type I Interferon Genes in Pleural Mesothelioma Confer Sensitivity to Oncolytic Measles Virus.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Clinical Outcomes With Recurrence After Pleurectomy/Decortication for Malignant Pleural Mesothelioma.
</td>
<td style="text-align:left;">
Ann. Thorac. Surg.
</td>
</tr>
<tr>
<td style="text-align:left;">
Not everything is what it seems: malignant pleural mesothelioma mimicking lung cancer.
</td>
<td style="text-align:left;">
Adv Respir Med
</td>
</tr>
<tr>
<td style="text-align:left;">
99mTc-HDP Bone Scintigraphy, SPECT/CT, and 18F-FDG PET/CT Diagnosis Imaging of Incidental Pleural Mesothelioma in a Patient With Biochemical Recurrences of Prostate Cancer: Is it Really a Coincidence?
</td>
<td style="text-align:left;">
Clin Nucl Med
</td>
</tr>
<tr>
<td style="text-align:left;">
Identification of a CD8+ T-cell response to a predicted neoantigen in malignant mesothelioma.
</td>
<td style="text-align:left;">
Oncoimmunology
</td>
</tr>
<tr>
<td style="text-align:left;">
The Role of Neoadjuvant Chemotherapy in Patients with Resectable Malignant Pleural Mesothelioma - An Institutional and National Analysis.
</td>
<td style="text-align:left;">
J. Natl. Cancer Inst.
</td>
</tr>
<tr>
<td style="text-align:left;">
Deep learning-based segmentation of malignant pleural mesothelioma tumor on computed tomography scans: application to scans demonstrating pleural effusion.
</td>
<td style="text-align:left;">
J Med Imaging (Bellingham)
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant Pleural Mesothelioma: State-of-the-Art on Current Therapies and Promises for the Future.
</td>
<td style="text-align:left;">
Front Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Primary squamous cell carcinoma of the pleura treated with nivolumab.
</td>
<td style="text-align:left;">
Respirol Case Rep
</td>
</tr>
<tr>
<td style="text-align:left;">
Paclitaxel-loaded expansile nanoparticles improve survival following cytoreductive surgery in pleural mesothelioma xenografts.
</td>
<td style="text-align:left;">
J. Thorac. Cardiovasc. Surg.
</td>
</tr>
<tr>
<td style="text-align:left;">
Light Fluence Rate and Tissue Oxygenation (S<sub>t</sub> O<sub>2</sub> ) Distributions Within the Thoracic Cavity of Patients Receiving Intraoperative Photodynamic Therapy for Malignant Pleural Mesothelioma.
</td>
<td style="text-align:left;">
Photochem. Photobiol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Effusion cytology of malignant mesothelioma enables earlier diagnosis and recognizes patients with better prognosis.
</td>
<td style="text-align:left;">
Diagn. Cytopathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Infrared navigation system for light dosimetry during pleural photodynamic therapy.
</td>
<td style="text-align:left;">
Phys Med Biol
</td>
</tr>
<tr>
<td style="text-align:left;">
A case of surgically treated bilateral metachronous malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Turk Gogus Kalp Damar Cerrahisi Derg
</td>
</tr>
<tr>
<td style="text-align:left;">
Comparison of serum biochemical markers in patients with mesothelioma and pleural plaques versus healthy individuals exposed to environmental asbestos.
</td>
<td style="text-align:left;">
Turk Gogus Kalp Damar Cerrahisi Derg
</td>
</tr>
<tr>
<td style="text-align:left;">
Lurbinectedin as second- or third-line palliative therapy in malignant pleural mesothelioma: an international, multi-centre, single-arm, phase II trial (SAKK 17/16).
</td>
<td style="text-align:left;">
Ann. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Preoperative prediction of unresectability in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J. Thorac. Cardiovasc. Surg.
</td>
</tr>
<tr>
<td style="text-align:left;">
Disease-Related Outcomes and Toxicities of Intensity Modulated Radiation Therapy After Lung-Sparing Pleurectomy for Malignant Pleural Mesothelioma: A Systematic Review.
</td>
<td style="text-align:left;">
Pract Radiat Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Impressive clinical response to anti-PD-1 therapy in epithelioid mesothelioma with high clonal PD-L1 expression and EML4-ALK rearrangement.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Prolonged Progression-Free Survival in a Patient With Malignant Pleural Mesothelioma Following Korean Herbal Medicine Treatment Alone: A Case Report.
</td>
<td style="text-align:left;">
Integr Cancer Ther
</td>
</tr>
<tr>
<td style="text-align:left;">
A phase II study of the combination of gemcitabine and imatinib mesylate in pemetrexed-pretreated patients with malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma of the pleura. A prospective therapeutic study of 132 patients from 1981-1985.
</td>
<td style="text-align:left;">
Klin. Wochenschr.
</td>
</tr>
<tr>
<td style="text-align:left;">
MicroRNA-98 is a prognostic factor for asbestos-induced mesothelioma.
</td>
<td style="text-align:left;">
J. Toxicol. Environ. Health Part A
</td>
</tr>
<tr>
<td style="text-align:left;">
Manipulating microRNAs for the Treatment of Malignant Pleural Mesothelioma: Past, Present and Future.
</td>
<td style="text-align:left;">
Front Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Remarkable response to nivolumab in sarcomatoid malignant pleural mesothelioma with high PD-L1.
</td>
<td style="text-align:left;">
Respirol Case Rep
</td>
</tr>
<tr>
<td style="text-align:left;">
Immunotherapy in Malignant Pleural Mesothelioma.
</td>
<td style="text-align:left;">
Front Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
How I treat malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
ESMO Open
</td>
</tr>
<tr>
<td style="text-align:left;">
Conversion surgery for locally advanced malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Gen Thorac Cardiovasc Surg
</td>
</tr>
<tr>
<td style="text-align:left;">
Molecular and immunological features of a prolonged exceptional responder with malignant pleural mesothelioma treated initially and rechallenged with pembrolizumab.
</td>
<td style="text-align:left;">
J Immunother Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Comparative analysis of prognostic histopathologic parameters in subtypes of epithelioid pleural mesothelioma.
</td>
<td style="text-align:left;">
Histopathology
</td>
</tr>
<tr>
<td style="text-align:left;">
Evaluation of gene expression levels in the diagnosis of lung adenocarcinoma and malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Turk Gogus Kalp Damar Cerrahisi Derg
</td>
</tr>
<tr>
<td style="text-align:left;">
Immune Checkpoint Inhibitors in Thoracic Malignancies: Review of the Existing Evidence by an IASLC Expert Panel and Recommendations.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Intramedullary Metastasis to the Cervical Spinal Cord from Malignant Pleural Mesothelioma: Review of the Literature and Case Reports.
</td>
<td style="text-align:left;">
Asian J Neurosurg
</td>
</tr>
<tr>
<td style="text-align:left;">
Single-center study to determine the safety and efficacy of CT-707 in Chinese patients with advanced anaplastic lymphoma kinase-rearranged non-small-cell lung cancer.
</td>
<td style="text-align:left;">
Thorac Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Diffuse mesothelin expression leads to worse prognosis through enhanced cellular proliferation in colorectal cancer.
</td>
<td style="text-align:left;">
Oncol Lett
</td>
</tr>
<tr>
<td style="text-align:left;">
Application of immunohistochemistry in diagnosis and management of malignant mesothelioma.
</td>
<td style="text-align:left;">
Transl Lung Cancer Res
</td>
</tr>
<tr>
<td style="text-align:left;">
Chemotherapy options versus “novel” therapies: how should we treat patients with malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Transl Lung Cancer Res
</td>
</tr>
<tr>
<td style="text-align:left;">
Surgery for pleural mesothelioma, when it is indicated and why: arguments against surgery for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Transl Lung Cancer Res
</td>
</tr>
<tr>
<td style="text-align:left;">
IgG4-related pleural disease with aortitis and submandibular glands involvement successfully treated with corticosteroid: case-based review.
</td>
<td style="text-align:left;">
Rheumatol. Int.
</td>
</tr>
<tr>
<td style="text-align:left;">
Randomised placebo-controlled cross-over study examining the role of anamorelin in mesothelioma (The ANTHEM study): rationale and protocol.
</td>
<td style="text-align:left;">
BMJ Open Respir Res
</td>
</tr>
<tr>
<td style="text-align:left;">
Not gene therapy, but genetic surgery-the right strategy to attack cancer.
</td>
<td style="text-align:left;">
Mol. Gen. Microbiol. Virol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Emerging Treatments for Malignant Pleural Mesothelioma: Where Are We Heading?
</td>
<td style="text-align:left;">
Front Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
T cell receptor repertoire characteristics both before and following immunotherapy correlate with clinical response in mesothelioma.
</td>
<td style="text-align:left;">
J Immunother Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Hypoxia Inducible Factor-1α Inhibition in Von Hippel Lindau-mutant Malignant Pleural Mesothelioma Cells.
</td>
<td style="text-align:left;">
Anticancer Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
Tumour cell PD-L1 expression is prognostic in patients with malignant pleural effusion: the impact of C-reactive protein and immune-checkpoint inhibition.
</td>
<td style="text-align:left;">
Sci Rep
</td>
</tr>
<tr>
<td style="text-align:left;">
Clinical Trials Eligibility of Patients With Malignant Pleural Mesothelioma: Use of Novel Therapies and Outcomes.
</td>
<td style="text-align:left;">
Clin Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Surgery for Mesothelioma After Radiation Therapy (SMART); A Single Institution Experience.
</td>
<td style="text-align:left;">
Front Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
The Biology of Malignant Mesothelioma and the Relevance of Preclinical Models.
</td>
<td style="text-align:left;">
Front Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Fully Human Antibodies for Malignant Pleural Mesothelioma Targeting.
</td>
<td style="text-align:left;">
Cancers (Basel)
</td>
</tr>
<tr>
<td style="text-align:left;">
Treatment of bronchial fistula after extraplural pneumonectomy using flexible bronchoscopy with the administration of OK432, fibroblast growth factor basic and fibrin glue sealant.
</td>
<td style="text-align:left;">
Gen Thorac Cardiovasc Surg
</td>
</tr>
<tr>
<td style="text-align:left;">
FDG-PET assessment of malignant pleural mesothelioma: Total Lesion volume and Total Lesion Glycolysis; the central role of volume.
</td>
<td style="text-align:left;">
J. Nucl. Med.
</td>
</tr>
<tr>
<td style="text-align:left;">
Targeted Phototherapy for Malignant Pleural Mesothelioma: Near-Infrared Photoimmunotherapy Targeting Podoplanin.
</td>
<td style="text-align:left;">
Cells
</td>
</tr>
<tr>
<td style="text-align:left;">
Genomic analysis in short- and long-term patients with malignant pleura mesothelioma treated with palliative chemotherapy.
</td>
<td style="text-align:left;">
Eur. J. Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Treatment patterns among patients with malignant pleural mesothelioma: An Italian, population-based nationwide study.
</td>
<td style="text-align:left;">
Thorac Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Mutational Profiling of Driver Tumor Suppressor and Oncogenic Genes in Brazilian Malignant Pleural Mesotheliomas.
</td>
<td style="text-align:left;">
Pathobiology
</td>
</tr>
<tr>
<td style="text-align:left;">
Low-dose photodynamic therapy promotes a cytotoxic immunological response in a murine model of pleural mesothelioma.
</td>
<td style="text-align:left;">
Eur J Cardiothorac Surg
</td>
</tr>
<tr>
<td style="text-align:left;">
Inhibition of miR-18a-3p reduces proliferation of mesothelioma cells and sensitizes them to cisplatin.
</td>
<td style="text-align:left;">
Oncol Lett
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant Pleural Mesothelioma: Genetic and Microenviromental Heterogeneity as an Unexpected Reading Frame and Therapeutic Challenge.
</td>
<td style="text-align:left;">
Cancers (Basel)
</td>
</tr>
<tr>
<td style="text-align:left;">
Nivolumab resulting in persistently elevated troponin levels despite clinical remission of myocarditis and myositis in a patient with malignant pleural mesothelioma: case report.
</td>
<td style="text-align:left;">
Transl Lung Cancer Res
</td>
</tr>
<tr>
<td style="text-align:left;">
Metformin-loaded chitosomes for treatment of malignant pleural mesothelioma - A rare thoracic cancer.
</td>
<td style="text-align:left;">
Int. J. Biol. Macromol.
</td>
</tr>
<tr>
<td style="text-align:left;">
ERS/ESTS/EACTS/ESTRO guidelines for the management of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Eur J Cardiothorac Surg
</td>
</tr>
<tr>
<td style="text-align:left;">
ERS/ESTS/EACTS/ESTRO guidelines for the management of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Eur. Respir. J.
</td>
</tr>
<tr>
<td style="text-align:left;">
Analysis of survival of patients with metastatic malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Tumori
</td>
</tr>
<tr>
<td style="text-align:left;">
Initial evaluation of nivolumab in patients with post-operative recurrence of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Jpn. J. Clin. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Irinotecan inducing sinus pause bradycardia in a patient with small round cell cancer.
</td>
<td style="text-align:left;">
BMJ Case Rep
</td>
</tr>
<tr>
<td style="text-align:left;">
Cisplatin plus pemetrexed therapy and subsequent immune checkpoint inhibitor administration for malignant peritoneal mesothelioma without pleural lesions: Case report.
</td>
<td style="text-align:left;">
Medicine (Baltimore)
</td>
</tr>
<tr>
<td style="text-align:left;">
Comparison of modified Response Evaluation Criteria in Solid Tumors, European Organization for Research and Treatment of Cancer criteria, and PET Response Criteria in Solid Tumors for evaluation of tumor response to chemotherapy and prognosis prediction in patients with unresectable malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Nucl Med Commun
</td>
</tr>
<tr>
<td style="text-align:left;">
TGFα Promotes Chemoresistance of Malignant Pleural Mesothelioma.
</td>
<td style="text-align:left;">
Cancers (Basel)
</td>
</tr>
<tr>
<td style="text-align:left;">
Anti-PD-1 antibody combined with chemotherapy suppresses the growth of mesothelioma by reducing myeloid-derived suppressor cells.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Prognostic Value of Ki67 Percentage, WT-1 Expression and p16/CDKN2A Deletion in Diffuse Malignant Peritoneal Mesothelioma: A Single-Centre Cohort Study.
</td>
<td style="text-align:left;">
Diagnostics (Basel)
</td>
</tr>
<tr>
<td style="text-align:left;">
Racial Disparities in Treatment Patterns and Survival Among Surgically Treated Malignant Pleural Mesothelioma Patients.
</td>
<td style="text-align:left;">
J Immigr Minor Health
</td>
</tr>
<tr>
<td style="text-align:left;">
Tumor-associated macrophage-derived inflammatory cytokine enhances malignant potential of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Cancer Sci.
</td>
</tr>
<tr>
<td style="text-align:left;">
Addition of radiotherapy to surgery and chemotherapy improves survival in localized malignant pleural mesothelioma: A Surveillance, Epidemiology, and End Results (SEER) study.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Volumetric PET response assessment outperforms conventional criteria in patients receiving high-dose pembrolizumab for malignant mesothelioma.
</td>
<td style="text-align:left;">
J. Nucl. Med.
</td>
</tr>
<tr>
<td style="text-align:left;">
Secondary renal amyloidosis associated with asbestos-related pleuropulmonary diseases.
</td>
<td style="text-align:left;">
CEN Case Rep
</td>
</tr>
<tr>
<td style="text-align:left;">
NTRK and ALK rearrangements in malignant pleural mesothelioma, pulmonary neuroendocrine tumours and non-small cell lung cancer.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Asbestos-related diseases.
</td>
<td style="text-align:left;">
Int. J. Tuberc. Lung Dis.
</td>
</tr>
<tr>
<td style="text-align:left;">
RapidPlan for Knowledge-Based Planning of Malignant Pleural Mesothelioma.
</td>
<td style="text-align:left;">
Pract Radiat Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Role of inflammation in the malignant transformation of pleural mesothelial cells induced by multi-walled carbon nanotubes.
</td>
<td style="text-align:left;">
Nanotoxicology
</td>
</tr>
<tr>
<td style="text-align:left;">
Cellular Immunotherapy and Locoregional Administration of CAR T-Cells in Malignant Pleural Mesothelioma.
</td>
<td style="text-align:left;">
Front Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Acquired multiple mutations ALK I1171N, L1196M and G1202R mediate lorlatinib resistance in EML4-ALK-rearranged malignant pleural mesothelioma: a case report.
</td>
<td style="text-align:left;">
Ther Adv Respir Dis
</td>
</tr>
<tr>
<td style="text-align:left;">
TLD1433-Mediated Photodynamic Therapy with an Optical Surface Applicator in the Treatment of Lung Cancer Cells In Vitro.
</td>
<td style="text-align:left;">
Pharmaceuticals (Basel)
</td>
</tr>
<tr>
<td style="text-align:left;">
A Phase II Trial of Alisertib (MLN8237) in Salvage Malignant Mesothelioma.
</td>
<td style="text-align:left;">
Oncologist
</td>
</tr>
<tr>
<td style="text-align:left;">
Gender-based Disparities in Receipt of Care and Survival in Malignant Pleural Mesothelioma.
</td>
<td style="text-align:left;">
Clin Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Questioning the prognostic role of BAP-1 immunohistochemistry in malignant pleural mesothelioma: A single center experience with systematic review and meta-analysis.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Clinical Features in Patients With Malignant Pleural Mesothelioma With 5-Year Survival and Evaluation of Original Diagnoses.
</td>
<td style="text-align:left;">
Clin Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
[Five Years PLEURATUMOR Register of the German Society of Thoracic Surgery].
</td>
<td style="text-align:left;">
Zentralbl Chir
</td>
</tr>
<tr>
<td style="text-align:left;">
Acute kidney injury after cytoreductive surgery and hyperthermic intraoperative cisplatin chemotherapy for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J. Thorac. Cardiovasc. Surg.
</td>
</tr>
<tr>
<td style="text-align:left;">
Video-assisted biopsy and talc pleurodesis for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Multimed Man Cardiothorac Surg
</td>
</tr>
<tr>
<td style="text-align:left;">
FDG PET versus CT radiomics to predict outcome in malignant pleural mesothelioma patients.
</td>
<td style="text-align:left;">
EJNMMI Res
</td>
</tr>
<tr>
<td style="text-align:left;">
Ganetespib in Combination with Pemetrexed-Platinum Chemotherapy in Patients with Pleural Mesothelioma (MESO-02): A Phase Ib Trial.
</td>
<td style="text-align:left;">
Clin. Cancer Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
Preliminary study highlights the potential of immune checkpoint inhibitors in sarcomatoid mesothelioma.
</td>
<td style="text-align:left;">
Transl Lung Cancer Res
</td>
</tr>
<tr>
<td style="text-align:left;">
Clinical significance of histologic subtyping of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Transl Lung Cancer Res
</td>
</tr>
<tr>
<td style="text-align:left;">
Integrative approach to cytologic and molecular diagnosis of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Transl Lung Cancer Res
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma: Treatment patterns and outcomes from the Spanish Lung Cancer Group.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Progress in the understanding of the immune microenvironment and immunotherapy in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Curr Drug Targets
</td>
</tr>
<tr>
<td style="text-align:left;">
Ovarian metastasis from malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Tumori
</td>
</tr>
<tr>
<td style="text-align:left;">
Delayed-Phase Enhancement for Evaluation of Malignant Pleural Mesothelioma on Computed Tomography: A Prospective Cohort Study.
</td>
<td style="text-align:left;">
Clin Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Connective tissue growth factor produced by cancer‑associated fibroblasts correlates with poor prognosis in epithelioid malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Oncol. Rep.
</td>
</tr>
<tr>
<td style="text-align:left;">
Dual Inhibition of CDK4/6 and PI3K/AKT/mTOR Signaling Impairs Energy Metabolism in MPM Cancer Cells.
</td>
<td style="text-align:left;">
Int J Mol Sci
</td>
</tr>
<tr>
<td style="text-align:left;">
New vistas in malignant mesothelioma: MicroRNA architecture and NRF2/MAPK signal transduction.
</td>
<td style="text-align:left;">
Life Sci.
</td>
</tr>
<tr>
<td style="text-align:left;">
Nivolumab-induced immune thrombocytopenia in a patient with malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Respir Med Case Rep
</td>
</tr>
<tr>
<td style="text-align:left;">
Determinants of plasma calretinin in patients with malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
BMC Res Notes
</td>
</tr>
<tr>
<td style="text-align:left;">
Randomized Study of Maintenance Pemetrexed Versus Observation for Treatment of Malignant Pleural Mesothelioma: CALGB 30901.
</td>
<td style="text-align:left;">
Clin Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Multiplex Soluble Biomarker Analysis from Pleural Effusion.
</td>
<td style="text-align:left;">
Biomolecules
</td>
</tr>
<tr>
<td style="text-align:left;">
Trabectedin in Malignant Pleural Mesothelioma: Results From the Multicentre, Single Arm, Phase II ATREUS Study.
</td>
<td style="text-align:left;">
Clin Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Mesothelioma of childhood.
</td>
<td style="text-align:left;">
Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
[Toxicity of the CYVADIC modification in patients with soft tissue sarcomas or malignant mesotheliomas].
</td>
<td style="text-align:left;">
Onkologie
</td>
</tr>
<tr>
<td style="text-align:left;">
Prognostic factors in diffuse malignant pleural mesothelioma. A study of 167 patients.
</td>
<td style="text-align:left;">
Chest
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma: prognostic variables in a registry of 180 patients, the Dana-Farber Cancer Institute and Brigham and Women’s Hospital experience over two decades, 1965-1985.
</td>
<td style="text-align:left;">
J. Clin. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
[Local administration of recombinant interferon-beta to patients with cancer-associated body cavity fluids].
</td>
<td style="text-align:left;">
Gan To Kagaku Ryoho
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma: a disease unaffected by current therapeutic maneuvers.
</td>
<td style="text-align:left;">
J. Clin. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
The role of computed tomography scanning in the initial assessment and the follow-up of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J. Thorac. Cardiovasc. Surg.
</td>
</tr>
<tr>
<td style="text-align:left;">
Clinicopathologic studies on mesothelioma of the pleura. Differentiated approach to treatment.
</td>
<td style="text-align:left;">
Scand J Thorac Cardiovasc Surg
</td>
</tr>
<tr>
<td style="text-align:left;">
Thrombocytosis in patients with malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Flow cytometric analysis of ploidy in immunohistochemically confirmed examples of malignant epithelial mesothelioma.
</td>
<td style="text-align:left;">
Am. J. Clin. Pathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Pleural mesothelioma.
</td>
<td style="text-align:left;">
Ann. Thorac. Surg.
</td>
</tr>
<tr>
<td style="text-align:left;">
Asbestos-related malignancy.
</td>
<td style="text-align:left;">
Crit. Rev. Oncol. Hematol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Phase II trial of carboplatin (JM8) in treatment of patients with malignant mesothelioma.
</td>
<td style="text-align:left;">
Cancer Chemother. Pharmacol.
</td>
</tr>
<tr>
<td style="text-align:left;">
A phase II study of the platinum analogues JM8 and JM9 in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Cancer Chemother. Pharmacol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Randomized comparison of cyclophosphamide, imidazole carboxamide, and adriamycin versus cyclophosphamide and adriamycin in patients with advanced stage malignant mesothelioma: a Sarcoma Intergroup Study.
</td>
<td style="text-align:left;">
J. Clin. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Characterization of a human malignant mesothelioma cell line (H-MESO-1): a biphasic solid and ascitic tumor model.
</td>
<td style="text-align:left;">
Cancer Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
The cytologic diagnosis of mesothelioma.
</td>
<td style="text-align:left;">
Semin Diagn Pathol
</td>
</tr>
<tr>
<td style="text-align:left;">
Diffuse malignant mesothelioma of the pleura–intrapleural treatment with doxorubicin.
</td>
<td style="text-align:left;">
Arch. Geschwulstforsch.
</td>
</tr>
<tr>
<td style="text-align:left;">
[Malignant diffuse peritoneal mesothelioma: clinical and therapeutic aspects. Apropos of a case with gelatinous ascites].
</td>
<td style="text-align:left;">
Rev Med Interne
</td>
</tr>
<tr>
<td style="text-align:left;">
Cisplatin administered by the intracavitary route as treatment for malignant mesothelioma.
</td>
<td style="text-align:left;">
Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
[Primary malignant tumors of the pleura].
</td>
<td style="text-align:left;">
Rontgenblatter
</td>
</tr>
<tr>
<td style="text-align:left;">
Minimal-change nephrotic syndrome associated with malignant mesothelioma.
</td>
<td style="text-align:left;">
Arch. Intern. Med.
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant peritoneal mesothelioma in a child.
</td>
<td style="text-align:left;">
Pediatr Pathol
</td>
</tr>
<tr>
<td style="text-align:left;">
The distinction of mesothelioma from adenocarcinoma in malignant effusions by electron microscopy.
</td>
<td style="text-align:left;">
Acta Cytol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Benign and malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Clin. Chest Med.
</td>
</tr>
<tr>
<td style="text-align:left;">
A prospective study of detorubicin in malignant mesothelioma.
</td>
<td style="text-align:left;">
Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Randomized trial of doxorubicin versus cyclophosphamide in diffuse malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Cancer Treat Rep
</td>
</tr>
<tr>
<td style="text-align:left;">
[Monoclonal gammopathies in the aged].
</td>
<td style="text-align:left;">
Minerva Med.
</td>
</tr>
<tr>
<td style="text-align:left;">
Phase II trial of high-dose cisplatin in patients with malignant mesothelioma.
</td>
<td style="text-align:left;">
Cancer Treat Rep
</td>
</tr>
<tr>
<td style="text-align:left;">
[A case of remission in diffuse pleural mesothelioma induced by anticancer chemotherapy with cisplatin and adriamycin].
</td>
<td style="text-align:left;">
Gan To Kagaku Ryoho
</td>
</tr>
<tr>
<td style="text-align:left;">
[Bromocriptine in Parkinson’s disease: pleuropulmonary toxicity].
</td>
<td style="text-align:left;">
Ann Med Interne (Paris)
</td>
</tr>
<tr>
<td style="text-align:left;">
Tetracycline sclerosis in the management of malignant pericardial effusion.
</td>
<td style="text-align:left;">
J. Clin. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Immunohistological study of malignant diffuse mesotheliomas of the pleura.
</td>
<td style="text-align:left;">
Histopathology
</td>
</tr>
<tr>
<td style="text-align:left;">
Thymostimulin in malignant pleural effusions.
</td>
<td style="text-align:left;">
Int J Tissue React
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma of the pleura: clinical aspects and symptomatic treatment.
</td>
<td style="text-align:left;">
Eur J Respir Dis
</td>
</tr>
<tr>
<td style="text-align:left;">
Conventional treatment and its effect on survival of malignant pleural mesothelioma in Western Australia.
</td>
<td style="text-align:left;">
Aust N Z J Med
</td>
</tr>
<tr>
<td style="text-align:left;">
Mesothelioma following Wilms’ tumor in childhood.
</td>
<td style="text-align:left;">
Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
[Thoracoscopic and computer tomographic findings in pleural mesotheliomas].
</td>
<td style="text-align:left;">
Rofo
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma of the pleura: a study of 52 treated and 64 untreated patients.
</td>
<td style="text-align:left;">
Thorax
</td>
</tr>
<tr>
<td style="text-align:left;">
Mesothelioma associated with the syndrome of inappropriate secretion of antidiuretic hormone.
</td>
<td style="text-align:left;">
Am. Rev. Respir. Dis.
</td>
</tr>
<tr>
<td style="text-align:left;">
Chemotherapy of diffuse malignant mesothelioma. Phase II trials of single-agent 5-fluorouracil and adriamycin.
</td>
<td style="text-align:left;">
Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
CT of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
AJR Am J Roentgenol
</td>
</tr>
<tr>
<td style="text-align:left;">
Treatment of six cases of mesothelioma with doxorubicin and cisplatin.
</td>
<td style="text-align:left;">
Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma. The University of Minnesota experience.
</td>
<td style="text-align:left;">
Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma: the role of computed tomography.
</td>
<td style="text-align:left;">
J Comput Tomogr
</td>
</tr>
<tr>
<td style="text-align:left;">
Pleurectomy and intraoperative brachytherapy and postoperative radiation in the treatment of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Int. J. Radiat. Oncol. Biol. Phys.
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma. A clinical review of 19 patients.
</td>
<td style="text-align:left;">
Scand J Thorac Cardiovasc Surg
</td>
</tr>
<tr>
<td style="text-align:left;">
Diagnosis and prognosis in malignant pleural mesothelioma: a prospective study.
</td>
<td style="text-align:left;">
Eur J Respir Dis
</td>
</tr>
<tr>
<td style="text-align:left;">
Diffuse malignant mesothelioma: a review.
</td>
<td style="text-align:left;">
West. J. Med.
</td>
</tr>
<tr>
<td style="text-align:left;">
CT of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
AJR Am J Roentgenol
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma in children: report of seven cases and review of the literature.
</td>
<td style="text-align:left;">
Med. Pediatr. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Intrapleural Corynebacterium parvum for malignant pleural effusions.
</td>
<td style="text-align:left;">
Thorax
</td>
</tr>
<tr>
<td style="text-align:left;">
DNA flow cytometry of pleural effusions. Comparison with pathology for the diagnosis of malignancy.
</td>
<td style="text-align:left;">
Anal Quant Cytol
</td>
</tr>
<tr>
<td style="text-align:left;">
Computed tomography of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J Comput Assist Tomogr
</td>
</tr>
<tr>
<td style="text-align:left;">
[Clinical aspects and course of 38 cases of malignant pleural mesothelioma observed in the Marseilles region].
</td>
<td style="text-align:left;">
Poumon Coeur
</td>
</tr>
<tr>
<td style="text-align:left;">
[Pleural mesothelioma. Problems, therapy and results].
</td>
<td style="text-align:left;">
Fortschr. Med.
</td>
</tr>
<tr>
<td style="text-align:left;">
High-dose methotrexate with citrovorum factor and vincristine in the treatment of malignant mesothelioma.
</td>
<td style="text-align:left;">
Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Chemotherapy for malignant mesothelioma; CAMEO.
</td>
<td style="text-align:left;">
Am. J. Clin. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Immunotherapy with BCG vaccine in 30 cases of mesothelioma.
</td>
<td style="text-align:left;">
S. Afr. Med. J.
</td>
</tr>
<tr>
<td style="text-align:left;">
Computed tomography in the assessment of malignant mesothelioma of the pleura.
</td>
<td style="text-align:left;">
Clin Radiol
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma of the pleura: review of 123 patients.
</td>
<td style="text-align:left;">
Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Diffuse malignant mesothelioma. Prospective evaluation of 69 patients.
</td>
<td style="text-align:left;">
Ann. Intern. Med.
</td>
</tr>
<tr>
<td style="text-align:left;">
Clinical staging and the tendency of malignant pleural mesotheliomas to remain localized.
</td>
<td style="text-align:left;">
Ann. Thorac. Surg.
</td>
</tr>
<tr>
<td style="text-align:left;">
The value of adriamycin in the treatment of diffuse malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Combined doxorubicin and radiation therapy in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Cancer Treat Rep
</td>
</tr>
<tr>
<td style="text-align:left;">
Surgical treatment of pleural mesothelioma.
</td>
<td style="text-align:left;">
J. Thorac. Cardiovasc. Surg.
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma of the pleura: relation between histological type and clinical behaviour.
</td>
<td style="text-align:left;">
Thorax
</td>
</tr>
<tr>
<td style="text-align:left;">
Monophasic mesenchymal synovial sarcoma: its identification by tissue culture.
</td>
<td style="text-align:left;">
Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
A review of the treatment of diffuse malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
IARC Sci. Publ.
</td>
</tr>
<tr>
<td style="text-align:left;">
Secreting peritoneal mesothelioma. Report of a case with cytological, ultrastructural, morphometric and histological studies.
</td>
<td style="text-align:left;">
Virchows Arch A Pathol Anat Histol
</td>
</tr>
<tr>
<td style="text-align:left;">
[Current indications for thoracoscopy].
</td>
<td style="text-align:left;">
Rev Fr Mal Respir
</td>
</tr>
<tr>
<td style="text-align:left;">
Diffuse malignant pleural mesothelioma in Glasgow.
</td>
<td style="text-align:left;">
Br J Dis Chest
</td>
</tr>
<tr>
<td style="text-align:left;">
[Intrapleural talc in malignant pleural effusions (author’s transl)].
</td>
<td style="text-align:left;">
Poumon Coeur
</td>
</tr>
<tr>
<td style="text-align:left;">
Pleural mesothelioma.
</td>
<td style="text-align:left;">
Scand J Thorac Cardiovasc Surg
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma: a metastasis to the face.
</td>
<td style="text-align:left;">
J Surg Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesotheliomas and chemotherapy.
</td>
<td style="text-align:left;">
J Surg Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Diffuse, mixed malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Ann. Thorac. Surg.
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Tumori
</td>
</tr>
<tr>
<td style="text-align:left;">
Multiple skeletal muscle metastases from malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Pathol. Res. Pract.
</td>
</tr>
<tr>
<td style="text-align:left;">
Aggressive multimodality therapy for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Ann. Thorac. Surg.
</td>
</tr>
<tr>
<td style="text-align:left;">
Radiotherapy in the treatment of malignant mesothelioma of the pleura, with special reference to its use in palliation.
</td>
<td style="text-align:left;">
Australas Radiol
</td>
</tr>
<tr>
<td style="text-align:left;">
[The clinical picture and therapy of malignant pleural mesothelioma].
</td>
<td style="text-align:left;">
Strahlenther Onkol
</td>
</tr>
<tr>
<td style="text-align:left;">
Surgical management of malignant mesothelioma.
</td>
<td style="text-align:left;">
Ann. Thorac. Surg.
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant peritoneal mesothelioma after Thorotrast exposure.
</td>
<td style="text-align:left;">
Am. J. Clin. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Clinical features and current treatment of diffuse malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
A proposed new international TNM staging system for malignant pleural mesothelioma. From the International Mesothelioma Interest Group.
</td>
<td style="text-align:left;">
Chest
</td>
</tr>
<tr>
<td style="text-align:left;">
[Pseudomesotheliomatous carcinoma in HIV infection].
</td>
<td style="text-align:left;">
Dtsch. Med. Wochenschr.
</td>
</tr>
<tr>
<td style="text-align:left;">
OV 632 and MOC 31 in the diagnosis of mesothelioma and adenocarcinoma: an assessment of their use in formalin fixed and paraffin wax embedded material.
</td>
<td style="text-align:left;">
J. Clin. Pathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Optimal management of malignant mesothelioma after subtotal pleurectomy: revisiting the role of intrapleural chemotherapy and postoperative radiation.
</td>
<td style="text-align:left;">
J Surg Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Use of photodynamic therapy for the management of pleural malignancies.
</td>
<td style="text-align:left;">
Semin Surg Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Intracavitary photodynamic therapy for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Semin Surg Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Evaluation of the clinical TNM staging system for malignant pleural mesothelioma: an assessment in 88 patients.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Treatment of experimental human mesothelioma using adenovirus transfer of the herpes simplex thymidine kinase gene.
</td>
<td style="text-align:left;">
Ann. Surg.
</td>
</tr>
<tr>
<td style="text-align:left;">
A phase II trial investigating primary immunochemotherapy for malignant pleural mesothelioma and the feasibility of adjuvant immunochemotherapy after maximal cytoreduction.
</td>
<td style="text-align:left;">
Ann. Surg. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Prevention of malignant seeding after invasive diagnostic procedures in patients with pleural mesothelioma. A randomized trial of local radiotherapy.
</td>
<td style="text-align:left;">
Chest
</td>
</tr>
<tr>
<td style="text-align:left;">
Pleural-based mesothelioma in immune competent rats: a model to study adenoviral gene transfer.
</td>
<td style="text-align:left;">
Ann. Thorac. Surg.
</td>
</tr>
<tr>
<td style="text-align:left;">
Pleural mesotheliomas–an analysis of 18 cases and review of the literature.
</td>
<td style="text-align:left;">
Medicine (Baltimore)
</td>
</tr>
<tr>
<td style="text-align:left;">
Characteristics of nine newly derived mesothelioma cell lines.
</td>
<td style="text-align:left;">
Ann. Thorac. Surg.
</td>
</tr>
<tr>
<td style="text-align:left;">
Intracavitary therapy of neoplastic effusions with cytokines: comparison among interferon alpha, beta and interleukin-2.
</td>
<td style="text-align:left;">
Support Care Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Prognostic significance of DNA aneuploidy in diffuse malignant mesothelioma.
</td>
<td style="text-align:left;">
Cytometry
</td>
</tr>
<tr>
<td style="text-align:left;">
[Treatment of malignant pleural effusion by percutaneous catheter drainage and chemical pleurodesis].
</td>
<td style="text-align:left;">
Minerva Chir
</td>
</tr>
<tr>
<td style="text-align:left;">
Parietal pleurectomy for malignant pleural effusion.
</td>
<td style="text-align:left;">
Ann. Surg. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
The role of growth factors and cytokines in the tumorigenesis and immunobiology of malignant mesothelioma.
</td>
<td style="text-align:left;">
Am. J. Respir. Cell Mol. Biol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Interferon (IFN)-alpha and IFN-gamma in combination with methotrexate: in vitro sensitivity studies in four human mesothelioma cell lines.
</td>
<td style="text-align:left;">
Anticancer Drugs
</td>
</tr>
<tr>
<td style="text-align:left;">
Brain metastasis from malignant mesothelioma–case report.
</td>
<td style="text-align:left;">
Neurol. Med. Chir. (Tokyo)
</td>
</tr>
<tr>
<td style="text-align:left;">
[Cardiac tamponade disclosing neoplasm: apropos of 23 cases].
</td>
<td style="text-align:left;">
Arch Mal Coeur Vaiss
</td>
</tr>
<tr>
<td style="text-align:left;">
Current approach to malignant mesothelioma of the pleura.
</td>
<td style="text-align:left;">
Chest
</td>
</tr>
<tr>
<td style="text-align:left;">
Mesothelioma and radical multimodality therapy: who benefits?
</td>
<td style="text-align:left;">
Chest
</td>
</tr>
<tr>
<td style="text-align:left;">
[Malignant mesothelioma of the pericardium. An anatomo-clinical study of 10 cases].
</td>
<td style="text-align:left;">
Arch Mal Coeur Vaiss
</td>
</tr>
<tr>
<td style="text-align:left;">
Combination chemotherapy with cisplatin-vinblastine in malignant mesothelioma.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Implantable access system for prolonged intrapleural immunotherapy.
</td>
<td style="text-align:left;">
Eur. Respir. J.
</td>
</tr>
<tr>
<td style="text-align:left;">
Intrapleural treatment with recombinant gamma-interferon in early stage malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Prognostic factors and survival in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Eur. Respir. J.
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma following radiation therapy.
</td>
<td style="text-align:left;">
Am. J. Med.
</td>
</tr>
<tr>
<td style="text-align:left;">
Operation and intracavitary photodynamic therapy for malignant pleural mesothelioma: a phase II study.
</td>
<td style="text-align:left;">
Ann. Thorac. Surg.
</td>
</tr>
<tr>
<td style="text-align:left;">
Spectrum of peritoneal mesothelioma in childhood: clinical and histopathologic features, including DNA cytometry.
</td>
<td style="text-align:left;">
Pediatr Hematol Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Thoracoscopy for the evaluation and treatment of pleural space disease.
</td>
<td style="text-align:left;">
Chest Surg. Clin. N. Am.
</td>
</tr>
<tr>
<td style="text-align:left;">
Contemporary approaches in the investigation and treatment of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Chest Surg. Clin. N. Am.
</td>
</tr>
<tr>
<td style="text-align:left;">
Pleural and pericardial mesothelioma in a general teaching hospital during the last fourteen years.
</td>
<td style="text-align:left;">
Zhonghua Yi Xue Za Zhi (Taipei)
</td>
</tr>
<tr>
<td style="text-align:left;">
Localized pleural mesothelioma. The clinical spectrum.
</td>
<td style="text-align:left;">
Chest
</td>
</tr>
<tr>
<td style="text-align:left;">
[A case of the localized fibrous mesothelioma which size decreased temporarily].
</td>
<td style="text-align:left;">
Kyobu Geka
</td>
</tr>
<tr>
<td style="text-align:left;">
Thoracic mesothelioma associated with abdominal mesenteric panniculitis.
</td>
<td style="text-align:left;">
Am. J. Gastroenterol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Trials in malignant mesothelioma. LCSG 851 and 882.
</td>
<td style="text-align:left;">
Chest
</td>
</tr>
<tr>
<td style="text-align:left;">
Intrapleural chemotherapy without pleurodesis for malignant pleural effusions. LCSG Trial 861.
</td>
<td style="text-align:left;">
Chest
</td>
</tr>
<tr>
<td style="text-align:left;">
A phase II trial of dose-escalated doxorubicin and ifosfamide/mesna in patients with malignant mesothelioma.
</td>
<td style="text-align:left;">
Ann. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Successful adenovirus-mediated gene transfer in an in vivo model of human malignant mesothelioma.
</td>
<td style="text-align:left;">
Ann. Thorac. Surg.
</td>
</tr>
<tr>
<td style="text-align:left;">
Neoplasms of the mediastinum, chest wall, and pleura.
</td>
<td style="text-align:left;">
Curr Opin Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
[Localized pleural mesothelioma].
</td>
<td style="text-align:left;">
Helv Chir Acta
</td>
</tr>
<tr>
<td style="text-align:left;">
Treatment of a patient with malignant mesothelioma with interferon-alpha 2 based on in vitro sensitivity tests.
</td>
<td style="text-align:left;">
Clin Investig
</td>
</tr>
<tr>
<td style="text-align:left;">
Intrapleural production of interleukin 6 during mesothelioma and its modulation by gamma-interferon treatment.
</td>
<td style="text-align:left;">
Cancer Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma. Extrapleural pneumonectomy and pleurectomy.
</td>
<td style="text-align:left;">
Chest Surg. Clin. N. Am.
</td>
</tr>
<tr>
<td style="text-align:left;">
Adjuvant therapy for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Chest Surg. Clin. N. Am.
</td>
</tr>
<tr>
<td style="text-align:left;">
Weekly high-dose cisplatin in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Ann. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural tumor in a child mimicking a mesothelioma.
</td>
<td style="text-align:left;">
Eur J Pediatr Surg
</td>
</tr>
<tr>
<td style="text-align:left;">
[Pleural mesothelioma: a clinicopathologic study of 42 cases].
</td>
<td style="text-align:left;">
Zhonghua Nei Ke Za Zhi
</td>
</tr>
<tr>
<td style="text-align:left;">
[The kinetics of IL-2 after pleural administration in the treatment of neoplastic pleurisy].
</td>
<td style="text-align:left;">
Rev Mal Respir
</td>
</tr>
<tr>
<td style="text-align:left;">
AIDS and malignant mesothelioma–is there a connection?
</td>
<td style="text-align:left;">
Chest
</td>
</tr>
<tr>
<td style="text-align:left;">
Interferon alpha and doxorubicin in malignant mesothelioma: a phase II study.
</td>
<td style="text-align:left;">
Aust N Z J Med
</td>
</tr>
<tr>
<td style="text-align:left;">
Diffuse pulmonary malignant mesothelioma: response to doxorubicin and 5-azacytidine.
</td>
<td style="text-align:left;">
Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Pleural mesothelioma presenting as an axillary lymph node metastasis with anemone cell appearance.
</td>
<td style="text-align:left;">
Ultrastruct Pathol
</td>
</tr>
<tr>
<td style="text-align:left;">
A phase II trial of pleurectomy/decortication followed by intrapleural and systemic chemotherapy for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J. Clin. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Treatment of primary or metastatic pleural effusion with intracavitary cytosine arabinoside and cisplatin. A phase II study.
</td>
<td style="text-align:left;">
Acta Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Treatment of malignant pleural mesothelioma with cisplatin, mitomycin C and alpha interferon.
</td>
<td style="text-align:left;">
Oncology
</td>
</tr>
<tr>
<td style="text-align:left;">
[Malignant pleural mesothelioma. A diagnostic and therapeutic challenge].
</td>
<td style="text-align:left;">
An Med Interna
</td>
</tr>
<tr>
<td style="text-align:left;">
Diagnostic and therapeutic thoracoscopy: techniques and indications in pulmonary medicine.
</td>
<td style="text-align:left;">
Tuber. Lung Dis.
</td>
</tr>
<tr>
<td style="text-align:left;">
[Thoracoscopy in pleural mesothelioma].
</td>
<td style="text-align:left;">
Zhonghua Jie He He Hu Xi Za Zhi
</td>
</tr>
<tr>
<td style="text-align:left;">
Differential expression of platelet derived growth factor-beta in malignant mesothelioma: a clue to future therapies?
</td>
<td style="text-align:left;">
Surg Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Pleural mesothelioma.
</td>
<td style="text-align:left;">
Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
High doses of intrapleural cisplatin in a case of malignant pleural mesothelioma. Clinical observations and pharmacokinetic analyses.
</td>
<td style="text-align:left;">
Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Pharmacokinetics of intrapleural recombinant interleukin-2 in immunotherapy for malignant pleural effusion.
</td>
<td style="text-align:left;">
Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Recombinant interferon alpha-2b in the treatment of diffuse malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Am. J. Clin. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma. Multivariate analysis of prognostic factors on 113 patients.
</td>
<td style="text-align:left;">
Anticancer Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
Thoracoscopy in pleural malignant mesothelioma: a prospective study of 188 consecutive patients. Part 1: Diagnosis.
</td>
<td style="text-align:left;">
Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Randomized phase II trial of cisplatin with mitomycin or doxorubicin for malignant mesothelioma by the Cancer and Leukemia Group B.
</td>
<td style="text-align:left;">
J. Clin. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
[Malignant peritoneal mesothelioma].
</td>
<td style="text-align:left;">
Harefuah
</td>
</tr>
<tr>
<td style="text-align:left;">
[Pleural mesothelioma. Review of 3 cases and role of thoracoscopy].
</td>
<td style="text-align:left;">
Rev Med Suisse Romande
</td>
</tr>
<tr>
<td style="text-align:left;">
In vitro effects of recombinant human interferon gamma on human mesothelioma cell lines.
</td>
<td style="text-align:left;">
Int. J. Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma: a clinicopathological study.
</td>
<td style="text-align:left;">
J Surg Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
A new device for the treatment of pleural malignancies: intrapleural chemohyperthermia preliminary report.
</td>
<td style="text-align:left;">
Oncology
</td>
</tr>
<tr>
<td style="text-align:left;">
Hypertrophic osteoarthropathy in childhood malignancy.
</td>
<td style="text-align:left;">
Med. Pediatr. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Intrapleural recombinant IL-2 in passive immunotherapy for malignant pleural effusion.
</td>
<td style="text-align:left;">
Chest
</td>
</tr>
<tr>
<td style="text-align:left;">
Clinical aspects of malignant mesothelioma in Australia.
</td>
<td style="text-align:left;">
Aust N Z J Med
</td>
</tr>
<tr>
<td style="text-align:left;">
Natural history and epidemiology of malignant mesothelioma.
</td>
<td style="text-align:left;">
Chest
</td>
</tr>
<tr>
<td style="text-align:left;">
Extrapleural pneumonectomy in the setting of a multimodality approach to malignant mesothelioma.
</td>
<td style="text-align:left;">
Chest
</td>
</tr>
<tr>
<td style="text-align:left;">
Pleurectomy/decortication and adjuvant therapy for malignant mesothelioma.
</td>
<td style="text-align:left;">
Chest
</td>
</tr>
<tr>
<td style="text-align:left;">
Node status has prognostic significance in the multimodality therapy of diffuse, malignant mesothelioma.
</td>
<td style="text-align:left;">
J. Clin. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
[Malignant pleural mesothelioma: clinical characteristics, prognostic factors and treatment].
</td>
<td style="text-align:left;">
Arch. Bronconeumol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Thoracoscopic management of malignant pleural effusions.
</td>
<td style="text-align:left;">
Clin. Chest Med.
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma: newer aspects of carcinogenesis, molecular genetics, and prospects for future therapies.
</td>
<td style="text-align:left;">
Surg Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma of 17 years’ duration with high pleural fluid concentration of hyaluronate.
</td>
<td style="text-align:left;">
Scand J Respir Dis
</td>
</tr>
<tr>
<td style="text-align:left;">
Intrapleural chemotherapy for patients with incompletely resected malignant mesothelioma: the UCLA experience.
</td>
<td style="text-align:left;">
J Surg Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
The proposed new international TNM staging system for malignant pleural mesothelioma: application to imaging.
</td>
<td style="text-align:left;">
AJR Am J Roentgenol
</td>
</tr>
<tr>
<td style="text-align:left;">
Parental cancer and genetic predisposition in malignant pleural mesothelioma: a case-control study.
</td>
<td style="text-align:left;">
Cancer Lett.
</td>
</tr>
<tr>
<td style="text-align:left;">
Post-irradiation malignant mesothelioma.
</td>
<td style="text-align:left;">
Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
The importance of surgical staging in the treatment of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J. Thorac. Cardiovasc. Surg.
</td>
</tr>
<tr>
<td style="text-align:left;">
Chemotherapy in malignant pleural mesothelioma. A review.
</td>
<td style="text-align:left;">
J. Clin. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Combined systemic chemoimmunotherapy in advanced diffuse malignant mesothelioma. Report of a phase I-II study of weekly cisplatin/interferon alfa-2a.
</td>
<td style="text-align:left;">
J. Clin. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Surgery followed by intracavitary plus systemic chemotherapy in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Tumori
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma after radiation therapy for breast cancer. A report of two additional patients.
</td>
<td style="text-align:left;">
Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Treatment of malignant mesothelioma with methotrexate and vinblastine, with or without platinum chemotherapy.
</td>
<td style="text-align:left;">
Chest
</td>
</tr>
<tr>
<td style="text-align:left;">
Prospective study of combination chemotherapy with cyclophosphamide, doxorubicin, and cisplatin for unresectable or metastatic malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Bronchoesophagopleural fistula after photodynamic therapy for malignant mesothelioma.
</td>
<td style="text-align:left;">
Ann. Thorac. Surg.
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma following treatment for Hodgkin’s disease.
</td>
<td style="text-align:left;">
J. Clin. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Clinical course of human epithelial-type malignant pleural mesothelioma replicated in an orthotopic-transplant nude mouse model.
</td>
<td style="text-align:left;">
Anticancer Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
A proposed new international TNM staging system for malignant pleural mesothelioma from the International Mesothelioma Interest Group.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Treatment and survival in diffuse malignant pleural mesothelioma; a study of 83 cases from the Massachusetts General Hospital.
</td>
<td style="text-align:left;">
Anticancer Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
Combined chemotherapy in pleurectomized malignant pleural mesothelioma patients.
</td>
<td style="text-align:left;">
J Chemother
</td>
</tr>
<tr>
<td style="text-align:left;">
Cytologic effects of photodynamic therapy in body fluids.
</td>
<td style="text-align:left;">
Diagn. Cytopathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
[Diagnosis and treatment of pleural mesothelioma: a report of 40 cases].
</td>
<td style="text-align:left;">
Zhonghua Zhong Liu Za Zhi
</td>
</tr>
<tr>
<td style="text-align:left;">
[Peritoneal mesothelioma. Contribution of MRI. Apropos of a case].
</td>
<td style="text-align:left;">
J Radiol
</td>
</tr>
<tr>
<td style="text-align:left;">
Treatment of pleural mesothelioma in an immunocompetent rat model utilizing adenoviral transfer of the herpes simplex virus thymidine kinase gene.
</td>
<td style="text-align:left;">
Hum. Gene Ther.
</td>
</tr>
<tr>
<td style="text-align:left;">
Extrapleural pneumonectomy in the multimodality therapy of malignant pleural mesothelioma. Results in 120 consecutive patients.
</td>
<td style="text-align:left;">
Ann. Surg.
</td>
</tr>
<tr>
<td style="text-align:left;">
Small cell carcinoma of lung simulating pleural mesothelioma. Report of 4 cases with autopsy confirmation.
</td>
<td style="text-align:left;">
Pathol. Res. Pract.
</td>
</tr>
<tr>
<td style="text-align:left;">
Paclitaxel for malignant pleural mesothelioma: a phase II study of the EORTC Lung Cancer Cooperative Group.
</td>
<td style="text-align:left;">
Br. J. Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Endobronchial inflammatory pseudotumour in a patient with B-cell chronic lymphocytic leukemia and malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Acta Clin Belg
</td>
</tr>
<tr>
<td style="text-align:left;">
[Malignant mesothelioma of the pleura].
</td>
<td style="text-align:left;">
Orv Hetil
</td>
</tr>
<tr>
<td style="text-align:left;">
[A case report of surgical resection of renal cell carcinoma with intrathoracic metastasis].
</td>
<td style="text-align:left;">
Nihon Kyobu Geka Gakkai Zasshi
</td>
</tr>
<tr>
<td style="text-align:left;">
[Malignant mesothelioma of the pleura: correlations between thoracoscopy and radiology].
</td>
<td style="text-align:left;">
Radiol Med
</td>
</tr>
<tr>
<td style="text-align:left;">
[Retroperitoneal malignant mesothelioma. A case report].
</td>
<td style="text-align:left;">
Nippon Hinyokika Gakkai Zasshi
</td>
</tr>
<tr>
<td style="text-align:left;">
[Solitary fibrous tumor of the pleura. Clinical case].
</td>
<td style="text-align:left;">
Minerva Chir
</td>
</tr>
<tr>
<td style="text-align:left;">
The role of cytologic evaluation of pleural fluid in the diagnosis of malignant mesothelioma.
</td>
<td style="text-align:left;">
Chest
</td>
</tr>
<tr>
<td style="text-align:left;">
A case of malignant pleural mesothelioma with metastasis to the orbit.
</td>
<td style="text-align:left;">
Jpn. J. Clin. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
[A case of localized pleural mesothelioma].
</td>
<td style="text-align:left;">
Kyobu Geka
</td>
</tr>
<tr>
<td style="text-align:left;">
Patterns of failure after trimodality therapy for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Ann. Thorac. Surg.
</td>
</tr>
<tr>
<td style="text-align:left;">
[Malignant mesothelioma of the pleura following radiotherapy of Hodgkin disease].
</td>
<td style="text-align:left;">
Bull Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Immunohistochemical differences between hyaluronan- and non-hyaluronan-producing malignant mesothelioma.
</td>
<td style="text-align:left;">
Eur. Respir. J.
</td>
</tr>
<tr>
<td style="text-align:left;">
Response to chemotherapy of brain metastases from malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Tumori
</td>
</tr>
<tr>
<td style="text-align:left;">
Pleural effusion cytology of embryonal rhabdomyosarcoma.
</td>
<td style="text-align:left;">
Diagn. Cytopathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
[Venous endoprosthesis. Palliative treatment of superior caval syndrome of neoplastic origin].
</td>
<td style="text-align:left;">
J Radiol
</td>
</tr>
<tr>
<td style="text-align:left;">
Retroviral gene transfer is inhibited by chondroitin sulfate proteoglycans/glycosaminoglycans in malignant pleural effusions.
</td>
<td style="text-align:left;">
J. Biol. Chem.
</td>
</tr>
<tr>
<td style="text-align:left;">
[Problems in diagnosis and therapy of malignant pleural mesothelioma].
</td>
<td style="text-align:left;">
Med. Klin. (Munich)
</td>
</tr>
<tr>
<td style="text-align:left;">
Surgically debulked malignant pleural mesothelioma: results and prognostic factors.
</td>
<td style="text-align:left;">
Ann. Surg. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Combined cisplatin, doxorubicin, and mitomycin for the treatment of advanced pleural mesothelioma: a phase II FONICAP trial. Italian Lung Cancer Task Force.
</td>
<td style="text-align:left;">
Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Localized benign pleural mesothelioma arising in a radiation field.
</td>
<td style="text-align:left;">
Clin Imaging
</td>
</tr>
<tr>
<td style="text-align:left;">
High CD44 expression on human mesotheliomas mediates association with hyaluronan.
</td>
<td style="text-align:left;">
Cancer J Sci Am
</td>
</tr>
<tr>
<td style="text-align:left;">
[A mesenchymal malignant mesothelioma that changed from mixed type to purely sarcomatous type].
</td>
<td style="text-align:left;">
Nihon Kyobu Shikkan Gakkai Zasshi
</td>
</tr>
<tr>
<td style="text-align:left;">
Gene therapy of experimental malignant mesothelioma using adenovirus vectors encoding the HSVtk gene.
</td>
<td style="text-align:left;">
Gene Ther.
</td>
</tr>
<tr>
<td style="text-align:left;">
Dihydro-5-azacytidine in malignant mesothelioma. A phase II trial demonstrating activity accompanied by cardiac toxicity. Cancer and Leukemia Group B.
</td>
<td style="text-align:left;">
Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma metastatic to the skin, presenting as inflammatory carcinoma.
</td>
<td style="text-align:left;">
Am J Dermatopathol
</td>
</tr>
<tr>
<td style="text-align:left;">
[Thoracoscopic surgery for diagnosis and treatment of pleural and mediastinal disease].
</td>
<td style="text-align:left;">
Nihon Kyobu Shikkan Gakkai Zasshi
</td>
</tr>
<tr>
<td style="text-align:left;">
Altered fractionation of hemithorax irradiation for pleural mesothelioma and failure patterns after treatment.
</td>
<td style="text-align:left;">
Acta Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
[Malignant mesothelioma. Diagnosis and treatment].
</td>
<td style="text-align:left;">
Rev Prat
</td>
</tr>
<tr>
<td style="text-align:left;">
Metastatic malignant mesothelioma presenting as colonic polyps.
</td>
<td style="text-align:left;">
Hum. Pathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Thoracic complications in patients undergoing intraperitoneal heated chemotherapy with mitomycin following cytoreductive surgery.
</td>
<td style="text-align:left;">
J Surg Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
[Photomicrographs of a pleural biopsy specimen, showing malignant mesothelioma and necrosis–malignant pleural mesothelioma in a patient with sarcoidosis].
</td>
<td style="text-align:left;">
Nihon Kyobu Shikkan Gakkai Zasshi
</td>
</tr>
<tr>
<td style="text-align:left;">
Incidence of malignant pleural mesothelioma after thoracic radiotherapy.
</td>
<td style="text-align:left;">
Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Photodynamic therapy as adjuvant therapy in surgically treated pleural malignancies.
</td>
<td style="text-align:left;">
Br. J. Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Innovative therapies for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Chest
</td>
</tr>
<tr>
<td style="text-align:left;">
Multimodality therapy for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Chest
</td>
</tr>
<tr>
<td style="text-align:left;">
Brachytherapy for non-small cell lung cancer and selected neoplasms of the chest.
</td>
<td style="text-align:left;">
Chest
</td>
</tr>
<tr>
<td style="text-align:left;">
[A resected case of diffuse malignant pleural mesothelioma diagnosed by thoracoscopic biopsy].
</td>
<td style="text-align:left;">
Nihon Kyobu Geka Gakkai Zasshi
</td>
</tr>
<tr>
<td style="text-align:left;">
Pathology of diffuse malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Semin. Thorac. Cardiovasc. Surg.
</td>
</tr>
<tr>
<td style="text-align:left;">
Chemotherapy for malignant mesothelioma.
</td>
<td style="text-align:left;">
Semin. Thorac. Cardiovasc. Surg.
</td>
</tr>
<tr>
<td style="text-align:left;">
Pleurectomy/decortication in the setting of multimodality treatment for diffuse malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Semin. Thorac. Cardiovasc. Surg.
</td>
</tr>
<tr>
<td style="text-align:left;">
Extrapleural pneumonectomy in the setting of multimodality therapy for diffuse malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Semin. Thorac. Cardiovasc. Surg.
</td>
</tr>
<tr>
<td style="text-align:left;">
New therapies in the treatment of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Semin. Thorac. Cardiovasc. Surg.
</td>
</tr>
<tr>
<td style="text-align:left;">
Pleural malignancies including mesothelioma.
</td>
<td style="text-align:left;">
Curr Opin Pulm Med
</td>
</tr>
<tr>
<td style="text-align:left;">
Experimental assessment of photodynamic therapy with chlorins for malignant mesothelioma.
</td>
<td style="text-align:left;">
Eur J Cardiothorac Surg
</td>
</tr>
<tr>
<td style="text-align:left;">
A case of malignant pleural mesothelioma following exposure to atomic radiation in Nagasaki.
</td>
<td style="text-align:left;">
Respirology
</td>
</tr>
<tr>
<td style="text-align:left;">
Phase III randomized trial of surgery with or without intraoperative photodynamic therapy and postoperative immunochemotherapy for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Ann. Surg. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Combination chemotherapy with cisplatin and/or doxorubicin in malignant mesothelioma. A retrospective study [corrected from prospective].
</td>
<td style="text-align:left;">
Anticancer Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
Multimodality management of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Chest
</td>
</tr>
<tr>
<td style="text-align:left;">
A review of chemotherapy trials for malignant mesothelioma.
</td>
<td style="text-align:left;">
Chest
</td>
</tr>
<tr>
<td style="text-align:left;">
Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience.
</td>
<td style="text-align:left;">
J. Clin. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
[Malignant pleural mesothelioma in 1997].
</td>
<td style="text-align:left;">
Schweiz Med Wochenschr
</td>
</tr>
<tr>
<td style="text-align:left;">
Effects of interleukin-2 for the treatment of malignant mesothelioma.
</td>
<td style="text-align:left;">
Oncol. Rep.
</td>
</tr>
<tr>
<td style="text-align:left;">
Phase I study of paclitaxel as a radiation sensitizer in the treatment of mesothelioma and non-small-cell lung cancer.
</td>
<td style="text-align:left;">
J. Clin. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Etoposide in malignant pleural mesothelioma: two phase II trials of the EORTC Lung Cancer Cooperative Group.
</td>
<td style="text-align:left;">
Eur. J. Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Higher doses of alpha-interferon do not increase the activity of the weekly cisplatin-interferon combination in advanced malignant mesothelioma.
</td>
<td style="text-align:left;">
Eur. J. Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Preoperative tumor volume is associated with outcome in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J. Thorac. Cardiovasc. Surg.
</td>
</tr>
<tr>
<td style="text-align:left;">
Transduction of non-small cell lung cancer cells by adenoviral and retroviral vectors.
</td>
<td style="text-align:left;">
Am. J. Respir. Cell Mol. Biol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Clinical features and epidemiology of malignant pleural mesothelioma in west Glasgow 1987-1992.
</td>
<td style="text-align:left;">
Scott Med J
</td>
</tr>
<tr>
<td style="text-align:left;">
Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B.
</td>
<td style="text-align:left;">
Chest
</td>
</tr>
<tr>
<td style="text-align:left;">
Thoracoscopy–state of the art.
</td>
<td style="text-align:left;">
Eur. Respir. J.
</td>
</tr>
<tr>
<td style="text-align:left;">
A case of malignant peritoneal mesothelioma showed complete remission with chemotherapy.
</td>
<td style="text-align:left;">
Jpn. J. Clin. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
[Value of thoracoscopy and talc pleurodesis in diagnosis and palliative treatment of malignant pleural mesothelioma].
</td>
<td style="text-align:left;">
Praxis (Bern 1994)
</td>
</tr>
<tr>
<td style="text-align:left;">
Dihydro-5-azacytidine and cisplatin in the treatment of malignant mesothelioma: a phase II study by the Cancer and Leukemia Group B.
</td>
<td style="text-align:left;">
Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Hyperplastic mesothelial cells in lymph nodes: report of six cases of a benign process that can stimulate metastatic involvement by mesothelioma or carcinoma.
</td>
<td style="text-align:left;">
Hum. Pathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Expression of HGF/SF in mesothelioma cell lines and its effects on cell motility, proliferation and morphology.
</td>
<td style="text-align:left;">
Br. J. Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Adenovirus-mediated herpes simplex virus thymidine kinase/ganciclovir gene therapy in patients with localized malignancy: results of a phase I clinical trial in malignant mesothelioma.
</td>
<td style="text-align:left;">
Hum. Gene Ther.
</td>
</tr>
<tr>
<td style="text-align:left;">
Gene therapy for malignant mesothelioma: a novel approach for an incurable cancer with increased incidence in Louisiana.
</td>
<td style="text-align:left;">
J La State Med Soc
</td>
</tr>
<tr>
<td style="text-align:left;">
[Diffuse primary malignant mesothelioma in abdominal cavity].
</td>
<td style="text-align:left;">
Arq Gastroenterol
</td>
</tr>
<tr>
<td style="text-align:left;">
Immunoreactivity of pleural malignant mesotheliomas to glutathione S-transferases.
</td>
<td style="text-align:left;">
APMIS
</td>
</tr>
<tr>
<td style="text-align:left;">
CT and MR in pleural disease.
</td>
<td style="text-align:left;">
Clin. Chest Med.
</td>
</tr>
<tr>
<td style="text-align:left;">
[Therapeutic strategy for pleural mesothelioma].
</td>
<td style="text-align:left;">
Nihon Geka Gakkai Zasshi
</td>
</tr>
<tr>
<td style="text-align:left;">
Gene therapy for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Hematol. Oncol. Clin. North Am.
</td>
</tr>
<tr>
<td style="text-align:left;">
Immunobiology and immune defense mechanisms of mesothelioma cells.
</td>
<td style="text-align:left;">
Monaldi Arch Chest Dis
</td>
</tr>
<tr>
<td style="text-align:left;">
Systemic drug therapy of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Monaldi Arch Chest Dis
</td>
</tr>
<tr>
<td style="text-align:left;">
Human malignant mesothelioma of the pleura: new perspectives for diagnosis and therapy.
</td>
<td style="text-align:left;">
Monaldi Arch Chest Dis
</td>
</tr>
<tr>
<td style="text-align:left;">
Cytokeratin markers in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Cancer Detect. Prev.
</td>
</tr>
<tr>
<td style="text-align:left;">
[Unusual metastasis of a malignant pleural mesothelioma].
</td>
<td style="text-align:left;">
Pneumologie
</td>
</tr>
<tr>
<td style="text-align:left;">
[Standards, Options, and Recommendations for the management of patients with malignant mesothelioma of the pleura. Fédération Nationale des Centres de Lutte Contre le Cancer].
</td>
<td style="text-align:left;">
Bull Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
[Benign fibrous mesothelioma: report of 8 cases].
</td>
<td style="text-align:left;">
Arch. Bronconeumol.
</td>
</tr>
<tr>
<td style="text-align:left;">
SV40 expression in human neoplastic and non-neoplastic tissues: perspectives on diagnosis, prognosis and therapy of human malignant mesothelioma.
</td>
<td style="text-align:left;">
Dev. Biol. Stand.
</td>
</tr>
<tr>
<td style="text-align:left;">
Operation and photodynamic therapy for pleural mesothelioma: 6-year follow-up.
</td>
<td style="text-align:left;">
Ann. Thorac. Surg.
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Eur. Respir. J.
</td>
</tr>
<tr>
<td style="text-align:left;">
Intrapleural administration of interleukin-2 for the treatment of patients with malignant pleural mesothelioma: a Phase II study.
</td>
<td style="text-align:left;">
Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Treatment results of 17 patients with diffuse pleural mesothelioma.
</td>
<td style="text-align:left;">
Ann Thorac Cardiovasc Surg
</td>
</tr>
<tr>
<td style="text-align:left;">
[Pleural malignant mesothelioma with osseous cartilaginous and rhabdomyogenic differentiation].
</td>
<td style="text-align:left;">
Nihon Kokyuki Gakkai Zasshi
</td>
</tr>
<tr>
<td style="text-align:left;">
Adenocarcinoma simulating mesothelioma: a clinicopathologic and immunohistochemical study of 29 cases.
</td>
<td style="text-align:left;">
Ann Diagn Pathol
</td>
</tr>
<tr>
<td style="text-align:left;">
The treatment of malignant mesothelioma with a gene modified cancer cell line: a phase I study.
</td>
<td style="text-align:left;">
Hum. Gene Ther.
</td>
</tr>
<tr>
<td style="text-align:left;">
Phase II trial of topotecan for the treatment of mesothelioma.
</td>
<td style="text-align:left;">
Am. J. Clin. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Localized fibrous tumours of the pleura: 15 new cases and review of the literature.
</td>
<td style="text-align:left;">
Eur J Cardiothorac Surg
</td>
</tr>
<tr>
<td style="text-align:left;">
[Modern approach to malignant pleural mesothelioma. 1) Pretherapeutic evaluation].
</td>
<td style="text-align:left;">
Srp Arh Celok Lek
</td>
</tr>
<tr>
<td style="text-align:left;">
Environmentally-induced malignant pleural mesothelioma and HLA distribution in Turkey.
</td>
<td style="text-align:left;">
Int. J. Tuberc. Lung Dis.
</td>
</tr>
<tr>
<td style="text-align:left;">
Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients.
</td>
<td style="text-align:left;">
J. Thorac. Cardiovasc. Surg.
</td>
</tr>
<tr>
<td style="text-align:left;">
[Malignant pleural mesothelioma. II. Modern therapeutic concepts].
</td>
<td style="text-align:left;">
Srp Arh Celok Lek
</td>
</tr>
<tr>
<td style="text-align:left;">
[Treatment strategy in pleural mesothelioma].
</td>
<td style="text-align:left;">
Langenbecks Arch Chir Suppl Kongressbd
</td>
</tr>
</tbody>
</table>
<p><br></p>

          </div>

          



          
        </div>

        <div class="body-footer">
          
          

          
        </div>

      </article>

      <footer class="site-footer">
  
  <p class="powered-by">
    
      <a href="/mesothelioma/privacy/">Privacy Policy</a>
    
    
        &middot; 
      <a href="/mesothelioma/terms/">Terms</a>
    
    
        &middot; 
      <a href="/mesothelioma/supp/faq/">FAQ</a>
    
  </p>
  

  <p class="powered-by">
    BioHub - UFPE &middot; 

    Powered by the
    <a href="https://sourcethemes.com/academic/" target="_blank" rel="noopener">Academic theme</a> for
    <a href="https://gohugo.io" target="_blank" rel="noopener">Hugo</a>.

    
  </p>
</footer>


    </main>
  </div>
</div>


      

    
    
    
      <script src="https://cdnjs.cloudflare.com/ajax/libs/jquery/3.4.1/jquery.min.js" integrity="sha256-CSXorXvZcTkaix6Yvo6HppcZGetbYMGWSFlBw8HfCJo=" crossorigin="anonymous"></script>
      <script src="https://cdnjs.cloudflare.com/ajax/libs/jquery.imagesloaded/4.1.4/imagesloaded.pkgd.min.js" integrity="sha256-lqvxZrPLtfffUl2G/e7szqSvPBILGbwmsGE1MKlOi0Q=" crossorigin="anonymous"></script>
      <script src="https://cdnjs.cloudflare.com/ajax/libs/jquery.isotope/3.0.6/isotope.pkgd.min.js" integrity="sha256-CBrpuqrMhXwcLLUd5tvQ4euBHCdh7wGlDfNz8vbu/iI=" crossorigin="anonymous"></script>
      <script src="https://cdnjs.cloudflare.com/ajax/libs/fancybox/3.5.7/jquery.fancybox.min.js" integrity="sha256-yt2kYMy0w8AbtF89WXb2P1rfjcP/HTHLT7097U8Y5b8=" crossorigin="anonymous"></script>

      

      
        
        <script src="https://cdnjs.cloudflare.com/ajax/libs/highlight.js/9.18.1/highlight.min.js" integrity="sha256-eOgo0OtLL4cdq7RdwRUiGKLX9XsIJ7nGhWEKbohmVAQ=" crossorigin="anonymous"></script>
        
        <script src="https://cdnjs.cloudflare.com/ajax/libs/highlight.js/9.18.1/languages/r.min.js"></script>
        
      

    

    
    

    
    
    <script>const code_highlighting = true;</script>
    

    
    
    <script>const isSiteThemeDark = false;</script>
    

    
    
    
    
    
    
    <script>
      const search_config = {"indexURI":"/mesothelioma/index.json","minLength":1,"threshold":0.3};
      const i18n = {"no_results":"No results found","placeholder":"Search...","results":"results found"};
      const content_type = {
        'post': "Posts",
        'project': "Projects",
        'publication' : "Publications",
        'talk' : "Talks"
        };
    </script>
    

    
    
    <script src="https://cdnjs.cloudflare.com/ajax/libs/anchor-js/4.1.1/anchor.min.js" integrity="sha256-pB/deHc9CGfFpJRjC43imB29Rse8tak+5eXqntO94ck=" crossorigin="anonymous"></script>
    <script>
      anchors.add();
    </script>
    

    
    
    <script id="search-hit-fuse-template" type="text/x-template">
      <div class="search-hit" id="summary-{{key}}">
      <div class="search-hit-content">
        <div class="search-hit-name">
          <a href="{{relpermalink}}">{{title}}</a>
          <div class="article-metadata search-hit-type">{{type}}</div>
          <p class="search-hit-description">{{snippet}}</p>
        </div>
      </div>
      </div>
    </script>
    

    
    
    <script src="https://cdnjs.cloudflare.com/ajax/libs/fuse.js/3.2.1/fuse.min.js" integrity="sha256-VzgmKYmhsGNNN4Ph1kMW+BjoYJM2jV5i4IlFoeZA9XI=" crossorigin="anonymous"></script>
    <script src="https://cdnjs.cloudflare.com/ajax/libs/mark.js/8.11.1/jquery.mark.min.js" integrity="sha256-4HLtjeVgH0eIB3aZ9mLYF6E8oU5chNdjU6p6rrXpl9U=" crossorigin="anonymous"></script>
    

    
    

    
    

    
    
    <script id="dsq-count-scr" src="https://procovid19.disqus.com/count.js" async></script>
    

    
    
    
    
    
    
    
    
    
      
    
    
    
    
    <script src="/mesothelioma/js/academic.min.37431be2d92d7fb0160054761ab79602.js"></script>

    






  
  

  
<div id="modal" class="modal fade" role="dialog">
  <div class="modal-dialog">
    <div class="modal-content">
      <div class="modal-header">
        <h5 class="modal-title">Cite</h5>
        <button type="button" class="close" data-dismiss="modal" aria-label="Close">
          <span aria-hidden="true">&times;</span>
        </button>
      </div>
      <div class="modal-body">
        <pre><code class="tex hljs"></code></pre>
      </div>
      <div class="modal-footer">
        <a class="btn btn-outline-primary my-1 js-copy-cite" href="#" target="_blank">
          <i class="fas fa-copy"></i> Copy
        </a>
        <a class="btn btn-outline-primary my-1 js-download-cite" href="#" target="_blank">
          <i class="fas fa-download"></i> Download
        </a>
        <div id="modal-error"></div>
      </div>
    </div>
  </div>
</div>

</body>
</html>
